

Exhibit 395

Specific Causation Expert Report: David Downs

Yair Lotan MD

Professor

Vice Chair of Clinical Affairs

Chief of Urologic Oncology

Jane and John Justin Distinguished Chair in Urology, In Honor of Claus G. Roehrborn, M.D.

UT Southwestern Medical Center at Dallas

Department of Urology

2001 Inwood WCB3 4th floor

Dallas, Texas 75390-9110

Ph: 214-648-0389

Fax: 214 648 8786

yair.lotan@utsouthwestern.edu

www.utsouthwestern.edu/urology

DocuSigned by:

Yair Lotan, MD

1CAA075F98C7448...

Yair Lotan M.D.

Table of Contents

I.	Scope of Report	1
II.	Personal Background/Qualifications	1
III.	Summary of Opinions	2
IV.	Records Reviewed	3
V.	Methodology	3
VI.	Classification of Evidence	4
VII.	Mr. Downs Time at Camp Lejeune, Medical History, and Cancer History	6
VIII.	The Levels of the Chemicals in the Water at Camp Lejeune Were at Sufficient Levels to Cause Mr. Downs' Kidney Cancer	7
IX.	ATSDR/Bove Data on the Levels of the Chemicals in the Water	10
X.	David Downs' Exposure	11
XI.	Kidney Cancer and the Cause of Kidney Cancer	15
XII.	TCE and Kidney Cancer Outside of Camp Lejeune	16
XIII.	TCE Mechanism of Injury	18
XIV.	Bradford Hill Analysis of Causation for David Downs	20
XV.	Differential Diagnosis of Etiology	22
XVI.	Defendant's Supplemental Interrogatory Responses	24
XVII.	Mr. Downs' Injuries	26
XVIII.	Summary	26

DATE: 2/6/25

Re: David Downs
DOB: [REDACTED]/34

I. Scope of Report

I have been asked to review the scientific and medical evidence concerning the potential causal relationship between Mr. David Downs' exposure to the contaminated water at Camp Lejeune, including known toxins TCE, PCE, 1,2-dichloroethylene (DCE) and vinyl chloride, and his diagnosis of kidney cancer. I have reviewed medical and scientific literature, including the epidemiology, toxicology, detection, and diagnosis of kidney cancer, the treatment options, and generally the risk factors for getting kidney cancer. I have also reviewed the records of David Downs. All of my opinions in this report are expressed to a reasonable degree of scientific and medical certainty.

II. Personal Background/Qualifications

I am a board-certified urologic surgeon whose practice focus is on cancers of the urologic system at University of Texas Southwestern Medical Center in Dallas, Texas. I serve as professor of urology, chief of urologic oncology and holder of the Jane and John Justin Distinguished Chair in Urology. I also serve as Vice Chair of Clinical Affairs of the Department of Urology and I am Head of the Clinical Research office. I am the medical director of the urology clinic at Parkland Health and Hospital System.

I have attached my curriculum vitae to this report as evidence of my background, training and experience. As a brief introduction to my education, I graduated from the University of Texas at Austin with highest honors and earned my medical degree from Baylor College of Medicine in Houston with honors. I performed my residency training in the department of urology at the University of Texas Southwestern Medical Center and graduated in 2003. I joined the faculty at the University of Texas Southwestern Medical Center in 2003 and have been a member of the faculty in good standing since then.

I have been in practice over 20 years and have a busy clinical practice mostly treating patients with urologic cancers. I perform over 250 surgeries per year and have over 2000 patient visits per year with the majority related to urologic cancers. I have been listed among the best urologists in Dallas over multiple years.

I have a particular focus in urologic cancers, and my research involves evaluation of the epidemiology of urologic cancers, the use of urine markers and molecular markers to determine which patients are at higher risk for recurrent cancer and novel therapies for cancer. I have published over 650 peer-reviewed research articles and several book chapters detailing urologic methods and procedures. I have led or coauthored several studies evaluating epidemiology, diagnosis, screening and treatment of kidney cancer.

I am an editorial reviewer for many medical periodicals, including the *Journal of the American Medical Association*, *Journal of Clinical Oncology*, *Journal of Urology*, *European Urology*,

Cancer, Urologic Oncology, and the *British Journal of Urology International*. I am involved with the American Urologic Association Guidelines panel for evaluation of hematuria and muscle invasive bladder cancer.

I have served as the Chair of the AUA core curriculum. I am on the core committee for the international bladder cancer group. I am on the external advisory board for a large NIH trial (CISTO) and the Prevail Steering Committee. I have also served on the American Urological Association Education Council. I serve on the Scientific Advisory Board of the Bladder Cancer Advocacy Network.

I currently hold a position as co-chair of the Harold C. Simmons Comprehensive Cancer Center disease-oriented team, focused on urologic cancers. I am a member of UT Southwestern's Clinical Research Planning Group and the Tissue Bank Steering Committee and Cancer Committee. I have presented my work and lead panel discussions at medical conferences around the world and belong to numerous professional organizations, including the American Urological Association, the Society of Urologic Oncology, and the Bladder Cancer Advocacy Network.

III. Summary of Opinions

Trichloroethylene (TCE), tetrachloroethylene (PCE), benzene, 1,2-dichloroethylene (DCE) and vinyl chloride, are known to cause kidney cancer. The data supporting this opinion is based on multiple studies evaluating the causal relationship and mechanistic effect of the toxins in the water at Camp Lejeune on cell lines and animal models.

The International Agency for Research on Cancer (IARC) classified TCE as a Group 1 carcinogen.¹ The ATSDR report itself states that there is sufficient evidence for causation for TCE causing kidney cancer.² There are multiple other governmental agencies that have found a causal relationship between TCE and kidney cancer, including EPA's most recent 2024 rule making wherein EPA banned the use of TCE.³ The evidence is clear that TCE causes kidney cancer and in Mr. Downs' case, it is **more likely than not** that the TCE in the water at Camp Lejeune caused his kidney cancer. The other toxins in the water, namely PCE and VC, are also known to be carcinogenic^{1,4} and also likely contributed to the kidney cancer in lesser amounts than the TCE.

Mr. Downs developed renal cell carcinoma of the right kidney which was diagnosed in 2016. He underwent surgery to remove the kidney and then subsequently developed metastatic kidney cancer found in 2024. His non-modifiable risk factors for kidney cancer were male sex and his age. His modifiable risk factor was his exposure to carcinogens in the water at Camp Lejeune, primarily TCE. The tetrachloroethylene (PCE) and vinyl chloride also likely contributed to Mr. Downs kidney cancer, although given the association between TCE and kidney cancer, TCE was likely the primary causative agent. Mr. Downs did not have significant other risk factors like family history, obesity, and extensive smoking.

Based on his overall history, David Downs' exposure to the water at Camp Lejeune was more likely than not the cause of his kidney cancer, necessarily exceeding the standard at issue in this case, an "at least as likely as not" standard.

All my opinions are expressed to a reasonable degree of scientific/medical certainty.

IV. Records Reviewed

During this evaluation, I reviewed and relied on the documents found in the materials considered list attached to this report.

V. Methodology

I have been asked to determine whether David Downs’ exposure to the contaminated water at Camp Lejeune was “at least as likely as not” a cause of his kidney cancer. In order to provide this opinion, I conducted a search of the published scientific literature using the National Library of Medicine’s PUBMED data base and reviewed the relevant peer-reviewed articles resulting from the search as well as other relevant reports such as the “ATSDR Assessment of the Evidence for the Drinking Water Contaminants at Camp Lejeune and Specific Cancers and Other Diseases”.² Reviews of epidemiological studies involving TCE and/or PCE exposure have been conducted by EPA (2011),⁵ IARC (2014)¹ and NTP (2015).⁶ In addition, I reviewed the meta-analyses that have recently been conducted by NCI researchers,^{7,8,9} and an IARC workgroup for TCE and kidney cancer, hematopoietic cancers and liver cancer, and PCE and bladder cancer.¹ ATSDR utilized these reviews and meta-analyses to identify epidemiological studies for TCE and PCE. I also reviewed other relevant studies regarding TCE and kidney cancer risk such as Hansen 2013, Vlaanderen 2013, Christensen 2013, Silver 2014, Buhagen 2016, Moore 2010, and Raaschou-Nielsen 2003.^{10,11,12,13,14,15,16}

I examined the risk factors for kidney cancer and contemporary evidence on kidney cancer prevention and screening. I assessed this by evaluating English-language meta-analyses and/or prospective randomized controlled trials published since January 2017. Where these were unavailable, original studies and previous systematic or narrative reviews were included in the evidence synthesis.

In evaluating for causation, I reviewed the medical records for Mr. Downs and his deposition to determine his risk factors for kidney cancer as well as his diagnosis and outcomes of his disease.

To determine the impact of exposure to the water at Camp Lejeune and Mr. Downs’ kidney cancer diagnosis, I used, in part, the Bradford Hill criteria. These are scientifically valid criteria that have been used to assess causation. In 1965 Bradford Hill concisely described these criteria in evaluating aspects of an association to especially consider before deciding that the most likely interpretation of the evidence is causation. The nine criteria to consider include the following:

1. Strength of the association
2. Consistency of the observed association.
3. Specificity of the association
4. Temporality, i.e., the temporal relation of the exposure to the observed event
5. Biological gradient, i.e., one which can reveal a biological gradient, or dose response curve

6. Plausibility, i.e., if the causation we suspect is biologically plausible.
7. Coherence: should not seriously conflict with the generally known facts of the the natural history and biology of the disease
8. Experiment, i.e., occasionally it is possible to appeal to experimental, or semi-experimental, evidence. For example, because of an observed association some preventive action is taken. Does it in fact prevent?
9. Analogy, i.e., in some circumstances it would be fair to judge by analogy.¹⁷

As Bradford Hill noted when he proposed these criteria, none of his nine points to consider can bring indisputable evidence for or against the cause-and-effect hypothesis and none can be required as a sine qua non. As noted in his paper, what the criteria can do, with greater or lesser strength, is to help inform the answer to the fundamental question – (1) is there any other way of explaining the set of facts available, and (2) is there any other answer equally, or more, likely than cause effect?

In addition, Bradford Hill notes in his address that “No formal tests of significance can answer those questions. Such tests can, and should, remind us of the effects that the play of chance can create, and they will instruct us in the likely magnitude of those effects. Beyond that they contribute nothing to the 'proof' of our hypothesis.”¹⁷

While I used the Bradford Hill criteria, in part, the conclusions in this report incorporate the patient’s clinical factors as well as the weight of evidence related to carcinogens.

This methodology is consistent with how I perform this type of analysis and how reasonable physicians in my field apply the same and similar standards.

VI. Classification of Evidence

The Agency for Toxic Substances and Disease Registry (ATSDR) report identified that several classification systems have been developed to reflect the strength of the evidence for a causal relationship between an exposure and a particular health effect.² These include the IARC, EPA and NTP findings.² The ATSDR’s assessment was primarily based on the epidemiological evidence. In their Assessment of the Evidence (2017), they used the classification scheme recommended by an IOM panel that reviewed the VA’s presumptive disability decision-making process for veterans.^{2,18} “This scheme makes clear when the evidence for causality is ‘at least as likely as not’ or at the level of ‘equipoise and above.’ ATSDR adopted this scheme because of its focus on the epidemiological evidence for causation (i.e., there is no category for evidence of a statistical association). Additionally, the scheme is one that is already in use by the U.S. Department of Veterans Affairs (VA) in its decision-making concerning compensation for service-related disability compensation claims.”² The classification scheme uses four categories:

1. Sufficient: the evidence is sufficient to conclude that a causal relationship exists.
2. Equipoise and Above: the evidence is sufficient to conclude that a causal relationship is at least as likely as not, but not sufficient to conclude that a causal relationship exists.

3. Below Equipoise: the evidence is not sufficient to conclude that a causal relationship is at least as likely as not, or is not sufficient to make a scientifically informed judgment.

4. Against: the evidence suggests the lack of a causal relationship.²

If the evidence for causation was categorized as “sufficient” or as “equipoise and above,” then the IOM panel anticipated that the VA would consider a presumptive service connection based on the evidence of causation.² “If the evidence for causation was categorized as ‘below equipoise,’ then the VA might reconsider the evidence at a later date as more research becomes available.”²

This same approach was used in the Camp Lejeune Justice Act.

The statute at issue in this case states:

PUBLIC LAW 117–168—AUG. 10, 2022 136 STAT. 1803

(1) IN GENERAL. —The burden of proof shall be on the party filing the action to show one or more relationships between the water at Camp Lejeune and the harm.

(2) STANDARDS. —To meet the burden of proof described in paragraph (1), a party shall produce evidence showing that the relationship between exposure to the water at Camp Lejeune and the harm is—

- (A) sufficient to conclude that a causal relationship exists; or
- (B) sufficient to conclude that a causal relationship is at least as likely as not.

The ATSDR Assessment of the Evidence (2017) further delineated the scientific underpinning of this statutory classification by stating:

“Sufficient evidence for causation: the evidence is sufficient to conclude that a causal relationship exists. This category would be met, for example, if:

- “1. There is sufficient evidence from human studies in which chance and biases (including confounding) can be ruled out with reasonable confidence, **or**
- “2. There is less than sufficient evidence from human studies but sufficient evidence in animal studies and strong evidence that the agent acts through a relevant mechanism in humans.

“Sufficient evidence from human studies can be provided by a meta-analysis and/or by several studies considered to have high utility.

“Considerations in assessing the evidence include several of Hill’s viewpoints: (1) temporal relationship, (2) consistent positive associations (e.g., risk ratio or odds ratio greater than 1.1), (3) magnitude of the effect estimate (e.g., risk ratio, odds ratio), (4) exposure-response relationship, and (5) biological plausibility (Hill 1965).

“Equipoise and above evidence for causation: The evidence is sufficient to conclude that a causal relationship is at least as likely as not, but not sufficient to conclude that a causal relationship exists. This category would be met, for example, if:

“1. The degree of evidence from human studies is less than sufficient but there is supplementary evidence from animal studies and/or mechanistic studies that supports causality, or

“2. A meta-analysis does not provide convincing evidence (e.g., the summary risk estimate is close to the null value of 1.0, i.e., ≤ 1.1), or if the meta-analysis observes a non-monotonic exposure-response relationship) but there is at least one epidemiological study considered to be of high utility occurring after the meta-analysis has been conducted, in which an association between the exposure and increased risk of the disease of interest has been found and in which chance and biases can be ruled out with reasonable confidence.

“3. A meta-analysis has not been conducted, but there is at least one epidemiological study considered to be of high utility in which an association between the exposure and increased risk of the disease of interest has been found and in which chance and biases can be ruled out with reasonable confidence.”²

VII. Mr. Downs Time at Camp Lejeune, Medical History, and Cancer History

David Downs was born on [REDACTED] 1934. He was stationed at Camp Lejeune between February 1960 and September 1961. He was exposed to PCE, TCE and VC at Hadnot Point and Tarawa Terrace. He was diagnosed with right kidney cancer in 2016 at the age of 82 and underwent a right-hand assist Nephrectomy on 7/26/2016. His pathology demonstrated a T1a G1 clear cell renal cell carcinoma. He had no family history of kidney cancer. He testified that he had a very limited smoking history of 5 years from 1960 to 1965 and quit more than 50 years prior to his diagnosis. There are medical records stating Mr. Downs smoked for 15 years, but Mr. Downs testified this is inaccurate. Mr. Downs was not obese and only had a slightly elevated BMI during any relevant time periods. He had no hypertension.

Mr. Downs served in Korea and Vietnam and therefore was potentially exposed to agent orange, even though there is no direct evidence of any such exposure. He worked in real estate after the military and retired in the 1980s. He has a family history of lung and prostate cancer.

Prior to his diagnosis he had a history of an enlarged prostate and prostatitis. He suffered from depression. He suffered from arthritis and had a right hip replacement in 2008. He had chronic venous insufficiency. He also had lumbar spine degenerative changes. He suffered from neuropathy.

After his diagnosis and as a consequence of having his kidney removed, he developed renal functional loss and had chronic kidney disease stage 3. He was disease free for approximately 8 years but developed iron deficiency anemia in 2024. In July 2024, he was found to have metastatic renal cell carcinoma to his jejunum. He underwent a robotic assisted laparoscopic small bowel resection August 20, 2024 and was found to have a 6.3cm metastatic renal cell carcinoma with lymph node involvement. He subsequently saw Dr. Mark Stone, a medical oncology specialist, who plans to monitor his cancer.

VIII. The Levels of the Chemicals in the Water at Camp Lejeune Were at Sufficient Levels to Cause Mr. Downs' Kidney Cancer

There were several epidemiological studies designed to study the exact exposure at issue in this case. The ATSDR and Dr. Bove et al. conducted a series of studies relating to Camp Lejeune and several diseases.

The Bove 2014a study compared the cancer mortality for marines and navy personnel stationed at Camp Lejeune to those stationed at Camp Pendleton.¹⁹ This design was chosen since Camp Lejeune and Camp Pendleton are both military bases that are likely to be similar populations.¹⁹ Camp Pendleton was chosen as a comparison cohort because it was assumed that people at Camp Lejeune were exposed to toxic chemicals while people at Camp Pendleton were not during the relevant period.¹⁹ The study calculated that on average, an individual in the Camp Lejeune cohort resided at the base for approximately 18 months.¹⁹

David Downs was at Camp Lejeune for a longer amount of time, approximately 589 days over a 20-month period. During that time, he had exposures to 43 microgram/liter-months of TCE, 939 microgram/liter-months of PCE and 122 microgram/liter-months of vinyl chloride at Tarawa Terrace and 282 microgram/liter-months of TCE at Hadnot Point.

When compared to Camp Pendleton, marines at Camp Lejeune demonstrated a hazard ratio of 1.35 (0.84-2.16) of dying from kidney cancer.¹⁹ This indicates that by virtue of being stationed at Camp Lejeune (rather than Camp Pendleton) the kidney-cancer risk increased by 35%. The authors also analyzed the kidney cancer risk for different cumulative exposures to the relevant chemicals.¹⁹ So, for example, if a marine was on base for one month during a time period when the concentration of TCE was 100 micrograms per liter, his cumulative exposure would have been 100 micrograms/liter-months. If he was on base for two months during that time period, his cumulative exposure would have been 200 micrograms/liter-months.

In the Bove 2014a study, for TCE, low exposure was defined as between 1 and 3,100 micrograms/liter-months.¹⁹ Medium exposure was defined as between 3,100 and 7,700 micrograms/liter-months.¹⁹ High exposure was defined as between 7,700 and 39,745 micrograms/liter-months.¹⁹ As such, Mr. Downs met criteria for low exposure to TCE. This was associated with a HR of 1.54.¹⁹

For all of the chemicals combined (which the authors called TVOC, or total volatile organic compounds), low exposure was defined as between 1 and 4,600 micrograms/liter-months.¹⁹ Medium exposure was defined as between 4,600 and 12,250 micrograms/liter-months.¹⁹ High exposure was defined as between 12,250 and 64,016 micrograms/liter-months.¹⁹ As such, Mr. Downs met criteria for low exposure to TVOC. This was associated with a HR of 1.42.¹⁹

In the Bove 2014a study, for PCE, low exposure was defined as between 1 and 155 micrograms/liter-months.¹⁹ Medium exposure was defined as between 155 - 380 micrograms/liter-months.¹⁹ High exposure was defined as between 380-8585 micrograms/liter-months.¹⁹ As such, Mr. Downs met criteria for high exposure to PCE. This was associated with a HR of 1.59.¹⁹

The authors calculated kidney cancer risk based on these exposure categories in two ways. First, they compared Camp Pendleton marines to Camp Lejeune Marine with either “No/very low cumulative exposure” or “low to high cumulative exposure.”¹⁹ They did this to make sure that the increased kidney cancer risk was being caused by “cumulative exposures to the contaminants” rather than “due to some other factor.”¹⁹

The results indicated that the kidney cancer risk was in fact due to the chemicals. For TCE, marines with No/Very low exposure (less than or equal to 1 microgram/liter-month) did not show an increased risk of kidney cancer (HR = 0.95, CI: 0.48-1.86). But for marines with low to high cumulative exposure (more than 1 microgram/liter-month), these marines had a 50% increased risk of kidney cancer compared to Camp Pendleton (HR =1.50, CI: 0.91-2.49).¹⁹ Mr. Downs was exposed to a range of TCE in his water at Hadnot Point of 9-19 micrograms/liter monthly over a 20-month period of time and a range of TCE at Tarawa Terrace of 1.5-2.9 micrograms/liter monthly over a 20-month period of time.

For TVOC—which, again is a combination of all the chemicals—marines with No/Very low exposure (less than or equal to 1 microgram/liter-month) did not show an increased risk of kidney cancer (HR = 0.92, CI: 0.46-1.85).¹⁹ But for marines with low to high cumulative exposure (more than 1 microgram/liter-month), these marines had a 50% increased risk of kidney cancer compared to Camp Pendleton (HR =1.50, CI: 0.91-2.47).¹⁹ Mr. Downs was at an increased risk based on his monthly exposure.

The authors also calculated the risk based on exposure compared to marines with lower levels of exposure at Camp Lejeune. For TCE, marines with low, medium, and high exposures had risks of 1.54, 1.21, and 1.52, respectively.¹⁹ For TVOC, marines with low, medium, and high exposures had risks of 1.42, 1.44, and 1.54, respectively.¹⁹ The authors noted they “observed a monotonic exposure-response relationship for kidney cancer” and TVOC and a “non-monotonic exposure-response trend for PCE and kidney cancer.”¹⁹

In sum, the results of Bove 2014a provide compelling evidence that exposure to Camp Lejeune water can cause kidney cancer. It also provides evidence that low levels of exposure to the relevant chemicals can cause kidney cancer.

Mr. Downs had an estimated level of exposure to contaminants in the Camp Lejeune water, in particular TCE and TVOC, that the data demonstrates is associated with the increased risks of kidney cancer shown above. For PCE, Mr. Downs exposure was in the highest category of all exposures and this category was shown to have significant increased risks of kidney cancer.

A second important report by Bove et al (Bove 2014b) compared civilians at Camp Lejeune to Civilians at Camp Pendleton.²⁰ The population of civilians at Camp Lejeune is similar to the population of Camp Pendleton. The stated purpose of the study was to answer one question of particular importance here: “to determine whether potential exposure of employees to contaminated drinking water at Camp Lejeune increased risk of mortality from cancers and other chronic diseases.”²⁰

Because “virtually all civilian workers at Camp Lejeune resided off-base,” and thus “exposure to the contaminated drinking water would occur only when the civilians were at work at the base,” this study provides particularly compelling evidence of the effect of even intermittent exposure to the CLJ water.²⁰ The risk ratio was 1.92 (0.58-6.34),²⁰ indicating that civilians at Camp Lejeune had a 92% higher risk of kidney cancer than those at Camp Pendleton—almost a doubling of the risk. This study again demonstrates that the chemicals at Camp Lejeune were present in sufficient quantities to cause kidney cancer. In particular, Mr. Downs lived and worked on base at Camp Lejeune for the entire time he was there. He would have had more daily exposure than individuals who resided off base.

A 2018 morbidity study was conducted by ATSDR and was based on a survey of more than 200,000 marines who were stationed at Camp Lejeune between 1972-1985 and a comparator group of 50,000 randomly selected marines who were stationed at Camp Pendleton during that same period.²¹ The survey also included more than 8,000 civilians who were at Camp Lejeune and a comparator of over 7,000 civilians who were stationed at Camp Pendleton.²¹ The purpose of the study was “to evaluate whether exposure to the contaminated drinking water at Camp Lejeune was associated with medically confirmed specific diseases of interest.”²¹ As compared to the marines at Camp Pendleton, the marines at Camp Lejeune had a relative risk of kidney cancer of 1.31 (.86-1.99), corresponding to a 31% increased risk.²¹ Civilians at Camp Lejeune had a relative risk of 1.52 (.69-3.35), corresponding to an increased risk of 52%.²¹

The authors performed analyses of kidney cancer risk based on exposure, comparing marines at Camp Pendleton to marines at Camp Lejeune with varying amounts of exposure to the specific chemicals in the water. These analyses used “water distribution system models” plus “residential locations and periods of residence at Camp Lejeune” to calculate “cumulative and average residential exposure to each contaminant.”²¹

For marines at Camp Lejeune with medium exposure to TCE (defined as between 110 and 11,030 ppb-months), there was a relative risk of kidney cancer of 1.33 (.84-2.13), a 33% increased risk versus their peers at Camp Pendleton.²¹ This corresponds with the estimated exposure for Mr. Downs to TCE, when his Hadnot Point exposure is factored into the analyses.

For civilians with medium TCE/PCE exposure (defined as between 10,868 and 50,563 ppb-months of TCE exposure or between 457 and 2118 ppb-months of PCE exposure), the relative risk was 1.80 (.68-4.76), corresponding to a 80% increased risk versus civilians at Camp Pendleton.²¹ Again, this corresponds with the estimated exposure for Mr. Downs with regard to his PCE exposure.

The Bove 2024 study examined mortality by cancer type using a longer time horizon than in the previous studies. Again, the study compared personnel at Camp Lejeune to those at Camp Pendleton.²² The study looked at personnel present at Camp Lejeune between 1972 and 1985.²² The study showed that Navy/Marines personnel at Camp Lejeune had a hazard ratio of 1.21 (CI: 0.95-1.54) compared to personnel at Camp Pendleton, *i.e.*, a 21% increased risk.²² The study authors also evaluated the risk of kidney cancer based on exposure, as measured by time spent on base. For marines/navy personnel on base, the authors found an increased risk of kidney cancer even at low duration, *i.e.*, 1-2 quarters on base—RR=1.33 (.95-1.86).²²

A 2024 update by Bove et al found an adjusted hazard ratio of 1.06 (0.95, 1.18) for kidney cancer incidence in marines in Camp Lejeune relative to those who served in Camp Pendleton.²³ Civilians in this study were found to have a higher HR of 1.12.²³

The Camp Lejeune epidemiology provides the best and most compelling evidence of the levels that are sufficient to cause kidney cancer, however, other epidemiology studies in different contexts provide relevant information as well. There are a number of additional levels seen in the literature relating to TCE and the other chemicals, such as PCE, that have been found to be causally associated to kidney cancer. These have been detailed in the General Causation reports of Drs. Hatten and Bird that I have reviewed. Mr. Downs would have met many of these levels as well, including his TCE, PCE and VC exposures. These reports inform my analysis in this case and support my opinions.

I have concluded that the water at Camp Lejeune was contaminated with significant levels of trichloroethylene (TCE) and other volatile organic compounds including perchloroethylene (PCE) and vinyl chloride (VC). Based upon the extended duration of time Mr. Downs was at Camp Lejeune, the very significantly elevated levels of the chemicals in the water and the frequency with which Mr. Downs came into contact with the toxins at issue, primarily TCE, it is reasonable to conclude Mr. Downs' exposure was substantial and not de minimis. There is scientific evidence to support causality of each toxin to kidney cancer, using the at least as likely as not standard or equipoise.

One can conclude to a reasonable degree of medical and scientific certainty, based on these studies and the case history of David Downs, that exposure to carcinogens at Camp Lejeune, primarily TCE, was “more likely than not” the cause of his kidney cancer. Also, the above evidence provides an adequate and valid basis for including the contaminated water at Camp Lejeune as a cause of Mr. Downs' kidney cancer.

IX. ATSDR/Bove Data on the Levels of the Chemicals in the Water

The ATSDR stated the following in its report regarding the contaminated water at issue,

“The Hadnot Point treatment plant provided drinking water to the main portion of the base at Camp Lejeune, including most of the barracks and workplaces. Samples of the Hadnot Point distribution system were conducted by the base in May and July 1982, December 1984, and throughout 1985. During the 1982 sampling, measured levels of TCE and PCE in the distribution system of Hadnot Point were as high as 1,400 ppb and 100 ppb, respectively. Vinyl chloride and benzene were also detected in the Hadnot Point distribution system during sampling conducted on or after December 1984. The Tarawa Terrace treatment plant provided drinking water to the Tarawa Terrace housing area at the base. Samples of the Tarawa Terrace distribution system were conducted by the base in May and July 1982, and February 1985 onward. During the July 1982 distribution system sampling, PCE was measured as high as 104 ppb and reached a maximum of 215 ppb during the February 1985 sampling. The current U.S. maximum contaminant levels (MCLs) for TCE and PCE are 5 ppb. The MCLs for vinyl chloride and benzene are 2 ppb

and 5 ppb, respectively. The MCLs for TCE, vinyl chloride and benzene were in effect as of 1989, and the MCL for PCE was in effect as of 1992. Historical reconstruction modeling of the drinking water contamination indicated that TCE and PCE levels above their current MCLs were likely present in the distribution systems since the 1950s. The highly contaminated supply wells serving these systems were shut down by February 1985. For the retrospective cohort study of Marines and Navy personnel at Camp Lejeune, the relevant exposure period was 1975 – January 1985. The estimated monthly average contaminant concentrations in the Hadnot Point and Tarawa Terrace systems during this period are shown in tables in the appendix of this report. In the Hadnot Point system, the median monthly estimated average concentrations of TCE, PCE, vinyl chloride and benzene was 366 ppb, 15 ppb, 22 ppb and 5 ppb, respectively. In the Tarawa Terrace system, the median monthly estimated average concentrations of PCE, TCE and vinyl chloride were 85 ppb, 4 ppb and 6 ppb. The median number of months a marine or Navy personnel was stationed at the base was 18 months.”²

I have also reviewed the levels of the toxins in the water from the water modeling reports that were done by ATSDR and Plaintiff’s expert Morris Maslia, which showed significant and substantial levels of the toxins at issue in the water at Camp Lejeune during the time Mr. Downs was present.

X. David Downs’ Exposure

David Downs served at Camp Lejeune from 2/1960 to 9/1961 and was located both at Hadnot Point and Tarawa Terrace. Mr. Downs lived at Tarawa Terrace and worked at Hadnot Point. This resulted in exposure to both TCE at Hadnot Point and trichloroethylene (TCE), tetrachloroethylene (PCE), 1,2-dichloroethylene (DCE) and vinyl chloride at Tarawa Terrace.

According to ATSDR, a marine in training at Camp Lejeune consumes an estimated 6 liters of water per day for three days per week and 3 liters per day the rest of the week.² Under warm weather conditions, a marine may consume between 1 and 2 quarts of water per hour and shower twice a day.¹⁹ According to the ATSDR, it is likely that during training, the water supplied in the field came from the Hadnot Point water system with both measured and estimated levels of TCE and PCE substantially higher than their MCLs.²

During Mr. Downs approximately 589 days of exposure at Camp Lejeune, he had exposures to approximately 43 microgram/liter TCE, 939 microgram/liter PCE and 122 microgram/liter vinyl chloride at Tarawa Terrace. He was exposed to approximately 282 microgram/liter TCE at Hadnot Point. Mr. Downs was exposed to the following specific levels of chemicals at Tarawa Terrace:

Exposure Dates	TC E (ug/l-M)	PCE (ug/l-M)(TechFlow MP Model)	PCE (ug/l-M)(MT3D MS Model)	VC (ug/l-M)	BZ (ug/l-M)
2/16/1960-02/29/1960	1	31	44	5	0
3/1/1960-03/31/1960	2	33	46	5	0
4/1/1960-04/30/1960	2	34	48	5	0
5/1/1960-05/31/1960	2	36	50	5	0
6/1/1960-06/01/1960; 06/02/1960-06/10/1960; 06/11/1960-06/30/1960	2	37	53	5	0
7/1/1960-7/31/1960	2	39	55	5	0
8/1/1960-8/31/1960	2	40	57	6	0
9/1/1960-9/30/1960	2	42	59	6	0
10/1/1960-10/31/1960	2	44	61	6	0
11/1/1960-11/30/1960	2	46	63	6	0
12/1/1960-12/31/1960	2	47	66	6	0
1/1/1961-1/31/1961	2	49	68	6	0
2/1/1961-2/4/1961; 2/5/1961-2/12/1961; 2/13/1961-2/28/1961	2	51	70	6	0
3/1/1961-3/30/1961	2	53	72	7	0
4/1/1961-4/30/1961	2	55	73	7	0
5/1/1961-5/8/1961; 5/9/1961-5/17/1961; 5/18/1961-5/31/1961	3	57	75	7	0
6/1/1961-6/22/1961; 6/23/1961-6/30/1961	3	59	77	7	0
7/1/1961-7/31/1961	3	60	79	7	0
8/1/1961-8/31/1961	3	62	81	7	0
9/1/1961-9/27/1961	3	64	83	8	0
	43	939	1281	122	0

The above chart reflects the total amounts of concentration per month (and cumulative) Mr. Downs would have been exposed to during his time living at Tarawa Terrace. Naturally, when he was working at Hadnot Point, he would have been exposed to the water at Hadnot Point in the concentrations that existed at those times.

There are three primary routes of exposure for an individual such as Mr. Downs to a water source such as the contaminated water at Camp Lejeune: ingestion, inhalation and dermal. Each of these likely played a role for Mr. Downs based on his records and deposition testimony.

At Camp Lejeune, Mr. Downs drank water from the faucet, and while working at Camp Lejeune, he drank from water fountains at the base headquarters or along his mail route. Downs Dep. 109:18-21, 110:8-17, 110:21-112:6. He drank from the water coolers several times a day. Downs 5-8-24 Dep. 22:4-7. He would drink coke from the fountain machine or water for lunch. Downs

5-8-24 Dep. 22:21 – 23:6. He also drank coffee and tea when he was at home. Downs Dep. 112:12-14. He would have water or coffee for dinner. Downs 5-8-24 Dep. 22:3-10.

Mr. Downs worked in base headquarters at Hadnot Point and also worked in Holcomb Boulevard. 01145_DOWNS_VBA_000000312; Downs Dep. 20: 5-7. Mr. Downs performed mail and delivery service, so he would be located across the base when he delivered mail once a week for four hours. 01145_DOWNS_VBA_000000312; Downs Dep. 20: 8-10, 68:13-19. He was on duty five days a week and, at least once a month, on weekends. Downs Dep. 97:8-13. When he was not on duty, he stayed at Tarawa Terrace where he lived with his wife. Downs Dep. 97:14-98:1, 98:17-99:2; 01145_DOWNS_VBA_0000001528; 01145_DOWNS_VBA_0000001530; 01145_DOWNS_VBA_0000001532.

He took a warm shower most days, once a day, for 15 minutes. Downs Dep. 115:2 -116:15.

Mr. Downs had a substantial exposure to the chemicals TCE, PCE and Vinyl Chloride. He was exposed to them on a daily basis for almost 600 days. Because Mr. Downs was drinking the toxic water, inhaling the toxic water and exposed to the toxic water on his skin, Mr. Downs was constantly exposed to these toxins during those 600 days. This is different, for example, from an occupational exposure wherein the person is only exposed during the day when they are working. When Mr. Downs would go home and spend time at his house, he was also consistently and substantially exposed to these toxins. The substantial nature of the exposure is made clear by the duration of the exposure (589 days), the amount of the exposure (discussed below), the frequency of the exposure (consistently throughout the day) and the intensity of the exposure (the levels of the toxins exposed to and the nature of the exposure through all three routes).

I was able to determine that Mr. Downs had substantial exposure based upon the records at issue, Mr. Downs's deposition and the ATSDR water modeling reports. However, I additionally reviewed exposure charts provided to me from Plaintiff's expert Kelly Reynolds. Dr. Reynolds put together charts that detail a reasonable estimated dose of ingestion exposure for Mr. Downs. These charts support my opinion that Mr. Downs sustained a substantial exposure that was causally related to his kidney cancer and is consistent with them. For example, Dr. Reynolds charts indicate that Mr. Downs would have likely ingested the following amounts of the toxins at issue in this case.

		Chart 1: 1L at each location	Chart 2: ATSDR RME with proportional work/residence exposures	Chart 3: ATSDR CTE with proportional work/residence exposures	Chart 4: Deposition Estimates with proportional work/residence exposures
	Cumulative ug/l-M	Cumulative consumption (total ug= days*concentration per L)	Cumulative consumption (total ug= days*concentration per ATSDR exposure assumptions)	Cumulative consumption (total ug= days*concentration per ATSDR exposure assumptions)	Cumulative consumption (total ug= days*concentration per deposition exposure assumptions)
Hadnot Point					
TCE	282	7,866	8,151	3,234	8,029
PCE	-	-	-	-	-
VC	-	-	-	-	-
BZ	-	-	-	-	-
Terawa Terrace					
TCE	43	1,240	2,635	1,046	2,596
PCE (ug/l-M)(TechFlowMP Model)	939	27,838	59,157	23,475	58,278
PCE (ug/l-M)(MT3DMS Model)	1,281	37,980	80,689	32,020	79,491
VC	122	3,586	7,615	3,022	7,502
BZ	-	-	-	-	-
Totals HP & TT					
TCE	325	9,106	10,786	4,280	10,626
PCE (ug/l-M)(TechFlo	939	27,838	59,157	23,475	58,278

wMP Model)					
PCE (ug/l-M)(MT3DM S Model)	1,281	37,980	80,689	32,020	79,491
VC	122	3,586	7,615	3,022	7,502
BZ	-	-	-	-	-

Ingestion of TCE in the range of 4,200 ppb to 10,700 ppb is clearly a substantial exposure. It would be substantial for any person in any circumstance. The same is true for Mr. Downs’ calculated ingestion of PCE. For example, the summary ranges for Mr. Downs ingestion of PCE are 23,400 to 59,100 ppb. This is substantial by any metric. The compounding part for Mr. Downs, and all individuals exposed at Camp Lejeune, is that this very significant and substantial ingestion relates to three different known carcinogens and three different pathways of exposure. The fact that there are multiple chemicals all increasing the risk for kidney cancer, makes the risk that much more significant. Further, these numbers do not account for inhalation and dermal exposure, which would necessarily make the actual dose of these chemicals higher.

XI. Kidney Cancer and the Cause of Kidney Cancer

Kidney cancer represents the 7th most commonly diagnosed malignancy overall in 2023.²⁴ While a majority of kidney cancers are localized and therefore have the potential for cure through minimally invasive surgical approaches, a steady approximate 20% of cases present as metastatic, which most often proves fatal.²⁵ A recent review of the epidemiology of renal cell carcinoma in the top urology journal evaluated the main risk factors for kidney cancer (KC).²⁶ The incidence increases steadily with age, with a peak age at diagnosis in the USA of 64 years.²⁶ There is a higher risk among men with an incidence that is approximately twofold higher for men than for women.²⁶ In the United States comparison of KC incidence by ethnicity revealed that KC diagnosis among Black individuals peaked at ASR 17.0/100 000, compared to 13.2/100 000 for White individuals.²⁶ Previously established risk factors for development of KC, including excess body weight, history of hypertension, and smoking, were thought to contribute to up to 50% of KC pathogenesis.²⁶ While smoking is a risk factor, the Prostate, Lung, Colorectal, and Ovarian (PLCO) study which was a screening study including 154,900 participants from the general population aged 55 through 74 year, found that the incidence of kidney cancer in men over the age of 70 was 0.61/1,000 person years for men overall and 0.6/1000 person years for those who smoked for less than 30 years and quit more than 15 years prior to diagnosis.²⁷ It is important to take any smoking history listed for Mr. Downs in the context of this study and other similar studies.

Furthermore, it has been consistently proven that several important chemicals are associated with KC development, including perfluorinated chemicals and aristolochic acid.²⁸ Furthermore, research has shown that microplastic or nanoplastic particle exposure causes toxicologic damage to the kidneys via oxidative stress and inflammation.²⁹ Trichloroethylene (TCE) is a chlorinated solvent frequently used in industry as degreasers for metal parts, among other industrial applications.¹¹ In 2012 the IARC classified TCE as carcinogenic to humans because of known

strong associations with the development of non-Hodgkin's lymphoma, multiple myeloma, and KC.¹ Owing to its lipophilic nature, TCE rapidly accumulates in the kidney, where it can be metabolized to cysteine-S-conjugates, the metabolites thought to be responsible for the carcinogenic effects. Prolonged exposure to TCE is associated with a significant increase in the risk of KC development (odds ratio 1.78, 95% CI 1.05–3.03) and mortality.³⁰ A recent epigenome-wide association study in TCE-exposed workers highlighted elevated genome-wide DNA methylation variation and differential expression of genes involved in cell matrix adhesion and interferon subtypes, known to be related to cancer development.³¹

XII. TCE and Kidney Cancer Outside of Camp Lejeune

Strong evidence exists outside of Camp Lejeune for the carcinogenesis of TCE with respect to kidney cancer.^{1,2,6,7,8,10,15,16,32,33,34} Epidemiologic research has centered upon workers most heavily exposed through occupational degreasing of metals and other materials. One exemplary case-control study, Charbotel et al., evaluated the effect of TCE on kidney cancer in 86 affected cases and 316 controls in a geography with high occupational exposure to cutting fluids.³² The authors utilized a job-task exposure matrix (JTEM) to establish cumulative exposure to TCE.³² A significant relationship was found with an OR 2.16 (95% CI, 1.02–4.60) when accounting for tobacco smoking and BMI.³² The study strengthened the argument for a causal association by also demonstrating a significant dose-response relationship ($p=0.04$).³²

The evidence provided by individual studies is strengthened by several meta-analyses and systematic reviews on the topic. Scott et al. in conjunction with the Environmental Protection Agency (EPA) carried out a systematic review on the effect of TCE upon kidney cancer.⁹ This review comprised 15 cohort and case-control studies specific to kidney cancer.⁹ The reported summary relative risk (RR) was 1.27 (95% CI 1.13-1.43) for overall TCE exposure and kidney cancer risk.⁹ Of note, a highest risk group was compiled from all studies with a preference toward quantification of cumulative exposure, though often only duration of exposure was reported. The RR for the highest exposure group was 1.58 (95% CI: 1.28-1.96).⁹ Lack of sensitivity to alternative risk estimate selections and removal of individual studies added to the robust nature of this study. Although tobacco exposure was not quantified in all included studies, the RR for lung cancer among those exposed was not significantly increased.⁹ Karami et al. performed a meta-analysis with similar findings.⁸ Though composed largely by studies overlapping with those evaluated by Scott et al., several new publications were included.⁸

Meta-analyses that have been conducted have observed an elevated summary RR in the 1.3-1.4 range and that higher cumulative exposures increased the risk of kidney cancer.^{2,9,33} The meta-analyses conducted by Scott and Jinot 2011 and Karami et al. 2012 reported no between-study heterogeneity or evidence of publication bias.^{2,9,33} Scott and Jinot 2011 concluded that confounding by smoking and other risk factors would have a minimal impact on the kidney cancer meta-analysis results.^{2,9} NTP (2015) in its Monograph on Trichloroethylene conclude that the increased risks found in the majority of epidemiological studies were unlikely to be explained by selection biases.^{2,6} IARC (2014) and EPA (2011) concluded that there is sufficient human evidence that TCE causes kidney cancer.^{1,2,5} The NTP concluded: "Epidemiological studies have demonstrated a causal relationship between trichloroethylene exposure and kidney cancer based on consistent evidence of increased risk across studies with different study designs, in different

geographical areas, and in different settings; evidence of increasing cancer risk with increasing level or duration of exposure; and meta-analyses showing statistically significantly increased cancer risk across studies.”^{2,6} NTP (2015) further noted that the increased risk of kidney cancer was found among individuals with the higher levels of exposure and in studies with better assessments of exposure and disease.^{2,6}

Several other studies have investigated the relationship between TCE and kidney cancer with varying results. Hansen et al. 2013 had a good study design due to its large pool cohort, evaluation of cancer incidence, documented TCE exposure, minimal confounding, and an analysis of exposure-response trend.² This study observed an elevated risk among those with the highest levels of urine TCA (RR=2.04; 95% CI: 0.81, 5.17).^{2,10} The study was limited because exposure levels among most workers were low.^{2,10} The study also relied on only a few urine TCA measurements to assess exposures and there were a small number of exposed cases in the exposure-response analysis.^{2,10} Two other studies did not observe an increased risk for kidney cancer.^{2,11,12} However, Vlaanderen et al. 2013 had severe limitations because it only had a small population who received high exposure and used a generic JEM which was likely to introduce considerable exposure misclassification.^{2,11} The Christensen et al. study was also severely limited due to few exposed cases.^{2,12} Four other studies including Silver et al. 2014, Buhagen et al. 2016, and the two Camp Lejeune studies, Bove et al. 2014 a, b, observed increased risks of kidney cancer.^{2,13,14,19,20}

One study of particular importance is Moore et al. 2010 because it not only evaluates exposure-response trends but also the interaction between TCE exposure and genotypes for the GSTT1 and renal-CCBL1 enzymes.^{2,15} These enzymes are highly active in the kidney and involved in the bioactivation of TCE (via GSH-conjugation pathway).^{2,15} NTP (2015) and ATSDR (2017) both considered Moore et al. 2010 of high utility.^{2,6} Moore et al. 2010 found an exposure-response trends for TCE exposure and kidney cancer.^{2,15} The study also found that those exposed to TCE with at least one intact GSTT1 allele had elevated risks for kidney cancer, but those with a functionally inactive GSTT1 enzyme (i.e., with two deleted alleles, the null genotype) had **no elevated risk**.^{2,15} Based on the interaction between TCE exposure and minor alleles for the renal-CCBL1 enzyme, the study supported the findings for the GSTT1 enzyme and the hypothesized mechanism for TCE-induced kidney cancer.^{2,15} Moore et al. therefore provides strong evidence for causality.^{2,15}

There is also body of literature identifying the likely mode of action for trichloroethylene-induced kidney cancer based on animal studies and mechanistic information. The available data provides support for a mutagenic and cytotoxic mode of action mediated by GSH-conjugation-derived metabolites.² “There is experimental evidence that GSH metabolites (particularly DCVC) are genotoxic and nephrotoxic and are both formed in and delivered to the kidney following exposure to trichloroethylene.”^{2,6} Exposure to TCE via inhalation or stomach tube has been observed to cause kidney cancer in rats.^{2,5}

Moore et al. 2010 and Raaschou-Nielsen 2003 found increased risk of kidney cancer with increasing duration of exposure to TCE.^{2,15,16} The Moore et al. 2010 study also suggested that an elevated risk could occur with a short duration of exposure (OR=1.22, 95% CI: 0.48, 3.12 for <1,080 hours exposure duration).^{2,15} Scott and Jinot 2011 and Kelsh et al. 2010 found an

increased risk with higher cumulative exposures.^{2,9,34} Bove et al. 2014a observed a monotonic trend for kidney cancer and cumulative exposure for TVOC at Camp Lejeune but not for TCE or the other contaminants when analyzed separately.^{2,19}

XIII. TCE Mechanism of Injury

Trichloroethylene (TCE) is a volatile organic compound that was widely used in industrial settings. Multiple lines of evidence support a link between TCE exposure and cancer, particularly kidney cancer.¹ TCE produces other toxic effects including neurotoxicity, immunotoxicity, developmental cardiac toxicity, kidney toxicity, liver toxicity, and male reproductive toxicity.³⁵

One mechanism of toxicity of TCE is through alterations of DNA methylation.³⁶ This commonly studied epigenetic mark involves the addition of a methyl group to cytosine that is adjacent to a guanine (a CpG) site. DNA methylation modulates transcription by altering accessibility of proteins to DNA and it is a key regulator of a number of important processes such as aging, disease, and development.³⁷ DNA methylation has also become increasingly recognized as a mediator of toxicity of environmental chemical exposures.³⁶

TCE induces epigenetic aberrations in various studies in cell lines and animal models.³¹ Human exposure to trichloroethylene is associated with increased variability of blood DNA methylation that is enriched in genes and pathways related to autoimmune disease and cancer.³¹ To evaluate associations between TCE exposure and DNA methylation in humans, Phillips et al. conducted an epigenome-wide association study (EWAS) in TCE exposed workers using the HumanMethylation450 BeadChip.³¹ They investigated differences in mean DNA methylation and differences in variability of DNA methylation between 73 control (< 0.005 ppm TCE), 30 lower exposed (< 10 ppm TCE), and 37 higher exposed (greater than or equal to 10 ppm TCE) subjects' white blood cells.³¹ They found that TCE exposure increased methylation variation globally (Kruskal-Wallis p-value = 3.75e-3) and in 25 CpG sites at a genome-wide significance level (Bonferroni p-value < 0.05).³¹ Human exposure to TCE "was associated with epigenetic alterations in genes involved in cell-matrix adhesions and interferon subtype expression, which are important in the development of autoimmune diseases; and in genes related to cancer development."³¹ These results suggest that DNA methylation may play a role in the pathogenesis of TCE exposure-related diseases and that TCE exposure may contribute to epigenetic drift.

The following is a table from ATSDR detailing some of the studies referenced above and that are relevant to this overall analysis:

Kidney Cancer

Reference, type of cancer data, total # of subjects, follow-up period	Exposure* (exposure assessment)	# exposed cases	RR (SIR, SMR, OR) & 95% CI	Exposure Duration information	Exposure intensity/cumulative exposure information
Kelsh 2010 meta-analysis	TCE	Not reported	sRR=1.42 (1.13, 1.77) – 23 studies; *More likely exposed*: sRR=1.34 (1.07, 1.67) – 8 cohort studies	"Shortest" duration: RR=1.50 (0.96, 2.36) – 7 studies "Longest" duration: RR=1.24 (0.69, 2.23) – 7 studies	"Low" cumulative exposure: RR=1.29 (0.68, 2.47) – 3 studies "High" cumulative exposure: RR=1.39 (0.75, 2.59) – 3 studies
Scott 2011, EPA meta-analysis	TCE	Not reported	sRR=1.27 (1.13, 1.43) – 15 studies; (11 incidence (I), 4 mortality M)		High cumulative exposure, summary RR=1.64 (1.31, 2.04) – 10 studies
Karami 2012 meta-analysis	TCE	478 (?)**	sRR=1.32 (1.17, 1.50) – 18 studies (9 cohort – 4 I, 5 M; 9 case-control – 8 I, 1 M)		–
Cohort Studies:					
Anttila 1995* ^o Incidence 849 1967-1992	PCE (blood PCE)	2	SIR=1.82 (0.22, 6.56)		
Raaschou-Nielsen 2003* Incidence 40,049 1964-1997	TCE (job title, plant air monitoring & Urine TCA data)	76		Duration of employment (yr) (SIR) # cases Men <1: 0.8 (0.5, 1.4) 14 1-4.9: 1.2 (0.8, 1.7) 25 ≥5: 1.6 (1.1, 2.3) 29 Women 1.1 (0.1, 3.8) 2 1.2 (0.2, 3.4) 3 1.5 (0.3, 4.3) 3	
Zhao 2005 ^d Incidence 5,049 1988-2000 NTP: High Utility	Aerospace TCE (JEM)	6 4			Cumulative Exposure (RR) Med: 1.9 (0.6, 5.2) High: 4.9 (1.2, 19.6)
Radican 2008* Mortality 10,730 men ^d 1953-2000 NTP: Moderate Utility	Aircraft maintenance TCE (walk-through surveys, interviews, job tasks, air monitoring data)	16		Cumulative Exposure (unit-yr) HR 0-5: 1.9 (0.6, 6.0) – 10 cases 5-25: 0.3 (0.0, 2.8) – 1 case >25: 1.2 (0.3, 4.3) – 5 cases	Exposure intensity (HR) # cases Low, intermittent: 1.6 (0.5, 4.8) 15 Low, continuous: 1.8 (0.6, 5.6) 11 Peak, infrequent: 1.0 (0.2, 5.7) 2 Peak, frequent: 1.1 (0.3, 4.0) 6

Reference, type of cancer data, total # of subjects, follow-up period	Exposure* (exposure assessment)	# exposed cases	RR (SIR, SMR, OR) & 95% CI	Exposure Duration information	Exposure intensity/cumulative exposure information
Lipworth 2011*** Mortality 5,830 (PCE) 1960-2008	Aircraft Manufacturing PCE (JEM)	13	Any exposure: SMR=0.80 (0.43, 1.37)	Duration of exposure (yr) (RR) # cases TCE <1: 0.84 (0.48, 1.47) 18 1-4: 1.10 (0.59, 2.04) 14 ≥5: 1.02 (0.55, 1.90) 15	PCE 1.26 (0.65, 2.45) 11 1.00 (0.50, 2.00) 10 1.02 (0.53, 1.99) 12
Hansen 2013 Incidence 5,553 Finland: 1967-2004 Sweden: 1958-2003 Denmark: 1968-2008 NTP: Moderate Utility	TCE (urine TCA)	32 19	SIR=1.01 (0.70, 1.42) 20 yr lag: SIR=1.11 (0.67, 1.73)		Urine TCA (mg/L): (RR) <5: referent 5-25: 1.1 (0.5, 2.7) – 11 cases 25-50: 0.8 (0.2, 3.0) – 3 cases ≥50: 2.0 (0.8, 5.2) – 9 cases
Silver 2014 Mortality 34,494 1969-2009	Microelectronics firm TCE (JEM) PCE (JEM) •	56			Cumulative exposure (5 exposure-yr) HR=1.24 (0.87, 1.77) HR=0.15 (0.01, 4.04)
Buhagen 2016 Incidence 997 males 1960-2010	Train maintenance TCE (union employment list)	13	SIR=1.7 (1.0, 3.0)		
Case-Control Studies:					
Pesch 2000* Incidence 935 cases 4,298 controls	Questionnaire and JTEM TCE PCE	M F 68 11 59 7 22 5 44 8 39 6 15 3		Cumulative exposure (percentiles) Odds ratios Males: 30th: 1.3 (1.0, 1.8) 60th: 1.1 (0.8, 1.5) 90th: 1.3 (0.8, 2.1) Females: 1.3 (0.7, 2.6) 0.8 (0.4, 1.9) 1.8 (0.6, 5.0) 30th: 1.2 (0.9, 1.7) 60th: 1.1 (0.7, 1.5) 90th: 1.3 (0.7, 2.3)	2.2 (0.9, 5.2) 1.5 (0.6, 3.8) 2.0 (0.5, 7.8)
Charbotel 2006* Incidence 86 cases 316 controls NTP: High Utility	TCE (occupational questionnaire & JTEM)	37	Ever exposed, OR=1.64 (0.95, 2.84)		Cumulative dose: (ORs) Low: 1.6 (0.8, 3.5) – 12 cases Med: 1.2 (0.5, 2.8) – 9 cases High: 2.2 (1.0, 4.6) – 16 cases

Reference, type of cancer data, total # of subjects, follow-up period	Exposure* (exposure assessment)	# exposed cases	RR (SIR, SMR, OR) & 95% CI	Exposure Duration information	Exposure intensity/cumulative exposure information
Moore 2010** Incidence 1,097 cases 1,476 controls NTP: High Utility	TCE (occupational questionnaire & JTEM)	29	High confidence, any exposure: OR=2.05 (1.13, 3.73)	<1,080 hours, OR=1.22 (0.48, 3.12) – 9 cases; ≥1,080 hours, OR=2.86 (1.31, 6.23) – 20 cases	<1.6 ppm-years: OR=1.77 (0.64, 4.80) – 9 cases; ≥1.6 ppm-years: OR=2.23 (1.07, 4.64) – 20 cases <0.076 ppm intensity: OR=1.73 (0.75, 4.02) – 13 cases; ≥0.076 ppm intensity: OR=2.41 (1.05, 5.56) – 16 cases
Vlaanderen 2013 Incidence 76,130 cases 380,650 controls 1961-2005	TCE (JEM) PCE (JEM) Benzene (JEM)	1,217 1,556 1,372 375 333 314 1359 1435 1560	Tertiles of cumulative exposure: 1. HR=1.01 (0.95, 1.07) 2. HR=1.02 (0.97, 1.08) 3. HR=1.00 (0.95, 1.07) 1. HR=1.11 (0.99, 1.24) 2. HR=0.96 (0.86, 1.08) 3. HR=0.94 (0.83, 1.06) 1. HR=1.00 (0.94, 1.06) 2. HR=1.00 (0.95, 1.06) 3. HR=1.06 (1.00, 1.12)		>90th percentile cumulative exposure: (HRs) TCE: 0.86 (0.75, 0.98) 251 cases PCE: 0.81 (0.65, 1.01) 88 cases >90th percentile, intensity x freq. exp. TCE: 1.00 (0.90, 1.30) 387 cases PCE: 1.01 (0.82, 1.25) 103 cases
Christensen 2013* Incidence 177 cases 533 controls	TCE PCE	5 2 2 2	Any exposure: OR=1.0 (0.3, 2.9) "substantial": OR=0.7 (0.1, 3.2) Any exposure: OR=1.6 (0.3, 9.4) "substantial": OR=3.1 (0.4, 24)	–	–
Dry Cleaning Workers: Studies					
Blair 2003 Mortality 5,369 1948-1993	Dry Cleaning	8	SMR=1.0 (0.4, 2.0)		Exposure intensity # cases Little/no: SMR=0.3 (0.0, 1.6) 1 Med/high: SMR=1.5 (0.6, 3.1) 7
Lynge 2006 Incidence 158 cases 785 controls 1970-2001	Dry Cleaning	29	RR=0.67 (0.43, 1.05)		

XIV. Bradford Hill Analysis of Causation for David Downs

To make this analysis more robust, I have looked at the Bradford Hill factors to make a determination as to what weight to give the causal association between the water at Camp Lejeune and Mr. Downs’ kidney cancer.¹⁷

An association between TCE exposure and kidney cancer has been identified in multiple studies involving occupational exposures and Camp Lejeune water system exposures. The following discussion evaluates the evidence in order to determine whether it is “more likely than not” that this demonstrated association is the cause of Mr. Downs’ kidney cancer.

Strength of Association: Many studies demonstrate elevated measures of association between TCE and kidney cancer.^{14,15,16,19,21,32,38,39,40,41,42,43,44,45,46,47} These range up to an OR of 10.8.⁴⁵ Similarly, multiple meta-analyses have identified an elevated measures of association ranging from RR 1.27 to RR 1.42, providing a realistic estimate of the true population risk of kidney cancer following exposure to TCE.^{9,33,34} This body of literature provides strong evidence that exposure to TCE is a cause of kidney cancer given the demonstrated strength of association in the epidemiologic literature.

Mr. Downs was stationed at Camp Lejeune between February 1960 and September 1961 and was exposed to PCE, TCE and VC at Hadnot Point and Tarawa Terrace. He had no other potential causes of kidney cancer that one would consider as likely as this environmental exposure, such as a significant family history or significant smoking history.

Consistency: The literature is comprehensive and consistent in demonstrating that TCE is a cause of kidney cancer among other cancers. There are both individual studies of largely inhalational occupational exposures^{11,14,15,16,32,38,39,40,41,42,43,44,45,46,47} and water system contamination^{19,20,21,30} that demonstrate a consistent association in different populations between TCE and kidney cancer. These also identify different routes of exposure which all result in exposure to TCE being associated with kidney cancer. This association is also consistent whether analyzing kidney cancer diagnosis^{11,14,15,16,21,32,41,42,43,45,47} and kidney cancer mortality.^{19,20,38,39,40,42,44,46}

Furthermore, cohort studies^{11,14,16,19,20,38,39,40,42,44,46,47} and case-control studies^{15,21,32,41,43,45} reach nearly identical conclusions.

There are similar conclusions in meta-analyses (Hansen 2013; Karami 2012; Kelsh 2010; Scott 2011).^{9,10,33,34} Since Mr. Downs was exposed to TCE and the other chemicals through a variety of routes (ingestion, inhalation and dermal) these studies all support this as a cause of his kidney cancer.

Exposure-Response: There are studies that support a monotonic exposure-response for increased intensity of TCE exposure with increased kidney cancer.^{15,21,32,34,45,47} Even subjects of low exposure were at higher risk for developing kidney cancer.

Temporality: Multiple studies utilized prolonged lags to ensure that exposure to TCE occurred sufficiently far before the identification of a kidney cancer case to be a cause of that outcome of interest.^{10,11,15,16,19,20,30,40,43,44,47,48} Other studies reported prolonged latency periods or follow up times.^{42,45,49} Such study designs provide evidence for causation that accounts for the principle of **temporality**, that the exposure of interest must occur sufficiently prior to the outcome of interest to be a possible cause.

Mr. Downs was diagnosed with kidney cancer in 2016 which is approximately 50 years after his exposure. This would be consistent with a sufficient lag time to develop cancer from a carcinogenic exposure.

Biological Plausibility: Exposure to TCE follows a clear biologically plausible pathway for causation on kidney cancer. As discussed previously, TCE induces epigenetic aberrations in various studies in cell lines and animal models.^{50,51,52,53} This provides clear support for a **biologically plausible** pathway from TCE exposure to development of kidney cancer.

Analogy: Trichloroethylene (TCE) is a volatile organic compound that was widely used in industrial settings. Multiple lines of evidence support a link between TCE exposure and cancer, particularly kidney cancer, which led the International Agency for Research on Cancer (IARC) to classify TCE as a Group 1 carcinogen.¹ TCE also produces other toxic effects including neurotoxicity, immunotoxicity, developmental cardiac toxicity, kidney toxicity, liver toxicity, and male reproductive toxicity.³⁵ There are other organic compounds, such as PCE, that are also carcinogenic in similar ways.¹

Mr. Downs was exposed to TCE as well as PCE and vinyl chloride. TCE is so clearly related to kidney cancer that it is likely the primary causal agent for Mr. Downs. However, the other chemicals he was exposed to likely contributed to his kidney cancer either additively or synergistically.

Experiment: There is no human **experimental** evidence of causation involving TCE and kidney cancer because it is unethical. However, there is as noted a vast amount of evidence from individual studies and meta-analyses that support the association of TCE and kidney cancer as well as data from military personnel and civilians stationed at Camp Lejeune when compared to those who served in camp Pendleton.^{19,20,21,22,23}

Specificity: There is evidence that TCE exposure is a cause of many cancers but not all cancers. There is strong evidence noted above that it is a cause of kidney cancer which is the cancer that Mr. Downs developed.

Coherence: The human, animal, and mechanistic literature provides a robust and **coherent** body of evidence for TCE exposure as a cause of kidney cancer. There is no substantial contrary data suggesting an alternative explanation for the observed measures of association. Similarly, Mr. Downs had clear exposure to TCE and other chemicals at Camp Lejeune and there is a lack of other strong risk factors for his kidney cancer.

XV. Differential Diagnosis of Etiology

In determining the potential causes of the kidney cancer Mr. Downs developed, I weighed the possible risk factors for the disease. The main risk factors he had for kidney cancer were his age and male sex, but he did not have other significant risk factors, like family history, obesity, and extensive smoking. Mr. Downs stated in his deposition he smoked for approximately 5 years during a time almost 50 years before his diagnosis. Some of his medical records say the smoking was on and off for 15 years. However, under either scenario, it was not likely causally related to his kidney cancer. Such a smoking history, approximately 50 years prior to his diagnosis, is very unlikely to be related to the development of his kidney cancer. Many studies indicate that smoking cessation for a period of time significantly reduces the likelihood of causing cancers.^{54,55}

His main carcinogenic exposure was to carcinogens, such as TCE, at Camp Lejeune. The evidence that TCE is a causative agent for kidney cancer is conclusive. His exposure to the other chemicals such as PCE and VC also likely contributed to his kidney cancer, either additively or synergistically. These chemicals are also known carcinogens. Mr. Downs' exposure to PCE was labeled by Bove and ATSDR to be in the highest exposure categories.

Mr. Downs served in Vietnam and may have been exposed to agent orange. However, there are only a few studies exploring a potential association between Agent Orange and renal cancer, as well as a low number of exposed cases in these studies with only 3 of 8 studies having more than 30 exposures. No studies were able to reach statistical significance in determining a relationship between Agent Orange exposure and renal cancers.⁵⁶

Table 8
Incidence of renal cancer in those exposed to Agent Orange [4]

Incidence					
Population	Malignancy	Exposed cases	Agent Orange chemical of interest	Relative risk (95% CI)	Study
Korean Vietnam Veterans	Renal cell carcinoma	181	All	0.7 (0.6–1.0)	Yi and Ohrr [30]
Korean Vietnam Veterans	Renal pelvis cancer	23	All	1.1 (0.4–2.5)	Yi and Ohrr [30]
Australian Vietnam Veterans	Renal cancers	125	All	1.0 (0.8–1.2)	ADVA [18]
Australian Conscripted Army National Service	Renal cancers	19	All	0.7 (0.4–1.0)	ADVA [36]
US Army Vietnam veterans, deployed	Renal cancers	55	All	0.9 (0.5–1.5)	Breslin et al. [28]
US Marines Vietnam veterans, deployed	Renal cancers	13	All	0.9 (0.5–1.5)	Breslin et al. [28]
Massachusetts Vietnam veterans diagnosed 1972–1983	Renal cancers	9	All	1.8 (1.0–3.5)	Kogan and Clapp [47]
Michigan Vietnam-era veterans	Renal cancers	21	All	1.4 (0.9–2.2)	Visintainer et al. [48]

Added to this is the lack of any actual evidence that Mr. Downs was exposed to agent orange. Therefore, any potential exposure to agent orange will be given little weight in this analyses.

The fact that Mr. Downs was diagnosed with kidney cancer approximately 50 years after his exposure is consistent with, unfortunately, how the toxins in the water at Camp Lejeune are known to effect humans. There are studies that account for significant lag times. As discussed above, this is consistent with the science and the medicine relating to these chemicals and kidney cancer.

Longer latency periods are consistent with the science because mutated carcinogens cause mutations in cells for the rest of a person's life. Human cancers develop due to the accumulation of genetic and epigenetic alterations. Genetic alterations are induced by aging, mutagenic chemicals, ultraviolet light, and other factors; whereas, epigenetic alterations are mainly by aging and chronic inflammation. The accumulation and patterns of alterations in normal cells reflect our past exposure levels and life history. Most accumulated alterations are considered as passengers, but their accumulation is correlated with cancer drivers.⁵⁷ Studies have shown that accumulation of genetic alteration levels are correlated with cancer risk.⁵⁷ Both genetic and epigenetic alterations are now known to be present not only in cancer cells but also in normal cells long before cancer develops.⁵⁷

“Cancer develops through a process of somatic evolution.”⁵⁸ Sequencing data from a single biopsy represents a snapshot of this process and can reveal the timing of specific genomic aberrations and the changing influence of mutational processes.⁵⁸ A study using whole-genome sequencing analysis of 2,658 cancers as part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) reconstructed the life history and evolution of mutational processes and driver mutation sequences of 38 types of cancer.⁵⁸ “Early oncogenesis is characterized by mutations in a constrained set of driver genes, and specific copy number gains, such as trisomy 7 in glioblastoma and isochromosome 17q in medulloblastoma.”⁵⁸ The study found that in 40% of the samples, the mutational spectrum changed significantly throughout tumor evolution.⁵⁸ At the later stages of tumor evolution there was a nearly fourfold diversification of driver genes and increased genomic instability.⁵⁸ In mitotic crisis, copy number alterations often occurred which led to simultaneous gains of chromosomal segments.⁵⁸ The timing analyses in the study suggested that “driver mutations often precede diagnosis by many years, if not decades.”⁵⁸ As such cancer risk related to carcinogen exposure such as TCE would only increase with time,

including at times fifty years out, similar to Mr. Downs. It makes little sense to claim that a cancer occurred too long after a mutagenic exposure to be causally connected to that exposure because the cells continue to mutate for life.

Mr. Downs had a BMI that ranged from 24-28 in the time period before and after his kidney cancer diagnosis and nephrectomy. This is such a small potential risk factor that it is given little weight.

I have taken into account all of the known risk factors that are scientifically valid and determined that there are none of them that are as likely as the water at Camp Lejeune to have caused Mr. Downs' kidney cancer.

As such I conclude to a reasonable degree of medical and scientific certainty that Mr. Downs' exposure to the water at Camp Lejeune was more likely than not the cause of his kidney cancer.

XVI. Defendant's Supplemental Interrogatory Responses

To even further analyze the facts of this case and rule out all potential non-Camp Lejeune related causes of Mr. Downs renal cell carcinoma, I reviewed Defendant's supplemental responses to Interrogatories sent to them by the Plaintiffs. In those responses, Defendant has stated: "There may be alternative causes or contributing factors for the Plaintiff's alleged illnesses and conditions." The following are the contentions made in the supplemental response. All of these contentions are not correct based on the facts of this case for the following reasons:

1. Defendant states: "Plaintiff was first diagnosed with kidney cancer just before his 82nd birthday and was also of advanced age when he was diagnosed with chronic kidney disease."
 - a. This is an incorrect contention since age is a very minor factor in risk for developing kidney cancer. Evaluating SEER statistics on age-adjusted incidence rate for kidney cancer in men, the rate of kidney cancer is 102.8 per 100,000 in men over age 75 and 92.9 per 100,000 in men ages 65-74.⁵⁹ This difference in incidence of 10 men per 100,000 is clinically insignificant.⁵⁹

**Kidney and Renal Pelvis
SEER 5-Year Age-Adjusted Incidence Rates, 2017-2021**

By Age, Male, All Races / Ethnicities, All Stages



Graph Data Table

Age	Rate per 100,000	Lower 95% C.I.	Upper 95% C.I.
Ages 65-74	92.9	91.8	93.9
Ages 75+	102.8	101.4	104.3

2. Defendant states: “A personal history of smoking cigarettes, being overweight or obese, diabetes or prediabetes, and exposure to secondhand smoke.”
 - a. Smoking: Defendant’s suggestion that smoking is the predominant cause of Mr. Downs’ kidney cancer is incorrect. According to his medical records, Mr. Downs had a very limited smoking history of 5 years from 1960 to 1965 and quit more than 50 years prior to his diagnosis. Even if it was on and off for 15 years, as suggested by some of his medical records, which Mr. Downs disputes, it would not likely have overridden the significant exposure to known carcinogenic toxins at Camp Lejeune, primarily TCE. Furthermore, smoking is not as strong a risk factor for kidney cancer, as compared to lung cancer (for example). The PLCO study which was a screening study including 154,900 participants from the general population aged 55 through 74 year found that the incidence of kidney cancer in men over the age of 70 was 0.61/1,000 person years for men overall and 0.6/1000 person years for those who smoked for less than 30 years and quit more than 15 years prior to diagnosis.²⁷ Thus, even if a person smoked for up to 30 years and quit 15 years prior to diagnosis, the overall risk would not be increased.²⁷ Mr. Downs therefore had very little increased risk based on his smoking, if any at all.
 - b. Obesity/hypertension: Mr. Downs was not obese. His BMI was indicative of only a slightly overweight individual, with no real connection to kidney cancer. He had no hypertension.
 - c. Diabetes: While there is a medical record from Craig Brown, D.O. that talks about diabetes as a diagnosis, there are no lab values to confirm this diagnosis. Dr. Brown in his deposition stated he did not diagnose Mr. Downs with diabetes (C. Brown depo. 96:5-8; 97:16 – 21). Following his treatment with Dr. Brown, who last saw Mr. Downs in December 2017, Mr. Downs was seen by other healthcare providers, including his current primary care provider Emily Brodin, FNP. Mr. Downs’ recent hemoglobin A1c of 5.1 on July 7, 2024, does not even put Mr. Downs in a pre-diabetic category. (Peoples Community Clinic of Newberg, p. 280/287; E. Brodin depo. 74:1 – 78:11). Mr. Downs medical records do not confirm a diagnosis of type-2 diabetes, and in fact demonstrate a normal hemoglobin A1c.

3. Defendant states: “The Plaintiff’s exposure to water at Camp Lejeune may not have been significant enough to cause the alleged illness or injury, and the length of time (latency period) between any exposure to the water at Camp Lejeune and the onset of the Plaintiff’s illness or injury may indicate an alternative cause or that the cause of the Plaintiff’s illness or injury is idiopathic.”
 - a. Levels of the Chemicals: As listed above, it is clear Mr. Downs was exposed to levels of the chemicals sufficient to cause kidney cancer. This list will not be repeated again, but Mr. Downs’ exposure exceeded multiple levels in the epidemiology literature from Camp Lejeune shown to have a causal relationship with kidney cancer.

- b. Time of Diagnosis: Again, as stated above, the time Mr. Downs was first diagnosed with kidney cancer is consistent with what would be expected from chemical exposures of this kind.

XVII. Mr. Downs' Injuries

I will talk about Mr. Downs' harms as a result of his kidney cancer, including the metastasis he recently developed. To a reasonable degree of medical certainty, the metastasis Mr. Downs developed was causally related to his original diagnosis of RCC in 2016 and the water at Camp Lejeune. Additionally:

1. The harms and injuries and damages suffered by Mr. Downs that are described in this report are permanent.
2. The treatment and care Mr. Downs has received and is now receiving is reasonable and medically necessary.
3. The Plaintiff is expected to live a normal life expectancy.
4. The medical billing relating to Mr. Downs' kidney cancer diagnosis and metastasis, the surgery to remove his kidney and the follow-up treatment related to his kidney cancer was reasonable and medically necessary.

XVIII. Summary

After reviewing the published literature and the reports of governmental agencies as well as the medical records of Mr. Downs, I conclude that Mr. Downs exposure to the water at Camp Lejeune was more likely than not the cause of his kidney cancer, necessarily exceeding the standard at issue in this case, an "at least as likely as not" standard.

There is overwhelming evidence that TCE exposure is a cause of kidney cancer and that Mr. Downs was exposed to TCE, PCE and vinyl chloride. Mr. Downs' exposure is more likely than not the cause of his kidney cancer. Using principles in the Bradford Hill analysis, not only is the at least "as likely as" standard met, but there is also sufficient evidence to establish causation of kidney cancer using a "more likely than not" standard.

In this case, multiple meta-analyses demonstrate risk estimates with elevated measures of association well in excess of the criteria set forth by ATSDR. The weight of evidence indicates that TCE is not only at least as likely as not the cause of Mr. Downs' kidney cancer but also that there is sufficient evidence to establish TCE exposure was the cause of his kidney cancer. As such, the fact that Mr. Downs was exposed to TCE and developed kidney cancer supports the Equipoise and above evidence for causation.

In addition to the fact Mr. Downs' exposure exceeded the levels in the epidemiology known to cause kidney cancer, Mr. Downs' exposure was substantial. The case specific records and Mr. Downs' deposition testimony are enough to conclude that his exposure was substantial. However,

the exposure charts from Plaintiff's expert Kelly Reynolds provide additional evidence of the substantiality of this exposure.

CITATIONS

¹ International Agency for Research on Cancer. Trichloroethylene, Tetrachloroethylene, and Some Other Chlorinated Agents. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*. 2014;106:1-514.

² Agency for Toxic Substances and Disease Registry. ATSDR Assessment of the Evidence for the Drinking Water Contaminants at Camp Lejeune and Specific Cancers and Other Diseases. 2017:1-150.

³ Environmental Protection Agency. Biden-Harris Administration Announces Latest Actions under Nation's Chemical Safety Law to Protect People from Cancer-Causing Chemicals Trichloroethylene and Perchloroethylene. December 9, 20214. <https://www.epa.gov/newsreleases/biden-harris-administration-announces-latest-actions-under-nations-chemical-safety-law>.

⁴ International Agency for Research on Cancer. Chemical Agents and Related Occupations. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*. 2012;100F:1-599.

⁵ Environmental Protection Agency. Toxicological Review of Trichloroethylene (CAS No. 79-01-6). 2011.

⁶ National Toxicology Program. Report on Carcinogens Monograph on Trichloroethylene (RoC Monograph 05). 2015:1-236.

⁷ Karami S, Colt JS, et al. A case-control study of occupation/industry and renal cell carcinoma risk. *BMC Cancer*. 2012. <http://www.biomedcentral.com/1471-2407/12/344>.

⁸ Karami S, Occupational trichloroethylene exposure and risk of lymphatic and haematopoietic cancers: a meta-analysis. *Occupational & Environmental Medicine*. 2013;70(8).

⁹ Scott CS & Jinot J. Trichlorethylene and Cancer: Systematic and Quantitative Review of Epidemiologic Evidence for Identifying Hazards. *International Journal of Environmental Research and Public Health*. 2011;8:4238-4272.

¹⁰ Hansen J, Sallmen M, et al. Risk of Cancer Among Workers Exposed to Trichloroethylene: Analysis of Three Nordic Cohort Studies. *JNCI*. 2013:869-877. doi:10.1093/jnci/djt107.

¹¹ Vlaanderen J, Straif K, Pukkala E, et al. Occupational exposure to trichloroethylene and perchloroethylene and the risk of lymphoma, liver, and kidney cancer in four Nordic countries. *Occup Environ Med*. 2013;70(6):393-401. doi:10.1136/oemed-2012-101188.

¹² Christensen KY, Vizcaya D, Richardson H, Lavoué J, Aronson K, Siemiatycki J. Risk of selected cancers due to occupational exposure to chlorinated solvents in a case-control study in montreal. *J Occup Environ Med*. 2013;55(2):198-208. doi:10.1097/JOM.0b013e3182728eab.

- ¹³ Silver SR, Pinkerton LE, et al. Retrospective Cohort Study of a Microelectronics and Business Machine Facility. *Am. J. Ind Med.* 2014;57(4):412-424. doi:10.1002/ajim.22288.
- ¹⁴ Buhagen M, Grønskag A, Fenstad Ragde S, Hilt B. Association between Kidney Cancer and Occupational Exposure to Trichloroethylene. *J Occup. Environ Med.* 2016;58(9):957-959. doi:10.1097/JOM.0000000000000838.
- ¹⁵ Moore LE, Boffetta P, Karami S, et al. Occupational trichloroethylene exposure and renal carcinoma risk: Evidence of genetic susceptibility by reductive metabolism gene variants. *Cancer Res.* 2010;70(16):6527-6536. doi:10.1158/0008-5472.CAN-09-4167.
- ¹⁶ Raaschou-Nielsen O, Hansen J, et al. Cancer Risk among Workers at Danish Companies using Trichloroethylene: A Cohort Study. *Am. J. of Epidemiology.* 2003;158(12):1182-1192.
- ¹⁷ Bradford Hill, A. The Environment and Disease: Association or Causation? President's Address January 14, 1965. *Proceedings of the Royal Society of Medicine.* 1965:295-300.
- ¹⁸ Institute of Medicine. Improving the Presumptive Disability Decision-Making Process for Veterans. *The National Academies Press.* 2008. <https://doi.org/10.17226/11908>.
- ¹⁹ Bove FJ, Ruckart PZ, et al. Evaluation of mortality among marines and navy personnel exposed to contaminated drinking water at USMC base Camp Lejeune: a retrospective cohort study. *Environmental Health.* 2014. <http://www.ehjournal.net/content/13/1/10>.
- ²⁰ Bove FJ, Ruckart PZ, et al. Mortality study of civilian employees exposed to contaminated drinking water at USMC Base Camp Lejeune: a retrospective cohort study. *Environmental Health.* 2014. <http://www.ehjournal.net/content/13/1/68>.
- ²¹ Agency for Toxic Substances and Disease Registry. Morbidity Study of Former Marines, Employees, and Dependents Potentially Exposed to Contaminated Drinking Water at U.S. Marine Corps Base Camp Lejeune. 2018:1-126.
- ²² Bove FJ, Greek A, et al. Evaluation of mortality among Marines, Navy personnel, and civilian workers exposed to contaminated drinking water at USMC base Camp Lejeune: a cohort study. *Environmental Health.* 2024. <https://doi.org/10.1186/s12940-024-01099-7>
- ²³ Bove F, Greek A, et al. Evaluation of cancer incidence among Marines and Navy personnel and civilian workers exposed to contaminated drinking water at USMC Base Camp Lejeune: a cohort study. *Environmental Health Perspectives.* 2024;132(10). <https://doi.org/10.1289/EHP14966>.
- ²⁴ Bell A, Rangaswami A, et al. Subsequent Renal Cancer Among Childhood Cancer Survivors: Analysis of Surveillance, Epidemiology, and End Result. *J. Pediatr Hematol. Oncol.* 2024;46(6):387-392.

- ²⁵ Siegel RL, Miller KD, et al.. Cancer Statistics 2023. *CA Cancer J Clin.* 2023;73:17-48. <https://doi.org/10.3322/caac.21763>.
- ²⁶ Bukavina L, Bensalah K, et al. Epidemiology of Renal Cell Carcinoma: 2022 Update. *European Urology.* 2022;82(5):529-542. <https://doi.org/10.1016/j.eururo.2022.08.019>.
- ²⁷ Lotan Y, Karam J, et al. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial. *Urol. Oncol.* 2016;34(4). doi: 10.1016/j.urolonc.2015.10.011.
- ²⁸ Stanifer JW, Stapleton HM, et al. Perfluorinated Chemicals as Emerging Environmental Threats to Kidney Health. *Clin. J. AM. Soc. Nephrol.* 2018;13(10):1479-1492. doi: 10.2215/CJN.04670418.
- ²⁹ Ahmed YH, El-Naggar ME, et al. Screening for polystyrene nanoparticle toxicity on kidneys of adult male albino rats using histopathological, biochemical, and molecular examination results. *Cell & Tissue Research.* 2022;388:149-165. <https://doi.org/10.1007/s00441-022-03581-5>.
- ³⁰ Andrew AS, Li M, et al. Kidney Cancer Risk Associated with Historic Groundwater Trichloroethylene Contamination. *International J. of Environ. Research & Public Health.* 2022;19. <https://doi.org/10.3390/ijerph19020618>.
- ³¹ Phillips RV, Rieswijk L, et al. Human exposure to trichloroethylene is associated with increased variability of blood DNA methylation that is enriched in genes and pathways related to autoimmune disease and cancer. *Epigenetics.* 2019;14(11):1112-1124. <https://doi.org/10.1080/15592294.2019.1633866>.
- ³² Charbotel B, Fevotte J, et al. Case-Control Study on Renal Cell Cancer and Occupational Exposure to Trichloroethylene. Part II: Epidemiological Aspects. *Ann. Occup. Hyg.* 2006;50(8):777-787. doi:10.1093/annhyg/mel039.
- ³³ Karami S, Lan Q, et al. Occupational trichloroethylene exposure and kidney cancer risk: a meta-analysis. *Occup. Environ. Med.* 2012;69:858-867. <https://doi.org/10.1136/oemed-2012-100932>.
- ³⁴ Kelsh MA, Alexander DD, et al. Occupational trichloroethylene exposure and kidney cancer: a meta-analysis. *Epidemiology.* 2010;21(1):95-102. doi: 10.1097/EDE.0b013e3181c30e92.
- ³⁵ Agency for Toxic S, Disease R. Toxicological Profile for Trichloroethylene (TCE). Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service; 2014.
- ³⁶ Baccarelli A & Bollati V. Epigenetics and environmental chemicals. *Curr. Opin. Pediatr.* 2009;21(2):243-251.

- ³⁷ Joseph DB, Strand D, & Vezina CM. DNA methylation in development and disease: an overview for prostate researchers. *Am. J. Clin. Exp. Urol.* 2018;6(6):197-218.
- ³⁸ Axelson O, Selden A, et al. Updated and expanded Swedish cohort study on trichloroethylene and cancer risk. *J. Occup. Med.* 1994;36(5):556-62.
- ³⁹ Blair A, Hartge P, et al. Mortality and cancer incidence of aircraft maintenance workers exposed to trichloroethylene and other organic solvents and chemicals: extended follow up. *Occup. Environ. Med.* 1998;55:161-171.
- ⁴⁰ Boice JD, Marano DE, et al. Mortality Among Rocketdyne Workers Who Tested Rocket Engines, 1948-1999. *JOEM.* 2006;48(10):1070-1092.
- ⁴¹ Dosemeci M, Cocco P, Chow WH. Gender differences in risk of renal cell carcinoma and occupational exposures to chlorinated aliphatic hydrocarbons. *Am J Ind Med.* 1999;36(1):54-59. doi:10.1002/(SICI)1097-0274(199907)36:1<54::AID-AJIM8>3.0.CO;2-0.
- ⁴² Henschler D, Vamvakas S, et al. Increased incidence of renal cell tumors in a cohort of cardboard workers exposed to trichloroethene. *Arch. Toxicol.* 1995;69(5):291-99. doi: 10.1007/s002040050173.
- ⁴³ Bruining T, Pesch B, et al. Renal Cell Cancer Risk and Occupational Exposure to Trichloroethylene: Results of a Consecutive Case-Control Study in Arsberg, Germany. *Am. J. of Industrial Med.* 2003;43:274-285.
- ⁴⁴ Radican L, Blair A, et al. Mortality of aircraft maintenance workers exposed to trichloroethylene and other hydrocarbons and chemicals: extended follow up. *J. Occup. Environ. Med.* 2008;50(11):1306-1319. doi:10.1097/JOM.0b013e3181845f7f.
- ⁴⁵ Vamvakas S, Bruining T, et al. Renal cell cancer correlated with occupational exposure to trichloroethene. *J. Cancer Res. Clin. Oncol.* 1998;124:374-382.
- ⁴⁶ Morgan RW, Kelsh MA, et al. Mortality of Aerospace Workers Exposed to Trichloroethylene. *Epidemiology.* 1998;9(4):424-431.
- ⁴⁷ Zhao Y, Krishnadasan A, Kennedy N, Morgenstern H, Ritz B. Estimated effects of solvents and mineral oils on cancer incidence and mortality in a cohort of aerospace workers. *Am J Ind Med.* 2005;48(4):249-258. doi:10.1002/ajim.20216.
- ⁴⁸ Purdue MP, Stewart P, et al. Occupational exposure to chlorinated solvents and kidney cancer:a case-control study. *Occup. Environ. Med.* 2017;17(4):268-274. doi:10.1136/oemed-2016-103849.
- ⁴⁹ Antilla A, Pukkala E, et al. Cancer Incidence among Finnish Workers Exposed to Halogenated Hydrocarbons. *JOEM.* 1995;37(7):797-806.

- ⁵⁰ Cui Y, Choudhury SR, & Irudayaraj J. Epigenetic toxicity of trichloroethylene: a single-molecule perspective. *Toxicology Research*. 2016;5.doi: 10.1039/c5tx00454c.
- ⁵¹ Gilbert, KM, Blossom SJ, et al. Chronic exposure to trichloroethylene increases DNA methylation of the Ifng promotor in CD4+ T cells. *Toxicol Letters*. 2015;260:1-7. doi:10.1016/j.toxlet.2016.08.017.
- ⁵² Gilbert KM, Blossom SJ, et al. Trichloroethylene-induced alterations in DNA methylation were enriched in polycomb protein binding sites in effector/memory CD4+ T cells. *Environmental Epigenetics*. 2017;3(3):1-16. doi: 10.1093/eep/dvx013.
- ⁵³ Palbykin B, Borg J, et al. Trichloroethylene Induces Methylation of the Serca2 Promotor in H9c2 Cells and Embryonic Heart. *Cardiovascular Toxicology*. 2011;11:204-214. doi: 10.1007/s12012-011-9113-3.
- ⁵⁴ Hunt JD, Van der Hel OL, et al. Renal cell carcinoma in relation to cigarette smoking: Meta-analysis of 24 studies. *Int. J. Cancer*. 2005;114:101-108.
- ⁵⁵ Liu X, Peveri G, et al. Dose-response relationship between cigarette smoking and kidney cancer: A systematic review and meta-analysis. *Critical Reviews in Oncology*. 2019;142:86-93. <https://doi.org/10.1016/j.critrevonc.2019.07.019>.
- ⁵⁶ Chang C, Benson M, & Fam MM. A review of Agent Orange and its associated oncologic risk of genitourinary cancers. *Urologic Oncology: Seminars and Original Investigations*. 2017;35(11):633-639. <https://doi.org/10.1016/j.urolonc.2017.08.029>.
- ⁵⁷ Takeshima H & Ushijima T. Accumulation of genetic and epigenetic alterations in normal cells and cancer risk. *Npj Precision Oncology*. 2019;7.
- ⁵⁸ Gerstung M, Jolly C, et al. The evolutionary history of 2,658 cancers. *Nature*. 2020;578:122-127. <https://doi.org/10.1038/s41586-019-1907-7>.
- ⁵⁹ SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. 2024. <https://seer.cancer.gov/statistics-network/explorer/>. Data source(s): SEER Incidence Data, November 2023 Submission (1975-2021), SEER 22 registries.

YAIR LOTAN'S CV


9/23/2024

Yair Lotan, M.D.
Professor of Urology
The University of Texas Southwestern Medical Center
2001 Inwood Rd, WCB3 4th floor
Dallas, TX 75390-9110
Ph: 214-648-0389
Fax: 214-648-8786
E-mail:
Yair.Lotan@UTSouthwestern.edu

Education

1985-1989: **Kingwood High School**, Houston, Texas: Valedictorian
1989-1993: **Univ. of Texas at Austin**, B. A. in Biology with Highest Honors: GPA:
3.98
1993-1997: **Baylor College of Medicine**, Houston, Texas: M. D. with Honors
Successfully completed licensing examinations
1995-1998: **The University of Texas Southwestern Medical Center at Dallas**
7/1997-6/1998: **The University of Texas Southwestern Medical Center at Dallas**
General Surgery Internship
7/1998-6/2003: **The University of Texas Southwestern Medical Center at Dallas**
Urology Residency
2005 Board Certification in Urology expires February 28, 2015
2013 Board Recertification in Urology expires February 28, 2025

Work Experience

9/2021-present Vice Chair of Clinical Affairs Department of Urology
9/2012-present: **The University of Texas Southwestern Medical Center**
Professor of Urology
Chief of Urologic Oncology
Jane and John Justin Distinguished Chair in Urology, In Honor of Claus
G. Roehrborn, M.D.
9/2008-8/2012 Associate Professor of Urology
Holder of the Helen J. and Robert S. Strauss Professorship in Urology
7/2003-8/2008: Assistant Professor of Urology
7/2002-6/2003: North Texas Planned Parenthood: Performing vasectomies
7/1999-6/2002: Dallas Veterans Affairs Emergency Room Physician 7/2000-6/2003:
Health South Rehabilitation Facility Staff physician
7/1996-6/1997: Archer, Waldner and Vickery: Houston, TX
Medical Consultant for law firm
Fall Semester 1990: **The University of Texas at Austin**: Research position cloning *E. Coli*
genes
7/1989-9/1989: **The University of Texas M. D. Anderson Cancer Center**
7/1990-9/1990 Summer internship studying cellular effects of interferon (1990), and
Involvement of Integrins and RGD polymers in metastasis of tumor cells
(1989).

Hospital Affiliations

William P. Clements Jr. University Hospital, Dallas, TX
Zale Lipshy University Hospital, Dallas, TX
Parkland Memorial Hospital, Dallas, TX
Dallas Veterans Administration Medical Center, Dallas, TX
John Peter Smith Hospital, Fort Worth, TX

Grants and Trials

1. 2022 – Pacific Edge - An Observation Study of CxBladder Monitoring for the Recurrence of Urothelial Carcinoma in Intermediate and High-Risk Patients
2. 08/2022-08/2024 Wilson Foundation: Optimal Screening Strategy for Bladder Cancer in at Risk Patients (A prospective screening trial) \$102,000)
3. 2022 – Convergent – Specimen Collection for Validation of UroSeq/UroAmplitude: A Urine Sequencing Diagnostic Platform for Detection and Surveillance of Bladder Cancer (INSITE)
4. 2022- SURGE – A Phase 1/2a Study of STM-413 Administered Intraoperatively to Patients Undergoing Transurethral Resection of Bladder Tumor (TURBT) for Recurrent High-Grade Papillary Bladder Cancer
5. 2021- Seagen, Inc – A Study of Intravesical enfortumab vedotin for Treatment of Patients with Non-Muscle Invasive Bladder Cancer
6. 2021 – Engene – A Phase I/2 Study of EG70 as an Intravesical Administration to Patients with BCG-Unresponsive NMIBC and High-Risk NMIBC Patients Who are BCG Naïve or Received Incomplete Treatment
7. 2021- Pacific Edge – An Observational Study of CxBladder Performance for Detection or Rule Out of Upper Tract Urothelial Cancer
8. 2021- Janssen – Phase 2b Clinical Trial Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 alone in Participants with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmett
9. 2020- A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guerin (BCG) and Recurred with High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions
10. 08/05/2021-07/31/2026: @R01CA198887-06A1 Multiplexed Protein Biomarker-Based Assay for the Detection of Bladder Cancer Rosser:PI
11. 2020-2022 Wilson Foundation: Improving Diagnosis & Treatment of Patients with Bladder Cancer by Using Advanced Genetic Analysis \$80,000. Expires December 2022. PI: Yair Lotan
12. 07/01/2020 – 06/30/2025 1R01CA252057-01 eRapamycin for Secondary Bladder Cancer Prevention, Svatek, PI
13. 2019-2029: Pacific Edge, LTD. Use of multiplexed molecular biomarker test Cxbladder, in Real World decision making to provide Clinical Utility Using a Randomized Design PI at UTSW.
14. 2017-2019 Wilson Foundation: Prospective Randomized Trial of Curcumin to Prevent Progression in Patients Undergoing Active Surveillance for Prostate Cancer Fund \$180,000. Expires: November 7, 2019. PI: Yair Lotan

15. 04/01/2018-3/31/2023 Baylor College of Medicine: Identify the DNA Adduct and Associated Metabolic Alterations in Bladder Cancer of Smokers: 1R01CA216426-01A1. PI at UT Southwestern.
16. 05/01/2019-04/30/2021 Cedars-Sinai Medical Center/NIH-NCI: Multiplexed Protein Biomarker-Based Assay for the Detection of Bladder Cancer; 7R01CA198887-04. PI at UT Southwestern.
17. 04/01/2018-03/31/2020 University of Michigan/NIH-NCI: EDRN Prostate MRI Biomarker Study and Reference Set; U24CA086368. PI at UT Southwestern.
18. 05/01/2016-04/30/2019 University of Hawaii/NIH: Multiplexed Protein Biomarker-Based Assay for the Detection of Bladder Cancer; 1R01-CA198887-01A1 REVISED; Expired: April 30, 2019. PI at UT Southwestern.
19. 12/26/12-12/26/22: Ockham Development Group (PI): RAD-IFN-CS-002 Phase 2 Study of rAd-IFN/Syn3 Following Intravesical Administration in Subjects with High Grade, BCG Refractory, Relapsed or Resistant Non-Muscle Invasive Bladder Cancer. PI at UT Southwestern
20. 4/25/14-4/25/24: Cato Inc. Protocol PC B308/13: Phase 3 Comparative Study of blue and white light cystoscopy in detection of bladder cancer patients. PI at UT Southwestern.
21. 3/1/17-3/1/22: MDx Health: Multi-institutional Study to Evaluate DNA Methylation Markers for Detection of Primary Bladder Cancers in Urine Samples from a Cohort of Patients with Hematuria. Study PI
22. 1/31/17-1/31/22: Cleveland Diagnostics: IsoPSA: PSA Isoforms in Peripheral Blood for More Accurate Prostate Cancer Diagnosis- A Prospective Pilot Study. PI at UT Southwestern.
23. 9/2/16-9/2/21: FKD Therapies OY: Protocol rAd-IRN-CS-003: A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN (rAd-IFN/Syn3) Administered Intravesically to Patients with High-Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC). PI at UT Southwestern.
24. 10/15/14-10/14/19. GenomeDx Biosciences: CU004 (PRO-IMPACT). PRO-IMPACT-Study of Decipher Prostate Cancer Classifier on Treatment Consideration following Radical Prostatectomy. PI at UT Southwestern.
25. 10/31/15-10/30/20. GenomeDx Biosciences (PI): OTD-106977. Multi-Institutional Study to Evaluate Molecular Staging Biomarkers in Patients Diagnosed with Bladder Cancer
26. 08/17-07/22 Southwest Oncology Group (PI) S1602. A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Native High-Grade Non-Muscle Invasive Bladder Cancer
27. 05/17-04/22. Profound Medical Inc (PI): GCP-10100 Evaluation of the TULSA-PRO MRI-Guided Transurethral Ultrasound Prostate Ablation Device in Patients with Localized Prostate Cancer: a Prospective, Single-Arm, Pivotal Clinical Study
28. 2013-2016 National Science Foundation/University of Texas at Arlington Collaborative Research: Functionalized Nano-Textured Surfaces to Isolate and Identify Tumor Cells, PI at UT Southwestern Medical Center. Expired: June 30, 2016.

29. 2016 Comparing Outcomes after Cystectomy based on status of molecular markers; STU 042011-125; Expires: March 11, 2016; PI: Yair Lotan
30. 2016 Aurora Kinase A as a Biomarker for the Detection of Bladder Cancer; Study00002394; Expired: February 10, 2016; PI: Yair Lotan
31. 2016 Clinical, non-intervention study of the Cxbladder® urine test for the detection of recurrent urinary tract Urothelial Carcinoma (UC); STU 112012-018A; Expired: February 3, 2016; PI: Yair Lotan
32. 2015 Efficacy of Bladder Screening in a High Risk Population; STU 032011-102; Expired: December 3, 2015; PI: Yair Lotan
33. 2015 Evaluation of the UroVysion Test in Predicting Recurrence and/or Progression of Disease in Patients Receiving initial BCG for Primary High Grade Papillary Ta-T1 and CIS Urothelial Carcinoma of the Bladder; STU 062013-045; Expired: August 26, 2015; PI: Yair Lotan
34. 2015 Prospective Study of the IMPACT of Decipher Prostate 1/7/2015 Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy {PRO-IMPACT}; STU 062014-038; Expired: August 10, 2015; PI: Yair Lotan
35. 2015 Randomized Trial of Adjuvant Curcumin after Radical Prostatectomy; STU 042013-080; PI: Yair Lotan
36. 4/25/14-4/25/24 - Abbott Molecular Inc: Protocol 9JG-08c05-2 Evaluation of UroVysion Test in Predicting Recurrence and/or Progression of Disease in Patients Receiving Initial BCG for Primary High Grade Ta-T1 and CIS Urothelial Carcinoma of the Bladder; PI: Yair Lotan
37. 5/2010 -5/2020 Society of Urologic Oncology: Clinical Trials Consortium.
38. 2010-2014 Cleveland Clinic Lerner College of Medicine at Case Western Reserve University/NIH HHSN261201000060CRECOVERY ACT – Tissue Source Site (TSS) Networks in Support of the Cancer Genome Atlas (TCGA) Program, PI at UT Southwestern Medical Center
39. 2008-2011 DOD (PC074348): Stereotactic Body Radiation Therapy (SBRT) for Underserved Populations in Men with Low- and Intermediate Risk Prostate Carcinoma: Co-Investigator.
40. 2011 – Alere Scarborough, Inc: Protocol 1103901: A Randomized Trial of Surveillance of Low-Grade Non-Invasive Bladder Cancer Using Standard Follow-Up versus Cystoscopy and NMP22®BladderChek® Test.
41. 2010-2016 - University of Michigan: NCI Grant number U01-CA 084986: Early detection research network (EDRN) PCA3 validation trial and urinary reference set.
42. 2010 - MD Anderson (1R01-CA151489-01): Aurora Kinase A as a Biomarker for the Detection of Bladder Cancer, Czerniak, PI
43. 2009 - MD Anderson (5P50-CA91846-10PPS2): MD Anderson Screening for Bladder Cancer
44. 2009 - Simmons Cancer Center grant: Randomized, Phase II Trial of Adjuvant Chemotherapy after Cystectomy Based on Status of Molecular Markers
45. 2009 - Alere Scarborough, Inc: Protocol 0825302: An Investigation of the NMP22 Bladderchek tests for early detection of bladder cancer.
46. 2008 - Abbott Molecular Inc: Validation of clinical utility of Reflex Fluorescence in situ hybridization assay in patients with atypical cytology for detection of urothelial carcinoma of the bladder

47. 2008-2009: NIH/NCRR (5 UL1 RR24982-02 Packer): (PI): Role: Co-Investigator: Role: Pilot Award Recipient PI: "Prospective Validation of Bladder Cancer Detection Nomogram and Biomarker Discovery"
48. 2006-2008: MD Anderson (MDA03-1-03): (PI): Phase I and II Clinical Trials of Chemoprevention Agents
49. NIH Loan Repayment Grant: 2004-2007
50. 2006-2007: Matritech, Inc: (PI) Efficacy of Screening for Bladder Cancer in a High Risk Population
51. 2004: American Cancer Society and Simmons Cancer Center (IRG0219601): (PI): use of proteomics to identify reliable serum proteomic biomarkers for the differentiation of normal and malignant prostate

Honors/Awards

- 2024 Top Urology/Oncology prostate Cancer USA
- 2023 AUA Honorary Member
- 2022 BJUI International – Bronze Award
- 2022 Best Doctors in Dallas 2022, D Magazine
- 2022 Castle Connolly Top Doctors
- 2023 Castle Connolly Top Doctors
- 2021 BJU International Bronze Award, January 2021
- 2021 Best Doctors in Dallas 2021, D Magazine
- 2020 Reviewer of the Month - European Urology, Your Platinum Journal, August 2020
- 2019 Best posters in a Poster Session/Expert-Guided Poster Tour at the 34th Annual EAU Congress in Barcelona, "Molecular subtyping reveals luminal bladder tumors have lower rates of pathological upstaging at radical cystectomy" and "Molecular characterization of neuroendocrine-like bladder cancer"
- 2018 Castle Connolly Top Doctor
- 2018 Best Doctors and "D Best" in Dallas 2018 awards, D Magazine
- 2017 Best Doctors in America
- 2017 Best Doctors and "D Best" in Dallas 2017 awards, D Magazine
- 2017 International Health Professional of the Year 2017
- 2016 Top Reviewer, *Urologic Oncology: Seminars and Original Investigations*
- 2016 Best Doctors and "D Best" in Dallas 2016 awards, D Magazine
- 2015 BJU International - Valued Reviewer
- 2014 Letter of Appreciation as Peer Reviewer, Department of Health and Human Services
- 2014 Best Doctors in Dallas 2014, D Magazine
- 2014 Resident Teaching Award. June 2014
- 2014 IBC Top 100 Health Professionals. July 2014
- 2013 Certificate of Excellence in Reviewing. *Urologic Oncology: Seminars and Original Investigations*
- 2013 "Best Poster" of the AUA Moderated Poster Session MP52-Bladder Cancer: Invasive (I) at the 2013 American Urological Association Annual Meeting, San Diego, CA. May 4-8, 2013
- 2013 "Five Year Prospective Evaluation of a Molecular Marker Panel for Prediction of Recurrence after Radical Cystectomy." (co-author & presenter).
- 2013 "Best Abstract" at the 2013 American Urological Association Annual Meeting, San Diego, CA. May 4-8, 2013. "Concordance in Molecular marker Status between

- Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study.” (co-author & presenter).
- 2013 America’s Top Surgeons
- 2013 Best Doctors in America
- 2012 Best Doctors in Dallas 2012, D Magazine
- 2012 Outstanding Reviewer Award. The Journal of Urology
- 2011 Best Reviewer Award. The Journal of Urology
- 2011 Society of Urologic Oncology Young Investigator Award
- 2011 Best Doctors in Dallas 2011, D Magazine
- 2011 Top Review’s Roll of Honour 2011 BJU International
- 2011 3rd Place AUA Foundation Research Forum: Showcasing Young Investigators. “Clinical Use of Molecular Biomarkers for Urothelial Carcinoma of the Bladder” Invited Speaker and Poster. American Urology Association, Washington, DC. May 14-19, 2011.
- 2010 Best Doctors in Dallas 2010, D Magazine
- 2010 Best Reviewer Award. The Journal of Urology
- 2009 American Society of Clinical Oncology (ASCO) Cancer Foundation Merit Award at the Genitourinary Cancers Symposium, February 26-28, 2009, Orlando, FL. “Comparison of cost of robotic, laparoscopic and open radical prostatectomy.” (senior author)
- 2008 Best Poster at the *Society of Urologic Oncology Annual Meeting on Extraordinary Opportunities for Discovery National Cancer Institute*, December 4-6th, 2008, National Institutes of Health, Bethesda, MD. “Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with bladder cancer.” (co-author)
- 2008 Resident Teaching Award. June 2008.
- 2008 “Best Poster” in *Diagnosis and staging of urothelial tumours II* at the 23rd *European Association of Urology Annual Meeting*, Milano, Italy. March 26-9, 2008. Multiple bio- markers for the prediction of bladder cancer recurrence and mortality.
- 2008 Who’s Who in America.
- 2007 3rd Place Poster at the *Society of Urologic Oncology Eight Annual Meeting on Extraordinary Opportunities for Discovery National Cancer Institute*, November 29th - December 1st, 2007, National Institutes of Health, Bethesda, Maryland. Multiple bio- markers for the prediction of bladder cancer recurrence and mortality.
- 2007 3rd Place Resident Poster Contest South Central Section Meeting 2007: “Use of apoptosis biomarkers for prediction of oncological outcomes after radical cystectomy.” (co-author)
- 2007 4th Place Resident Poster Contest South Central Section Meeting 2007: “Multiple bio-markers for the prediction of bladder cancer recurrence and mortality.” (senior author)
- 2007 5th Place Resident Poster Contest South Central Section Meeting 2007: “Outcomes of patients with clinical T1 grade 3 bladder urothelial cell bladder carcinoma treated with radical cystectomy.” (senior author)
- 2006 Best Poster in bladder cancer: diagnosis and staging III at the European Association of Urology Annual Meeting, Paris, April 5-8, 2006: “Survivin expression is associated with bladder cancer presence, stage, progression, metastasis, and mortality.”
- 2006 2nd Place Resident Poster Contest South Central Section Meeting 2006: “Cooperative effect of cell cycle regulators expression on bladder cancer development and aggressiveness.” (senior author)
- 2005 First Place Resident Poster Contest South Central Section Meeting 2005: “Efficacy of Cyberknife Stereotactic Radiosurgical Treatment for Localized Prostate Cancer: A Murine Model.” (senior author)

2005 3rd Place Resident Poster Contest South Central Section Meeting 2005: "Soluble Fas-a promising novel urinary marker for the detection of bladder transitional cell carcinoma." (co-author)

2003 Gerald P. Murphy Scholar Award: Recognition of Research in Prostate Cancer

2002 The Pfizer Scholars in Urology Award

2002 Visiting Resident: Northwestern University Medical Center

2002 First Place, Samuel Ambrose Socioeconomic Essay Contest at the American Urological Association Annual Meeting in Orlando, Florida: "Cost effective treatment of ureteropelvic junction obstruction: A decision tree analysis"

2002 Award for excellence in urology pathology course

2001 Award for excellence in urology pathology course

1996 Alpha Omega Alpha Honor Society: Baylor College of Medicine

1994 Dr. T. P. Lyon Scholarship: Baylor College of Medicine

1994 Basic Science Honors Award: Baylor College of Medicine

1993 Biochemistry Honors Award: Baylor College of Medicine

1992 Endowed Presidential Scholarship: The University of Texas at Austin

1989-1993 Dean's Scholars of Science Honors Program: The University of Texas at Austin
Phi Beta Kappa Honor Society

1989 National Merit Scholar

Professional Society Memberships

American Urologic Association (AUA)
Dallas County Medical Society (DCMS)
R.O.C.K. Society
Society of Urologic Oncology (SUO)
South Central Section of the AUA (SCSAUA)
Texas Medical Association (TMA)
Texas Urological Society (TUS)

Administrative Activity

Vice chair of Clinical Affairs 2021-present
Chief of Urologic Oncology 7/2011-present
UTSW Urology Department, Head of Clinical Research 2012 - present
Disease Oriented Team Co-Leader GU for Simmons Cancer Center 2008 - present
Urology Clinic Medical Director, Parkland Health and Hospital System 7/2011- present
Medical Director, Urology Clinic 4/2010 – 3/2022
UT Southwestern University Hospital Cancer Committee 2012- present
Parkland Hospital Cancer Committee
Frisco Facility Planning Committee
Clinical Transformation Task Force– Task Force#2–Governance Aligned with Goals 8/2015-present
Same Day Care & Extended Hours Taskforce Co-chair 2020 - present
Service Chief, Urology Service, Parkland Health and Hospital System 11/2010 – 6/2011
Six-Year Plan: 2020-2026 - Clinical Transformation Committee
Six-Year Plan: 2016-2022 - Clinical Transformation Research Subcommittee
Six-Year Plan: 2014-2020 - Research Subcommittee
Six-Year Plan: 2012-2018 - Research Subcommittee University Cancer Committee
Surgical Ambulatory Committee
Tissue Bank Steering Committee

Ambulatory Operations Council 3/2016 – present
UTSW Faculty Senate 6/2004 – 8/2010
UT Southwestern New Patient Access Committee
Zale Medical Executive Committee 2008-2010
UT Southwestern Biorepository Oversight Committee 2021 - 2023

External Committees/Specialty Offices Held

Eugene Frenkel Scholars Committee 2024-2025
American Urological Association Clinical Trials Collective (AUACTC), Activity Overview (Chair) 2024

1. Resource Constraints
2. Clinical Trial Navigators
3. Physician Awareness
4. Underrepresented Patients

American College of Radiology 2024

1. Pretreatment Staging of Muscle-Invasive Bladder Cancer

International Bladder Cancer Forum 2023

1. Urinary Biomarkers

Bladder and Kidney Academy 2023

1. Diagnosis & Evaluation: Biomarkers

IBCG Core Committee 2020-Present

1. 2023 BCG Unresponsive Disease: Recommendations for Optimal Sequencing/Patient Selection
2. 2023 Bladder Conservation in MIBC: Recommendations for TMT, Partial Cystectomy, Observation Post NAC/IO.

CISTO Study External Advisory Board 2020-Present
Prevail Steering Committee 2020-Present
American Urological Association Hematuria Cancer Guidelines Panel 2018-2019
American Urological Association Education Council 2015 - 2019
American Urological Association Muscle Invasive Bladder Cancer Guidelines Panel 2015
American Urological Association Core Curriculum Chair 2015 -2019
American Urological Association Core Curriculum Vice-Chair 2014
American Urological Association Core Curriculum Editor Non-Muscle invasive and Muscle-Invasive Bladder Cancer Sections 2015-Present
American Urological Association National Ultrasound Faculty 2007-2012
American Urological Association Research Committee (Delegate) - 2009
American Urological Association Abstract Review Team Member 2011-present
ICUD Epidemiology and Economics of Stone Disease Committee Chair October 12-16, 2014
Genitourinary Cancers Symposium Program Committee – Program Committee Representative 2016-2018
Genitourinary Cancers Symposium Session Auditor 2/2018

1. Welcome and General Session 4: Current and Future Directions of Muscle-Invasive Bladder Cancer

Genitourinary Cancers Symposium Session Auditor 2/2017

1. Welcome and General Session 4: Optimizing Outcomes in Muscle-Invasive and Metastatic Bladder Cancer (ARS)
2. Urothelial Carcinoma: Year in Review and Keynote Lecture Society of Urologic Oncology

President Young Urologic Oncologist (YUO) 2010 - 2011 Young Urologic Oncologist Steering Committee
Clinical Trial Consortium – Bladder Cancer Bladder Cancer Advocacy Network (BCAN)
BCAN Scientific Advisory Board BCAN Steering Committee
2012 Bladder Cancer Think Tank - Co-Chair
2013 Bladder Cancer Think Tank – Chair
2014 Bladder Cancer Think Tank – Co-Chair
Bladder Cancer Research Network (BCRN) Management Committee
European Association of Urology 2013-present – Abstract Reviewer
American Urological Association Abstract Review Team Leader 2017
General & Epidemiological Trends and Socioeconomics: Value of Care, Cost & Outcomes Measures, Team 14
American Urological Association Abstract Review Team Leader 2018
General & Epidemiological Trends and Socioeconomics: Value of Care, Cost & Outcomes Measures, Team 15
American Urological Association Abstract Review Team Leader 2019
General & Epidemiological Trends and Socioeconomics: Value of Care, Cost & Outcomes Measures, Team 16
American Urological Association Abstract Review Team Leader 2022
General & Epidemiological Trends and Socioeconomics: Value of Care, Cost & Outcomes Measures, Team 17
American Urological Association Abstract Review Team Leader 2023
General & Epidemiological Trends and Socioeconomics: Value of Care, Cost & Outcomes Measures, Team 18
BCRN Management Committee October 1, 2018
American Urological Association Core Curriculum 2022 Review Cycle
John Hopkins University/American Urological Association Planning Committee 2023
Eugene Frenkel Scholars Committee 2023-2024

Editorial Activities: Reviewer

2003-present: Cancer
2004-present: Urology
2004-present: Journal of Endourology
2004-present: Journal of Urology
2004-present: Asian Journal of Andrology
2005-present: Clinical Cancer Research
2005-present: Cancer Letters
2005-present: Brazilian Journal of Urology
2006-present: International Journal of Radiation Oncology, Biology, Physics
2006-present: British Journal of Urology International
2006-present: Clinical Cancer Research
2006-present: Journal of Investigative Medicine
2006-present: Medical Science Monitor
2006-present: International Journal of Cancer
2006-present: Cytopathology
2006-present: Journal of Urologic Oncology
2006-present: European Urology
2007-present: Oncogene
2007-present: European Journal of Cancer
2010-present: Journal of the American Medical Association
2019-present: Lancet Oncology

2020-present: The Lancet

Editorial Activities

2008-present: European Urology - Editorial Board at Large
2010-7/2020: British Journal of Urology International - Editorial Board
2013-12/2017: Journal of Urology - Assistant Editor
2014-2016: Bladder Cancer - Editorial Board 2015-present: EU Focus Editorial Board
2016-2018: Bladder Cancer - Associate Editor for Reviews
2017-present: European Urology Oncology – Editorial Board at Large
2020-present: Journal of Clinical Medicine
2021-present Urologic Oncology: Seminars and Original Investigations – Editorial Board
2021-present Urologic Oncology: Seminars and Original Investigations – Consulting Editor

Peer-Reviewed Publications

1. **Lotan Y**, Xu XC, Shalev M, Lotan R, Williams R, Wheeler TM, Thompson TC, Kadmon D: Differential expression of nuclear retinoid receptors in normal and malignant prostates. *J Clin Oncol.* 2000 Jan;18(1):116-21. PMID: 10623701.
2. **Lotan Y**, Roehrborn CG: Cost effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy in the follow-up of patients with transitional cell carcinoma of the bladder: a decision analytical approach. *J Urol.* 2002 Jan;167(1):75-9.
3. Gettman MT, **Lotan Y**, Corwin TS, Smith TG, Napper CA, Lindberg G, Cadeddu JA: Radiofrequency coagulation of renal parenchyma: comparison of effects of energy generators on treatment efficacy. *J Endourol* 2002 Mar;16(2):83-8. PMID: 11962560.
4. Gettman MT, **Lotan Y**, Napper CA, and Cadeddu JA: Transvaginal laparoscopic nephrectomy: development and feasibility in the porcine model. *Urology* 2002 March: 59 (3): 446-50. PMID: 11880100.
5. **Lotan Y**, Gettman MT, Roehrborn CG, Cadeddu JA, Pearle MS: Management of ureteral calculi: a cost comparison and decision-making analysis. *J Urol.* 2002 Apr;167 (4):1621-1629. PMID: 11912376.
6. **Lotan Y**, and Roehrborn CG: Clearance rates of total prostate specific antigen (psa) after radical prostatectomy in African Americans and Caucasians. *Prostate cancer and Prostatic Diseases.* 2002; 5, 111-114.
7. **Lotan Y**, Gettman MT, Ogan K, Baker LA, Cadeddu JA.: Clinical use of the Holmium:Yag laser in laparoscopic partial nephrectomy *J Endourol.* 2002 Jun;16(5):289- 92. PMID; 12184078.
8. **Lotan Y**, Gettman MT, Roehrborn CG, Pearle MS, Cadeddu JA.: Cost comparison for laparoscopic nephrectomy and open nephrectomy: analysis of individual parameters. *Urology.* 2002 Jun;59(6):821-5. PMID: 12031360.
9. Gettman MT, **Lotan Y**, Lindberg G, Napper CA, Hoopman J, Pearle MS, Cadeddu JA: Laparoscopic interstitial laser coagulation of renal tissue with and without hilar occlusion in the porcine model. *J Endourol* 2002 Oct;16(8):565-70. PMID: 12470463.
10. Ogan K, **Lotan Y**, Koeneman K, Pearle MS, Cadeddu JA, Rassweiler J: Laparoscopic versus open retroperitoneal lymph node dissection: a cost analysis. *J Urol.* 2002 Nov;168(5):1945-9. PMID: 12394682.

11. Ogan K, Wilhelm D, Lindberg G, **Lotan Y**, Napper C, Hoopman J, Pearle MS, Cadeddu JA.: Laparoscopic partial nephrectomy with a diode laser: porcine results. J Endourol 2002 Dec;16(10):749-53. PMID: 12542878.
12. Gettman MT, **Lotan Y**, Roehrborn CG, Cadeddu JA, Pearle MS: Cost-Effective Treatment for Ureteropelvic Junction Obstruction: A Decision Tree Analysis. J Urol 2003 Jan;169(1):228-232. PMID: 12478142.
13. **Lotan Y** and Roehrborn CG: Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta- analyses. Urology 2003 Jan;61(1):109-18. PMID: 12559279.
14. **Lotan, Y**, Gettman, M. T., Roehrborn, C. G., Pearle M. S., Cadeddu, J. A.: Laparoscopic nephrectomy is cost effective compared with open nephrectomy in a large county hospital. JLSLS, 7: 111-5, 2003. PMID: 12856840.
15. **Lotan, Y.**, Duchene, D. A., Cadeddu, J. A., Koeneman, K. S.: Cost Comparison of Hand Assisted Laparoscopic Nephrectomy and Open Nephrectomy: Analysis of Individual Parameters. J Urol. 2003 Sep;170(3):752-755. PMID: 12913690.
16. Gettman MT, **Lotan Y**, Cadeddu JA: Laparoscopic treatment of ovarian vein syndrome. JLSLS. 2003 Jul-Sep;7(3):257-60. PMID: 14558716.
17. Duchene DA, **Lotan Y**, Cadeddu JA, Sagalowsky AI, Koeneman KS: Histopathology of Surgically Managed Renal Tumors: Analysis of a Contemporary Series. Urology 2003 Nov; 62 (5): 827-830. PMID: 14624902.
18. **Lotan Y**, Roehrborn CG, McConnell JD, Hendin BN: Factors Influencing the Outcomes of Penile Prosthesis Surgery at a Teaching Institution. Urology 2003 Nov; 62 (5): 918- 921. PMID: 14624920.
19. Johnson DB, Taylor GD, **Lotan Y**, Sagalowsky AI, Koeneman KS, Cadeddu JA: Effects of Radiofrequency Ablation On Renal Function and Blood Pressure. J Urol 2003 Dec; 170 (6 part 1): 2234-2236. PMID: 14634386.
20. Shariat SF, **Lotan Y**, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM, Ashfaq R.: Survivin expression is associated with features of biologically aggressive prostate cancer. Cancer. 2004 Feb 15;100(4):751-7. PMID: 14770431.
21. **Lotan Y**, Gettman MT, Lindberg G, Napper CA, Hoopman J, Pearle MS, Cadeddu JA.: Laparoscopic Partial Nephrectomy Using Holmium Laser in a Porcine Model. JLSLS. 2004 Jan-Mar;8(1):51-5. PMID: 14974664.
22. **Lotan Y**, Duchene DA, Cadeddu JA, Sagalowsky AI, Koeneman KS. Changing Management of Organ Confined Renal Masses: A new treatment Algorithm. J Endourol 2004 April 18;(3):263-268. PMID: 15225392.
23. **Lotan Y**, Shariat SF, Khoddami SM, Saboorian H, Koeneman KS, Cadeddu JA, Sagalowsky AI, McConnell JD, Roehrborn CG.: The percent of biopsy cores positive for cancer is a predictor of advanced pathologic stage and poor clinical outcomes in patients treated with radical prostatectomy. J Urol. 2004 Jun;171(6, Part 1 Of 2):2209- 2214. PMID; 15126787.
24. Khoddami SM, Shariat SF, **Lotan Y**, Saboorian H, McConnell JD, Sagalowsky AI, Roehrborn CG, Koeneman KS: Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy. BJU Int. 2004 Jul;94(1):42-6. PMID: 15217428.
25. Lorenzo AJ, Samuelson ML, Docimo SG, Baker LA, **Lotan Y**. Cost Analysis Of Laparoscopic Versus Open Orchiopexy In The Management Of Unilateral Nonpalpable Testicles. J Urol. 2004 Aug;172(2):712-716. PMID: 15247768.
26. **Lotan Y**, Cadeddu JA, Gettman MT. The New Economics of Radical Prostatectomy: Evaluation of Laparoscopic and Robot-Assisted Techniques. J Urol. 2004 Oct;172(4, Part 1 Of 2):1431-1435. PMID: 15371862.

27. **Lotan Y**, Jeffrey A. Cadeddu, Claus G. Roehrborn, Key H. Stage. The Value Of Your Time: Evaluation Of Changes In Medicare Reimbursement Rates On The Practice Of Urology. *J Urol* 2004 Nov; 172 (5 part 1): 1958-62. PMID: 15540765.
28. **Lotan Y**, Jeffrey A. Cadeddu, Claus G. Roehrborn, Charles Y. C. Pak and Margaret S. Pearle. Cost-effectiveness of medical management strategies for nephrolithiasis. *J. Urol.* 2004 Dec. 172:2275-2281. PMID: 15538248.
29. **Lotan Y**, Cadeddu JA, Lee JJ, Roehrborn CG, Lippman SM. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. *J Clin Oncol.* 2005 Mar 20;23(9):1911-20. PMID: 15774783.
30. Shariat SF, Zippe C, Ludecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, Akaza H, Sawczuk I, Serretta V, Huland H, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Wians F Jr, Roehrborn CG, **Lotan Y**, Perrotte P, Benayoun S, Marberger MJ, Karakiewicz PI. Nomograms Including Nuclear Matrix Protein 22 For Prediction Of Disease Recurrence And Progression In Patients With Ta, T1 Or Cis Transitional Cell Carcinoma Of The Bladder. *J Urol.* 2005 May;173(5):1518- 1525. PMID; 15821471.
31. Eggener SE, **Lotan Y**, and Cheng EY. Magnetic resonance angiography (MRA) for the non-palpable testis: a cost and cancer risk analysis. *J Urol.* 2005 May;173(5):1745- 1750.
32. Malaeb BS, Martin DJ, Littooy FN, **Lotan Y**, Waters WB, Flanigan RC, Koeneman KS. Utility of Screening Renal Ultrasonography: Identification of Renal Cell Carcinoma in an Elderly Asymptomatic Population. *BJU Int.* 2005 May;95(7):977-81. PMID: 15839917.
33. **Lotan Y**, Cadeddu JA. Cost Comparison of Nephron-Sparing Renal Tumor Surgical Techniques. *BJU Int.* 2005 May;95(7):1039-42 .
34. Gordon SA, Stage KH, Tansey KE, **Lotan Y**. Conservative management of priapism in acute spinal cord injury. *Urology.* 2005 Jun; 65(6): 1195-7. PMID: 15913719.
35. **Lotan Y**, Cadeddu JA. A cost comparison of nephron-sparing surgical techniques for renal tumor. *BJU Int* 2005 May; 95(7): 1039-42. PMID: 15839927.
36. **Lotan Y**, Cadeddu JA, Pearle MS. International comparison of cost effectiveness of medical management strategies for nephrolithiasis. *Urol Res.* 2005 Jun; 33(3): 223-30. Epub 2005 May 28. PMID: 15924256.
37. Shariat SF, Herman MP, Casella R, **Lotan Y**, Karam JA, Stenman UH. Urinary Levels of Tumor-Associated Trypsin Inhibitor (TATI) in the Detection of Transitional Cell Carcinoma of the Urinary Bladder. *Eur Urol.* 2005 Sep;48(3):424-31. PMID: 15963628.
38. Svatek RS, Lee D, **Lotan Y**. Correlation of Office-Based Cystoscopy and Cytology with Histologic Diagnosis: How Good is the Gold Standard? *Urology.* 2005 Jul;66(1):65-8. PMID: 15992876.
39. Margulis V, Matsumoto ED, Svatek R, Kabbani W, Cadeddu JA, **Lotan Y**. Application of novel hemostatic agent during laparoscopic partial nephrectomy. *J Urol.* 2005 Aug;174(2):761-4. PMID: 16006972.
40. **Lotan Y**, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Perotte P, Schoenberg MP, Lerner SP, Sagalowsky AI. Lymphovascular Invasion Is Independently Associated With Overall Survival, Cause- Specific Survival, and Local and Distant Recurrence in Patients With Negative Lymph Nodes at Radical Cystectomy. *J Clin Oncol.* 2005 Sep 20;23(27):6533-9. PMID: 16116151.

41. Anderson JK, Murdock A, Cadeddu JA, **Lotan Y**. Cost Comparison of Laparoscopic versus Radical Retropubic Prostatectomy. *Urology*. 2005 Sep;66(3):557-60. PMID: 16140077.
42. Shariat SF, Ashfaq R, Roehrborn CG, Slawin KM, **Lotan Y**. Expression of Survivin and Apoptotic Biomarkers in Benign Prostatic Hyperplasia. *J Urol*. 2005 Nov;174(5):2046-50. PMID: 16217391.
43. Shariat SF, Duchene D, Kabbani W, Mucher Z, **Lotan Y**. Gastrointestinal Hemorrhage as First Manifestation of a Metastatic Testicular Tumor. *Urology*. 2005 Dec;66(6):1319. PMID: 16360470.
44. Shariat SF, Abdel-Aziz KF, Roehrborn CG, **Lotan Y**. Pre-operative Percent Free PSA Predicts Clinical Outcomes in Patients Treated with Radical Prostatectomy with Total PSA Levels below 10 ng/ml. *Eur Urol* 2006 Feb;49(2):293-302. PMID: 16387412.
45. Svatek RS, Herman MP, **Lotan Y**, Casella R, Hsieh JT, Sagalowsky AI, Shariat SF. Soluble Fas-A promising novel urinary marker for the detection of recurrent superficial bladder cancer. *Cancer*. 2006 Apr 15; 106(8): 1701-7. PMID: 16541433.
46. Palapattu GS, Shariat SF, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, **Lotan Y**, Vazina A, Gupta A, Sagalowsky AI, Lerner SP, Schoenberg MP; Bladder Cancer Research Consortium. Cancer specific outcomes of patients with pt0 disease following radical cystectomy. *J Urol*. 2006 May;175(5):1645-9. PMID: 16600721.
47. **Lotan Y**, Stanfield J, Cho LC, Sherwood JB, Abdel-Aziz KF, Chang CH, Forster K, Kabbani W, Hsieh JT, Choy H, Timmerman R. Efficacy of High Dose per Fraction Radiation for Implanted Human Prostate Cancer in a Nude Mouse Model. *J Urol*. 2006 May;175(5):1932-6. PMID: 16600801.
48. Walsh L, Stanfield JL, Cho LC, Chang CH, Forster K, Kabbani W, Cadeddu JA, Hsieh JT, Choy H, Timmerman R, **Lotan Y**. Efficacy of Ablative High-Dose-per-Fraction Radiation for Implanted Human Renal Cell Cancer in a Nude Mouse Model. *Eur Urol*. 2006 Mar 29; 50(4): 795-800. Epub 2006 Mar 29. PMID: 16632182.
49. Rogers CG, Palapattu GS, Shariat SF, Karakiewicz PI, Bastian PJ, **Lotan Y**, Gupta A, Vazina A, Gilad A, Sagalowsky AI, Lerner SP, Schoenberg MP. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. *J Urol*. 2006 Jun;175(6):2048-53. PMID: 16697800.
50. Svatek RS, Sagalowsky AI, **Lotan Y**. Economic impact of screening for bladder cancer using bladder tumor markers: A decision analysis. *Urol Oncol*. 2006 Jul-Aug;24(4):338- 43. PMID: 16818188.
51. Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI, **Lotan Y**. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. *Eur Urol* 2007 Jan; 51(1): 137-49; discussion 149-51. Epub 2006. Jun 8. PMID: 16793197.
52. Karakiewicz PI, Shariat SF, Palapattu GS, Perrotte P, **Lotan Y**, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg M, Lerner SP. Precystectomy Nomogram for Prediction of Advanced Bladder Cancer Stage. *Eur Urol*. 2006 Dec; 50(6): 1254-60. Discussion 1261-2. Epub 2006 Jun 23. PMID: 16831511.
53. **Lotan Y**, Svatek RS, and Sagalowsky AI. Should we screen for bladder cancer in a high-risk population?: a cost per life-year saved analysis. *Cancer*. 2006 Sep 1;107(5):982-90. PMID: 16862567.
54. Shariat SF, Marberger MJ, **Lotan Y**, Sanchez-Carbayo M, Zippe C, Ludecke G, Boman H, Sawczuk I, Friedrich MG, Casella R, Mian C, Eissa S, Akaza H, Serretta V,

- Huland H, Hedelin H, Raina R, Miyanaga N, Sagalowsky AI, Roehrborn CG, Karakiewicz PI. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. *J Urol*. 2006 Sep;176(3):919-26. PMID: 16890655.
55. Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, **Lotan Y**. The cost of prostate cancer chemoprevention: a decision analysis model. *Cancer Epidemiol Biomarkers Prev*. 2006 Aug;15(8):1485-9. Erratum in: *Cancer Epidemiol Biomarkers Prev*. 2007 May;16(5):1042. PMID: 16896037.
56. Park S, Anderson JK, Matsumoto ED, **Lotan Y**, Josephs S, Cadeddu JA. Radiofrequency ablation of renal tumors: intermediate-term results. *J Endourol*. 2006 Aug;20(8):569-73. PMID: 16903817.
57. Shariat SF, Ashfaq R, Sagalowsky AI, **Lotan Y**. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. *Hum Pathol*. 2006 Dec;37(12):1568-76. Epub 2006 Aug 10. PMID: 16949911.
58. Svatek RS, **Lotan Y**, Hermann M, Duchene DA, Sagalowsky AI, Cadeddu JA. The influence of clinical and pathological stage discrepancy on cancer specific survival in patients treated for renal cell carcinoma. *J Urol*. 2006 Oct;176(4):1321-5. PMID: 16952621.
59. Karakiewicz PI, Shariat SF, Palapattu GS, Gilad AE, **Lotan Y**, Rogers CG, Vazina A, Gupta A, Bastian PJ, Perrotte P, Sagalowsky AI, Schoenberg M, Lerner SP. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. *J Urol*. 2006 Oct;176(4):1354-62. PMID: 16952631.
60. Shariat SF, Palapattu GS, Amiel GE, Karakiewicz PI, Rogers CG, Vazina A, Schoenberg MP, Lerner SP, Sagalowsky AI, **Lotan Y**. Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. *Urology*. 2006 Sep;68(3):538-42. Epub 2006 Sep 18. PMID: 16979748.
61. Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI, **Lotan Y**. Concomitant Carcinoma In Situ Is a Feature of Aggressive Disease in Patients With Organ-Confined TCC at Radical Cystectomy. *Eur Urol*. 2007 Jan;51(1):152-60. Epub 2006 Sep 11. PMID: 17011114.
62. Stern JM, Anderson JK, **Lotan Y**, Park S, Cadeddu JA. Nicotinamide adenine dinucleotide staining immediately following radio frequency ablation of renal tumors-is a positive stain synonymous with ablative failure? *J Urol*. 2006 Nov;176(5):1969-72; discussion 1972. PMID: 17070222.
63. Shariat SF, Karakiewicz PI, Palapattu GS, **Lotan Y**, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg MP, Lerner SP. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the bladder cancer research consortium. *J Urol*. 2006 Dec;176(6):2414-22. PMID: 17085118.
64. Nielsen ME, Shariat SF, Karakiewicz PI, **Lotan Y**, Rogers CG, Amiel GE, Bastian PJ, Vazina A, Gupta A, Lerner SP, Sagalowsky AI, Schoenberg MP, Palapattu GS; for the Bladder Cancer Research Consortium (BCRC). Advanced Age Is Associated with Poorer Bladder Cancer-Specific Survival in Patients Treated with Radical Cystectomy. *Eur Urol*. 2007 Mar;51(3):699-708. Epub 2006 Nov 13. PMID: 17113703.
65. Shariat SF, Karakiewicz PI, Palapattu GS, Amiel GE, **Lotan Y**, Rogers CG, Vazina A, Bastian PJ, Gupta A, Sagalowsky AI, Schoenberg M, Lerner SP. Nomograms provide improved accuracy for predicting survival after radical cystectomy. *Clin Cancer Res*. 2006 Nov 15;12(22):6663-76. PMID: 17121885.

66. Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, **Lotan Y**. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. *Clin Cancer Res*. 2006 Dec 15;12(24):7369-73. PMID: 17189409.
67. Vitaly Margulis, Joshua M Stern, Arthur I Sagalowsky and **Yair Lotan**. Radical cystectomy for transitional cell carcinoma of the bladder: what percentage of patients qualify for bladder preservation protocols? *Curr Urol* 2007;1:24-27.
68. Shariat SF, Ashfaq R, Sagalowsky AI, **Lotan Y**. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. *J Urol*. 2007 Feb;177(2):481- 7; discussion 487. PMID: 17222615.
69. Karam JA, **Lotan Y**, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, Shariat SF. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. *Lancet Oncol*. 2007 Feb;8(2):128-36. PMID: 17267327.
70. Park S, Jaffer O, **Lotan Y**, Saboorian H, Roehrborn CG, Cadeddu JA. Contemporary laparoscopic and open radical retropubic prostatectomy: pathologic outcomes and Kattan postoperative nomograms are equivalent. *Urology*. 2007 Jan;69(1):118-22. PMID: 17270631.
71. Margulis V, Shariat SF, Ashfaq R, Thompson M, Sagalowsky AI, Hsieh JT, **Lotan Y**. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. *J Urol*. 2007 Mar;177(3):1163-8. PMID: 17296438.
72. Shariat SF, Zlotta AR, Ashfaq R, Sagalowsky AI, **Lotan Y**. Cooperative effect of cell- cycle regulators expression on bladder cancer development and biologic aggressiveness. *Modern Pathology*. 2007 Apr; 20(4): 445-459. PMID: 17384651.
73. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, **Lotan Y**. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. *Cancer* 2007 Mar 15; 109(6): 1106-13. PMID: 17311310.
74. Karam JA, **Lotan Y**, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. *Prostate*. 2007 May; 67(6): 614-622. PMID: 17299799.
75. Stern JM, Svatek R, Park S, Hermann M, **Lotan Y**, Sagalowsky AI, Cadeddu JA. Intermediate comparison of partial nephrectomy and radiofrequency ablation for clinical T1a renal tumours. *BJU Int*. 2007 Aug;100(2):287-90. PMID: 17617136.
76. Malaeb BS, Rashid HH, **Lotan Y**, Khoddami SM, Shariat SF, Sagalowsky AI, McConnell JD, Roehrborn CG, Koeneman KS. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts. *Urol Oncol*. 2007 Jul-Aug;25(4):291-7. PMID: 17628294.
77. Karam JA, Shariat SF, Huang HY, Pong RC, Ashfaq R, Shapiro E, **Lotan Y**, Sagalowsky AI, Wu XR, Hsieh JT. Decreased DOC-2/DAB2 Expression in Urothelial Carcinoma of the Bladder. *Clin Cancer Res*. 2007 Aug 1;13(15 Pt 1):4400-4406. PMID: 17671122.
78. Walsh LP, Anderson JK, Baker MR, Han B, Hsieh JT, **Lotan Y**, Cadeddu JA. In vitro assessment of the efficacy of thermal therapy in human renal cell carcinoma. *Urology*. 2007 Aug;70(2):380-4. PMID: 17826524.
79. Stern JM, Stanfield J, **Lotan Y**, Park S, Hsieh JT, Cadeddu JA. Efficacy of laser- activated gold nanoshells in ablating prostate cancer cells in vitro. *J Endourol*. 2007 Aug;21(8):939-43. PMID: 17867958.

80. Shariat SF, Bensalah K, Karam JA, Roehrborn CG, Gallina A, **Lotan Y**, Slawin KM, Karakiewicz PI. Preoperative Plasma HER2 and Epidermal Growth Factor Receptor for Staging and Prognostication in Patients with Clinically Localized Prostate Cancer. *Clin Cancer Res.* 2007 Sep 15;13(18 Pt 1):5377-84. PMID: 17875766.
81. Karam JA, **Lotan Y**, Ashfaq R, Sagalowsky AI, Shariat SF. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. *Urology* 2007 Sep;70(3):482-6. PMID: 17905101.
82. Huang HY, Shariat SF, Sun TT, Lepor H, Shapiro E, Hsieh JT, Ashfaq R, **Lotan Y**, Wu XR. Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. *Hum Pathol.* 2007 Nov;38(11):1703- 13. Epub 2007 Aug 17. PMID: 17707461.
83. Nielsen ME, Palapattu GS, Karakiewicz PI, **Lotan Y**, Bastian PJ, Lerner SP, Sagalowsky AI, Schoenberg MP, Shariat SF. A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome. *BJU Int.* 2007 Nov;100(5):1015-20. PMID: 17784888.
84. Park S, Pearle MS, Cadeddu JA, **Lotan Y**. Laparoscopic and open partial nephrectomy: cost comparison with analysis of individual parameters. *J Endourol.* 2007 Dec;21(12):1449-54. PMID: 18186682.
85. Shariat SF, Ashfaq R, Sagalowsky AI, **Lotan Y**. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. *Urol Oncol.* 2007 Nov-Dec;25(6):468- 75. PMID: 18047954.
86. Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, **Lotan Y**. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. *Cancer.* 2008 Mar 1; 112(5): 1058-65. PMID: 18186497.
87. Shariat SF, Svatek RS, Kabbani W, Walz J, **Lotan Y**, Karakiewicz PI, Roehrborn CG. Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy. *BJU Int.* 2008 Jan;101(2):232-7. PMID: 17868422.
88. Shariat SF, Karakiewicz PI, Ashfaq R, Lerner SP, Palapattu GS, Cote RJ, Sagalowsky AI, **Lotan Y**. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. *Cancer.* 2008 Jan 15;112(2):315-25. PMID: 18008359.
89. Margulis V, **Lotan Y**, Shariat SF. Survivin: a promising biomarker for detection and prognosis of bladder cancer. *World J Urol* 2008 Feb; 26(1): 59-65. Epub 2007 Oct 26. PMID: 17962949.
90. Bensalah K, Pearle M, **Lotan Y**. Cost-Effectiveness of Medical Expulsive Therapy Using Alpha-Blockers for the Treatment of Distal Ureteral Stones. *Eur Urol.* 2008 Feb;53(2):411-9. PMID: 17889988.
91. Bensalah K, Zeltser I, Tuncel A, Cadeddu J, **Lotan Y**. Evaluation of costs and morbidity associated with laparoscopic radiofrequency ablation and laparoscopic partial nephrectomy for treating small renal tumours. *BJU Int.* 2008 Feb;101(4):467-71. Epub 2007 Oct 8. PMID: 17922853.
92. Bastian PJ, Hutterer GC, Shariat SF, Rogers CG, Palapattu GS, **Lotan Y**, Vazina A, Amiel GE, Gupta A, Sagalowsky AI, Lerner SP, Schoenberg MP, Karakiewicz PI; from the Bladder Cancer Research Consortium. Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival. *BJU Int.* 2008 Feb;101(4):450-4. PMID: 17850359.

93. Gupta A, **Lotan Y**, Bastian PJ, Palapattu GS, Karakiewicz PI, Raj GV, Schoenberg MP, Lerner SP, Sagalowsky AI, Shariat SF. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. *Urology*. 2008 Feb; 71(2):302-7. PMID: 18308108.
94. **Lotan Y**, Shariat SF, the NMP22 Study Group. Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. *BJU Int*. 2008 Jun; 101(11): 1362-7. Epub Feb. 18. PMID: 18284410.
95. Hutterer GC, Karakiewicz PI, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Elissa S, Akaza H, Serretta V, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Perrotte P, **Lotan Y**, Marberger MJ, Shariat SF. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma. *BJU Int*. 2008 Mar; 101(5):561-5. PMID: 18257856.
96. Margulis V, **Lotan Y**, Montorsi F, Shariat SF. Predicting survival after radical cystectomy for bladder cancer. *BJU Int*. 2008 Jul; 102(1): 15-22. Epub Mar 5. PMID: 18325050.
97. Lucas SM, Svatek RS, Olgin G, Arriaga Y, Kabbani W, Sagalowsky AI, **Lotan Y**. Conservative management in selected patients with upper tract urothelial carcinoma compares favourably with early radical surgery. *BJU Int*. 2008 Jul;102(2):172-6 Epub 2008 Jul 1. PMID: 18341624.
98. Bensalah K, Raman JD, Bagrodia A, Marvin A, **Lotan Y**. Does obesity impact the costs of partial and radical nephrectomy? *J Urol*. 2008 May; 179(5):1714-7; discussion 1717- 8. Epub 2008 Mar 17. PMID: 18343428.
99. Raman JD, Thomas J, Lucas SM, Bensalah K, **Lotan Y**, Trimmer C, Cadeddu JA. Radiofrequency ablation for T1a tumors in a solitary kidney: promising intermediate oncologic and renal function outcomes. *Can J Urol*. 2008 Apr; 15(2):3980-5. PMID: 18405445.
100. Karam JA, Margulis V, Montorsi F, Karakiewicz PI, **Lotan Y**, Kikuchi E, Wiezer A, Zigeuner R, Bolenz C, Shariat SF. Carcinoma in situ of the Upper Urinary Tract Treated with Radical nephroureterectomy – Results from a Multicenter Study. *Eur Urol*. 2008 Oct;54(4):961-3. Epub 2008 May 8. PMID: 18485573.
101. **Lotan Y**, Bensalah K, Ruddell T, Shariat SF, Sagalowsky AI, Ashfaq R. Prospective Evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. *J Urol*. 2008 Jun; 179(6):2164-9. Epub 2008 Apr 18. PMID: 18423745.
102. Bensalah K, Tuncel A, Raman JD, Pearle MS, **Lotan Y**. Determinants of quality of life for patients with kidney stones. *J Urol*. 2008 Jun; 179(6):2238-43; discussion 2243. Epub 2008 Apr 18. PMID: 18423704.
103. Walz J, Shariat SF, Suardi N, Perrotte P, **Lotan Y**, Palapattu GS, Gupta A, Bastian PJ, Rogers CG, Vazina A, Amiel GE, Sagalowsky AI, Schoenberg M, Lerner SP, Karakiewicz PI. Adjuvant chemotherapy for bladder cancer does not alter cancer- specific survival after cystectomy in a matched case-control study. *BJU Int*. 2008 Jun; 101(11):1356-61. PMID: 18454792.
104. Gupta A, **Lotan Y**, Ashfaq R, Roehrborn CG, Raj GV, Aragaki, CC, Montoris F, Shariat SF. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. *Eur Urol*. 2009 May;55(5):1124-33. Epub 2008 Jun 23. PMID: 18585843.

105. **Lotan Y**, Bagrodia A, Roehrborn CG, Scott J. Are urologists fairly reimbursed for complex procedures: failure of 22 modifier? *Urology*. 2008 Sep;72(3):494-7. Epub 2008 Jul 2. PMID: 18597834.
106. Brugarolas J, **Lotan Y**, Watumull L, Kabbani W. Sirolimus in metastatic renal cell carcinoma. *J Clin Oncol*. 2008 Jul 10;26(20):3457-60. PMID: 18612163.
107. Brikowski TH, **Lotan Y**, Pearle MS. Climate-related increase in the prevalence of urolithiasis in the United States. *Proc Natl Acad Sci U.S.A.* 2008 Jul 15;105(28):9841-6. Epub 2008 Jul 14. PMID: 18626008.
108. Bagrodia A, Gupta A, Raman JD, Bensalah K, Pearle MS, **Lotan Y**. Impact of body mass index on cost and clinical outcomes after percutaneous nephrostolithotomy. *Urology*. 2008 Oct;72(4):756-60. Epub 2008 Aug 2. PMID: 18718645.
109. Park HS, Park WS, Bondaruk J, Tanaka N, Katayama H, Lee S, Spiess PE, Steinberg JR, Wang Z, Katz RL, Dinney C, Elias KJ, **Lotan Y**, Naeem RC, Baggerly K, Sen S, Grossman HB, Czerniak B. Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. *J. Natl Cancer Inst.* 2008 Oct 1; 100(19):1401- 11. Epub 2008 Sep 23. PMID: 18812553.
110. Fernández MI, Shariat SF, Margulis V, Bolenz C, Montorsi F, Suardi N, Remzi M, Wood CG, Roscigno M, Kikuchi E, Oya M, Zigeuner R, Langner C, Weizer A, **Lotan Y**, Koppie TM, Raman JD, Karakiewicz P, Bensalah K, Schultz M, Bernier P. Evidence-based Sex-Related Outcomes after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Results of Large Multicenter Study. *Urology*. 2009 Jan;73(1):142-6. Epub 2008 Oct 8. PMID: 18845322.
111. Remzi M, Haitel A, Margulis V, Karakiewicz P, Montorsi F, Kikuchi E, Zigeuner R, Weizer A, Bolenz C, Bensalah K, Suardi N, Raman JD, **Lotan Y**, Waldert M, Ng CK, Fernández M, Koppie TM, Ströbel P, Kabbani W, Murai M, Langner C, Roscigno M, Wheat J, Guo CC, Wood CG, Shariat SF. Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. *BJU Int*. 2009 Feb; 103(3):307-11. Epub 2008 Oct. 16. PMID: 18990163.
112. Bolenz C, Shariat SF, Fernández MI, Margulis V, **Lotan Y**, Karakiewicz P, Remzi M, Kikuchi E, Zigeuner R, Weizer A, Montorsi F, Bensalah K, Wood CG, Roscigno M, Langner C, Koppie TM, Raman JD, Mikami S, Michel MS, Ströbel P. Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph-node density. *BJU Int*. 2009 Feb; 103(3): 302-6. Epub 2008 Oct 16. PMID: 18990164.
113. Bagrodia A, Raman JD, Bensalah K, Pearle MS, **Lotan Y**. Synchronous Bilateral Percutaneous Nephrostolithotomy: Analysis of Clinical Outcomes, Cost and Surgeon Reimbursement. *J Urol*. 2009 Jan;181(1):149-53. Epub 2008 Nov 13. PMID: 19012904.
114. Gupta A, Karakiewicz PI, Roehrborn CG, **Lotan Y**, Zlotta AR, Shariat SF. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. *Clin Cancer Res*. 2008 Nov 15; 14(22):7385-90. PMID: 19010854.
115. Lucas SM, Nuss G, Stern J, **Lotan Y**, Sagalowsky AI, Cadeddu JA, Raj GV. The Screening for Occult Renal Disease (SCORED) value is associated with a higher risk for having or developing chronic kidney disease in patients treated for small, unilateral renal masses. *Cancer*. 2008 Nov 15;113(10):2681-6. PMID: 18853420.
116. Capitanio U, Suardi N, Shariat SF, **Lotan Y**, Palapattu GS, Bastian PJ, Gupta A, Vazina A, Schoenberg M, Lerner SP, Sagalowsky AI, Karakiewicz PI. Assessing the

- minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. *BJU Int.* 2009 May;103(10):1359-62. Epub 2008 Dec 8. PMID: 19076140.
117. Kikuchi E, Margulis V, Karakiewicz PI, Roscigno M, Mikami S, **Lotan Y**, Remzi M, Bolenz C, Langner C, Weizer A, Montorsi F, Bensalah K, Koppie TM, Fernández MI, Raman JD, Kassouf W, Wood CG, Suardi N, Oya M, Shariat SF. Lymphovascular Invasion Predicts Clinical Outcomes in Patients With Node-Negative Upper Tract Urothelial Carcinoma. *J Clin Oncol.* 2009 Feb.1;27(4):612-8. Epub 2008 Dec15. PMID: 19075275.
 118. Nieder AM, **Lotan Y**, Nuss GR, Langston JP, Vyas S, Manoharan M, Soloway MS. Are patients with hematuria appropriately referred to Urology? A multi-institutional questionnaire based survey. *Urol Oncol.* 2010 Sep-Oct;28(5):500-3. Epub 2008 Dec 20. PMID: 19097811.
 119. Ng CK, Shariat SF, Lucas SM, Bagrodia A, **Lotan Y**, Scherr DS, Raman JD. Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper-tract urothelial carcinoma? *Urol Oncol.* 2011 Jan-Feb;29(1):27-32. Epub 2008 Dec 30. PMID: 19117771.
 120. Margulis V, **Lotan Y**, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, Montorsi F, Bastian PJ, Nielsen ME, Miller SC, Rigaud J, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI, Shariat SF. Multi-Institutional Validation of the Predictive Value of Ki-67 Labeling Index in Patients with Urinary Bladder Cancer. *J Natl Cancer Inst.* 2009 Jan21;101(2):114-9. Epub 2009 Jan 13. PMID: 19141773.
 121. Raman JD, Bagrodia A, Gupta A, Bensalah K, Cadeddu JA, **Lotan Y**, Pearle MS. Natural history of residual fragments following percutaneous nephrostolithotomy. *J Urol.* 2009 Mar; 181(3):1163-8. Epub 2009 Jan 18. PMID: 19152935.
 122. Bagrodia A, Grover S, Srivastava A, Gupta A, Bolenz C, Sagalowsky AI, **Lotan Y**. Impact of body mass index on clinical and cost outcomes after radical cystectomy. *BJU Int.* 2009 Aug;104(3):326-30. Epub 2009 Feb 11. PMID 19220244.
 123. Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, **Lotan Y**, Weizer A, Raman JD, Wood CG, et al; The Upper Tract Urothelial Carcinoma Collaboration. Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration. *Cancer.* 2009 Mar 15;115(6): 1224-33. PMID: 19156917.
 124. **Lotan Y**, Capitanio U, Shariat SF, Hutterer GC, Karakiewicz PI. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. *BJU Int.* 2009 May;103(10):1368-74. Epub Mar 11. PMID: 19338566.
 125. Stern JM, Gupta A, Raman JD, Cost N, Lucas S, **Lotan Y**, Raj GV, Cadeddu JA. Radiofrequency ablation of small renal cortical tumours in healthy adults: renal function preservation and intermediate oncological outcome. *BJU Int.* 2009 Sep;104(6):786-9. Epub 2009 Apr 4. PMID: 19426196.
 126. Roscigno M, Shariat SF, Margulis V, Karakiewicz P, Remzi M, Kikuchi E, Langner C, **Lotan Y**, Weizer A, Bensalah K, Raman JD, Bolenz C, Guo CC, Wood CG, Zigeuner R, Wheat J, Kabbani W, Koppie TM, Ng CK, Suardi N, Bertini R, Fernández MI, Mikami S, Isida M, Michel MS, Montorsi F. Impact of Lymph Node Dissection on Cancer Specific Survival in Patients With Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy. *J Urol.* 2009 June; 181(6):2482-2489. Epub 2009 April 16. PMID: 19371878.

127. Oh JH, **Lotan Y**, Gurnaini P, Rosenblatt KP, Gao J. Prostate cancer biomarker discovery using high performance mass spectral serum profiling. *Comput Methods Programs Biomed.* 2009 Oct;96(1):33-41. Epub 2009 May 6. PMID: 19423179.
128. Shariat SF, Bolenz C, Godoy G, Fradet Y, Ashfaq R, Karakiewicz PI, Isbarn H, Jeldres C, Rigaud J, Sagalowsky AI, **Lotan Y**. Predictive Value of Combined Immunohistochemical Markers in Patients With pT1 Urothelial Carcinoma at Radical Cystectomy. *J Urol.* 2009 Jul;182(1):78-84; discussion 84. Epub 2009 May 17. PMID: 19447418.
129. **Lotan Y**, Elias K, Svatek RS, Bagrodia A, Nuss G, Moran B, Sagalowsky AI. Bladder Cancer Screening in a High Risk Asymptomatic Population Using a Point of Care Urine Based Protein Tumor Marker. *J Urol.* 2009 Jul;182(1):52-7; discussion 58. Epub 2009 May 17. PMID: 19450825.
130. Isbarn H, Karakiewicz PI, Shariat SF, Capitanio U, Palapattu GS, Sagalowsky AI, **Lotan Y**, Schoenberg MP, Amiel GE, Lerner SP, Sonpavde G. Residual Pathological Stage at Radical Cystectomy Significantly Impacts Outcomes for Initial T2N0 Bladder Cancer. *J Urol.* 2009 Aug;182(2):459-65; discussion 465. Epub 2009 Jun 13. PMID: 19524971.
131. Bagrodia A, Gupta A, Raman JD, Bensalah K, Pearle MS, **Lotan Y**. Predictors of Cost and Clinical Outcomes of Percutaneous Nephrostolithotomy. *J Urol.* 2009 Aug;182(2):586-90. Epub 2009 Jun 17. PMID: 19535106.
132. Gupta A, Raman JD, Leveillee RJ, Wingo MS, Zeltser IS, **Lotan Y**, Trimmer C, Stern JM, Cadeddu JA. General Anesthesia and Contrast-Enhanced Computed Tomography to Optimize Renal Percutaneous Radiofrequency Ablation: Multi-Institutional Intermediate-Term Results. *J Endourol.* 2009 Jul;23(7):1099-105. Epub 2009 Jun 16. PMID: 19530948.
133. van Rhijn BW, Burger M, **Lotan Y**, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR. Recurrence and Progression of Disease in Non-Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy. *Eur Urol.* 2009 Sep; 56(3):430-42. Epub 2009 Jun 26. PMID: 19576682.
134. **Lotan Y**, Kamat AM, Porter MP, Robinson VL, Shore N, Jewett M, Schelhammer PF, deVere White R, Quale D, Lee CT; bladder Cancer Think Tank; Bladder Cancer Advocacy Network; Society of Urologic Oncology. Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the bladder Cancer Advocacy Network, and the Society of Urologic Oncology. *Cancer* 2009 sep 15; 115(18): 4096-103. PMID: 19536899.
135. Bolenz C, **Lotan Y**, Ashfaq R, Shariat SF. Estrogen and Progesterone Hormonal Receptor Expression in Urothelial Carcinoma of the Bladder. *Eur Urol.* 2009 Dec; 56(6): 1093-5. Epub 2009 Jul 7. PMID: 19596509.
136. Raman JD, Ng CK, Scherr DS, Margulis V, **Lotan Y**, Bensalah K, Patard JJ, Kikuchi E, Montorsi F, Zigeuner R, Weizer A, Bolenz C, Koppie TM, Isbarn H, Jeldres C, Kabbani W, Remzi M, Waldert M, Wood CG, Roscigno M, Oya M, Langner C, Wolf JS, Ströbel P, Fernández M, Karakiewicz P, Shariat SF. Impact of Tumor Location on Prognosis for Patients with Upper Tract Urothelial Carcinoma Managed by Radical Nephroureterectomy. *Eur Urol.* 2010 Jun; 57(6): 1072-9. Epub 2009 Jul 15. PMID: 19619934.
137. Shariat SF, **Lotan Y**, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Müller SC, Karam JA, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI, Cote RJ. p53 Predictive Value for pT1-2 N0 Disease at Radical Cystectomy. *J Urol.* 2009 Sep; 182(3):907-13. Epub 2009 Jul 17. PMID: 19616250.

138. Bensalah K, Tuncel A, Raman JD, Bagrodia A, Pearle M, **Lotan Y**. How Physician and Patient Perceptions Differ Regarding Medical Management of Stone Disease. *J Urol*. 2009 Sep;182(3):998-1004. Epub 2009 Jul 18. PMID: 19616801.
139. Shariat SF, Bolenz C, Karakiewicz PI, Fradet Y, Ashfaq R, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Rigaud J, Müller SC, Lerner SP, Montorsi F, Sagalowsky AI, Cote RJ, **Lotan Y**. p53 expression in patients with advanced urothelial cancer of the urinary bladder. *BJU Int*. 2010 Feb;105(4):489-95. Epub 2009 Jul 31. PMID: 19659466.
140. Waldert M, Karakiewicz PI, Raman JD, Remzi M, Isbarn H, **Lotan Y**, Capitanio U, Bensalah K, Marberger MJ, Shariat SF. A delay in radical nephroureterectomy can lead to upstaging. *BJU Int*. 2010 Mar; 105(6):812-7. Epub 2009 Sep 3. PMID: 19732052.
141. Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Tilki D, Otto W, Capitanio U, Izawa JI, Ficarra V, Lerner S, Sagalowsky AI, Schoenberg M, Kamat A, Dinney CP, **Lotan Y**, Shariat SF. Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort. *Eur Urol*. 2010 Feb;57(2):300-9. Epub 2009 Sep 12. PMID: 19766384.
142. **Lotan Y**, Bolenz C, Gupta A, Hotze T, Ho R, Cadeddu JA, Roehrborn CG. The effect of the approach to radical prostatectomy on the profitability of hospitals and surgeons. *BJU Int*. Jun;105(11):1531-1535. Epub 2009 Oct 28. PMID: 19874301.
143. Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Lerner SP, Sagalowsky AI, Cote RJ, **Lotan Y**. Combination of Multiple Molecular Markers Can Improve Prognostication in Patients With Locally Advanced and Lymph Node Positive Bladder Cancer. *J Urol*. 2010 Jan(183(1)):68-75. Epub 2009 Nov 11. PMID: 19913255.
144. Bolenz C, Gupta A, Hotze T, Ho R, Cadeddu JA, Roehrborn CG, **Lotan Y**. Cost Comparison of Robotic, Laparoscopic, and Open Radical Prostatectomy for Prostate Cancer. *Eur Urol*. 2010 Mar;57(3):453-8. Epub 2009 Nov 11. PMID: 19931979.
145. Raman JD, Bagrodia A, Bensalah K, Pearle MS, **Lotan Y**. Residual Fragments After Percutaneous Nephrolithotomy: Cost Comparison of Immediate Second Look Flexible Nephroscopy Versus Expectant Management. *J Urol*. 2010 Jan;183(1):188-93. Epub 2009 Nov 12. PMID: 19913809.
146. Schlomer BJ, Ho R, Sagalowsky A, Ashfaq R, **Lotan Y**. Prospective Validation of the Clinical Usefulness of Reflex Fluorescence In Situ Hybridization Assay in Patients With Atypical Cytology for the Detection of Urothelial Carcinoma of the Bladder. *J Urol*. 2010 Jan;183(1):62-7. Epub 2009 Nov 12. PMID: 19913822.
147. Shariat SF, Godoy G, **Lotan Y**, Droller M, Karakiewicz PI, Raman JD, Isbarn H, Weizer A, Remzi M, Roscigno M, Kikuchi E, Bolenz C, Bensalah K, Koppie TM, Kassouf W, Wheat JC, Zigeuner R, Langner C, Wood CG, Margulis V. Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy. *BJU Int*. 2010 Jun; 105(12): 1672-1677. Epub 2009 Nov 13. PMID: 19912201.
148. Shariat SF, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y, Isbarn H, Montorsi F, Jeldres C, Bastian PJ, Nielsen ME, Müller SC, Sagalowsky AI, **Lotan**

- Y.** Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. *Clin Cancer Res.* 2009 Nov 15;15(22):7012-9. Epub 2009 Nov 10. PMID: 19903782.
149. Tilki D, Svatek RS, Karakiewicz PI, Isbarn H, Reich O, Kassouf W, Fradet Y, Novara G, Fritsche HM, Bastian PJ, Izawa JI, Stief CG, Ficarra V, Lerner SP, Schoenberg M, Dinney CP, Skinner E, **Lotan Y**, Sagalowsky AI, Shariat SF. Characteristics and Outcomes of Patients With pT4 Urothelial Carcinoma at Radical Cystectomy: A Retrospective International Study of 583 Patients. *J Urol.* 2010 Jan; 183(1): 87-93. Epub 2009 Nov 24. PMID: 19942232.
150. Raman JD, Shariat SF, Karakiewicz PI, **Lotan Y**, Sagalowsky AI, Roscigno M, Montorsi F, Bolenz C, Weizer AZ, Wheat JC, Ng CK, Scherr DS, Remzi M, Waldert M, Wood CG, Margulis V; for the Upper-Tract Urothelial Carcinoma Collaborative Group. Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy? *Urol Oncol.* 2011 Nov-Dec; 29(6): 716-23. Epub 2010 Jan 6. PMID: 20056458.
151. Bolenz C, Shariat SF, Karakiewicz PI, Ashfaq R, Ho R, Sagalowsky AI, **Lotan Y**. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. *BJU Int.* 2010 Oct;106(8):1216-22. Epub 2010 Jan 19. PMID: 20089105.
152. Tilki D, Reich O, Karakiewicz PI, Novara G, Kassouf W, Ergün S, Fradet Y, Ficarra V, Sonpavde G, Stief CG, Skinner E, Svatek RS, **Lotan Y**, Sagalowsky AI, Shariat SF. Validation of the AJCC TNM Substaging of pT2 Bladder Cancer: Deep Muscle Invasion Is Associated with Significantly Worse Outcome. *Eur Urol.* 2010 Jul; 58(1): 112-7. Epub 2010 Jan 20. PMID: 20097469.
153. Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, Bastian PJ, Volkmer BG, Kassouf W, Novara G, Fritsche HM, Izawa JI, Ficarra V, Lerner SP, Sagalowsky AI, Schoenberg MP, Kamat AM, Dinney CP, **Lotan Y**, Marberger MJ, Fradet Y. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. *BJU Int.* 2010 May; 105(10):1402-1414. Epub 2010 Feb 2. PMID: 20132195.
154. Tilki D, Reich O, Svatek RS, Karakiewicz PI, Kassouf W, Novara G, Ficarra V, Chade DC, Fritsche HM, Gerwens N, Izawa JI, Lerner SP, Schoenberg M, Stief CG, Skinner E, **Lotan Y**, Sagalowsky AI, Shariat SF. Characteristics and Outcomes of Patients With Clinical Carcinoma In Situ Only Treated With Radical Cystectomy: An International Study of 243 Patients. *J Urol.* 2010 May; 183(5):1757-63. Epub 2010 Mar 17. PMID: 20299059.
155. Shariat SF, Youssef RF, Gupta A, Chade DC, Karakiewicz PI, Isbarn H, Jeldres C, Sagalowsky AI, Ashfaq R, **Lotan Y**. Association of Angiogenesis Related Markers With Bladder Cancer Outcomes and Other Molecular Markers. *J Urol.* 2010 May 183(5):1744- 50. Epub 2010 Mar 17. PMID: 20299037.
156. Bolenz C, Gupta A, Hotze T, Ho R, Cadeddu JA, Roehrborn CG, **Lotan Y**. The influence of body mass index on the cost of radical prostatectomy for prostate cancer. *BJU Int.* 2010 Oct; 106(8):1188-93. Epub 2010 Mar 23. PMID: 20346046.
157. Novara G, Svatek RS, Karakiewicz PI, Skinner E, Ficarra V, Fradet Y, **Lotan Y**, Isbarn H, Capitanio U, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Tilki D, Dinney CP, Lerner SP, Schoenberg M, Volkmer BG, Sagalowsky AI, Shariat SF. Soft Tissue Surgical Margin Status is a Powerful Predictor of Outcomes After Radical Cystectomy: A Multicenter Study of More Than 4,400 Patients. *J Urol.* 2010 Jun; 183(6): 2165-70. PMID: 20399473.

158. Wheat JC, Weizer AZ, Wolf JS Jr, **Lotan Y**, Remzi M, Margulis V, Wood CG, Montorsi F, Roscigno M, Kikuchi E, Zigeuner R, Langner C, Bolenz C, Koppie TM, Raman JD, Fernández M, Karakiewicz P, Capitanio U, Bensalah K, Patard JJ, Shariat SF. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. *Urol Oncol*. 2012 May-Jun; 30(3): 252-8. Epub 2010 May 6. PMID: 20451416.
159. Robinson VL, Porter M, Messing E, Fradet Y, Kamat AM, **Lotan Y**. BCAN Think Tank session 2: Molecular detection of bladder cancer, the path to progress. *Urol Oncol* 2010 May-Jun; 28(3): 334-7. PMID: 20439033.
160. Youssef RF, Schlomer BJ, Ho R, Sagalowsky AI, Ashfaq R, **Lotan Y**. Role of fluorescence in situ hybridization in bladder cancer surveillance of patients with negative cytology. *Urol Oncol*. 2012 May-Jun; 39(3): 273-7. Epub 2010 May 6. PMID: 20451422.
161. Brien JC, Shariat SF, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE, Terrell JD, Lucas SM, **Lotan Y**, Boorjian SA, Raman JD. Preoperative Hydronephrosis, Ureteroscopic Biopsy Grade and Urinary Cytology Can Improve Prediction of Advanced Upper Tract Urothelial Carcinoma. *J. Urol*. 2010 Jul; 184(1):69- 73. Epub 2010 May 15. PMID: 20478585.
162. Bolenz C, Ho R, Nuss GR, Ortiz N, Raj GV, Sagalowsky AI, **Lotan Y**. Management of elderly patients with urothelial carcinoma of the bladder: guideline concordance and predictors of overall survival. *BJU Int*. 2010 Nov; 106(9): 1324-9. PMID: 20500510.
163. Elias K, Svatek RS, Gupta S, Ho R, **Lotan Y**: High-risk patients with hematuria are not evaluated according to guideline recommendations. *Cancer*. 2010; Jun 15; 116(12): 2954-2959. PMID: 20564400.
164. Margulis V, Youssef RF, Karakiewicz PI, **Lotan Y**, Wood CG, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Shariat SF; Upper Tract Urothelial Carcinoma Collaborative Group. Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. *J Urol*. 2010 Aug;184(2):453-8. Epub 2010 Jun 17. PMID: 20620397.
165. **Lotan Y**, Shariat SF, Schmitz-Dräger BJ, Sanchez-Carbayo M, Jankevicius F, Racioppi M, Minner SJ, Stöhr B, Bassi PF, Grossman HB. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. *Urol Oncol* 2010 Jul- Aug; 28(4) 441-8. PMID: 20610281.
166. Tilki D, Svatek RS, Karakiewicz PI, Novara G, Seitz M, Sonpavde G, Gupta A, Kassouf W, Fradet Y, Ficarra V, Skinner E, **Lotan Y**, Sagalowsky AI, Stief CG, Reich O, Shariat SF. pT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder. *J Urol*. 2010 Aug;184(2):470-4. Epub 2010 Jun 17. PMID: 20620401.
167. Tilki D, Svatek RS, Novara G, Seitz M, Godoy G, Karakiewicz PI, Kassouf W, Fradet Y, Fritsche HM, Sonpavde G, Izawa JI, Ficarra V, Lerner SP, Schoenberg M, Stief CG, Dinney CP, Skinner E, **Lotan Y**, Sagalowsky AI, Reich O, Shariat SF. Stage pT0 at Radical Cystectomy Confers Improved Survival: An International Study of 4,430 Patients. *J Urol*. 2010 Sep;184(3):888-94. Epub 2010 Jul 17. PMID: 20643448.
168. Raj GV, Karavadia S, Schlomer B, Arriaga Y, **Lotan Y**, Sagalowsky A, Frenkel E. Contemporary use of perioperative cisplatin-based chemotherapy in patients

- with muscle-invasive bladder cancer. *Cancer*. 2011 Jan 15; 117(2): 276-82. Epub 2010 Sep 9. PMID: 20830767.
169. Barbieri CE, **Lotan Y**, Lee RK, Sonpavde G, Karakiewicz PI, Robinson B, Scherr DS, Shariat SF. Tissue-based molecular markers for bladder cancer. *Minerva Urol Nefrol*. 2010 Sep;62(3):241-58. PMID: 20940694.
170. Donnally CJ 3rd, Gupta A, Bensalah K, Tuncel A, Raman J, Pearle MS, **Lotan Y**. Longitudinal evaluation of the SF-36 quality of life questionnaire in patients with kidney stones. *Urol Res*. 2011 Apr; 39(2): 141-6. Epub 2010 Oct 6. PMID: 20924571.
171. Murray S, Haverkorn RM, **Lotan Y**, Lemack GE. Mesh kits for anterior vaginal prolapse are not cost effective. *Int Urogynecol J Pelvic Floor Dysfunct*. 2011 Apr;22(4):447-52. Epub 2010 Oct 9. PMID: 20936256.
172. Mir C, Shariat SF, Van Der Kwast TH, Ashfaq R, **Lotan Y**, Evans A, Skeldon S, Hanna S, Vajpeyi R, Kuk C, Alkhateeb S, Morote J, Van Rhijn BW, Bostrom P, Yao J, Miyamoto H, Jewett M, Fleshner N, Messing E, Zlotta AR. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. *BJU Int*. 2011 Jul; 108(1): 24-30. Epub 2010 Nov 10. PMID: 21070579.
173. Sonpavde G, Khan MM, Svatek RS, Lee R, Novara G, Tilki D, Lerner SP, Amiel GE, Skinner E, Karakiewicz PI, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Ficarra V, Dinney CP, **Lotan Y**, Fradet Y, Shariat SF. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. *BJU Int*. 2011 Sep; 108(5): 687-92. Epub 2010 2010 Nov. 19. PMID: 21087453.
174. Youssef R, Kapur P, Kabbani W, Shariat SF, Mosbah A, Abol-Enein H, Ghoniem M, **Lotan Y**. Bilharzial vs non-bilharzial related bladder cancer: pathological characteristics and value of cyclooxygenase-2-expression. *BJU Int*. 2011 Jul; 108(1): 31-7. Epub 2010 Nov 24. PMID: 21105986.
175. Youssef RF, Shariat SF, Kapur P, Dabbani W, Ghoneim T, King E, Cockburn A, Mosbah A, Abol-Enein H, Ghoneim M, **Lotan Y**. Expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder. *Hum Pathol*. 2011 Mar;42(3):347-355. Epub 2010 Nov 26. PMID: 21111452.
176. Erickstad L, Reed G, Bhat D, Roehrborn CG, **Lotan Y**. Use of electronic medical records to identify patients at risk for prostate cancer in an academic institution. *Prostate Cancer Prostatic Dis*. 2011 Mar;14(1):85-9. Epub 2010 Dec 14. PMID: 21151199.
177. Youssef RF, Shariat SF, **Lotan Y**, Wood CG, Sagalowsky AI, Zigeuner R, Langner C, Montorsi F, Bolenz C, Margulis V. Prognostic Effect of Urinary Bladder Carcinoma In Situ on Clinical Outcome of Subsequent Upper Tract Urothelial Carcinoma. *Urology*. 2011 Apr;77(4):861-6. Epub 2010 Dec 16. PMID: 21167566.
178. Svatek R, **Lotan Y**. Cost Utility of Prostate Cancer Chemoprevention with Dutasteride in Men with an elevated PSA. *Cancer Prev Res (Phila)*. 2011 Feb;4(2):277-83. Epub 2010 Dec 16. PMID: 21163937.
179. Sonpavde G, Khan MM, Lerner SP, Svatek RS, Novara G, Karakiewicz PI, Skinner E, Tilki D, Kassouf W, Fradet Y, Dinney CP, Fritsche HM, Izawa JI, Bastian PJ, Ficarra V, Schoenberg M, Sagalowsky AI, **Lotan Y**, Shariat SF. Disease-Free Survival at 2 or 3 Years Correlates with 5-Year Overall Survival of Patients Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer. *J Urol*. 2011 Feb;185(2):456-61. Epub 2010 Dec 17. PMID: 21167527.

180. Mir SA, Cadeddu JA, Sleeper JP, **Lotan Y**. Cost Comparison of Robotic, Laparoscopic and Open Partial Nephrectomy. *J Endourol*. 2011 Mar;25(3):447-53. Epub 2011 Jan 19. PMID: 21247335.
181. Youssef RF, Shariat SF, Kapur P, Kabbani W, Mosbah A, Abol-Enein H, Ghoniem M, **Lotan Y**. Prognostic Value of Cyclooxygenase-2 Expression in Squamous Cell Carcinoma of the Bladder. *J Urol*. 2011 Mar;185(3):1112-7. Epub 2011 Jan 21. PMID: 21255800.
182. Messer J, Shariat SF, Brien JC, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE, Steinberg G, Terrell JD, Lucas SM, **Lotan Y**, Boorjian SA, Raman JD. Urinary Cytology Has a Poor Performance for Predicting Invasive or High-Grade Upper-Tract Urothelial Carcinoma. *BJU Int*. 2011 Sep; 108(5): 701-5. Epub 2011 Feb 14. PMID: 21320275.
183. Youssef RF, Shariat SF, **Lotan Y**, Wood CG, Sagalowsky AI, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M, Kabbani W, Langner C, Guo CC, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Margulis V. Upper Urinary Tract Urothelial Carcinoma with Loco-Regional Nodal Metastases: Insights from the Upper Tract Urothelial Carcinoma Collaboration. *BJU Int*. 2011 Oct;108(8): 1286-91. Epub 2011 Feb 18. PMID: 21332905.
184. Sonpavde G, Khan MM, Svatek RS, Lee R, Novara G, Tilki D, Lerner SP, Amiel GE, Skinner E, Karakiewicz PI, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Scherr DS, Ficarra V, Dinney CP, **Lotan Y**, Fradet Y, Shariat SF. Prognostic Risk Stratification of Pathological Stage T3N0 Bladder Cancer after Radical Cystectomy. *J. Urol*. 2011 Apr;185(4):1216-21. Epub 2011 Feb 22. PMID: 21334687.
185. Gurbuz C, Youssef RF, Shariat SF, **Lotan Y**, Wood CG, Sagalowsky AI, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Margulis V. The Impact of Previous Ureteroscopic Tumor Ablation on Oncologic Outcomes after Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma. *J Endourol*. 2011 May;25(5):775-9. Epub 2011 Mar 9. PMID: 21388245.
186. Bolenz C, West AM, Ortiz N, Kabbani W, **Lotan Y**. Urinary Cytology for the Detection of Urothelial Carcinoma of the Bladder-A Flawed Adjunct to Cystoscopy? *Urol Oncol*. 2013 Apr; 31(3): 366-71. Epub 2011 Mar 16. PMID: 21414815.
187. Zlotta AR, Roumeguere T, Kuk C, Alkhateeb S, Rorive S, Lemy A, van der Kwast TH, Fleshner NE, Jewett MA, Finelli A, Schulman C, **Lotan Y**, Shariat SF, Nortier J. Select Screening in a Specific High-Risk Population of Patients Suggests a Stage Migration Toward Detection of Non-Muscle-Invasive Bladder Cancer. *Eur Urol*. 2011 Jun;59(6):1026-31. Epub 2011 Apr 1. PMID: 21458152.
188. Boike TP, **Lotan Y**, Cho LC, Brindle J, Deroose P, Xie XJ, Yan J, Foster R, Pistenmaa D, Perkins A, Cooley S, Timmerman R. Phase I Dose-Escalation Study of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer. *J Clin Oncol*. 2011 May 20;29(15):2020-6. Epub 2011 Apr 4. PMID: 21464418.
189. Kassouf W, Svatek RS, Shariat SF, Novara G, Lerner SP, Fradet Y, Bastian PJ, Aprikian A, Karakiewicz PI, Fritsche HM, Dinney CP, Tilki D, Kamat AM, Izawa JI, Ficarra V, **Lotan Y**, Sagalowsky AI, Schoenberg MP, Skinner EC. Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. *Urol Oncol*. 2013 May; 31(4): 480-6. Epub 2011 Apr 8. PMID: 21478035.
190. Ehdaie B, Chromecki TF, Lee RK, **Lotan Y**, Margulis V, Karakiewicz PI, Novara G, Raman JD, Ng C, Lowrance WT, Scherr DS, Shariat SF. Obesity Adversely

- Impacts Disease Specific Outcomes in Patients With Upper Tract Urothelial Carcinoma. *J Urol.* 2011 Jul;186(1):66-72. Epub 2011 May 14. PMID: 21571333.
191. Scales CD Jr, Krupski TL, Curtis LH, Matlaga B, **Lotan Y**, Pearle MS, Saigal C, Preminger GM; for the Urologic Diseases in America Project. Practice Variation in the Surgical Management of Urinary Lithiasis. *J Urol.* 2011 Jul;186(1):146-50. Epub 2011 May 14. PMID: 21575964.
192. Chung W, Bondaruk J, Jelinek J, **Lotan Y**, Liang S, Czerniak B, Issa JP. Detection of Bladder Cancer Using Novel DNA Methylation Biomarkers in Urine Sediments. *Cancer Epidemiol Biomarkers Prev.* 2011 Jul;20(7):1483-91. Epub 2011 May 17. PMID: 21586619.
193. Bolenz C, Gupta A, Roehrborn CG, **Lotan Y**. Predictors of Costs for Robotic-Assisted Laparoscopic Radical Prostatectomy. *Urol Oncol.* 2011 May-Jun;29(3):325-9. PMID: 21555102.
194. Youssef RF, Shariat SF, **Lotan Y**, Cost N, Wood CG, Sagalowsky AI, Zigeuner R, Langner C, Chromecki TF, Montorsi F, Bolenz C, Margulis V. Urothelial Carcinoma At The Uretero-Enteric Junction: Multi-Center Evaluation of Oncologic Outcomes after Radical Nephroureterectomy. *Urol Oncol.* 2013 Jul; 31(5):676-681. Epub 2011 Jun 25. PMID: 21704538.
195. Kapur P, **Lotan Y**, King E, Kabbani W, Mitra AP, Mosbah A, Abol-Enein H, Ghoneim M, Youssef RF. Primary Adenocarcinoma of the Urinary Bladder: Value of Cell Cycle Biomarkers. *Am J Clin Pathol.* 2011 Jun;135(6):822-30. PMID: 21571954.
196. **Lotan Y**, Pearle MS. Cost-Effectiveness of Primary Prevention Strategies for Nephrolithiasis. *J Urol.* 2011 Aug;186(2):550-5. Epub 2011 Jun 16. PMID: 21683379.
197. Patschan O, Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, **Lotan Y**, Hotakainen K, Stenman UH, Bjartell A. Association of Tumor-Associated Trypsin Inhibitor (TATI) Expression with Molecular Markers, Pathologic Features and Clinical Outcomes of Urothelial Carcinoma of the Urinary Bladder. *World J Urol.* 2012 Dec;30(6):785-94. Epub 2011 Jul 8. PMID: 21739120.
198. Roscigno M, Brausi M, Heidenreich A, **Lotan Y**, Margulis V, Shariat SF, Van Poppel H, Zigeuner R. Lymphadenectomy at the Time of Nephroureterectomy for Upper Tract Urothelial Cancer. *Eur Urol.* 2011 Oct; 60(4): 776-83. Epub 2011 Jul 14. PMID: 21798659.
199. Kucejova B, Peña-Llopis S, Yamasaki T, Sivanand S, Tran TA, Alexander S, Wolff NC, **Lotan Y**, Xie XJ, Kabbani W, Kapur P, Brugarolas J. Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. *Mol Cancer Res.* 2011 Sep; 9(9): 1225-65. Epub 2011 Jul 28. PMID: 21798997.
200. Adibi M, Youssef R, Shariat SF, **Lotan Y**, Wood CG, Sagalowsky AI, Zigeuner R, Montorsi F, Bolenz C, Margulis V. Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over the three decades. *Int J Urol.* 2012 Dec;19(12):1060-6. Epub 2012 Aug 12. PMID: 22882743.
201. Barbieri CE, Cha EK, Chromecki TF, Dunning A, **Lotan Y**, Svatek RS, Scherr DS, Karakiewicz PI, Sun M, Mazumdar M, Shariat SF. Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial. *BJU Int.* 2012 Mar; 109(5): 685-90. Epub 2011 Aug 18. PMID: 21851550.
202. Messer JC, Terrell JD, Herman MP, Ng CK, Scherr DS, Scoll B, Boorjian SA, Uzzo RG, Wille M, Eggener SE, Lucas SM, **Lotan Y**, Shariat SF, Raman JD. Multi-institutional validation of the ability of preoperative hydronephrosis to predict

- advanced pathologic tumor stage in upper-tract urothelial carcinoma. *Urol Oncol*. 2013 Aug; 31(6): 904-8. Epub 2011 Sep 9. PMID 21906967.
203. Chromecki TF, Cha EK, Fajkovic H, Margulis V, Novara G, Scherr DS, **Lotan Y**, Raman JD, Kassouf W, Bensalah K, Weizer A, Kikuchi E, Roscigno M, Remzi M, Matsumoto K, Walton TJ, Pycha A, Ficarra V, Karakiewicz PI, Zigeuner R, Pummer K, Shariat SF. The Impact of Tumor Multifocality on Outcomes in Patients Treated With Radical Nephroureterectomy. *Eur Urol*. 2012 Feb; 61(2): 245-53. Epub 2011 Sep 28. PMID: 21975249.
204. Putluri N, Shojaie A, Vasu VT, Vareed SK, Nalluri S, Putluri V, Thangjam GS, Panzitt K, Tallman CT, Butler C, Sana TR, Fischer SM, Sica G, Brat DJ, Shi H, Palapattu GS, **Lotan Y**, Weizer AZ, Terris MK, Shariat SF, Michailidis G, Sreekumar A. Metabolomic Profiling Reveals Potential Markers and Bioprocesses Altered in Bladder Cancer Progression. *Cancer Res*. 2011 Dec 15; 71(24): 7376-7386. Epub 2011 Oct 11. PMID: 21990318.
205. Chromecki TF, Mauermann J, Cha EK, Svatek RS, Fajkovic H, Karakiewicz PI, **Lotan Y**, Tilki D, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Novara G, Fritsche HM, Ficarra V, Stief CG, Dinney CP, Skinner E, Pummer K, Fradet Y, Shariat SF. Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy. *World J Urol*. 2012 Dec;30(6):753-9. Epub 2011 Oct. 19. PMID: 22009117.
206. Shariat SF, Ehdaie B, Rink M, Cha EK, Svatek RS, Chromecki TF, Fajkovic H, Novara G, David SG, Daneshmand S, Fradet Y, **Lotan Y**, Sagalowsky AI, Clozel T, Bastian PJ, Kassouf W, Fritsche HM, Burger M, Izawa JI, Tilki D, Abdollah F, Chun FK, Sonpavde G, Karakiewicz PI, Scherr DS, Gonen M. Clinical Nodal Staging Scores for Bladder Cancer: A Proposal for Preoperative Risk Assessment. *Eur Urol*. 2012 Feb; 61(2): 237- 42. Epub 2011 Oct 21. PMID: 22033174.
207. Terrell JD, Elias KJ, Sagalowsky AI, **Lotan Y**. Patients with a negative cystoscopy and negative Nmp22® Bladderchek® test are at low risk of missed transitional cell carcinoma of the bladder: a prospective evaluation. *Int Braz J Urol*. 2011 Nov-Dec;37(6):706-11. PMID: 22234001.
208. Tracy CR, Gupta A, Pearle MS, **Lotan Y**. Calcium Phosphate Content Does Not Affect Stone-Free Rate after Percutaneous Nephrolithotomy. *J Urol*. 2012 Jan; 187(1): 169- 172. Epub 2011 Nov 17. PMID: 22100002.
209. Shariat SF, Chromecki TF, Cha EK, Karakiewicz PI, Sun M, Fradet Y, Isbarn H, Scherr DS, Bastian PJ, Pummer K, Fajkovic H, Sagalowsky AI, Ashfaq R, Doblinger M, Cote RJ, **Lotan Y**. Risk Stratification of Organ Confined Bladder Cancer After Radical Cystectomy Using Cell Cycle Related Biomarkers. *J Urol*. 2012 Feb;187(2):457-62. Epub 2011 Dec 15. PMID: 22177145.
210. Adibi M, Pearle MS, **Lotan Y**. Cost-effectiveness of standard vs intensive antibiotic regimens for transrectal ultrasonography (TRUS)-guided prostate biopsy prophylaxis. *BJU Int* 2012 Jul; 110(2 Pt 2):E86-91. Epub 2011 Nov 24. PMID: 22115356.
211. Hodges JC, **Lotan Y**, Boike TP, Benton R, Barrier A, Timmerman RD: Cost-effectiveness of SBRT versus IMRT: an emerging initial radiation treatment option for organ-confined prostate cancer. *Am J Manag Care* 2012 May 1; 18(5): e186-93. PMID: 22694113.
212. Rink M, Fajkovic H, Cha EK, Gupta A, Karakiewicz PI, Chun FK, **Lotan Y**, Shariat SF. Death Certificates Are Valid for the Determination of Cause of Death in Patients With Upper and Lower Tract Urothelial Carcinoma. *Eur Urol*. 2012 Apr;61(4):854-855. Epub 2012 Jan 5. PMID: 22226583.

213. Fajkovic H, Cha EK, Jeldres C, Donner G, Chromecki TF, Margulis V, Novara G, **Lotan Y**, Raman JD, Kassouf W, Seitz C, Bensalah K, Weizer A, Kikuchi E, Roscigno M, Remzi M, Matsumoto K, Breinl E, Pycha A, Ficarra V, Montorsi F, Karakiewicz PI, Scherr DS, Shariat SF. Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma. *J Urol* 2012 Mar; 187(3): 845-851. Epub 2012 Jan 15. PMID: 22248522.
214. Volkmer JP, Sahoo D, Chin RK, Ho PL, Tang C, Kurtova AV, Willingham SB, Pazhanisamy SK, Contreras-Trujillo H, Storm TA, **Lotan Y**, Beck AH, Chung BI, Alizadeh AA, Godoy G, Lerner SP, van de Rijn M, Shortliffe LD, Weissman IL, Chan KS. Three differentiation states risk-stratify bladder cancer into distinct subtypes. *Proc Natl Acad Sci USA* 2012 Feb 7; 109(6): 2078-2083. Epub 2012 Jan 19. PMID: 22308455.
215. Cha EK, Shariat SF, Kormaksson M, Novara G, Chromecki TF, Scherr DS, **Lotan Y**, Raman JD, Kassouf W, Zigeuner R, Remzi M, Bensalah K, Weizer A, Kikuchi E, Bolenz C, Roscigno M, Koppie TM, Ng CK, Fritsche HM, Matsumoto K, Walton TJ, Ehdaie B, Tritschler S, Fajkovic H, Martinez-Salamanca JI, Pycha A, Langner C, Ficarra V, Patard JJ, Montorsi F, Wood CG, Karakiewicz PI, Margulis V. Predicting Clinical Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. *Eur Urol.* 2012 Apr;61(4):818-25. Epub 2012 Jan 23. PMID: 22284969.
216. Svatek RS, Rosenberg JE, Galsky MD, Lee CT, Latini DM, Bochner BH, Weizer AZ, Apolo AB, Sridhar SS, Kamat AM, Hansel D, Flaig TW, Smith ND, **Lotan Y**. Summary of the 6th annual bladder cancer think tank: New directions in urologic research. *Urol Oncol.* 2013 Oct; 31(7): 968-73. Epub 2012 Jan 31. PMID: 22300756.
217. Rink M, Ehdaie B, Cha EK, Green DA, Karakiewicz PI, Babjuk M, Margulis V, Raman JD, Svatek RS, Fajkovic H, Lee RK, Novara G, Hansen J, Daneshmand S, **Lotan Y**, Kassouf W, Fritsche HM, Pycha A, Fisch M, Scherr DS, Shariat SF; for the Bladder Cancer Research Consortium (BCRC). Stage-Specific Impact of Tumor Location on Oncologic Outcomes in Patients With Upper and Lower Tract Urothelial Carcinoma Following Radical Surgery. *Eur Urol.* 2012 Oct;62(4):677-684. Epub 2012 Feb 15. PMID: 22349570.
218. Rink M, Cha EK, Green D, Hansen J, Robinson BD, **Lotan Y**, Sagalowsky AI, Chun FK, Karakiewicz PI, Fisch M, Scherr DS, Shariat SF. Biomolecular Predictors of Urothelial Cancer Behavior and Treatment Outcomes. *Curr Urol Rep.* 2012 Apr; 13(2): 122-35. Epub 2012 Feb 23. PMID: 22354565.
219. Clements T, Messer JC, Terrell JD, Herman MP, Ng CK, Scherr DS, Scoll B, Boorjian SA, Uzzo RG, Wille M, Eggener SE, Lucas SM, **Lotan Y**, Shariat SF, Raman JD. High- grade ureteroscopic biopsy is associated with advanced pathology of upper-tract urothelial carcinoma tumors at definitive surgical resection. *J Endourol.* 2012 Apr; 26(4): 398-402. Epub 2012 Feb 24. PMID: 22192113.
220. Youssef R, Kapur P, Shariat SF, Arendt T, Kabbani W, Mosbah A, Abol-Enein H, Ghoneim M, **Lotan Y**. Prognostic value of apoptotic markers in squamous cell carcinoma of the urinary bladder. *BJU Int.* 2012 Oct;110(7):961-6. Epub 2012 Feb 28. PMID: 22372762.
221. Nielsen ME, Smith AB, Pruthi RS, Guzzo TJ, Amiel G, Shore N, **Lotan Y**. Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey. *BJU Int.* 2012 Oct;110(7):967-72. Epub 2012 Apr 4. PMID: 22487336.
222. **Lotan Y**, Goodman PJ, Youssef RF, Svatek RS, Shariat SF, Tangen CM, Thompson IM Jr, Klein EA. Evaluation of Vitamin E and Selenium Supplementation for the

- Prevention of Bladder Cancer in SWOG Coordinated SELECT. *J Urol.* 2012 Jun; 187(6):2005-10. Epub 2012 Apr 11. PMID: 22498220.
223. Bagrodia A, Youssef RF, Kapur P, Darwish OM, Cannon C, Belsante MD, Gerecci D, Sagalowsky AI, Shariat SF, **Lotan Y**, Margulis V. Prospective Evaluation of Molecular Markers for the Staging and Prognosis of Upper Tract Urothelial Carcinoma. *Eur Urol.* 2012 Jul; 62(1):e27-29. Epub 2012 Apr 17. PMID: 22552216.
224. Xylinas E, Rink M, Cha EK, Clozel T, Lee RK, Fajkovic H, Comploj E, Novara G, Margulis V, Raman JD, **Lotan Y**, Kassouf W, Fritsche HM, Weizer A, Martinez-Salamanca JI, Matsumoto K, Zigeuner R, Pycha A, Scherr DS, Setiz C, Walton T, Trinh QD, Karakiewicz PI, Matin S, Montorsi F, Zerbib M, Shariat SF; for the Upper Tract Urothelial Carcinoma Collaboration. Impact of Distal Ureter Management on Oncologic Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. *Eur Urol.* 2014 Jan; 65(1): 210-7. Epub 2012 May 4. PMID: 22579047.
225. Seideman CA, Sleeper JP, **Lotan Y**. Cost Comparison of Robotic-Assisted and Laparoscopic Pyeloplasty. *J Endourol.* 2012 Aug; 26(8): 1044-8. Epub 2012 May 23. PMID: 22494052.
226. Sivanand S, Peña-Llopis S, Zhao H, Kucejova B, Spence P, Pavia-Jimenez A, Yamasaki T, McBride DJ, Gillen J, Wolff NC, Morlock L, **Lotan Y**, Raj GV, Sagalowsky A, Margulis V, Cadeddu JA, Ross MT, Bentley DR, Kabbani W, Xie SJ, Kapur P, Williams NS, Brugarolas J. A validated tumograft model reveals activity of dovitinib against renal cell carcinoma. *Sci Transl Med.* 2012 Jun 6; 4(137):137ra75. PMID: 22674553.
227. Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, Leng N, Pavia-Jiménez A, Wang S, Yamasaki T, Zhrebker L, Sivanand S, Spence P, Kinch L, Hambuch T, Jain S, **Lotan Y**, Margulis V, Sagalowsky AI, Summerour PB, Kabbani W, Wong SW, Grishin N, Laurent M, Xie XJ, Haudenschild CD, Ross MT, Bentley DR, Kapur P, Brugarolas J. Erratum: BAP1 loss defines a new class of renal cell carcinoma. *Nat Genet.* 2012 Jun 10; 44(7): 751-9. Erratum in: *Nat Genet* 2012 Sep; 44(9): 1072. PMID: 22683710.
228. **Lotan Y**, Buendia Jiménez I, Lenoir-Wijnkoop I, Daudon M, Molinier L, Tack I, Nuijten MJ. Primary prevention of nephrolithiasis is cost-effective for a national healthcare system. *BJU Int.* 2012 Dec; 110(11 Pt C):E1060-7. Epub 2012 Jun 11. PMID: 22686216.
229. Rink M, Robinson BD, Green DA, Cha EK, Hansen J, Comploj E, Margulis V, Raman JD, Ng CK, Remzi M, Bensalah K, Kabbani W, Haitel A, Rioux-Leclercq N, Guo CC, Chun FK, Kikuchi E, Kassouf W, Sircar K, Sun M, Sonpavde G, **Lotan Y**, Pycha A, Karakiewicz PI, Scherr DS, Shariat SF. Impact of Histological Variants on Clinical Outcomes of Patients with Upper Urinary Tract Urothelial Carcinoma. *J Urol.* 2012 Aug; 188(2): 398-404. Epub 2012 Jun 13. PMID: 22698626.
230. Shariat SF, Rink M, Ehdaie B, Xylinas E, Babjuk M, Merseburger AS, Svatek RS, Cha EK, Tagawa ST, Fajkovic H, Novara G, Karakiewicz PI, Trinh QD, Daneshmand S, **Lotan Y**, Kassouf W, Fritsche HM, Chun FK, Sonpavde G, Joul A, Scherr DS, Gonen M. Pathologic Nodal Staging Score for Bladder Cancer: A Decision Tool for Adjuvant Therapy after Radical Cystectomy. *Eur Urol.* 2013 Feb; 63(2): 371-8. Epub 2012 Jun 16. PMID: 22727174.
231. Chromecki TF, Cha EK, Fajkovic H, Rink M, Ehdaie B, Svatek RS, Karakiewicz PI, **Lotan Y**, Tilki D, Bastian PJ, Daneshmand S, Kassouf W, Durand M, Novara G, Fritsche HM, Burger M, Izawa JI, Brisuda A, Babjuk M, Pummer K, Shariat SF.

- Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. *BJU Int.* 2013 Feb; 111(2): 249-55. Epub 2012 Jun 21. PMID: 22727036.
232. Rink M, Xylinas E, Margulis V, Cha EK, Ehdaie B, Raman JD, Chun FK, Matsumoto K, **Lotan Y**, Furberg H, Babjuk M, Pycha A, Wood CG, Karakiewicz PI, Fisch M, Scherr DS, Shariat SF. For the Upper Tract Urothelial Carcinoma Collaboration. Impact of Smoking on Oncologic Outcomes of Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy. *Eur Urol.* 2013 Jun; 63(6): 1082-90. Epub 2012 Jun 22. PMID: 22743166.
233. Rink M, Sjoberg D, Comploj E, Margulis V, Xylinas E, Lee RK, Hansen J, Cha EK, Raman JD, Remzi M, Bensalah K, Novara G, Matin SF, Chun FK, Kikuchi E, Kassouf W, Martinez-Salamanca JI, **Lotan Y**, Seitz C, Pycha A, Zigeuner R, Karakiewicz PI, Scherr DS, Vickers AJ, Shariat SF. Risk of Cancer-specific Mortality following Recurrence After Radical Nephroureterectomy. *Ann Surg Oncol.* 2012 Dec; 19(13): 4337-44. Epub 2012 Jul 18. PMID: 22805867.
234. Rink M, Hansen J, Cha EK, Green DA, Babjuk M, Svatek RS, Xylinas E, Tagawa ST, Faison T, Novara G, Karakiewicz PI, Daneshmand S, **Lotan Y**, Kassouf W, Fritsche HM, Pycha A, Comploj E, Tilki D, Bastian PJ, Chun FK, Dahlem R, Scherr DS, Shariat SF. Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. *BJU Int.* 2013 Jan; 111(1): 74-78. Epub 2012 Jul 19. PMID: 22809039.
235. Fajkovic H, Cha EK, Jeldres C, Robinson BD, Rink M, Xylinas E, Chromecki TF, Breinl E, Svatek RS, Donner G, Tagawa ST, Tilki D, Bastian PJ, Karakiewicz PI, Volkmer BG, Novara G, Joulal A, Faison T, Sonpavde G, Daneshmand S, **Lotan Y**, Scherr DS, Shariat SF. Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis. *Eur Urol.* 2013 Nov; 64(5): 837-45. Epub 2012 Jul 20. PMID: 22877503.
236. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeny LA, La Vecchia C, Shariat S, **Lotan Y**. Epidemiology and Risk Factors of Urothelial Bladder Cancer. *Eur Urol.* 2013 Feb; 63(2): 234-41. Epub 2012 Jul 25. PMID: 22877502.
237. Rink M, Shariat SF, Xylinas E, Fitzgerald JP, Hansen J, Green DA, Kamat AM, Novara G, Daneshmand S, Fradet Y, Tagawa ST, Bastian PJ, Kassouf W, Trinh QD, Karakiewicz PI, Fritsche HM, Tilki D, Chun FK, Volkmer BG, Babjuk M, Merseburger AS, Scherr DS, **Lotan Y**, Svatek RS. Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy? *World J Urol.* 2012 Dec;30(6):807-14. Epub 2012 July 26. PMID: 22832587.
238. Adibi M, Youssef R, Shariat SF, **Lotan Y**, Wood CG, Sagalowsky AI, Zigeuner R, Montorsi F, Bolenz C, Margulis V. Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: Comparison over the three decades. *Int J Urol.* 2012 Aug 12. [Epub ahead of print] PMID: 22882743.
239. Bagrodia A, Rachaionda V, Delafuente K, Toombs S, Yeh O, Scales J, Roehrborn CG, **Lotan Y**. Surgeon Fatigue: Impact of Case Order on Perioperative Parameters and Patient Outcomes. *J Urol.* 2012 Oct; 188(4):1291-6. Epub 2012 Aug 16. PMID: 22902028.
240. Rink M, Furberg H, Zabor EC, Xylinas E, Babjuk M, Pycha A, **Lotan Y**, Karakiewicz PI, Novara G, Robinson BD, Montorsi F, Chun FK, Scherr DS, Shariat SF. Impact of Smoking and Smoking Cessation on Oncologic Outcomes in Primary Non-muscle-invasive Bladder Cancer. *Eur Urol.* 2013 Apr; 63(4): 724-32. Epub 2012 Aug 21. PMID: 22925575.

241. Rink M, Lee DJ, Kent M, Xylinas E, Fritsche HM, Babjuk M, Brisuda A, Hansen J, Green DA, Aziz A, Cha EK, Novara G, Chun FK, **Lotan Y**, Bastian PJ, Tilki D, Gontero P, Pycha A, Baniel J, Mano R, Ficarra V, Trinh QD, Tagawa ST, Karakiewicz PI, Scherr DS, Sjoberg DD, Shariat SF; for the Bladder Cancer Research Consortium. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. *BJU Int*. 2013 Mar; 111(3b): E30-E36. Epub 2012 Sep 3. PMID: 22938654.
242. Hodges JC, **Lotan Y**, Boike TP, Benton R, Barrier A, Timmerman RD. Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer. *J Oncol Pract*. 2012 May; 8(3 Suppl):e31s-7s. PMID: 22942832.
243. Bolenz C, Freedland SJ, Hollenbeck BK, **Lotan Y**, Lowrance WT, Nelson JB, Hu JC. Costs of Radical Prostatectomy for Prostate Cancer: A Systematic Review. *Eur Urol*. 2014 Feb; 65(2): 316-24. Epub 2012 Sep 5. PMID: 22981673.
244. **Lotan Y**, Jiménez IB, Lenoir-Wijnkoop I, Daudon M, Molinier L, Tack I, Nuijten MJ. Increased Water Intake as a Prevention Strategy for Recurrence of Urolithiasis: Major Impact of Compliance on Cost-Effectiveness. *J Urol*. 2013 Mar; 189(3): 935-9. Epub 2012 Sep 24. PMID: 23017509.
245. Fajkovic H, Cha EK, Xylinas E, Rink M, Pycha A, Seitz C, Bolenz C, Dunning A, Novara G, Trinh QD, Karakiewicz PI, Margulis V, Raman JD, Walton TJ, Baba S, Carballido J, Otto W, Montorsi F, **Lotan Y**, Kassouf W, Fritsche HM, Bensalah K, Zigeuner R, Scherr DS, Sonpavde G, Roupret M, Shariat SF. Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. *World J Urol*. 2013 Feb; 31(1):5-11. Epub 2012 Sep 26. PMID: 23011256.
246. Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, Shariat SF, Xylinas E, Schmitz-Dräger BJ, **Lotan Y**, Jenkins LC, Droller M, van Rhijn BW, Karakiewicz PI. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers. *Eur*. 2013 Jan; 63(1): 4-15. Epub 2012 Oct 4. PMID: 23083902.
247. Adibi M, Hornberger B, Bhat D, Raj G, Roehrborn CG, **Lotan Y**. Reduction in Hospital Admission Rates Due to Post-Prostate Biopsy Infections After Augmenting Standard Antibiotic Prophylaxis. *J Urol*. 2013 Feb; 189(2): 535-40. Epub 2012. Oct 8. PMID: 22982426.
248. Rink M, Xylinas E, Babjuk M, Hansen J, Pycha A, Complog E, **Lotan Y**, Sun M, Karakiewicz PI, Abdennabi J, Fajkovic H, Loidl W, Chun FK, Fisch M, Scherr DS, Shariat SF. Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer. *J Urol*. 2012 Dec; 188(6): 2120-7. Epub 2012 Oct 18. PMID: 23083868.
249. Rippel CA, Nikkel L, Lin YK, Danawala Z, Olorunnisomo V, Youssef RF, Pearle MS, **Lotan Y**, Raman JD. Residual fragments following ureteroscopic lithotripsy: incidence and predictors on postoperative computerized tomography. *J Urol*. 2012 Dec; 188(6): 2246-2251. Epub 2012 Oct 22. PMID: 23083650
250. Rouprêt M, Hupertan V, Seisen T, Colin P, Xylinas E, Yates DR, Fajkovic H, **Lotan Y**, Raman D, Zigeuner R, Remzi M, Bolenz C, Novara G, Kassouf W, Ouzzane A, Rozet F, Cussenot O, Martinez-Salamanca JI, Fritsche HM, Walton TJ, Wood CG, Bensalah K, Karakiewicz PI, Montorsi F, Margulis V, Shariat SF; French National Database on Upper Tract Tumors and the Upper Tract Urothelial Carcinoma Collaboration (UTUCC). Prediction of cancer-specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an

- optimized post-operative nomogram using decision curve analysis. *J Urol*. 2013 May;189(5):1662-9. Epub 2012 Oct 24. PMID: 23103802.
251. Xylinas E, Rink M, Novara G, Green DA, Clozel T, Fritsche HM, Guillonneau B, **Lotan Y**, Kassouf W, Tilki D, Babjuk M, Karakiewicz PI, Montorsi F, Abdemmanbi J, Trink QD, Svatek RS, Scherr DS, Zerbib M, Shariat SF. Predictors of Survival in Patients with Soft Tissue Surgical Margin Involvement at Radical Cystectomy. *Ann Surg Oncol*. 2013 Mar; 20(3): 1027-34. Epub 2012 Oct. 26. PMID: 23099729.
252. Buteau A, Seideman CA, Svatek RS, Youssef RF, Chakrabarti G, Reed G, Bhat D, **Lotan Y**. What is evaluation of hematuria by primary care physicians? Use of electronic medical records to assess practice patterns with intermediate follow-up. *Urol Oncol*. 2014 Feb; 32(2):128-34. Epub 2012 Nov 13. PMID: 23153858.
253. Hilton WM, **Lotan Y**, Parekh DJ, Basler JW, Svatek RS. Alvimopan for prevention of postoperative paralytic ileus in radical cystectomy patients: a cost-effectiveness analysis. *BJU Int*. 2013 Jun; 111(7):1054-60. Epub 2012 Nov 21. PMID: 23171223.
254. Tilki D, Shariat SF, **Lotan Y**, Rink M, Karakiewicz PI, Schoenberg MP, Lerner SP, Sonpavde G, Sagalowsky AI, Gupta A. Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with T1 disease and negative lymph nodes after radical cystectomy. *BJU Int*. 2013 Jun; 111(8): 1215-21. Epub 2012 Nov 26. PMID: 23181623.
255. Rink M, Zabor ED, Furberg H, Xylinas E, Ehdaie B, Novara G, Babjuk M, Pycha A, **Lotan Y**, Trinh QD, Chun FK, Lee RK, Karakiewicz PI, Fisch M, Robinson BC, Scherr DS, Shariat SF. Impact of Smoking and Smoking Cessation on Outcomes in Bladder Cancer Patients Treated with Radical Cystectomy. *Eur Urol*. 2013 Sep; 64(3) 456-64. Epub 2012 Nov 27. PMID: 23206854.
256. Kluth LA, Fajkovic H, Xylinas E, Crivelli JJ, Passoni N, Rouprêt M, Becker A, Comploj E, Pycha A, Homang S, Gupta A, **Lotan Y**, Karakiewicz PI, Gontero P, Chun FK, Fisch M, Scherr DS, Shariat SF. Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. *World J Urol*. 2013 Oct; 31(5):1029-36. Epub 2012 Nov 30. PMID: 23196773.
257. Xylinas E, Rink M, Margulis V, Faison T, Comploj E, Novara G, Raman JD, **Lotan Y**, Guillonneau B, Weizer A, Pycha A, Scherr DS, Seitz C, Sun M, Trinh QD, Karakiewicz PI, Montorsi F, Zerbib M, Gönen M, Shariat SF; UTUC Collaboration. Prediction of true nodal status in patients with pathological lymph node negative upper tract urothelial carcinoma at radical nephroureterectomy. *J Urol*. 2013 Feb; 189(2): 468-73. Epub 2012 Dec 14. PMID: 23253960.
258. Chang SS, Dinney CP, Donat SM, Dham P, Gore JL, **Lotan Y**, Parekh DJ, Solit DB, O'Donnell PH, Feng FY, Hansel D, Milowsky MI. 12th Annual meeting of the Society of Urologic Oncology (SUO) bladder cancer sessions I and II summary report. *Urol Oncol* 2012 Nov-Dec; 30(6): 944-7. PMID: 23218073.
259. Sutherland TN, Pearle MS, **Lotan Y**. How Much Is a Kidney Worth? Cost-Effectiveness of Routine Imaging after Ureteroscopy to Prevent Silent Obstruction. *J Urol*. 2013 Jun;189(6):2136-41. Epub 2012 Dec 28. PMID: 23276510.
260. Hu JC, Freedland SJ, Hollenbeck BK, **Lotan Y**, Lowrance WT, Nelson BJ, Bolenz C. Reply from authors re: Suzanne Biehn Stewart, Shelby D. Reed, Judd W. Moul. Will the future of health care lead to the end of the robotic golden years? *Eur Urol*. 2014 Feb; 65(2): 327-8. Epub 2013 Jan 3. PMID: 23313035.
261. Darwish OM, Kapur P, Youssef RF, Bagrodia A, Belsante M, Alhalabi F, Sagalowsky AI, **Lotan Y**, Margulis V. Cumulative Number of Altered Biomarkers in Mammalian Target of Rapamycin Pathway Is an Independent Predictor of Outcome in Patients

- With Clear Cell Renal Cell Carcinoma. *Urology* 2013 Mar; 81(3): 581-6. Epub 2013 Jan 3. PMID: 23290145.
262. Larré S, Catto JS, Cookson MS, Messing EM, Shariat SF, Soloway MS, Svatek RS, **Lotan Y**, Zlotta AR, Grossman HB. Screening for Bladder Cancer: Rationale, Limitations, Whom to Target, and Perspectives. *Eur Urol.* 2013 Jun; 63(6): 1049-58. Epub 2013 Jan 8. PMID: 23313034.
263. Kluth LA, Xylinas E, Crivelli JJ, Passoni N, Comploj E, Pycha A, Chrystal J, Sun M, Karakiewicz PI, Gontero P, **Lotan Y**, Chun FK, Fisch M, Scherr DS, Shariat SF. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder. *J Urol.* 2013 Aug; 190(2): 480-6. Epub 2013 Jan 31. PMID: 23376707.
264. da Silva RD, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Chade D, Guglielmetti GB, Pycha A, **Lotan Y**, Karakiewicz PI, Sun M, Fajkovic H, Zerbib M, Scherr DS, Shariat SF. Impact of Statin Use on Oncologic Outcomes in Patients with Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. *J Urol.* 2013 Aug; 190(2): 487-92. Epub 2013 Feb 8. PMID: 23395802.
265. Belsante M, Darwish O, Youssef R, Bagrodia A, Kapur P, Sagalowsky AI, **Lotan Y**, Margulis V. Lymphovascular invasion in clear cell renal cell carcinoma- Association with disease-free and cancer-specific survival. *Urol Oncol.* 2014 Jan; 32(1): 30.e23-8. Epub 2013 Feb 18. PMID: 23428539.
266. Rausch S, **Lotan Y**, Youssef RF. Squamous cell carcinogenesis and squamous cell carcinoma of the urinary bladder: A contemporary review with focus on nonbilharzial squamous cell carcinoma. *Urol Oncol* 2014 Jan 32(1): 32.e11-6. Epub 2013 Feb 20. PMID: 23433891.
267. Xylinas E, Rink M, Robinson BD, **Lotan Y**, Babjuk M, Brisuda A, Green DA, Kluth LA, Pycha A, Fradet Y, Faison T, Lee RK, Karakiewicz PI, Zerbib M, Scherr DS, Shariat SF. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. *Eur J Cancer.* 2013 May;49(8):1889-97. Epub 2013 Mar 4. PMID: 23466126.
268. Xylinas E, Rink M, Margulis V, Clozel T, Lee RK, Comploj E, Novara G, Raman JD, **Lotan Y**, Weizer A, Roupret M, Pycha A, Scherr DS, Seitz C, Ficarra V, Trinh QD, Karakiewicz PI, Montorsi F, Zerbib M, Shariat SF; UTUC Collaboration. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. *BJU Int.* 2013 Aug; 112(4): 453-61. Epub 2013 Mar 6. PMID: 23464979.
269. Rink M, Xylinas E, Trinh QD, **Lotan Y**, Margulis V, Raman JD, Fisch M, Lee RK, Chun FK, Abdennabi J, Seitz C, Pycha A, Zlotta AR, Karakiewicz PI, Babjuk M, Scherr DS, Shariat SF; Upper Tract Urothelial Carcinoma Collaboration (UTUCC): Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes. *BJU Int.* 2013 Sep; 112(5): 623-37. Epub 2013 Mar 6. PMID: 23465088.
270. Bagrodia A, Kuehhas FE, Gayed BA, Wood CG, Raman JD, Kapur P, Derweesh IH, Bensalah K, Sagalowsky AI, Shariat SF, **Lotan Y**, Margulis V. Comparative Analysis of Oncologic Outcomes of Partial Ureterectomy vs Radical Nephroureterectomy in Upper Tract Urothelial Carcinoma. *Urology.* 2013 May;81(5):972-7. Epub 2013 Mar 20. PMID: 23523292.
271. Smith PJ, **Lotan Y**, Raj GV, Sagalowsky AI, Margulis V. Assessing treatment response after induction Bacillus Calmette-Guerin for carcinoma in situ of the urinary bladder: can post-induction random bladder biopsies be avoided? *Cytopathology.* 2014 Apr; 25(2):108-11. Epub 2013 Apr 2. PMID: 23551700.

272. **Lotan Y**, Bagrodia A, Passoni N, Rachakonda V, Kapur P, Arriaga Y, Bolenz C, Margulis V, Raj GV, Sagalowsky AI, Shariat SF. Prospective Evaluation of a Molecular Marker Panel for Prediction of Recurrence and Cancer-specific Survival After Radical Cystectomy. *Eur Urol.* 2013 Sep; 64(3): 465-71. Epub 2013 Apr 3. PMID: 23571005.
273. Gayed BA, Seideman C, **Lotan Y**. Cost Effectiveness of Fluorescence in Situ Hybridization in Patients with Atypical Cytology for the Detection of Urothelial Carcinoma. *J Urol.* 2013 Oct; 190(4): 1181-6. Epub 2013 Apr 9. PMID: 23583531.
274. Belsante MJ, Zhao LC, Hudak SJ, **Lotan Y**, Morey AF. Cost Effectiveness Of Risk- Stratified Follow-Up After Urethral Reconstruction: A Decision Analysis. *J Urol.* 2013 Oct; 190(4): 1292-7. Epub 2013 Apr 11. PMID: 23583856.
275. Bagrodia A, Harrow B, Liu ZW, Olweny EO, Faddegon S, Yin G, Tan YK, Han WK, **Lotan Y**, Margulis V, Cadeddu JA. Evaluation of anatomic and morphologic nomogram to predict malignant and high-grade disease in a cohort of patients with small renal masses. *Urol Oncol.* 2014 Jan; 32(1):37.e17-23. Epub 2013 Apr 28. PMID: 23628308.
276. Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, Rosario DJ, Scattoni V, **Lotan Y**. Systematic Review of Complications of Prostate Biopsy. *Eur Urol.* 2013 Dec; 64(6): 876-92. Epub 2013 Jun 4. PMID: 23787356
277. Gayed BA, Youssef RF, Bagrodia A, Kapur P, Darwish OM, Krabbe LM, Sagalowsky A, **Lotan Y**, Margulis V. Prognostic Role of Cell Cycle and Proliferative Biomarkers in Patients with Clear Cell Renal Cell Carcinoma. *J Urol.* 2013 Nov; 190(5): 1662-7. Epub 2013 Jun 20. PMID: 23792148.
278. Crivelli JJ, Xylinas E, Kluth LA, da Silva RD, Chrystal J, Novara G, Karakiewicz PI, David SG, Scherr DS, **Lotan Y**, Shariat SF. Effect of statin use on outcomes of non- muscle-invasive bladder cancer. *BJU Int.* 2013 Jul;112(2):E4-E12. PMID: 23795797.
279. Kluth LA, Abdollah F, Xylinas E, Rieken M, Fajkovic H, Sun M, Karakiewicz PI, Seitz C, Schramek P, Herman MP, Becker A, Loidl W, Pummer K, Nonis A, Lee RK, **Lotan Y**, Scherr DS, Seiler D, Chun FK, Graefen M, Tewari A, Gönen M, Montorsi F, Shariat SF, Briganti A. Pathologic Nodal Staging Scores in Patients Treated with Radical Prostatectomy: A Postoperative Decision Tool. *Eur Urol.* 2013 Jul 2. [Epub ahead of print]. PMID: 23850255.
280. McDunn JE, Li Z, Adam KP, Neri BP, Wolfert RL, Milburn MV, **Lotan Y**, Wheeler TM. Metabolomic signatures of aggressive prostate cancer. *Prostate.* 2013 Oct; 73(14): 1547-60. Epub 2013 Jul 3. PMID: 23824564.
281. Krabbe LM, Bagrodia A, **Lotan Y**, Gayed BA, Darwish OM, Youssef RF, John G, Harrow B, Jacobs C, Gaitonde M, Sagalowsky AI, Shariat SF, Kapur P, Margulis V. Prospective analysis of ki-67 as an independent predictor of oncologic outcomes in patients with high grade upper tract urothelial carcinoma. *J Urol.* 2014 Jan; 191(1):28-34. Epub 2013 Jul 16. PMID: 23871758.
282. Xylinas E, Kluth LA, Rieken M, Lee RK, Elghouayel M, Ficarra V, Margulis V, **Lotan Y**, Rouprêt M, Martinez-Salamanca JI, Matsumoto K, Seitz C, Karakiewicz PI, Zerbib M, Scherr DS, Shariat SF; UTUC Collaboration. Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy. *BJU Int.* 2014 Jul;114(1):56-61. Epub 2013 Aug 12. PMID: 24053463.
283. Gayed BA, Youssef RF, Bagrodia A, Darwish OM, Kapur P, Sagalowsky A, **Lotan Y**, Margulis V. Ki67 is an independent predictor of oncological outcomes in

- patients with localized clear-cell renal cell carcinoma. *BJU Int* 2014 Apr; 113(4): 668-73. Epub 2013 Aug 13. PMID: 23937277.
284. Xylinas E, Kent M, Kluth L, Pycha A, Comploj E, Svatek RS, **Lotan Y**, Trinh QD, Karakiewicz PI, Holmang S, Scherr DS, Zerbib M, Vickers AJ, Shariat SF. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non- muscle-invasive urothelial carcinoma of the bladder. *Br J Cancer*. 2013 Sep 17; 109(6): 1460-6. Epub 2013 Aug 27. PMID: 23982601.
285. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, **Lotan Y**, Karakiewicz PI, Holmäng S, Babjuk M, Fajkovic H, Seitz C, Klatte T, Pycha A, Bachmann A, Scherr DS, Shariat SF. Long-term Cancer-specific Outcomes of TaG1 Urothelial Carcinoma of the Bladder. *Eur Urol*. 2014 Jan; 65(1): 201-9. Epub 2013 Aug 27. PMID: 23998688.
286. Chang KH, Li R, Kuri B, **Lotan Y**, Roehrborn CG, Liu J, Vessella R, Nelson PS, Kapur P, Guo X, Mirzaei H, Auchus RJ, Sharifi N. A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer. *Cell*. 2013 Aug 29; 154(5): 1074-84. PMID: 23993097.
287. Rieken M, Kluth LA, Xylinas E, Seitz C, Fajkovic H, Karakiewicz PI, **Lotan Y**, Briganti A, Loidl W, Faison T, Crivelli JJ, Scherr DS, Bachmann A, Tewari AK, Kautzky-Willer A, Pummer K, Shariat SF. Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy. *Prostate Cancer Prostatic Dis*. 2013 Sep 3 [Epub ahead of print]. PMID: 23999669.
288. Kluth LA, Xylinas E, Rieken M, Ghouayel ME, Sun M, Karakiewicz PI, **Lotan Y**, Chun FK, Boorjian SA, Lee RK, Briganti A, Rouprêt M, Fisch M, Scherr DS, Shariat SF. Impact of Perioperative Blood Transfusion on the Outcome of Patients undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder. *BJU Int*. 2014 Mar; 113(3): 393-8. PMID: 24053618.
289. Xylinas E, Kluth LA, Rieken M, Karakiewicz PI, **Lotan Y**, Shariat SF. Urine markers for detection and surveillance of bladder cancer. *Urol Oncol*. 2013 Sep 17. [Epub ahead of print]. PMID: 24054865.
290. Kluth LA, Xylinas E, Rieken M, Chun FK, Fajkovic H, Becker A, Karakiewicz PI, Passoni N, Herman M, **Lotan Y**, Seitz C, Schramek P, Remzi M, Loidl W, Guillonneau B, Rouprêt M, Briganti A, Scherr DS, Graefen M, Tewari AK, Shariat SF. Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy? *Urol Oncol*. 2014 Jan; 32(1): 47.e1-8. Epub 2013 Sep 18. PMID: 24055425.
291. Xylinas E, Kluth L, Passonni N, Trinh QD, Rieken M, Lee RK, Fajkovic H, Novarra G, Margulis V, Raman JD, **Lotan Y**, Rouprêt M, Aziz A, Fritsches HM, Weizer A, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Walton T, Karakiewicz PI, Montorsi F, Zerbib M, Scherr DS, Shariat SF; for the UTUC Collaboration. Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool. *Eur Urol*. 2014 Mar; 65(3): 650-8. Epub 2013 Sep 19. PMID: 24070577.
292. Krabbe LM, **Lotan Y**, Bagrodia A, Gayed BA, Darwish OM, Youssef RJ, Bolenz C, Sagalowsky AI, Raj GV, Shariat SF, Kapur P, Margulis V. Prospective comparison of molecular signatures in urothelial cancer of the bladder and the upper urinary tract: is there evidence for discordant biology? *J Urol*. 2013 Sep 20. [Epub ahead of print]. PMID: 24060642.
293. Rieken M, Xylinas E, Kluth L, Trinh QD, Lee RK, Fajkovic H, Novara G, Margulis V, **Lotan Y**, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Karakiewicz PI, Scherr DS, Briganti A, Kautzky-Willer A, Bachmann A, Shariat SF;

- UTUC Collaboration. Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. *Eur J Surg Oncol.* 2014 Jan; 40(1): 113-20. Epub 2013 Sep 20. PMID 24113620.
294. Rieken M, Kluth LA, Xylinas E, Fajkovic H, Becker A, Karakiewicz PI, Herman M, **Lotan Y**, Seitz C, Schramek P, Remzi M, Loidl W, Pummer K, Lee RK, Faison T, Scherr DS, Kautzky-Willer A, Bachmann A, Tewari A, Shariat SF. Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. *World J Urol.* 2013 Sep 24. [Epub ahead of print] PMID: 24062093.
295. Kapur P, Christie A, Raman JD, Then MT, Nuhn P, Buchner A, Bastian P, Seitz C, Shariat SF, Bensalah K, Rioux-Leclercq N, Xie XJ, **Lotan Y**, Margulis V, Brugarolas J. BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort in patients with clear cell renal cell carcinoma. *J Urol* 2014 Mar; 191(3): 603-10. Epub 2013 Sep 25. PMID: 24076305.
296. Pesch B, Taeger D, Johnen G, Gawrych K, Bonberg N, Schwentner C, Wellhäußer H, Kluckert M, Leng G, Nasterlack M, **Lotan Y**, Stenzl A, Brüning T; the UroScreen Study Group. Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines. *Int Arch Occup Environ Health.* 2013 Oct 16. [Epub ahead of print]. PMID: 24129706.
297. Ploussard G, Shariat SF, Dragomir A, Kluth LA, Xylinas E, Masson-Lecomte A, Rieken M, Rink M, Matsumoto K, Kikuchi E, Klatter T, Boorjian SA, **Lotan Y**, Roghmann F, Fairey AS, Fradet Y, Black PC, Rendon R, Izawa J, Kassouf W. Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time. *Eur Urol.* 2013 Oct 9. [Epub ahead of print]. PMID: 24139235.
298. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, **Lotan Y**, Karakiewicz PI, Sun M, Fajkovic H, Babjuk M, Bachmann A, Scherr DS, Shariat SF. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. *Urol Oncol.* 2014 Jan; 32(1): 49.e7-49.e14. Epub 2013 Oct 17. PMID: 24140245.
299. Youssef RF, **Lotan Y**, Sagalowsky AI, Shariat SF, Wood CG, Raman JD, Langner C, Zigeuner R, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Margulis W. Radical nephroureterectomy for pathologic T4 upper tract urothelial cancer: can oncologic outcomes be improved with multimodality therapy? *Int Braz J Urol* 2013 Sep-Oct; 39(5): 614-21. PMID: 24267122.
300. Krabbe LM, Westerman ME, Bagrodia A, Gayed BA, Darwish OM, Haddad AQ, Khalil D, Kapur P, Sagalowsky AI, **Lotan Y**, Margulis V. Dysregulation of beta-catenin is an independent predictor of oncological outcomes in patients with clear cell renal cell carcinoma. *J Urol.* 2014 Jun; 191(6): 171-7. Epub 2013 Nov 26. PMID: 24291548.
301. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, **Lotan Y**, Karakiewicz PI, Fajkovic H, Babjuk M, Kautzky-Willer A, Bachmann A, Scherr DS, Shariat SF. Association of Diabetes Mellitus and Metformin Use with Oncological Outcomes of Patients with non-muscle invasive Bladder Cancer. *BJU Int.* 2013 Dec; 112(8): 1105-12. PMID: 24053906.
302. Kluth LA, Rieken M, Xylinas E, Kent M, Rink M, Rouprêt M, Sharifi N, Jamzadeh A, Kassouf W, Kaushik D, Boorjian SA, Roghmann F, Noldus J, Masson-Lecomte A, Vordos d, Ikeda M, Matsumoto K, Hagiwara M, Kikuchi E, Fradet Y, Izawa J, Rendon R, Fairey A, **Lotan Y**, Bachmann A, Zerbib M, Fisch M, Scherr DS, Vickers A, Shariat SF. Gender-specific Differences in Clinicopathologic Outcomes Following

- Radical Cystectomy: An International Multi-Institutional Study of More than 8000 Patients. *Eur Urol.* 2013 Dec 5 [Epub ahead of print]. PMID: 24331151.
303. Klatte T, Xylinas E, Rieken M, Kluth LA, Rouprêt M, Pycha A, Fajkovic H, Seitz C, Karakiewicz PI, **Lotan Y**, Babjuk M, de Martino M, Scherr DS, Shariat SF. Impact of ABO blood type on outcomes of patients with primary non-muscle-invasive bladder cancer. *J Urol.* 2014 May; 191(5): 1238-43. Epub 2013 Dec 11. PMID: 24333243.
304. Xylinas E, Kluth LA, **Lotan Y**, Daneshmand S, Rieken M, Karakiewicz PI, Shariat SF. Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. *Urol Oncol.* 2014 Apr; 32(3): 230-2. Epub 2013 Dec 11. PMID: 24332648.
305. Arbin AA, Guerra F, Greco M, Marra E, Gandee L, Xiao G, **Lotan Y**, Gasparre G, Hsieh JT, Moro L. Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2. *Oncogenesis.* 2013 Dec 16; 2:e82. PMID: 24336406.
306. Krabbe LM, Westerman ME, Bagrodia A, Gayed BA, Khalil D, Kapur P, Shariat SF, Raj GV, Sagalowsky AI, Cadeddu JA, **Lotan Y**, Margulis V. Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: Results of current series and a review of the literature. *Urol Oncol.* 2014 Jan; 32(1):54.e19-26. PMID: 24360665.
307. Shariat SF, Passoni N, Bagrodia A, Rachakonda V, Xylinas E, Robinson B, Kapur P, Sagalowsky AI, **Lotan Y**. Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy. *BJU Int.* 2014 Jan; 113(1): 70-6. PMID: 24053584.
308. Lee DJ, Xylinas E, Rieken M, Khani F, Klatte T, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Guo CC, Rioux-Leclercq N, Haitel A, Bolenz C, Bensalah K, Sagalowsky AI, Montorsi F, **Lotan Y**, Shariat SF, Robinson BD, Margulis V. Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma. *Eur Urol.* 2013 Dec 25. [Epub ahead of print]. PMID: 24388440.
309. Wang LC, Xylinas E, Kent MT, Kluth LA, Rink M, Jamzadeh A, Rieken M, Al Awamlh BA, Trinh QD, Sun M, Karakiewicz PI, Novara G, Chrystal J, Zerbib M, Scherr DS, **Lotan Y**, Vickers A, Shariat SF. Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. *Urol Oncol.* 2014 Jan 13. [Epub ahead of print]. PMID: 24433754.
310. Svatek RS, Hollenbeck BK, Holmäng S, Lee R, Kim S, Stenzl A, **Lotan Y**. The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease. *Eur Urol.* 2014 Jan 21. [Epub ahead of print]. PMID: 24472711.
311. The Cancer Genome Atlas Research Network. Comprehensive characterization of urothelial bladder carcinoma. *Nature.* 2014 Jan 29. [Epub ahead of print]. PMID: 24476821; PubMed Central PMCID: PMC3962515.
312. Messer JC, Shariat SF, Dinney CP, Novara G, Fradet Y, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, **Lotan Y**, Skinner EC, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Wei C, Lerner SP, Curiel TJ, Kamat AM, Svatek RS. Female Gender is Associated with a Worse Survival after Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Competing Risk Analysis. *Urology.* 2014 Apr; 83(4): 863-8. Epub 2014 Jan 31. PMID: 24485993.
313. Klatte T, Xylinas E, Rieken M, Rouprêt M, Fajkovic H, Seitz C, Karakiewicz PI, **Lotan Y**, Babjuk M, de Martino M, Shariat SF. Effect of ABO blood type on mortality in

- patients with urothelial carcinoma of the bladder treated with radical cystectomy. *Urol Oncol*. Jul; 32(5): 625-30. Epub 2014 Feb 1. PMID: 24495451.
314. Rausch S, Gaisa N, Youssef RF, **Lotan Y**, Stenzl A, Kälble T. [Squamous cell lesions of the urinary bladder]. *Urologe A* 2014 Mar; 53(3): 368-74. PMID: 24549798.
315. Wang S, Kollipara RK, Srivastava N, Li R, Ravindranathan P, Hernandez E, Freeman E, Humphries CG, Kapur P, **Lotan Y**, Fazli L, Gleave ME, Plymate SR, Raj GV, Hsieh JT, Kittler R. Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. *Proc Natl Acad Sci USA* 2014 Mar 18; 111(11): 4251-6. Epub 2014 Mar 3. PMID: 24591637; PubMed Central PMCID: PMC3964108.
316. Jacobs CD, Chun SG, Yan J, Xie XJ, Pistenmaa DA, Hannan R, **Lotan Y**, Roehrborn CG, Choe KS, Kim DN. Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy. *Cancer Biol Ther*. 2014 Jun 1; 15(6): 699-706. Epub 2014 Mar 21. PMID: 24658086; PubMed Central PMCID: PMC4049786.
317. Passoni NM, Fajkovic H, Xylinas E, Kluth L, Seitz C, Robinson BD, Roprêt M, Chun FK, **Lotan Y**, Roehrborn CG, Crivelli JJ, Karakiewicz PI, Scherr DS, Rink M, Graefen M, Schramek P, Briganti A, Montorsi F, Tewari A, Shariat SF. Prognosis of patients with pelvic lymph node metastasis following radical prostatectomy: value of extranodal extension and size of the largest lymph node metastasis. *BJU Int*. 2014 Oct; 114-(4): 503-10. Epub 2014 Apr 3 PMID: 24053552.
318. Rieken M, Schubert T, Xylinas E, Kluth L, Rouprêt M, Trinh QD, Lee RK, Al Hussein Al Awamlh B, Fajkovic H, Novara G, Margulis V, **Lotan Y**, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Karakiewicz PI, Scherr DS, Briganti A, Bachmann A, Shariat SF; for the UTUC Collaboration. Association of perioperative blood transfusion with oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. *Eur J Surg Oncol*. 2014 Apr 13. [Epub ahead of print]. PMID: 24780094.
319. Lucca I, Kassouf W, Kapoor A, Fairey A, Rendon RA, Izawa JI, Black PC, Fajkovic H, Seitz C, Remzi M, Nyirády P, Rouprêt M, Margulis V, **Lotan Y**, de Martino M, Hofbauer SL, Karakiewicz PI, Briganti A, Novara G, Shariat SF, Klatte T. The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. *BJU Int*. 2014 May 13. [Epub ahead of print]. PMID: 24825476.
320. **Lotan Y**, Svatek RS, Krabbe LM, Xylinas E, Klatte T, Shariat SF. Prospective External Validation of Model for Bladder Cancer Detection. *J Urol* Nov; 192(5): 1343-8. Epub 2014 May 21. PMID: 24859442.
321. Lucca I, Rouprêt M, Kluth L, Rink M, Tilki D, Fajkovic H, Kassouf W, Hofbauer SL, de Martino M, Karakiewicz PI, Briganti A, Trinh QD, Seitz C, Fritsche HM, Burger M, **Lotan Y**, Kramer G, Shariat SF, Klatte T. Adjuvant cisplatin-based combination chemotherapy for lymph node-positive urothelial carcinoma of the bladder following radical cystectomy: a retrospective international study of more than 1500 patients. *BJU Int*. 2015 May; 115(5): 722-7. Epub 2015 Jan 6. PMID: 24905084.
322. Kim DW, Cho LC, Straka C, Christie A, **Lotan Y**, Pistenmaa D, Kavanagh BD, Nanda A, Kueplian P, Brindle J, Cooley S, Perkins A, Raben D, Xie XJ, Timmerman RD. Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. *Int J. Radiat Oncol Biol Phys* 2014 Jul 1; 89(3): 509-17. PMID: 24929162.

323. Kluth LA, Abdollah F, Xylinas E, Rieken M, Fajkovic H, Seitz C, Sun M, Karakiewicz PI, Schramek P, Herman MP, Becker A, Hansen J, Ehdaie B, Loidl W, Pummer K, Lee RK, **Lotan Y**, Scherr DS, Seiler D, Ahyai SA, Chun FK, Graefen M, Tewari A, Nonis A, Bachmann A, Montorsi F, Gönen M, Briganti A, Shariat SF. Clinical nodal staging scores for prostate cancer: a proposal for preoperative assessment. *Br J Cancer* 2014 Jul 15. Epub 2014 Jul 8. PMID: 25003663; PubMed Central PMCID: PMC4102948.
324. Antonelli JA, Maalouf NM, Pearle MS, **Lotan Y**. Use of the national health and nutrition examination survey to calculate the impact of obesity and diabetes on cost and prevalence of urolithiasis in 2030. *Eur Urol* 2014 Oct; 66(4): 724-9. Epub 2014 Jul 9. PMID: 25015037.
325. Chung PH, Krabbe LM, Darwish OM, Westerman ME, Bagroida A, Gayed BA, Haddad AQ, Kapur P, Sagalowsky AI, **Lotan Y**, Margulis V. Degree of hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract. *Urol Oncol* 2014 Jul 8. [Epub ahead of print]. PMID: 25022858.
326. Krabbe LM, Svatek RS, Shariat SF, Messing E, **Lotan Y**. Bladder cancer risk: Use of the PCLO and NLST to identify a suitable screening cohort. *Urol Oncol*. 2015 Feb; 33(2):65.e19-25. Epub 2014 Jul 16. PMID: 25044253.
327. Ploussard G, Xylinas E, **Lotan Y**, Novara G, Margulis V, Rouprêt M, Matsumoto K, Karakiewicz PI, Montorsi F, Remzi M, Seitz C, Scherr DS, Kapoor A, Fairey AS, Rendon R, Izawa J, Black PC, Lacombe L, Shariat SF, Kassouf W. Conditional Survival After Radical Nephroureterectomy for Upper Tract Carcinoma. *Eur Urol*. 2015 Apr;67(4):803- 12. Epub 2014 Aug 19. PMID: 25145551.
328. Bobulescu IA, **Lotan Y**, Zhang J, Rosenthal TR, Rogers JT, Adams-Huet B, Sakhaee K, Moe OW. Triglycerides in the human kidney cortex: relationship with body size. *PLoS One*. 2014 Aug 29;9(8):e101285. eCollection 2014. PubMed PMID: 25170827; PubMed Central PMCID: PMC4149342.
329. Haddad AQ, Kapur P, Singla N, Raman JD, Then MT, Nuhn P, Buchner A, Bastian P, Seitz C, Shariat SF, Bensalah K, Rioux-Leclercq N, Sagalowsky A, **Lotan Y**, Margulis V. Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma. *Cancer*. 2014 Sep 3. [Epub ahead of print] PubMed PMID: 25186283.
330. Youssef RF, von Rundstedt FC, Kapur P, Mosbah A, Abol-Enein H, Ghoneim M, **Lotan Y**. Utility of Biomarkers in the Prediction of Oncological Outcome after Radical Cystectomy for Squamous Cell Carcinoma. *J Urol*. 2015 Feb; 193(2): 451-6. Epub 2014 Sep 6. PMID: 25200806.
331. Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Vasdev N, Yu EY, Youssef D, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, **Lotan Y**, Garcia JA, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black PC. Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. *Eur Urol*. 2015 Feb;67(2):241-9. Epub 2014 Sep 23. PMID: 25257030.
332. Chung O, Vongpatanasin W, Bonaventura K, **Lotan Y**, Sohns C, Haverkamp W, Dorenkamp M. Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension. *J Hypertens* 2014 Sep 24. [Epub ahead of print] PMID: 25255395.

333. Kim SP, Gross CP, Smaldone MC, Han LC, Van Houten H, **Lotan Y**, Svatek RS, Thompson RH, Karnes RJ, Trinh QD, Kutikov A, Shah ND. Perioperative outcomes and hospital reimbursement by type of radical prostatectomy: results from a privately insured patient population. *Prostate Cancer Prostatic Dis.* 2015 Mar; 18(1): 13-7. Epub 2014 Oct 14. PMID: 25311766.
334. Lucca I, Shariat SF, Briganti A, **Lotan Y**, Roehrborn CG, Montorsi F, Remzi M, Seitz C, Fajkovic H, Klingler C, Karakiewicz PI, Sun M, Rouprêt M, Loidl W, Pummer K, Klatte T. Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model. *Urol Oncol.* 2015 Feb;33(2):71.e21-6. Epub 2014 Oct 23. PMID: 25443275.
335. Bagrodia A, Krabbe LM, Gayed BA, Kapur P, Bernstein I, Xie XJ, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, **Lotan Y**, Margulis V. Evaluation of the prognostic significance of altered Mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma. *Urology* 2014 Nov; 84(5): 1134-40. Epub 2014 Oct 24. PMID: 25443916.
336. Mathieu R, Shariat SF, Seitz C, Karakiewicz PI, Fajkovic H, Sun M, **Lotan Y**, Scherr DS, Tewari A, Montorsi F, Briganti A, Rouprêt M, Lucca I, Margulis V, Rink M, Kluth LA, Rieken M, Bachman A, Xylinas E, Robinson BD, Bensalah K, Margreiter M. Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy. *World J Urol.* 2014 Oct 26. [Epub ahead of print]. PMID: 25344896.
337. Gayed BA, Bagrodia A, Gaitonde M, Krabbe LM, Meissner M, Kapur P, Youssef RD, Sagalowsky A, **Lotan Y**, Margulis V. Feasibility of obtaining biomarker profiles from endoscopic biopsy specimens in upper tract urothelial carcinoma: Preliminary results. *Urol Oncol.* 2015 Jan;33(1):18.e21-6. Epub 2014 Nov 7. PMID: 25454486.
338. Wei JT, Feng Z, Partin AW, Brown E, Thompson I, Sokoll L, Chan DW, **Lotan Y**, Kibel AS, Busby JE, Bidair M, Lin DW, Taneja SS, Viterbo R, Joon AY, Dahlgren J, Kagan J, Srivastava S, Sanda MG. Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer? *J Clin Oncol.* Dec 20; 32(36): 4066-72. Epub 2014 Nov 10. PMID: 25385735.
339. Krabbe LM, Bagrodia A, Haddad AQ, Kapur P, Khalil D, Hynan LS, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, **Lotan Y**, Margulis V. Multi-institutional Validation of the Predictive Value of KI-67 in Patients with High-Grade Urothelial Carcinoma of the Upper Urinary Tract. *J Urol.* 2015 May; 193(5): 1486-93. Epub 2014 Nov 11. PMID: 25451830.
340. Durinck S, Stawiski EW, Pavía-Jiménez A, Modrusan Z, Kapur P, Jaiswal BS, Zhang N, Toffessi-Tcheuyap V, Nguyen TT, Pahuja KB, Chen YJ, Saleem S, Chaudhuri S, Heldens D, Jackson M, Peña-Llopis S, Guillory J, Toy K, Ha C, Harris CJ, Holloman E, Hill HM, Stinson J, Rivers CS, Janakiraman V, Wang W, Kinch LN, Grishin NV, Haverly PM, Chow B, Gehring JS, Reeder J, Pau G, Wu TD, Margulis V, **Lotan Y**, Sagalowsky A, Pedrosa I, de Sauvage FJ, Brugarolas J, Seshagiri S. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. *Nat Genet* 2014 Nov 17. [Epub ahead of print] PMID: 25401301.
341. Seideman C, Canter D, Kim P, Cordon B, Weizer A, Oliva I, Rao J, Inman BA, Posch M, Herr H, **Lotan Y**. Multicenter evaluation of the role of UroVysion FISH assay in

- surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence? *World J. Urol* 2014 Nov 25. [Epub ahead of print] PMID: 25420920.
342. Youssef RF, Kapur P, Mosbah A, Abol-Enein H, Ghoneim M, **Lotan Y**. Role of fibroblast growth factor in squamous cell carcinoma of the bladder: Prognostic biomarker and potential therapeutic target. *Urol Oncol*. 2014 Dec 1 [Epub ahead of print]. PMID: 25477183.
343. Schmitz-Dräger BJ, Droller M, Lokeshwar VB, **Lotan Y**, Hudson MA, van Rhijn BW, Marberger MJ, Fradet Y, Hemstreet GP, Malmstrom PU, Ogawa O, Karakiewicz PI, Shariat SF. Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus. *Urol Int*. 2015; 94(1): 1-24. Epub 2014 Dec 10. PMID: 25501325.
344. Wittmann BM, Stirdivant SM, Mitchell MW, Wulff JE, McDunn JE, Li Z, Dennis-Barrie A, Neri BP, Milburn MV, **Lotan Y**, Wolfert RL. *PLoS One*. 2014 Dec 26;9(12): e115870. eCollection 2014. PMID: 25541698.
345. Birnbaum JK, Feng Z, Gulati R, Fan J, **Lotan Y**, Wei JT, Etzioni R. Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer. *Cancer Epidemiol Biomarkers Prev*. 2015 Apr; 24(4): 677-82. Epub 2015 Jan 22. PMID: 25613117.
346. Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Tilki D, Otto W, Capitanio U, Izawa JI, Ficarra V, Lerner S, Sagalowsky AI, Schoenberg M, Kamat A, Dinney CP, **Lotan Y**, Shariat SF. Corrigendum to "Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort: [Eur Urol 2010; 57:300-9]=. *Eur Urol* 2015 Jul; 68(1): 171. Epub 2015 Feb 18. PMID: 26088736.
347. Mork M, Hubosky SG, Roupret M, Margulis V, Raman J, **Lotan Y**, O'Brien T, You N, Shariat SF, Matin SF. Lynch Syndrome: A Primer for Urologists and Panel Recommendations. *J Urol*. 2015 Jul; 194(1): 21-9. Epub 2015 Feb 21. PMID: 25711197.
348. Chung PH, Darwish OM, Roehrborn CG, Kapur P, **Lotan Y**. Histologic upgrading in patients eligible for active surveillance on saturation biopsy. *Can J Urol* 2015 Feb; 22(1): 7656-60. PMID: 25694015.
349. **Lotan Y**, Haddad AQ, Costa DN, Pedrosa I, Rofsky NM, Roehrborn CG. Decision analysis model comparing cost of multiparametric magnetic resonance imaging vs. repeat biopsy for detection of prostate cancer in men with prior negative findings on biopsy. *Urol Oncol*. 2015 Jun; 33(6): e9-266.e.16. Epub 2015 Apr 7. PMID: 25858102.
350. Singla N, Gayed VA, Bagrodia A, Krabbe LM, Palazzi KL, Mirheydar H, Harrow B, Jacobs C, Youssef R, Darwish O, Sagalowsky A, **Lotan Y**, Derweesh I, Margulis V. Multi-institutional analysis of renal function outcomes following radical nephroureterectomy and partial ureterectomy for upper tract urothelial carcinoma. *Urol Oncol*. 2015 Jun; 33(6): 268.e1-7. Epub 2015 Apr 7. PMID: 25862284.
351. Bishoy A, Gayed, Jessica Gillen, Alana Lee Christie, Samuel Peña-Llopis, Xian-Jin Xie, Jingshen Yan, Jose A. Karam, Ganesh V. Raj, Arthur Sagalowsky, **Yair Lotan**, Vitaly Margulis, James Brugarolas. Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma. *BMC Urology*. 2015 Apr 3; 15(1):24. PMID: 25885592.

352. Lucca I, Jichlinski P, Shariat SF, Rouprêt M, Rieken M, Kluth LA, Rink M, Mathieu R, Mbeutcha A, Maj-Hes A, Fajkovic H, Briganti A, Seitz C, Karakiewicz PI, de Martino M, **Lotan Y**, Babjuk M, Klätte T. Eur Urol Focus. 2016 Apr;2(1):79-85. doi: 10.1016/j.euf. 2015.03.001. Epub 2015 May 29. PMID: 28723455.
353. Starke N, Singla N, Haddad A, **Lotan Y**. Long-term outcomes of high risk bladder cancer screening cohort. BJU Int. 2016 Apr;117(4):611-7. Epub 2015 Jun 3. PMID: 25891519.
354. Velasco A, Chung O, Raza F, Pandey A, Brinker S, Arbique D, Price A, **Lotan Y**, Das SR, Vongpatanasin W. Cost-Effectiveness of Therapeutic Drug Monitoring in Diagnosing Primary Aldosteronism in Patients with Resistant Hypertension. J Clin Hypertens (Greenwich) 2015 Apr 27. [Epub ahead of print] PMID: 25917401.
355. **Lotan Y**. Promises and challenges of fluorescence cystoscopy. Urol Oncol. 2015 Jun;33(6):261-4. Epub 2015 Apr 27. PMID: 25937623.
356. Youssef RF, Krabbe LM, Shariat SF, **Lotan Y**, Sagalowsky AI, Raman J, Wood CG, Weizer A, Roscigno M, Montorsi F, Bolenz C, Remzi M, Bensalah K, Kassouf W, Margulis V. TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma. World J Urol. 2015 Dec;33(12):1965-72. Epub 2015 May 10. PMID: 25957592.
357. Krabbe LM, Bagrodia A, Westerman ME, Gayed BA, Haddad AQ, Sagalowsky AI, Shariat SF, Kapur P, **Lotan Y**, Margulis V. Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different? World J Urol 2015 May 20. [Epub ahead of print] PMID: 25991599.
358. Ilaria Lucca, Patrice Jichlinski, Shahrokh F. Shariat, Morgan Rouprêt, Malte Rieken, Luis A. Kluth, Michael Rink, Romain Mathieu, Aurelie Mbeutcha, Agnes Maj-Hes, Harun Fajkovic, Alberto Briganti, Christian Seitz, Pierre I. Karakiewicz, Michela de Martino, Yair Lotan, Marko Babjuk, Tobias Klätte. The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysis. Eur Urol Focus. 2016 Apr;2(1):79-85. Epub 2015 May 29.
359. Ying J, Wang CJ, Yan J, Liauw SL, Straka C, Pistenmaa D, Xie XJ, **Lotan Y**, Roehrborn C, Kim DN. Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy. Am J Clin Oncol 2015 Jul 9. [Epub ahead of print] PMID: 26165416.
360. Costa DN, **Lotan Y**, Rofsky NM, Roehrborn C, Liu A, Hornberger A, Xi Y, Francis F, Pedrosa I. Assessment of Prospectively Assigned Likert Scores for Targeted MR Imaging-Transrectal US Fusion Biopsies in Patient with Suspected Prostate Cancer. J Urol 2015 Jul 17. [Epub ahead of print]. PMID: 26192254.
361. Zargar-Shoshtari K, Zargar H, **Lotan Y**, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black P. A Multi-Institutional Analysis of Outcomes in Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy. J Urol. 2015 Jul 20. [Epub ahead of print] PMID: 26205531.
362. Mathieu R, Klätte T, Lucca I, MBeutcha A, Seitz C, Karakiewicz PI, Fajkovic H, Sun M, **Lotan Y**, Scherr DS, Montorsi F, Briganti A, Rouprêt M, Margulis V, Rink M, Kluth LA, Rieken M, Kenner L, Susani M, Robinson BD, Xylinas E, Loidl W, Shariat SF. Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study. BJU Int 2016 Aug;118(2):243-9. doi: 10.1111/bju.13224. Epub 2015 Aug 13. 26189876.
363. Mathieu R, Klätte T, Margulis V, Karam JA, Rouprêt M, Seitz C, Karakiewicz PI, Fajkovic H, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A,

- Bensalah K, **Lotan Y**, Rink M, Kluth LA, Scherr DS, Robinson BD, Shariat SF. Surviving is not an independent prognostic factor for patients with upper tract urothelial carcinoma: A multi- institutional study. *Urol Oncol*. Epub 2015 Jul 27. 2015 Nov;33(11):495.e15-22. PMID: 26228160.
364. Krabbe LM, Westerman ME, Margulis V, Raj GV, Sagalowsky AI, Courtney K, Arriaga Y, **Lotan Y**. Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer. *Can J Urol*. 2015 Aug;22(4):7865-75. PMID: 26267024.
365. Haddad AQ, Jiang L, Cadeddu JA, **Lotan Y**, Gahan JC, Hynan LS, Gupta N, Raj GV, Sagalowsky AI, Margulis V. Statin Use and Serum Lipid Levels are Associated with Survival Outcomes after Surgery for Renal Cell Carcinoma. *Urology*. 2015 Sep 25. [Epub ahead of print]. PMID: 26416007.
366. Ramirez D, Gupta A, Canter D, Harrow B, Dobbs RW, Kucherov V, Mueller E, Streeper N, Uhlman MA, Svatek RS, Messing EM, **Lotan Y**. Microscopic hematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer. *BJU Int*. 2016 May;117(5):783-6. Epub 2015 Oct 29. PMID: 26435378.
367. Palmboos PL, Wang L, Yang H, Wang Y, Leflein J, Ahmet ML, Wilkinson JE, Kumar- Sinha C, Ney G, Tomlins SA, Daignault SD, Kunju LP, Wu XR, **Lotan Y**, Liebert M, Ljungman M, Simeone DM. ATDC (TRIM29) Drives Invasive Bladder Cancer Formation. *Cancer Res*. 2015 Oct 15. [Epub ahead of print]. PMID: 26471361.
368. Zargar H, Zargar-Shoshtari K, **Lotan Y**, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black P. Final Pathologic Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer: Does pT0 Predict Better Survival Than pTa/Tis/T1? *J Urol*. 2016 Apr;195(4 Pt 1):886-93. doi: 10.1016/j.juro.2015.10.133. Epub 2015 Oct 29. PMID: 26521718.
369. **Lotan Y**, Karam JA, Shariat SF, Gupta A, Roupret M, Bensalah K, Margulis V. Renal- cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial. *Urol Oncol*. Apr;34(4):167-.e9-16. Epub 2015 Nov 18. PMID: 26602092.
370. Mbeutcha A, Lucca I, Margulis V, Karam JA, Wood CG, de Martino M, Mathieu R, Haitel A, Xylinas E, Kluth L, Rouprêt M, Karakiewicz PI, Briganti A, Rink M, Rieken M, Weizer AZ, Raman JD, Rioux-Leclecq N, Bolenz C, Bensalah K, **Lotan Y**, Seitz C, Remzi M, Shariat SF, Klatter T. Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. *World J Urol*. 2016 Aug;34(8):1155-61. doi: 10.1007/s00345-015-1737-7. Epub 2015 Dec 11. PMID: 26658888.
371. Krabbe LM, **Lotan Y**. Should patients newly diagnosed with bladder cancer be screened for lung cancer? *Int J Urol*. 2016 Apr;23(4):346-7. Epub 2016 Jan 14. PMID: 26765318.
372. Rundstedt FV, Kimal R, Ma J, Arnold J, Gohlke J, Putluri V, Krishnapuram R, Piyarathna DB, **Lotan Y**, Gödde D, Roth S, Störkel S, Levitt JM, Michailidis G, Lerner SP, Coarfa C, Sreekumar A, Putluri N. Integrative pathway analysis of metabolic signature in bladder cancer - a linkage to the Cancer Genome Atlas Project and prediction of survival. *J Urol*. 2016 Jan 20. [Epub ahead of print]. PMID: 26802582.
373. Morgan MS, Antonelli JA, **Lotan Y**, Shakir N, Kavoussi N, Cohen A, Pearle MS. Use of an electronic medical record to assess patient-reported morbidity after ureteroscopy. *J Endourol*. 2016 May;30 Suppl 1:S46-51. Epub 2016 Feb 11. PMID: 26864676.
374. Canvasser NE, Stouder K, Lay AH, Gahan JC, **Lotan Y**, Margulis V, Raj GV, Sagalowsky AI, Cadeddu JA. The Utility of Chest X-Rays for T1a Renal Cell

- Carcinoma Surveillance. *J Urol*. 2016 Feb 12. [Epub ahead of print]. PMID: 26880407.
375. Zhou J, Luo J, Wu K, Yun EJ, Kapur P, Pong RC, Du Y, Wang B, Authement C, Hernandez E, Yang J, Xiao G, Cha TL, Wu HC, Wu D, Margulis V, **Lotan Y**, Brugarolas J, He D, Hsieh JT. Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies. *Oncogene*. 2016 Feb 15. [Epub ahead of print]. PMID: 26876207.
376. Dutta R, Okhunov Z, Vernez SL, Kaler K, Gulati AT, Youssef RF, Nelson K, **Lotan Y**, Landman J. Cost Comparisons Between Different Techniques of Percutaneous Renal Biopsy for Small Renal Masses. *J Endourol*. 2016 May;30 Suppl 1:S28-33. Epub 2016 Feb 26. PMID: 26915901.
377. Mathieu R, Lucca I, Vartolomei MD, MBeutcha A, Klatter T, Seitz C, Karakiewicz PI, Fajkovic H, Sun M, **Lotan Y**, Montorsi F, Briganti A, Rouprêt M, Margulis V, Rink M, Rieken M, Kenner L, Susani M, Wolfgang L, Shariat SF. Role of Survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study. *BJU Int*. 2017 Feb;119(2):234-238. doi: 10.1111/bju.13472. Epub 2016 Apr 5. PMID: 26940243.
378. Costa DN, Yuan Q, Xi Y, Rofsky NM, Lenkinski RE, **Lotan Y**, Roehrborn CG, Francis F, Travalini D, Pedrosa I. Comparison of prostate cancer detection at 3-T MRI with and without an endorectal coil: A prospective, paired-patient study. *Urol Oncol*. 2016 Jun;34(6):255.e7-255.e13. Epub 2016 Mar 9. PMID: 26971190.
379. Fajkovic H, Mathieu R, Lucca I, Hiess M, Hübner N, Al Awamlh BA, Lee R, Briganti A, Karakiewicz P, **Lotan Y**, Roupret M, Rink M, Kluth L, Loidl W, Seitz C, Klatter T, Kramer G, Susani M, Shariat SF. Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy. *Urol Oncol*. 2016 May;34(5):233.e1-6. Epub 2016 Mar 10. PMID: 26973136.
380. Hannan R, Tumati V, Xie XJ, Cho LC, Kavanagh BD, Brindle J, Raben D, Nanda A, Cooley S, Kim DW, Pistenmaa D, **Lotan Y**, Timmerman R. Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial. *Eur J Cancer*. 2016 May;59:142-51. doi: 10.1016/j.ejca.2016.02.014. Epub 2016 Mar 29. PMID: 27035363.
381. Hutchinson R, Sundaram V, Folkert M, **Lotan Y**. Decision analysis model evaluating the cost of a temporary hydrogel rectal spacer before prostate radiation therapy to reduce the incidence of rectal complications. *Urol Oncol*. 2016 Jul;34(7):291.e19-26. Epub 2016 Mar 30. PubMed PMID: 27038698.
382. Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzebec P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, **Lotan Y**, van der Kwast TH, Culine S, Allory Y, van Rhijn BW. Tumor Heterogeneity of Fibroblast Growth Factor Receptor 3 (FGFR3) Mutations in Invasive Bladder Cancer: Implications for Peri- Operative anti-FGFR3 Treatment. *Ann Oncol*. 2016 Jul;27(7):1311-6. Epub 2016 Apr 18. PubMed PMID: 27091807.
383. Favaretto RL, Bahadori A, Mathieu R, Haitel A, Grubmüller B, Margulis V, Karam JA, Rouprêt M, Seitz C, Karakiewicz PI, Cunha IW, Zequi SC, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Jacquet-Kammerer S, Bensalah K, **Lotan Y**, Bachmann A, Rink M, Briganti A, Shariat SF. Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial

- carcinoma: a multi-institutional study. *World J Urol.* 2017 Jan;35(1):113-120. doi: 10.1007/s00345-016-1835-1. Epub 2016 Apr 29. PMID: 27129576.
384. Spradling K, **Lotan Y**, Shokeir A, Abol-Enein H, Mosbah A, Morgan JB, Ghoneim M, Youssef RF. Lymphovascular invasion is associated with oncologic outcomes following radical cystectomy for squamous cell carcinoma of the urinary bladder. *Urol Oncol.* 2016 Sep;34(9):417.e1-8. Epub 2016 May 2. PubMed PMID: 27157247.
385. Mariotti GC, Costa DN, Pedrosa I, Falsarella PM, Martins T, Roehrborn CG, Rofsky NM, Xi Y, M Andrade TC, Queiroz MR, **Lotan Y**, Garcia RG, Lemos GC, Baroni RH. Magnetic resonance/transrectal ultrasound fusion biopsy of the prostate compared to systematic 12-core biopsy for the diagnosis and characterization of prostate cancer: multi-institutional retrospective analysis of 389 patients. *Urol Oncol.* 2016 Sep;34(9):416.e9-416.e14. Epub 2016 May 16. PMID: 27197921.
386. Singla N, Haddad AQ, Passoni NM, Meissner M, **Lotan Y**. Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer. *World J Urol.* 2017 Jan;35(1):105-111. doi: 10.1007/s00345-016-1853-z. Epub 2016 May 18. PMID: 27194044.
387. Raman JD, Warrick JI, Caruso C, Yang Z, Shuman L, Bruggeman RD, Shariat S, Karam JA, Wood C, Weizer AZ, Remzi M, Haitel A, Bensalah K, Rioux-Leclercq N, Bolenz C, Roscigno M, Krabbe LM, Kapur P, **Lotan Y**, Margulis V, DeGraff DJ. Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated with Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract. *Urology.* 2016 Aug;94:314.e1-7. doi: 10.1016/j.urology.2016.05.030. Epub 2016 May 20. PMID: 27215483.
388. **Lotan Y**, Antonelli J, Jiménez IB, Gharbi H, Herring R, Beaver A, Dennis A, Von Merveldt D, Carter S, Cohen A, Poindexter J, Moe OW, Pearle MS. The kidney stone and increased water intake trial in steel workers: results from a pilot study. *Urolithiasis.* 2017 Apr;45(2):177-183. doi: 10.1007/s00240-016-0892-7. Epub 2016 May 26. PMID: 27228999.
389. Sheth KR, Haddad AQ, Ashorobi OS, Meissner MA, Sagalowsky AI, **Lotan Y**, Margulis V. Prognostic serum markers in patients with high-grade upper tract urothelial carcinoma. *Urol Oncol.* 2016 Sep;34(9):418.e9-418.e16. PMID: 27234379.
390. Soria F, Moschini M, Haitel A, Wirth GJ, Karam JA, Wood CG, Rouprêt M, Margulis V, Karakiewicz PI, Briganti A, Raman JD, Kammerer-Jacquet SF, Mathieu R, Bensalah K, **Lotan Y**, Özsoy M, Remzi M, Gust KM, Shariat SF. HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). *World J Urol.* 2017 Feb;35(2):251-259. doi: 10.1007/s00345-016-1871-x. Epub 2016 Jun 7. PMID: 27272502.
391. Duivenvoorden WC, Daneshmand S, Canter D, **Lotan Y**, Black PC, Abdi H, van Rhijn BW, Fransen van de Putte EE, Zareba P, Koskinen I, Kassouf W, Traboulsi SL, Kukreja JE, Boström PJ, Shayegan B, Pinthus JH. Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy. *J Urol.* 2016 Dec;196(6):1627-1633. Epub 2016 Jun 14. PMID: 27312316.
392. Kim J, Davis JW, Klein EA, Magi-Galluzzi C, **Lotan Y**, Ward JF, Pisters LL, Basler JW, Pettaway CA, Stephenson A, Li Ning Tapia EM, Efsthathiou E, Wang X, Do KA, Lee JJ, Gorlov IP, Vornik LA, Hoque AM, Prokhorova IN, Parnes HL, Lippman SM, Thompson IM, Brown PH, Logothetis CJ, Troncoso P. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. *EBioMedicine.* 2016 May;7:85- 93. PMID: 27322462; PMCID: PMC4909608.

393. Passoni NM, Shariat SF, Bagrodia A, Francis F, Rachakonda V, Xylinas E, Kapur P, Sagalowsky AI, **Lotan Y**. Concordance in Biomarker Status between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5- year Prospective Study. *Bladder Cancer*. 2016 Jan 7;2(1):91-99. PMID: 27376130; PMCID: PMC4927883.
394. Dutta R, Abdelhalim A, Martin JW, Vernez SL, Faltas B, **Lotan Y**, Youssef RF. Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. *Urol Oncol*. 2016 Dec;34(12):531.e1-531.e6. Epub 2016 Jul 14. PMID: 27427223.
395. Singla N, Hutchinson R, Menegaz C, Haddad AQ, Jiang L, Sagalowsky AI, Cadeddu JA, **Lotan Y**, Margulis V. Comparing Changes in Renal Function After Radical Surgery for Upper Tract Urothelial Carcinoma and Renal Cell Carcinoma. *Urology*. 2016 Oct;96:44- 53. doi: 10.1016/j.urology.2016.07.015. Epub 2016 Jul 18. PMID: 27443467.
396. Singla N, Hutchinson R, Haddad A, Sagalowsky A, **Lotan Y**, Margulis V. Preoperative hydronephrosis is associated with less decline in renal function after radical nephroureterectomy for upper tract urothelial carcinoma. *Can J Urol*. 2016 Aug;23(4):8334-41. PMID: 27544555.
397. Soria F, Shariat SF, Lerner SP, Fritsche HM, Rink M, Kassouf W, Spiess PE, **Lotan Y**, Ye D, Fernández MI, Kikuchi E, Chade DC, Babjuk M, Grollman AP, Thalmann GN. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper- tract urothelial carcinoma (UTUC). *World J Urol*. 2017 Mar;35(3):379-387. doi: 10.1007/s00345-016-1928-x. Epub 2016 Sep 7. Review. PMID: 27604375.
398. Kim DN, Straka C, Cho LC, **Lotan Y**, Yan J, Kavanagh B, Raben D, Cooley S, Brindle J, Xie XJ, Pistenmaa D, Timmerman R. Early and multiple PSA bounces can occur following high-dose prostate stereotactic body radiation therapy: Subset analysis of a phase 1/2 trial. *Pract Radiat Oncol*. 2017 Jan-Feb;7(1):e43-e49. doi: 10.1016/j.prro.2016.06.010 Epub 2016 Jun 24. PMID: 27637137.
399. Passoni N, Gayed B, Kapur P, Sagalowsky AI, Shariat SF, **Lotan Y**. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer. *Urol Oncol*. 2016 Nov;34(11):485.e7-485.e14. Epub 2016 Sep 13. PMID: 27637323.
400. Hutchinson R, Akhtar A, Haridas J, Bhat D, Roehrborn C, **Lotan Y**. Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate-specific antigen screening. *Cancer*. 2016 Dec 15;122(24):3785-3793. doi: 10.1002/cncr.30330. Epub 2016 Sep 22. PMID: 27658175.
401. Krabbe LM, Eminaga O, Shariat SF, Hutchinson RC, **Lotan Y**, Sagalowsky AI, Raman JD, Wood CG, Weizer AZ, Roscigno M, Montorsi F, Bolenz C, Novara G, Kikuchi E, Fajkovic H, Rapoport LM, Glybochko PV, Zigeuner R, Remzi M, Bensalah K, Kassouf W, Margulis V. Post-Operative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma. *J Urol*. 2016 Sep 23. pii: S0022- 5347(16)31376-3. [Epub ahead of print]. PMID: 27670916.
402. Billy H, Cordon, Matthias D. Hofer, Ryan C. Hutchinson, Gregory A. Broderick, **Yair Lotan**, Allen F. Morey. Superior Cost Effectiveness of Penile Plication vs Intralesional Collagenase Injection for Treatment of Peyronie's Disease Deformities. *Urology Practice*. 2017 Mar;4(2):118-125. doi: http://dx.doi.org/10.1016/j.urpr.2016.04.005. Epub 2016 Oct 6.
403. Wirth GJ, Haitel A, Moschini M, Soria F, Klatte T, Hassler MR, Bensalah K, Briganti A, Karam JA, **Lotan Y**, Margulis V, Raman JD, Remzi M, Rioux-Leclercq N,

- Robinson BD, Rouprêt M, Wood CG, Shariat SF. Androgen receptor expression is associated with adverse pathological features in ureteral but not in pelvicalyceal urothelial carcinomas of the upper urinary tract. *World J Urol.* 2016 Oct 11. [Epub ahead of print]. PMID: 27730305.
404. Singla N, Fang D, Su X, Bao Z, Cao Z, Jafri SM, Xiong G, Zhang L, Hutchinson R, Sagalowsky A, **Lotan Y**, Li X, Zhou L, Raman JD, Margulis V. A multi-institutional comparison of clinicopathologic characteristics and oncologic outcomes of upper tract urothelial carcinoma in China and the United States. 2017 May;197(5):1208-1213. doi: 10.1016/j.juro.2016.11.094. Epub 2016 Nov 22. PMID: 27887951.
405. Arnold Egloff SA, Du L, Loomans HA, Starchenko A, Su PF, Ketova T, Knoll PB, Wang J, Haddad AQ, Fadare O, Cates JM, **Lotan Y**, Shyr Y, Clark PE, Zijlstra A. Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer. *Oncotarget.* 2017 Jan 3;8(1):722-741. doi: 10.18632/oncotarget.13546. PMID: 27894096. PMCID: PMC5352192.
406. Costa DN, Kay FU, Pedrosa I, Kolski L, **Lotan Y**, Roehrborn CG, Hornberger B, Xi Y, Francis F, Rofsky NM. An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancer-Preliminary experience. *Urol Oncol.* 2017 Apr;35(4):149.e15-149.e21. doi: 10.1016/j.urolonc.2016.11.006. Epub 2016 Dec 9. PMID: 27939349. PMCID: PMC5366083.
407. Cha EK, Fajkovic H, Jeldres C, Chromecki TF, Rink M, Margulis V, Novara G, **Lotan Y**, Raman JD, Kassouf W, Bensalah K, Weizer A, Roscigno M, Pycha A, Ficarra V, Montorsi F, Scherr DS, Shariat SF. Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma. *J Clin Oncol.* 2012 Feb 10;30(5_suppl):281. doi: 10.1200/jco.2012.30.5_suppl.281. PMID: 27968127.
408. Cha EK, Shariat SF, Kormaksson M, Novara G, Rink M, **Lotan Y**, Scherr D, Raman JD, Kassouf W, Zigeuner R, Bensalah K, Weizer AZ, Bolenz C, Roscigno M, Koppie TM, Fritsche HM, Ficarra V, Langner C, Wood CG, Margulis V.; Upper Tract Urothelial Carcinoma Collaborative Group. Predicting Clinical Outcomes after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. *J Clin Oncol.* 2012 Feb 10;30(5_suppl):267. doi: 10.1200/jco.2012.30.5_suppl.267. PMID: 27968247.
409. Palmboos PL, Wang L, Yang H, Detzler T, Ney G, **Lotan Y**, Wilkerson JE, Kunju P, Ljungman M, Liebert M, Simeone DM. ATDC as a novel oncogene in bladder cancer. *J Clin Oncol.* 2012 Feb 10;30(5_suppl):269. doi: 10.1200/jco.2012.30.5_suppl.269. PMID: 27968252.
410. Kavalieris L, O'Sullivan P, Frampton C, Guilford P, Darling D, Jacobson E, Suttie J, Raman JD, Shariat SF, **Lotan Y**. Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. *J Urol.* 2016 Dec 14. pii: S0022-5347(16)31930-9. doi:10.1016/j.juro.2016.12.010. [Epub ahead of print]. PMID: 27986532.
411. Haddad AQ, Luo JH, Krabbe LM, Darwish O, Gayed B, Youssef R, Kapur P, Rakheja D, **Lotan Y**, Sagalowsky A, Margulis V. Prognostic Value of Tissue Based Biomarker Signature in Clear Cell Renal Cell Carcinoma. *BJU Int.* 2017 May;119(5):741-747. doi: 10.1111/bju.13776. Epub 2017 Feb 9. PMID: 28075543.
412. Mobley A, Zhang S, Bondaruk J, Wang Y, Majewski T, Caraway NP, Huang L, Shoshan E, Velazquez-Torres G, Nitti G, Lee S, Lee JG, Fuentes-Mattei E, Willis

- D, Zhang L, Guo CC, Yao H, Baggerly K, **Lotan Y**, Lerner SP, Dinney C, McConkey D, Bar-Eli M, Czerniak B. Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior. *Sci Rep*. 2017 Jan 19;7:40714. doi: 10.1038/srep40714. PMID: 28102366. PMCID: PMC5244380.
413. Canvasser NE, Alken P, Lipkin M, Nakada SY, Sodha HS, Tepeler A, **Lotan Y**. The economics of stone disease. *World J Urol*. 2017 Jan 20. doi:10.1007/s00345-017-2003-y. [Epub ahead of print]. PMID: 28108799.
414. Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, Lichtenberg TM, Murray BA, Ghayee HK, Else T, Ling S, Jefferys SR, de Cubas AA, Wenz B, Korpershoek E, Amelio AL, Makowski L, Rathmell WK, Gimenez-Roqueplo AP, Giordano TJ, Asa SL, Tischler AS; Cancer Genome Atlas Research Network., Pacak K, Nathanson KL, Wilkerson MD. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. *Cancer Cell*. 2017 Feb 13;31(2):181-193. doi:10.1016/j.ccell.2017.01.001. Epub 2017 Feb 2. PMID: 28162975. Collaborator.
415. **Lotan Y**, O'Sullivan P, Raman JD, Shariat SF, Kavalieris L, Frampton C, Guilford P, Luxmanan C, Suttie J, Crist H, Scherr D, Asroff S, Goldfischer E, Thill J, Darling D. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. *Urol Oncol*. 2017 Mar 30. pii: S1078-1439(17)30108-4. doi: 10.1016/j.urolonc.2017.03.008. [Epub ahead of print]. PMID: 28366272.
416. Sorokin I, Canvasser NE, Margulis V, **Lotan Y**, Raj G, Sagalowsky A, Gahan JC, Cadeddu JA. The utility of axial abdominal imaging after partial nephrectomy for T1 renal cell carcinoma surveillance. *J Urol*. 2017 Apr 22. pii: S0022-5347(17)57747-2. [Epub ahead of print]. PMID: 28442383.
417. Sorokin I, Mamoulakis C, Miyazawa K, Rodgers A, Talati J, **Lotan Y**. Epidemiology of stone disease across the world. *World J Urol*. 2017 Feb 17. doi:10.1007/s00345-017-2008-6. [Epub ahead of print]. PMID: 28213860.
418. Gore JL, Plessis MD, Santiago-Jiménez M, Yousefi K, Thompson DJS, Karsh L, Lane BR, Franks M, Chen DYT, Bandyk M, Bianco FJ Jr, Brown G, Clark W, Kibel AS, Kim HL, Lowrance W, Manoharan M, Maroni P, Perrapato S, Sieber P, Trabulsi EJ, Waterhouse R, Davicioni E, **Lotan Y**, Lin DW. Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study. *Cancer*. 2017 Apr 19. doi: 10.1002/cncr.30665. [Epub ahead of print]. PMID: 28422278.
419. Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, **Lotan Y**, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein JM. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. *J Urol*. 2017 Apr 26. pii: S0022-5347(17)57836-2. doi: 10.1016/j.juro.2017.04.086. [Epub ahead of print]. PMID: 28456635.
420. Piyarathna DWB, Rajendiran TM, Putluri V, Vantaku V, Soni T, von Rundstedt FC, Donepudi SR, Jin F, Maity S, Ambati CR, Dong J, Gödde D, Roth S, Störkel S, Degener S, Michailidis G, Lerner SP, Pennathur S, **Lotan Y**, Coarfa C, Sreekumar A, Putluri N. Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder. *Eur Urol Focus*. 2017 Apr 20. pii: S2405-4569(17)30107-4. doi: 10.1016/j.euf.2017.04.005. [Epub ahead of print]. PMID: 28753886.
421. Sanda MG, Feng Z, Howard DH, Tomlins SA, Sokoll LJ, Chan DW, Regan MM, Groskopf J, Chipman J, Patil DH, Salami SS, Scherr DS, Kagan J, Srivastava S, Thompson IM Jr, Siddiqui J, Fan J, Joon AY, Bantis LE, Rubin MA, Chinnayian AM, Wei JT; and the EDRN-PCA3 Study Group., Bidair M, Kibel A, Lin DW, **Lotan Y**,

- Partin A, Taneja S. Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. *JAMA Oncol.* 2017 Aug 1;3(8):1085-1093. doi: 10.1001/jamaoncol.2017.0177. Epub 2017 May 18. PMID: 28520829.
422. Foerster B, Moschini M, Abufaraj M, Soria F, Gust KM, Rouprêt M, Karakiewicz PI, Briganti A, Rink M, Kluth L, Mathieu R, Margulis V, **Lotan Y**, Aziz A, John H, Shariat SF; UTUC Collaboration. Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma. *Clin Genitourin Cancer.* 2017 Jun 19. pii: S1558-7673(17)30169-6. doi: 10.1016/j.clgc.2017.06.003. [Epub ahead of print]. PMID: 28694147.
423. Krabbe LM, Heitzplatz B, Preuss S, Hutchinson RC, Woldu SL, Singla N, Boegemann M, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Rapoport LM, Glybochko PV, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, **Lotan Y**, Xylinas E, Margulis V. Prognostic Value of PD-1 and PD-L1 Expression in Patients with High-Grade Upper Tract Urothelial Carcinoma. *J Urol.* 2017 Jun 28. pii: S0022-5347(17)77052-8. doi: 10.1016/j.juro.2017.06.086. [Epub ahead of print]. PMID: 28668287.
424. D'Andrea D, Moschini M, Foerster B, Abufaraj M, Margulis V, Karam J, **Lotan Y**, Raman J, Mathieu R, Rouprêt M, Karakiewicz PI, Briganti A, Haitel A, Shariat SF. Caveolin-1 Expression in Upper Tract Urothelial Carcinoma. *Eur Urol Focus.* 2017 Jul 1. pii: S2405-4569(17)30162-1. doi:10.1016/j.euf.2017.06.011. [Epub ahead of print]. PMID: 28753840.
425. Tumati V, Jackson WC, Abugharib AE, Raj G, Roehrborn C, Lotan Y, Courtney K, Bagrodia A, Gahan JC, Zumsteg ZS, Folkert MR, Laine AM, Hannan R, Spratt DE, Desai NB. Natural history of 'second' biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study. *BJU Int.* 2018 Mar;121(3):365-372. doi: 10.1111/bju.13926. Epub 2017 Jul 5. PMID: 28581200.
426. Rieken M, Shariat SF, Karam JA, Foerster B, Khani F, Gust K, Abufaraj M, Wood CG, Weizer AZ, Raman JD, Guo CC, Rioux-Leclercq N, Haitel A, Bensalah K, **Lotan Y**, Bachmann A, De Marzo AM, Robinson BD, Margulis V. Frequency and prognostic value of PTEN loss in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. *J Urol.* 2017 Jul 11. pii: S0022-5347(17)77101-7. doi: 10.1016/j.juro.2017.06.096. [Epub ahead of print]. PMID: 28709887.
427. Hutchinson R, Singla N, Krabbe LM, Woldu S, Chen G, Rew C, Tachibana I, **Lotan Y**, Cadeddu JA, Margulis V. Increased use of antihypertensive medications after partial nephrectomy vs. radical nephrectomy. *Urol Oncol.* 2017 Jul 15. pii: S1078-1439(17)30341-1. doi: 10.1016/j.urolonc.2017.06.057. [Epub ahead of print]. PMID: 28720410.
428. Jones RT, Hassan Rezaeian N, Desai NB, Lotan Y, Jia X, Hannan R, Kim DWN, Hornberger B, Dubas J, Laine AM, Zelefsky MJ, Timmerman RD, Folkert MR. Dosimetric comparison of rectal-sparing capabilities of rectal balloon vs injectable spacer gel in stereotactic body radiation therapy for prostate cancer: lessons learned from prospective trials. *Med Dosim.* 2017 Jul 31. pii: S0958-3947(17)30067-5. doi: 10.1016/j.meddos.2017.07.002. [Epub ahead of print]. PMID: 28774760.
429. Sahu D, **Lotan Y**, Wittmann B, Neri B, Hansel DE. Metabolomics analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer. *Cancer Med.* 2017 Aug 1. doi: 10.1002/cam4.1109. [Epub ahead of print]. PMID: 28766915.
430. Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, **Lotan Y**, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein

- JM. Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. *J Oncol Pract*. 2017 Aug 10;JOP2017024919. doi: 10.1200/JOP.2017.024919. [Epub ahead of print]. PMID: 28796558.
431. Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, **Lotan Y**, Svatek RS, Bivalacqua TJ, Grubb RL 3rd, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G, Sawutz DG, Yla-Herttuala S, Parker NR, Dinney CPN. Intravesical rAd-IFN α /Syn3 for Patients with High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. *J Clin Oncol*. 2017 Aug 23;JCO2017723064. doi: 10.1200/JCO.2017.72.3064. [Epub ahead of print]. PMID: 28834453.
432. Woldu SL, Matulay JT, Clinton TN, Singla N, Krabbe LM, Hutchinson RC, Sagalowsky A, Lotan Y, Margulis V, Bagrodia A. Impact of hospital case volume on testicular cancer outcomes and practice patterns. *Urol Oncol*. 2018 Jan;36(1):14.e7-14e15. doi: 10.1016/j.urolonc.2017.08.024. Epub 2017 Sep 19. PMID: 28935185.
433. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Peadarallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ; TCGA Research Network, Weinstein JN, Kwiatkowski DJ, Lerner SP. *Cell*. 2017 Oct 19;171(3):540-556.e25. doi: 10.1016/j.cell.2017.09.007. Epub 2017 Oct 5. PMID: 28988769.
434. Wallace E, Higuchi R, Satya M, McCann L, Sin ML, Bridge JA, Wei H, Zhang J, Wong E, Hiar A, Mach KE, Scherr D, Egerdie RB, Ohta S, Sexton WJ, Meng MV, Weizer AZ, Woods M, Jansz GK, Zadra J, **Lotan Y**, Liao JC. Development of a 90-minute integrated non-invasive urinary assay for bladder cancer detection. *J Urol*. 2017 Oct 20. pii: S0022-5347(17)77760-9. doi: 10.1016/j.juro.2017.09.141. [Epub ahead of print]. PMID: 29061538.
435. Woldu SL, Aydin AM, Rao AV, Hutchinson RC, Singla N, Clinton TN, Krabbe LM, Passoni NM, Raj GV, Miller DS, Amatruda JF, Sagalowsky AI, **Lotan Y**, Arriaga Y, Margulis V, Bagrodia A. Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-Based Analysis. *Urology*. 2017 Oct 24. pii: S0090-4295(17)31102-0. doi: 10.1016/j.urology.2017.08.059. [Epub ahead of print]. PMID: 29079210.
436. Singla N, Fang D, Su X, Bao Z, Cao Z, Robyak H, Xiong G, Zhang L, Woldu S, Hutchinson R, Sagalowsky A, **Lotan Y**, Li X, Zhou L, Raman JD, Margulis V. Preoperative predictors of nonorgan-confined disease in upper-tract urothelial carcinoma differ between China and the United States. *Urol Oncol*. 2018 Mar;36(3):88.e11-88.e18. doi: 10.1016/j.urolonc.2017.10.029. Epub 2017 Nov 23. PMID: 29174945.
437. Daneshmand S, Patel S, **Lotan Y**, Pohar K, Trabulsi E, Woods M, Downs T, Huang W, Jones J, O'Donnell M, Bivalacqua T, DeCastro J, Steinberg G, Kamat A, Resnick M, Konety B, Schoenberg M, Jones JS; Flexible Blue Light Study Group Collaborators, Bazargani S, Cookson M, Cross B, Lallas CD, Djaladat H, Gomella L, Johnson M, McKiernan J, Mann M, Merrill M, Nielsen M, Pierorazio P, Pruthi R,

- Sankin A, Schuckman A, Shabsigh A, Shah JB, Smith A, Stratton K, Taylor J, Weight C, Wenske S. Efficacy and Safety of Blue Light Flexible Cystoscopy With Hexaminolevulinate (HAL) in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multi-Center Study. *J Urol*. 2017 Dec 2. pii: S0022-5347(17)78004-4. doi: 10.1016/j.juro.2017.11.096. [Epub ahead of print]. PMID: 29203268.
438. Vantaku V, Donepudi SR, Ambati CR, Jin F, Putluri V, Nguyen K, Rajapakshe K, Coarfa C, Battula VL, **Lotan Y**, Putluri N. Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer. *Oncotarget*. 2017 Sep 16;8(56):95620-95631. doi: 10.18632/oncotarget.21038. eCollection 2017 Nov 10. PMID: 29221154.
439. Xylinas E, Kent M, Dabi Y, Rieken M, Kluth LA, Al Awamlh BAH, Ouzaid I, Pycha A, Comploj E, Svatek RS, **Lotan Y**, Karakiewicz PI, Holmang S, Shariat SF. Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C. *Urol Oncol*. 2018 Mar;36(3):89.e1-89.e5. doi: 10.1016/j.urolonc.2017.11.010. Epub 2017 Dec 5. PMID: 29221642.
440. Woldu SL, Ci B, Hutchinson RC, Krabbe LM, Singla N, Passoni NM, Clinton TN, Raj GV, Miller DS, Sagalowsky AI, **Lotan Y**, Xie Y, Margulis V, Bagrodia A. Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis. *Urol Oncol*. 2017 Dec 26. pii: S1078-1439(17)30611-7. doi: 10.1016/j.urolonc.2017.12.001. [Epub ahead of print]. PMID: 29288008.
441. Zhang S, Wang Y, Bondaruk J, Majewski T, Yao H, Lee S, Lee JG, Cogdell D, **Lotan Y**, Dinney C, Wei P, Baggerly K, Czerniak B. Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test. *Eur Urol Focus*. 2018 Feb 7. pii: S2405-4569(18)30018-X. doi: 10.1016/j.euf.2018.01.017. [Epub ahead of print]. PMID: 29428551.
442. Masuda N, Ogawa O, Park M, Liu AY, Goodison S, Dai Y, Kozai L, Furuya H, **Lotan Y**, Rosser CJ, Kobayashi T. *Oncotarget*. 2018 Jan 3;9(6):7101-7011. Doi: 10.18632/oncotarget.23872. eCollection 2018 Jan 23. PMID: 29467953.
443. Costa DN, Passoni NM, Leyendecker JR, de Leon AD, **Lotan y**, Roehrborn CG, Otero-Muinelos S, Grewal H, Xi Y, Francis F, Rofsky NM, Pedrosa I. Diagnostic Utility of a Likert Scale Versus Qualitative Descriptors and Length of Capsular Contact for Determining Extraprostatic Tumor Extension at Multiparametric Prostate MRI. *AJR Am J Roentgenol*. 2018 Feb 28;1-7. doi: 10.2214/AJR.17.18849. [Epub ahead of print]. PMID 29489410.
444. Kittler R, Shiang C, Hutchinson R, Kollipara RK, Kapur P, Franto F, **Lotan Y**. Grade progression in urothelial carcinoma can occur with high or low mutational homology: a first-step toward tumor-specific care in initial low-grade bladder cancer. *Oncotarget*. 2018 Jan 6;9(10):9415-9424. Doi:10.18632/oncotarget.24072. eCollection 2018 Feb 6. PMID: 29507699.
445. **Lotan Y**, Woldu SL, Sanli O, Black P, Milowsky MI. Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer. *BJU Int*. 2018 Mar 31. doi: 10.1111/bju.14220. [Epub ahead of print] PMID: 29603871
446. Woldu SL, Hutchinson RC, Singla N, Hornberger B, Roehrborn CG, **Lotan Y**. Prospective Monitoring and Adapting Strategies for Prevention of Infection Following Transrectal Prostate Procedures. *Urol Pract*. 2018 Mar;5(2):124-131. doi: 10.1016/j.urpr.2017.03.002. Epub 2017 Mar 18. PMID: 29687052

447. Palmer LS, Seideman CA, **Lotan Y**. Cost-effectiveness of antimicrobial prophylaxis for children in the RIVUR trial. *World J Urol*. 2018 Sep;36(9):1441-1447. doi: 10.1007/s00345-018-2302-y. Epub 2018 Apr 30. PMID: 29707736
448. Singla N, Krabbe LM, Aydin AM, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, **Lotan Y**, Bagrodia A, Kapur P, Margulis V. Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. *Urol Oncol*. 2018 Jul;36(7):343.e1-343.e8. doi: 10.1016/j.urolonc.2018.04.004. Epub 2018 May 7 . PMID:29748098
449. Martin JW, Vernez SL, **Lotan Y**, Abdelhalim A, Dutta R, Shokeir A, Abol-Enein H, Mosbah A, Ghoneim M, Youssef RF. Pathological characteristics and prognostic indicators of different histopathological types of urinary bladder cancer following radical cystectomy in a large single-center Egyptian cohort. *World J Urol*. 2018 May 14. doi: 10.1007/s00345-018-2331-6. [Epub ahead of print] PMID:29761225
450. Vasdev N, Zargar H, Noël JP, Veeratterapillay R, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Morgan TM, Bivalacqua TJ, North S, Barocas DA, **Lotan Y**, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Holzbeierlein JM, Thorpe A, Black PC. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. *World J Urol*. 2018 Jun 7. doi: 10.1007/s00345-018-2361-0. [Epub ahead of print] PMID: 29882105
451. Smith AB, Daneshmand S, Patel S, Pohar K, Trabulsi E, Woods M, Downs T, Huang W, Taylor J, Jones J, O'Donnell M, Bivalacqua T, DeCastro J, Steinberg G, Kamat A, Resnick M, Konety B, Schoenberg M, Jones JS, **Lotan Y**; Flexible Blue Light Study Group Collaborators. Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study. *BJU Int*. 2018 Jul 6. doi: 10.1111/bju.14481. [Epub ahead of print] PMID: 29979488
452. Courtney KD, Bezwada D, Mashimo T, Pichumani K, Vemireddy V, Funk AM, Wimberly J, McNeil SS, Kapur P, **Lotan Y**, Margulis V, Cadeddu JA, Pedrosa I, DeBerardinis RJ, Malloy CR, Bachoo RM, Maher EA. Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo. *Cell Metab*. 2018 Aug 21. pii: S1550-4131(18)30463-7. doi: 10.1016/j.cmet.2018.07.020. [Epub ahead of print] PMID: 30146487
453. **Lotan Y**, Black P, Caba L, Chang S, Cookson M, Daneshmand S, Kamat A, McKiernan J, Pruthi R, Ritch C, Steinberg G, Svatek R, Zwarthoff E. Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review. *European Association of Urology*. doi.org/10.1016/j.euo.2018/04.010.
454. Hooton TM, Vecchio M, Iroz A, Tack I, Dornic Q, Seksek I, **Lotan Y**. Effects of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial. *JAMA Intern Med*. 2018 Nov 1;178(11):1509-1515. doi: 10.1001/jamainternmed.2018.4204. PMID:30285042.
455. Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, Kiemenev L, **Lotan Y**, Pang K, Silverman DT, Znaor A, Catto JWF. Epidemiology of Bladder

- Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. *Eur Urol.* 2018 Dec;74(6):784-795. doi: 10.1016/j.eururo.2018.09.001. Epub 2018 Sep 26. PMID:30268659.
456. Hutchinson R, Singla N, Akhtar A, Haridas J, Bhat D, Roehrborn C, **Lotan Y**. Seniority of primary care physicians is associated with a decrease in PSA ordering habits in the years surrounding the United States Preventative Services Task Force recommendation against PSA screening. *Urol Oncol.* 2018 Nov;36(11):500.e21-500.e27. doi: 10.1016/j.urolonc.2018.07.011. Epub 2018 Sep 18. PMID:30241954.
457. Woldu SL, Matulay JT, Clinton TN, Singla N, Freifeld Y, Sanli O, Krabbe LM, Hutchinson RC, **Lotan Y**, Hammers H, Hannan R, Brugarolas J, Bagrodia A, Margulis V. Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study. *Clin Genitourin Cancer.* 2018 Dec;16(6):e1221-e1235. doi: 10.1016/j.clgc.2018.08.001. Epub 2018 Aug 25. PMID:30217763.
458. Woldu SL, Sanli O, Clinton TN, **Lotan Y**. Validating the predictors of outcomes after radical cystectomy for bladder cancer. *Cancer.* 2019 Jan 15;125(2):223-231. doi: 10.1002/cncr.31799. Epub 2018 Oct 6. PMID: 30291813
459. Valenberg FJPV, Hiar AM, Wallace E, Bridge JA, Mayne DJ, Beqaj S, Sexton WJ, **Lotan Y**, Weizer AZ, Jansz GK, Stenzl A, Danella JF, Shepard B, Cline KJ, Williams MB, Montgomery S, David RD, Harris R, Klein EW, Bradford TJ, Wolk FN, Westenfelder KR, Trainer AF, Richardson TA, Egerdie RB, Goldfarb B, Zadra JA, Ge S, Zhao S, Simon IM, Campbell SA, Rhees B, Bates MP, Higuchi RG, Witjes JA. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. *Eur Urol.* 2018 Dec 12. pii: S0302-2838(18)30959-X. doi: 10.1016/j.eururo.2018.11.055. [Epub ahead of print]. PMID: 30553612.
460. Freifeld Y, Xi Y, Passoni N, Woldu S, Hornberger B, Goldberg K, Bagrodia A, Raj G, Margulis V, Cadeddu J, **Lotan Y**, Francis F, Pedrosa I, Roehrborn C, Costa D. Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy. *Urologic Oncology: Seminars and Original Investigations* Volume 37, Issue 1, January 2019, Pages 57-62.
461. Freifeld Y, Diaz de Leon A, Xi Y, Pedrosa I, Roehrborn CG, **Lotan Y**, Francis F, Costa DN. Diagnostic Performance of Prospectively Assigned Likert Scale Scores to Determine Extraprostatic Extension and Seminal Vesicle Invasion With Multiparametric MRI of the Prostate. *AJR Am J Roentgenol.* 2019 Mar;212(3):576-581. doi: 10.2214/AJR.18.20320. Epub 2018 Dec 27. PMID: 30589381.
462. Tse J, Ghandour R, Singla N, **Lotan Y**. Molecular Predictors of Complete Response Following Neoadjuvant Chemotherapy in Urothelial Carcinoma of the Bladder and Upper Tracts. *Int J Mol Sci.* 2019 Feb 13;20(4). pii: E793. doi: 10.3390/ijms20040793. Review. PMID:30781730
463. Stovsky M, Klein EA, Chait A, Manickam K, Stephenson AJ, Wagner M, Dineen M, **Lotan Y**, Partin A, Baniel J, Kestranek A, Gawande P, Zaslavsky B. Clinical Validation of IsoPSA, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer. *J Urol.* 2019 Feb 15;101097JU00000000000000185. doi: 10.1097/JU.0000000000000185. [Epub ahead of print]. PMID: 30810464.
464. Vantaku V, Dong J, Ambati CR, Perera D, Donepudi SR, Amara CS, Putluri V, Ravi SS, Robertson MJ, Piyaarathna DWB, Villanueva M, von Rundstedt FC, Karanam B, Ballester LY, Terris MK, Bollag RJ, Lerner SP, Apolo AB, Villanueva H, Lee M, Sikora AG, **Lotan Y**, Sreekumar A, Coarfa C, Putluri N. Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer. *Clin Cancer Res.* 2019 Jun 15;25(12):3689-3701.

- doi: 10.1158/1078-0432.CCR-18-1515. Epub 2019 Mar 7. PMID: 30846479; PMCID: PMC6571061
465. Owyong M, **Lotan Y**, Kapur P, Panwar V, McKenzie T, Lee TK, Zi X, Martin JW, Mosbah A, Abol-Enein H, Ghoneim M, Youssef RF. Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder. *Urol Oncol*. 2019 Mar 22. pii: S1078-1439(19)30093-6. doi: 10.1016/j.urolonc.2019.02.017. [Epub ahead of print]. PMID: 30910351.
466. Costa DN, Goldberg K, Leon AD, **Lotan Y**, Xi Y, Aziz M, Freifeld Y, Margulis V, Raj G, Roehrborn CG, Hornberger B, Desai N, Bagrodia A, Francis F, Pedrosa I, Cadeddu JA. Magnetic Resonance Imaging-guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate. *Eur Urol Oncol*. 2019 Jul;2(4):397-404. doi: 10.1016/j.euo.2018.08.022. Epub 2018 Sep 20. PMID: 31277776.
467. Ghandour R, Freifeld Y, Singla N, **Lotan Y**. Evaluation of Hematuria in a Large Public Health Care System. *Bladder Cancer*, vol. 5, no. 2, pp. 119-129, 2019, published: 16 August 2019. DOI: 10.3233/BLC-190221.
468. Tse J, Singla N, Ghandour R, **Lotan Y**, Margulis V. Current advances in BCG-unresponsive non-muscle invasive bladder cancer. *Expert Opin Investig Drugs*. 2019 Sep;28(9):757-770. doi: 10.1080/13543784.2019.1655730. Epub 2019 Aug 15. PMID: 31412742.
469. Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall'Era MA, Douglas J, Boormans JL, Van der Heijden MS, Wu CL, van Rhijn BWG, Gupta S, Grivas P, Mouw KW, Murugan P, Fazli L, Ra S, Konety BR, Seiler R, Daneshmand S, Mian OY, Efstathiou JA, **Lotan Y**, Black PC. Molecular Characterization of Neuroendocrine-like Bladder Cancer. *Clin Cancer Res*. 2019 Jul 1;25(13):3908-3920. doi: 10.1158/1078-0432.CCR-18-3558. Epub 2019 Apr 5. PMID: 30952638.
470. Ghandour R, Singla N, **Lotan Y**. Treatment Options and Outcomes in Nonmetastatic Muscle Invasive Bladder Cancer. *Trends Cancer*. 2019 Jul;5(7):426-439. doi: 10.1016/j.trecan.2019.05.011. Epub 2019 Jun 22. PMID: 31311657.
471. Vantaku V, Putluri V, Bader DA, Maity S, Ma J, Arnold JM, Rajapakshe K, Donepudi SR, von Rundstedt FC, Devarakonda V, Dubrulle J, Karanam B, McGuire SE, Stossi F, Jain AK, Coarfa C, Cao Q, Sikora AG, Villanueva H, Kavuri SM, **Lotan Y**, Sreekumar A, Putluri N. Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression. *Oncogene*. 2019 Aug 5. doi: 10.1038/s41388-019-0902-7. Epub ahead of print. PMID: 31383940.
472. **Lotan Y**, Bivalacqua TJ, Downs T, Huang W, Jones J, Kamat AM, Konety B, Malmström PU, McKiernan J, O'Donnell M, Patel S, Pohar K, Resnick M, Sankin A, Smith A, Steinberg G, Trabulsi E, Woods M, Daneshmand S. Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018. *Nat Rev Urol*. 2019 Jun;16(6):377-386. doi: 10.1038/s41585-019-0184-4. PMID: 31019310.
473. Raskolnikov D, Brown B, Holt SK, Ball AL, **Lotan Y**, Strobe S, Schroeck F, Ullman R, Lipman R, Smith AB, Gore JL. Reduction of Pain during Flexible Cystoscopy: A Systematic Review and Meta-Analysis. *J Urol*. 2019 Dec;202(6):1136-1142. doi: 10.1097/JU.0000000000000399. Epub 2019 Jun 20. PMID: 31219763.
474. Amara CS, Vantaku V, **Lotan Y**, Putluri N. Recent advances in the metabolomic study of bladder cancer. *Expert Rev Proteomics*. 2019 Apr;16(4):315-324. doi: 10.1080/14789450.2019.1583105. Epub 2019 Feb 26. PMID: 30773067; PMCID: PMC6538267.

475. Konety B, Shore N, Kader AK, Porten S, Daneshmand S, Lough T, **Lotan Y**. Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy. *Eur Urol*. 2019 Aug;76(2):238-243. doi: 10.1016/j.eururo.2019.04.035. Epub 2019 May 16. PMID: 31103391.
476. Moschini M, Zamboni S, Soria F, Mathieu R, Xylinas E, Tan WS, Kelly JD, Simone G, Meraney A, Krishna S, Konety B, Mattei A, Baumeister P, Mordasini L, Montorsi F, Briganti A, Gallina A, Stabile A, Sanchez-Salas R, Cathelineau X, Rink M, Necchi A, Karakiewicz PI, Rouprêt M, Koupparis A, Kassouf W, Scherr DS, Ploussard G, Boorjian SA, **Lotan Y**, Sooriakumaran P, Shariat SF. Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes. *J Clin Med*. 2019 Aug 9;8(8):1192. doi: 10.3390/jcm8081192. PMID: 31395826; PMCID: PMC6722857.
477. Vantaku V, Amara CS, Piyarathna DWB, Donepudi SR, Ambati CR, Putluri V, Tang W, Rajapakshe K, Estecio MR, Terris MK, Castro PD, Ittmann MM, Williams SB, Lerner SP, Sreekumar A, Bollag R, Coarfa C, Kornberg MD, **Lotan Y**, Ambs S, Putluri N. DNA methylation patterns in bladder tumors of African American patients point to distinct alterations in xenobiotic metabolism. *Carcinogenesis*. 2019 Nov 25;40(11):1332-1340. doi: 10.1093/carcin/bgz128. PMID: 31284295; PMCID: PMC6875901.
478. Aydin AM, Singla N, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Westerman ME, Sagalowsky AI, Shariat SF, **Lotan Y**, Bagrodia A, Kapur P, Margulis V, Krabbe LM. Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. *World J Urol*. 2019 Nov;37(11):2419-2427. doi: 10.1007/s00345-019-02678-x. Epub 2019 Feb 13. PMID: 30759271.
479. Ghandour R, Ashbrook C, Freifeld Y, Singla N, El-Asmar JM, **Lotan Y**, Margulis V, Eggener S, Woldu S, Bagrodia A. Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle. *Eur Urol Oncol*. 2019 Jul 1:S2588-9311(19)30082-3. doi: 10.1016/j.euo.2019.06.007. Epub ahead of print. PMID: 31272940.
480. Stovsky M, Klein EA, Chait A, Manickam K, Stephenson AJ, Wagner M, Dineen M, **Lotan Y**, Partin A, Baniel J, Kestranek A, Gawande P, Boris Zaslavsky. Clinical Validation of IsoPSA™, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer. *J Urol*. 2019 Jun;201(6):1115-1120. doi: 10.1097/JU.000000000000185. PMID: 30810464.
481. **Lotan Y**, Margulis V. Predicting recurrence in patients with localised renal cell carcinoma after nephrectomy. *Lancet Oncol*. 2019 Apr;20(4):473-475. doi: 10.1016/S1470-2045(19)30024-5. Epub 2019 Mar 14. PMID: 30880069.
482. Freifeld Y, Ghandour R, Singla N, Woldu S, Clinton T, Kulangara R, Bagrodia A, Matin SF, Petros FG, Raman JD, Robyak H, Yan J, Zhu H, Rapoport L, **Lotan Y**, Margulis V. Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma. *Urol Oncol*. 2019 Oct;37(10):758-764. doi: 10.1016/j.urolonc.2019.06.009. Epub 2019 Aug 2. PMID: 31378586.
483. **Lotan Y**, Boorjian SA, Zhang J, Bivalacqua TJ, Porten SP, Wheeler T, Lerner SP, Hutchinson R, Francis F, Davicioni E, Svatek RS, Chen CL, Black PC, Gibb EA. Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors. *Eur Urol*. 2019 Aug;76(2):200-206. doi: 10.1016/j.eururo.2019.04.036. Epub 2019 May 12. PMID:31092337.
484. **Lotan Y**, Inman BA, Davis LG, Kassouf W, Messing E, Daneshmand S, Canter D, Marble HT, Joseph AM, Jewell S, Boorjian SA. Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus

- Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial. *J Urol*. 2019 Nov;202(5):920-926. doi: 10.1097/JU.0000000000000355. Epub 2019 Oct 9. PMID: 31120373.
485. Freifeld Y, **Lotan Y**. Effect of blue-light cystoscopy on contemporary performance of urine cytology. *BJU Int*. 2019 Aug;124(2):251-257. doi: 10.1111/bju.14574. Epub 2018 Oct 21. PMID: 30281893.
486. de Jong JJ, Liu Y, Robertson AG, Seiler R, Groeneveld CS, van der Heijden MS, Wright JL, Douglas J, Dall'Era M, Crabb SJ, van Rhijn BWG, van Kessel KEM, Davicioni E, Castro MAA, **Lotan Y**, Zwarthoff EC, Black PC, Boormans JL, Gibb EA. Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis. *Genome Med*. 2019 Oct 17;11(1):60. doi: 10.1186/s13073-019-0669-z. PMID: 31619281; PMCID: PMC6796434.
487. Jubber I, Shariat SF, Conroy S, Tan WS, Gordon PC, **Lotan Y**, Messing EM, Stenzl A, Rhijn BV, Kelly JD, Catto JWF, Cumberbatch MG. Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis. *Eur Urol*. 2019 Nov 29:S0302-2838(19)30776-6. doi: 10.1016/j.eururo.2019.10.010. Epub ahead of print. PMID: 31791622.
488. Freifeld Y, Woldu SL, Singla N, Clinton T, Bagrodia A, Hutchinson R, **Lotan Y**, Margulis V. Impact of Hospital Case Volume on Outcomes Following Radical Nephrectomy and Inferior Vena Cava Thrombectomy. *Eur Urol Oncol*. 2019 Nov;2(6):691-698. doi: 10.1016/j.euo.2018.10.005. Epub 2018 Nov 16. PMID: 31411983; PMCID: PMC6697235.
489. Zhang S, Wang Y, Bondaruk J, Majewski T, Yao H, Lee S, Lee JG, Cogdell D, **Lotan Y**, Dinney C, Wei P, Baggerly K, Czerniak B. Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test. *Eur Urol Focus*. 2019 Jul;5(4):664-675. doi: 10.1016/j.euf.2018.01.017. Epub 2018 Feb 7. PMID: 29428551; PMCID: PMC6081265.
490. Kim J, Thompson B, Han S, **Lotan Y**, McDonald JG, Ye J. Uptake of HDL-cholesterol contributes to lipid accumulation in clear cell renal cell carcinoma. *Biochim Biophys Acta Mol Cell Biol Lipids*. 2019 Dec;1864(12):158525. doi: 10.1016/j.bbalip.2019.158525. Epub 2019 Sep 9. PMID: 31513923; PMCID: PMC6832851.
491. Gore JL, du Plessis M, Zhang J, Dai D, Thompson DJS, Karsh L, Lane B, Franks M, Chen DYT, Bianco FJ Jr, Brown G, Clark W, Kibel AS, Kim H, Lowrance W, Manoharan M, Maroni P, Perrapato S, Sieber P, Trabulsi EJ, Waterhouse R, Spratt DE, Davicioni E, **Lotan Y**, Lin DW. Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial. *Pract Radiat Oncol*. 2020 Mar-Apr;10(2):e82-e90. doi: 10.1016/j.prro.2019.09.016. Epub 2019 Nov 21. PMID: 31761540.
492. Grivas P, Bismar TA, Alva AS, Huang HC, Liu Y, Seiler R, Alimohamed N, Cheng L, Hyndman ME, Dabbas B, Black PC, Davicioni E, Wright JL, Ornstein MC, Mian OY, Kaimakliotis HZ, Gibb EA, **Lotan Y**. Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. *Urol Oncol*. 2019 Dec 4:S1078-1439(19)30459-4. doi: 10.1016/j.urolonc.2019.11.004. Epub ahead of print. PMID: 31812633.
493. Yeh HC, Margulis V, Singla N, Hernandez E, Panwar V, Woldu SL, Karam JA, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Li CC, Ke HL, Li WM, Lee HY, Rapoport LM, **Lotan Y**, Kapur P, Shariat SF, Hsieh JT, Wu WJ. PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. *Urol Oncol*. 2019 Dec 17:S1078-1439(19)30483-1. doi: 10.1016/j.urolonc.2019.11.010. Epub ahead of print. PMID: 31862213.

494. Black AJ, Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Griffin J, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, **Lotan Y**, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Daneshmand S, Sridhar SS, Black PC. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. *Urol Oncol*. 2020 Jan;38(1):3.e17-3.e27. doi: 10.1016/j.urolonc.2019.09.023. Epub 2019 Oct 31. PMID: 31676278.
495. D'Andrea D, Black PC, Zargar H, Zargar-Shoshtari K, Zehetmayer S, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, **Lotan Y**, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Shariat SF. Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. *Urol Oncol*. 2020 Feb 11:S1078-1439(20)30011-9. doi: 10.1016/j.urolonc.2020.01.010. Epub ahead of print. PMID: 32057595.
496. Lafin JT, Singla N, Woldu SL, **Lotan Y**, Lewis CM, Majmudar K, Savelyeva A, Kapur P, Margulis V, Strand DW, Murray MJ, Amatruda JF, Bagrodia A. Serum MicroRNA-371a-3p Levels Predict Viable Germ Cell Tumor in Chemotherapy-naïve Patients Undergoing Retroperitoneal Lymph Node Dissection. *Eur Urol*. 2020 Feb;77(2):290-292. doi: 10.1016/j.eururo.2019.10.005. Epub 2019 Nov 5. No abstract available. PMID: 31699528
497. de Jong JJ, Liu Y, Boorjian SA, Bivalacqua TJ, Porten SP, Wheeler T, Davicioni E, Svatek RS, Boormans JL, Black PC, **Lotan Y**, Gibb EA. A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Upstaging. *J Urol*. 2020 Feb 14:101097JU0000000000000798. doi: 10.1097/JU.0000000000000798. Epub ahead of print. PMID: 32074006.
498. de Jong JJ, Boormans JL, van Rhijn BWG, Seiler R, Boorjian SA, Konety B, Bivalacqua TJ, Wheeler T, Svatek RS, Douglas J, Wright J, Dall'Era M, Crabb SJ, Efstathiou JA, van der Heijden MS, Mouw KW, Miyamoto DT, **Lotan Y**, Black PC, Gibb EA, Porten SP. Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. *Eur Urol Oncol*. 2020 Mar 20:S2588-9311(20)30035-3. doi: 10.1016/j.euo.2020.02.010. Epub ahead of print. PMID: 32205136.
499. Yeh HC, Li CC, Chien TM, Li CY, Cheng YC, Woldu SL, Robyak H, Huang CN, Ke HL, Li WM, Lee HY, Yeh BW, Yang SF, Tu HP, Sagalowsky AI, Raman JD, Singla N, Margulis V, **Lotan Y**, Hsieh JT, Wu WJ. Interethnic differences in the impact of body mass index on upper tract urothelial carcinoma following radical nephroureterectomy. *World J Urol*. 2020 Apr 21. doi: 10.1007/s00345-020-03204-0. Online ahead of print. PMID: 32318857.
500. Yeh HC, Li CC, Wen SC, Singla N, Woldu SL, Robyak H, Huang CN, Ke HL, Li WM, Lee HY, Li CY, Yeh BW, Yang SF, Tu HP, Shariat SF, Sagalowsky AI, Raman JD, **Lotan Y**, Hsieh JT, Margulis V, Wu WJ. Validation of Hyponatremia as a Prognostic Predictor in Multiregional Upper Tract Urothelial Carcinoma. *J Clin Med*. 2020 Apr 23;9(4):1218. doi: 10.3390/jcm9041218. PMID: 32340364 Free PMC article.
501. Singla N, Hutchinson RC, Ghandour RA, Freifeld Y, Fang D, Sagalowsky AI, Lotan Y, Bagrodia A, Margulis V, Hammers HJ, Woldu SL. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy

- era: An analysis of the National Cancer Database. *Urol Oncol.* 2020 Jun; 38(6):604.e9-604.e17. doi: 10.1016/j.urolonc.2020.02.029. Epub 2020 Apr 3. PMID: 32253116.
502. Barocas DA, Boorjian SA, Alvarez RD, Downs TM, Gross CP, Hamilton BD, Kobashi KC, Lipman RR, **Lotan Y**, Ng CK, Nielsen ME, Peterson AC, Raman JD, Smith-Bindman R, Souter LH. Microhematuria: AUA/SUFU Guideline. *J Urol.* 2020 Oct;204(4):778-786. doi: 10.1097/JU.0000000000001297. Epub 2020 Jul 23. PMID: 32698717.
503. **Lotan Y**, Chaplin I, Ahmadi H, Meng X, Roberts S, Ladi-Seyedian S, Bagrodia A, Margulis V, Woldu S, Daneshmand S. Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer. *BJU Int.* 2020 Jul 10. doi: 10.1111/bju.15166. Online ahead of print. PMID: 32648957.
504. Freifeld Y, Ghandour R, Singla N, Woldu S, Bagrodia A, **Lotan Y**, Rapoport LM, Gazimiev M, Delafuente K, Kulangara R, Robyak H, Petros FG, Raman JD, Matin SF, Margulis V. Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy. *Urol Oncol.* 2020 Sep;38(9):737.e11-737.e16. doi: 10.1016/j.urolonc.2020.05.002. Epub 2020 Jul 5. PMID: 32641241.
505. Ghandour RA, Kusin S, Wong D, Meng X, Singla N, Freifeld Y, Bagrodia A, Margulis V, Sagalowsky A, **Lotan Y**, Woldu SL. Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy? *Urol Oncol.* 2020 Sep;38(9):736.e11-736.e18. doi: 10.1016/j.urolonc.2020.05.032. Epub 2020 Jul 17. PMID: 32684514.
506. Johnson BA, Best SL, Nakada SY, Tracy C, Steinberg RL, Thomas L, Marien T, Miller N, Kolitz E, Cohen A, Pearle MS, **Lotan Y**, Antonelli JA. Initial Results from the M-STONE Group: A Multi-Center Collaboration to Study Treatment Outcomes in Nephrolithiasis Evaluation. *J Endourol.* 2020 Sep;34(9):919-923. doi: 10.1089/end.2020.0108. PMID: 32660266.
507. **Lotan Y**, Schalken J, Lawrentschuk N. Personalized Medicine in Urologic Oncology. *Société Internationale d'Urologie Journal, Molecular Biomarkers in Urologic Oncology *Inaugural Edition**. 2020 October, vol. 1, no. 1.
508. Todenhöfer T, Lodde M, van Kessel K, Pichler R, Vlahou A, **Lotan Y**. Urinary-Based Markers for Bladder Cancer Detection. *Société Internationale d'Urologie Journal, Molecular Biomarkers in Urologic Oncology *Inaugural Edition**. 2020 October, vol. 1, no. 1.
509. Krabbe L-M, Gakis G, **Lotan Y**. Clinical Utility of Bladder Cancer Biomarkers. *Société Internationale d'Urologie Journal, Molecular Biomarkers in Urologic Oncology *Inaugural Edition**. 2020 October, vol. 1, no. 1.
510. Pradere B, D'Andrea D, Schuettfort VM, Foerster B, Quhal F, Mori K, Abufaraj M, Margulis V, Deuker M, Briganti A, Muilwijk T, Hendricksen K, **Lotan Y**, Karakiewicz P, F Shariat S; UTUC collaboration. Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma. *World J Urol.* 2020 Oct 16. doi: 10.1007/s00345-020-03479-3. Online ahead of print. PMID: 33067726.
511. Fang D, Singla N, Bao Z, Jafri SM, Su X, Cao Z, Xiong G, Zhang L, Woldu S, Hutchinson R, Sagalowsky A, **Lotan Y**, Li X, Raman JD, Margulis V, Zhou L. The Significance of Preoperative Serum Sodium and Hemoglobin in Outcomes of Upper Tract Urothelial Carcinoma: Multi-Center Analysis Between China and the United States. *Cancer Manag Res.* 2020 Oct 8;12:9825-9836. doi: 10.2147/CMAR.S267969. eCollection 2020. PMID: 33116841 Free PMC article.

512. Kardoust Parizi M, Shariat SF, Margulis V, Mori K, **Lotan Y**. Value of tumour-infiltrating immune cells in predicting response to intravesical BCG in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis. *BJU Int.* 2020 Oct 18. doi: 10.1111/bju.15276. Online ahead of print.PMID: 33073457 Review.
513. Pradere B, D'Andrea D, Schuettfort VM, Foerster B, Quhal F, Mori K, Abufaraj M, Margulis V, Deuker M, Briganti A, Muilwijk T, Hendricksen K, Lotan Y, Karakiewicz P, F Shariat S; UTUC collaboration. Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma. *World J Urol.* 2020 Oct 16. doi: 10.1007/s00345-020-03479-3. Online ahead of print.PMID: 33067726.
514. Kardoust Parizi M, Shariat SF, Margulis V, Mori K, **Lotan Y**. Value of tumour-infiltrating immune cells in predicting response to intravesical BCG in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis. *BJU Int.* 2020 Oct 18. doi: 10.1111/bju.15276. Online ahead of print.PMID: 33073457 Review.
515. Bagrodia A, Savelyeva A, Lafin JT, Speir RW, Chesnut GT, Frazier AL, Woldu SL, Margulis V, Murray MJ, Amatruda JF, **Lotan Y**. Impact of circulating microRNA test (miRNA-371a-3p) on appropriateness of treatment and cost outcomes in patients with Stage I non-seminomatous germ cell tumours. *BJU Int.* 2020 Oct 30. doi: 10.1111/bju.15288. Online ahead of print.PMID: 33124175.
516. Cooley LF, Weiner A, Meng X, Woldu S, Meeks J, **Lotan Y**. Survival by T Stage for Patients with Localized Bladder Cancer: Implications for Future Screening Trials. *Bladder Cancer* (2020) DOI 10.3233/BLC-200381 IOS Press.
517. Soria F, Black PC, Fairey AS, Cookson MS, Yu EY, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Wright JL, Thorpe AC, Morgan TM, Daneshmand S, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, **Lotan Y**, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Shariat SF, Gontero P. Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. *BJU Int.* 2020 Nov 5. doi: 10.1111/bju.15289. Online ahead of print.PMID: 33152179.
518. Kenigsberg AP, Smith W, Meng X, Ghandour R, Rapoport L, Bagrodia A, **Lotan Y**, Woldu SL, Margulis V. Robotic Nephroureterectomy vs Laparoscopic Nephroureterectomy: Increased Utilization, Rates of Lymphadenectomy, Decreased Morbidity Robotically. *J Endourol.* 2020 Nov 16. doi: 10.1089/end.2020.0496. Epub ahead of print. PMID: 33081512.16.
519. Bukavina L, Mishra K, Mahran A, Fernstrum A, Ray A 3rd, Markt S, Schumacher F, Conroy B, Abouassaly R, MacLennan G, Smith G, Ferry E, Wong D, **Lotan Y**, Chaparala H, Sharp D, Alazem K, Moinzadeh A, Adamic B, Zagaja G, Kang P, Lawry H, Lee B, Calaway A, Ponsky L. "Robotic fatigue?" - The impact of case order on positive surgical margins in robotic-assisted laparoscopic prostatectomy. *Urol Oncol.* 2020 Nov 4:S1078-1439(20)30561-5. doi: 10.1016/j.urolonc.2020.10.071. Online ahead of print.PMID: 33160844.
520. Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J Jr, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, **Lotan Y**, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL Jr, Sankin AI, Boyd A, O'Donnell MA, Sawutz D, Philipson R, Coll R, Narayan VM, Treasure FP, Yla-Herttuala S, Parker NR, Dinney CPN. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. *Lancet Oncol.* 2020 Nov 27:S1470-2045(20)30540-4. doi: 10.1016/S1470-2045(20)30540-4. Online ahead of print.PMID: 33253641.

521. Singla N, Christie A, Freifeld Y, Ghandour RA, Woldu SL, Clinton TN, Petros FG, Robyak H, Yeh HC, Fang D, Enikeev D, Bagrodia A, Sagalowsky AI, **Lotan Y**, Raman JD, Matin SF, Margulis V. Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma. *Urol Oncol.* 2020 Dec;38(12):933.e7-933.e12. doi: 10.1016/j.urolonc.2020.04.025. Epub 2020 May 16. PMID: 32430254.
522. Rosenzweig B, Bex A, Dotan ZA, Frydenberg M, Klotz L, **Lotan Y**, Schulman CC, Tsaur I, Ramon J. Trends in urologic oncology clinical practice and medical education under COVID-19 pandemic: An international survey of senior clinical and academic urologists. *Urol Oncol.* 2020 Dec;38 (12):929.e1-929.e10. doi: 10.1016/j.urolonc.2020.09.015. Epub 2020 Oct 7. PMID: 33036903 Free PMC article.
523. Howard JM, Woldu SL, Daneshmand S, **Lotan Y**. Enhanced Endoscopy with IMAGE1 S CHROMA Improves Detection of Nonmuscle Invasive Bladder Cancer During Transurethral Resection. *J Endourol.* 2020 Dec 4. doi: 10.1089/end.2020.0821. Online ahead of print. PMID: 33176470.
524. **Lotan Y**, Stovsky M, Rochelle R et al: Decision analysis model comparing cost of IsoPSA™ vs repeat biopsy for detection of clinically significant prostate cancer in men with previous negative findings on biopsy. *Urol Pract* 2021; 8: 40.
525. **Lotan Y**, Wright JL, Smith AB. Institute for clinical and economic review: BCG Unresponsive disease. *Uro Today.* April 2020.
526. Bhanvadia R, Ashbrook C, Gahan J, Mauck R, Bagrodia A, Margulis V, **Lotan Y**, Roehrborn C, Woldu S. Perioperative outcomes and cost of robotic vs open simple prostatectomy in the modern robotic era: results from the National Inpatient Sample. *BJU Int.* 2020 Sep 27. doi: 10.1111/bju.15258. Online ahead of print. PMID: 32981194.
527. Valenberg FJPV, Hiar AM, Wallace E, Bridge JA, Mayne DJ, Beqaj S, Sexton WJ, **Lotan Y**, Weizer AZ, Jansz GK, Stenzl A, Danella JF, Cline KJ, Williams MB, Montgomery S, David RD, Harris R, Klein EW, Bradford TJ, Wolk FN, Westenfelder KR, Trainer AF, Richardson TA, Egerdie RB, Goldfarb B, Zadra JA, Lu X, Simon IM, Campbell SA, Bates MP, Higuchi RG, Witjes JA. Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria. *Urol Oncol.* 2021 Feb;4(1):93-101. doi: 10.1016/j.euo.2020.09.001. Epub 2020 Sep 28. PMID: 33004290.
528. Klotz L, Pavlovich CP, Chin J, Hatiboglu G, Koch M, Penson D, Raman S, Oto A, Fütterer J, Serrallach M, Relle J, **Lotan Y**, Heidenreich A, Bonekamp D, Haider M, Tirkes T, Arora S, Macura KJ, Costa DN, Persigehl T, Pantuck AJ, Bomers J, Burtnyk M, Staruch R, Eggner S. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. *J Urol.* 2021 Mar;205(3):769-779. doi: 10.1097/JU.0000000000001362. Epub 2020 Oct 6. PMID: 33021440 Clinical Trial.
529. Rosenzweig B, Bex A, Dotan ZA, Frydenberg M, Klotz L, **Lotan Y**, Schulman CC, Tsaur I, Ramon J. Trends in urologic oncology clinical practice and medical education under COVID-19 pandemic: An international survey of senior clinical and academic urologist. *Urol Oncol.* 2020 Dec;38(12):929.e1-929.e10. doi: 10.1016/j.urolonc.2020.09.015. Epub 2020 Oct 7. PMID: 33036903.
530. Pradere B, D'Andrea D, Schuettfort VM, Foerster B, Quhal F, Mori K, Abufaraj M, Margulis V, Deuker M, Briganti A, Muilwijk T, Hendricksen K, **Lotan Y**, Karakiewicz P, F Shariat S; UTUC collaboration. Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma. *World J Urol.* 2020 Oct 16. doi: 10.1007/s00345-020-03479-3. Online ahead of print. PMID: 33067726.
531. Kardoust Parizi M, Shariat SF, Margulis V, Mori K, **Lotan Y**. Value of tumour-infiltrating immune cells in predicting response to intravesical BCG in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis. *BJU Int.* 2021

- Jun;127(6):617-625. doi: 10.1111/bju.15276. Epub 2020 Nov 9.PMID: 33073457 Review.
532. Kenigsberg AP, Smith W, Meng X, Ghandour R, Rapoport L, Bagrodia A, **Lotan Y**, Woldu SL, Margulis V. Robotic Nephroureterectomy vs Laparoscopic Nephroureterectomy: Increased Utilization, Rates of lymphadenectomy, Decreased Morbidity Robotically. *J Endourol.* 2021 Mar;35(3):312-318. doi: 10.1089/end.2020.0496. Epub 2020 Nov 16.PMID: 33081512.
533. Fang D, Singla N, Bao Z, Jafri SM, Su X, Cao Z, Xiong G, Zhang L, Woldu S, Hutchinson R, Sagalowsky A, **Lotan Y**, Li X, Raman JD, Margulis V, Zhou L. The Significance of Preoperative Serum Sodium and Hemoglobin in Outcomes of Upper Tract Urothelial Carcinoma: Multi-Center Analysis Between China and the United States. *Cancer Manag Res.* 2020 Oct 8;12:9825-9836. doi: 10.2147/CMAR.S267969. eCollection 2020.PMID: 33116841.
534. Bagrodia A, Savelyeva A, Labin JT, Speir RW, Chesnut GT, Frazier AL, Woldu SL, Margulis V, Murray MJ, Amatruda JF, **Lotan Y**. Impact of circulating microRNA test (miRNA-371a-3p) on appropriateness of treatment and cost outcomes in patients with Stage I non-seminomatous germ cell tumours. *BJU Int.* 2021 Jul;128(1):57-64. doi: 10.1111/bju.15288. Epub 2020 Nov 19.PMID: 33124175.
535. Soria F, Black PC, Fairey AS, Cookson MS, Yu EY, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Wright JL, Thorpe AC, Morgan TM, Daneshmand S, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, **Lotan Y**, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Shariat SF, Gontero P. Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. *BJU Int.* 2021 Jul;128(1):79-87. doi: 10.1111/bju.15289. Epub 2020 Nov 21.PMID: 33152179.
536. Bukavina L, Mishra K, Mahran A, Fernstrum A, Ray A 3rd, Markt S, Schumacher F, Conroy B, Abouassaly R, MacLennan G, Smith G, Ferry E, Wong D, **Lotan Y**, Chaparala H, Sharp D, Alazem K, Moinzadeh A, Adamic B, Zagaja G, Kang P, Lawry H, Lee B, Calaway A, Ponsky L. "Robotic fatigue?" - The impact of case order on positive surgical margins in robotic-assisted laparoscopic prostatectomy. *Urol Oncol.* 2021 Jun;39(6):365.e17-365.e23. doi: 10.1016/j.urolonc.2020.10.071. Epub 2020 Nov 5.PMID: 33160844.
537. Howard JM, Woldu SL, Daneshmand S, **Lotan Y**. Enhanced Endoscopy with IMAGE1 S CHROMA Improves Detection of Nonmuscle Invasive Bladder Cancer During Transurethral Resection. *J Endourol.* 2021 May;35(5):647-651. doi: 10.1089/end.2020.0821. Epub 2020 Dec 4.PMID: 33176470.
538. Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J Jr, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, **Lotan Y**, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL Jr, Sankin AI, Boyd A, O'Donnell MA, Sawutz D, Philipson R, Coll R, Narayan VM, Treasure FP, Yla-Herttuala S, Parker NR, Dinney CPN. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. *Lancet Oncol.* 2021 Jan;22(1):107-117. doi: 10.1016/S1470-2045(20)30540-4. Epub 2020 Nov 27.PMID: 33253641 Clinical Trial.
539. Woldu SL, Ng CK, Loo RK, Slezak JM, Jacobsen SJ, Tan WS, Kelly JD, Lough T, Darling D, van Kessel KEM, de Jong JJ, van Criekinge W, Shariat SF, Hiar A, Brown S, Boorjian SA, Barocas DA, Svatek RS, **Lotan Y**. Evaluation of the New American Urological

- Association Guidelines Risk Classification for Hematuria. *J Urol*. 2021 May;205(5):1387-1393. doi: 10.1097/JU.0000000000001550. Epub 2020 Dec 24. PMID: 33356483.
540. Ames KS, Baky F, Blair S, Sanchez J, Franklin W, Barefoot A, Mears J, Magness P, Johnson B, Bakare T, Hudak S, Antonelli J, Hutchinson R, **Lotan Y**, Woldu SL. Simple Nephrectomy in a Tertiary Care Safety Net Hospital-Patient Characteristics, Causes, Cost, and Renal Function Implications. *Urology*. 2021 Mar;149:98-102. doi: 10.1016/j.urology.2020.12.013. Epub 2020 Dec 24. PMID: 33359487.
541. Kardoust Parizi M, Margulis V, **Lotan Y**, Mori K, Shariat SF. Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma. *Urol Oncol*. 2021 Feb 25:S1078-1439(21)00048-X. doi: 10.1016/j.urolonc.2021.01.025. Online ahead of print. PMID: 33642228 Review.
542. Folkert MR, Zelefsky MJ, Hannan R, Desai NB, **Lotan Y**, Laine AM, Kim DWN, Neufeld SH, Hornberger B, Kollmeier MA, McBride S, Ahn C, Roehrborn C, Timmerman RD. A Multi-Institutional Phase 2 Trial of High-Dose SabR for Prostate Cancer Using Rectal Spacer. *Int J Radiat Oncol Biol Phys*. 2021 Mar 19:S0360-3016(21)00285-6. doi: 10.1016/j.ijrobp.2021.03.025. Online ahead of print. PMID: 33753140.
543. Necchi A, de Jong JJ, Raggi D, Briganti A, Marandino L, Gallina A, Bandini M, Dabbas B, Davicioni E, Capitanio U, Montorsi F, Seiler R, Wright JL, **Lotan Y**, Black PC, Gibb EA. Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab. *Eur Urol*. 2021 Mar 27:S0302-2838(21)00212-8. doi: 10.1016/j.eururo.2021.03.014. Online ahead of print. PMID: 33785257.
544. Cowan B, Klein E, Jansz K, Westenfelder K, Bradford T, Peterson C, Scherr D, Karsh LI, Egerdie B, Witjes A, Trainer A, Harris R, Goldfarb B, Flax S, Kroeger R, Boyd B, Liao J, Patel S, Bridge J, Reuter V, Quigley N, Brown S, Zhao S, Satya M, Bates M, Simon IM, Campbell S, **Lotan Y**. Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert® Bladder Cancer Monitor) for surveillance in patients with non-muscle-invasive bladder cancer. *BJU Int*. 2021 Apr 1. doi: 10.1111/bju.15418. Online ahead of print. PMID: 33793062.
545. Rajendiran S, Maji S, Haddad A, **Lotan Y**, Nandy RR, Vishwanatha JK, Chaudhary P. MicroRNA-940 as a Potential Serum Biomarker for Prostate Cancer. *Front Oncol*. 2021 Mar 19;11:628094. doi: 10.3389/fonc.2021.628094. eCollection 2021. PMID: 33816263.
546. Woldu SL, Souter L, Boorjian SA, Barocas DA, **Lotan Y**. Urinary-based tumor markers enhance microhematuria risk stratification according to baseline bladder cancer prevalence. *Urol Oncol*. 2021 Apr 12:S1078-1439(21)00132-0. doi: 10.1016/j.urolonc.2021.03.022. Online ahead of print. PMID: 33858747.
547. Vanarsa K, Enan S, Patel P, Strachan B, Sam Titus ASCL, Dennis A, **Lotan Y**, Mohan C. Urine protein biomarkers of bladder cancer arising from 16-plex antibody-based screens. *Oncotarget*. 2021 Apr 13;12(8):783-790. doi: 10.18632/oncotarget.27941. eCollection 2021 Apr 13. PMID: 33889301.
548. Lafin JT, Kenigsberg AP, Meng X, Abe D, Savelyeva A, Singla N, Woldu SL, **Lotan Y**, Mauck RJ, Lewis CM, Margulis V, Wong D, Jia L, Kapur P, Xu L, Speir RW, Chesnut GT, Frazier AL, Strand DW, Coleman N, Murray MJ, Amatruda JF, Bagrodia A. Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection. *Eur Urol Open Sci*. 2021 Apr;26:83-87. doi: 10.1016/j.euro.2021.02.003. Epub 2021 Mar 5. PMID: 33997822.
549. Kenigsberg AP, Gold S, Grant L, **Lotan Y**. The Economics of Cystoscopy: A Microcost Analysis. *Urology*. 2021 May 16:S0090-4295(21)00398-8. doi: 10.1016/j.urology.2021.05.008. Online ahead of print. PMID: 34010677.
550. Schuettfort VM, Pradere B, Trinh QD, D'Andrea D, Quhal F, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Rink M, Karakiewicz PI, Chlosta P, Yuen-Chun Teoh J, **Lotan**

- Y, Scherr D, Abufaraj M, Moschini M, Shariat SF. Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. *Cancer Immunol Immunother*. 2021 May 23. doi: 10.1007/s00262-021-02953-0. Online ahead of print.PMID: 34023914.
551. Chu CE, Sjöström M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, **Lotan Y**, Black PC, Porten SP, Feng FY, Chou J. Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin. *Clin Cancer Res*. 2021 Jun 9:clincanres.4175.2020. doi: 10.1158/1078-0432.CCR-20-4175. Online ahead of print.PMID: 34108177.
552. **Lotan Y**. Metabolic syndrome and bladder cancer. *BJU Int*. 2021 Jul;128(1):1-2. doi: 10.1111/bju.15322.PMID: 34160131 No abstract available.
553. Kukreja JB, Schroeck FR, **Lotan Y**, Gore JL, Ullman R, Lipman RR, Murray MBB, Chisolm S; Cystoscopy Discomfort Working Group, Smith AB. Discomfort and relieving factors among patients with bladder cancer undergoing office-based cystoscopy. *Urol Oncol*. 2021 Jun 20:S1078-1439(21)00215-5. doi: 10.1016/j.urolonc.2021.05.009. Online ahead of print.PMID: 34162499.
554. Schuettfort VM, Pradere B, D'Andrea D, Grossmann NC, Quhal F, Mostafaei H, Laukhtina E, Mori K, Rink M, Karakiewicz PI, Motlagh RS, Katayama S, **Lotan Y**, Scherr D, Abufaraj M, Fajkovic H, Compérat E, Enikeev D, Shariat SF. Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes After Radical Cystectomy. *J Urol*. 2021 Jun 28:101097JU0000000000001936. doi: 10.1097/JU.0000000000001936. Online ahead of print.PMID: 34181469.
555. Kukreja JB, Schroeck FR, **Lotan Y**, Gore JL, Ullman R, Lipman RR, Ballard Murray MB, Chisolm S, CDWG, Smith AB. Discomfort and Relieving Factors among Patients with Bladder Cancer Undergoing Office-Based Cystoscopy. *Urol Oncol*. May 2021. In Press.
556. **Lotan Y**. New American Urological Association Guideline for Risk Classification of Hematuria. *Journal of Urology. Practice Update*. May 2021.
557. Meng X, Chaplin I, Ghandour R, **Lotan Y**. Office-Based blue light flexible cystoscopy improves diagnostic capabilities. *Videourology* Vol.34.No2. 1 Apr 2020.doi.org/10.1089/vid.2019.0081.
558. Reyes R, Rios E, Barney S, Hugen C, Michalek J, Lotan Y, Messing E, Svatek R. A randomized feasibility trial comparing surveillance regimens for patients with low and low-intermediate risk non-muscle invasive bladder cancer. *Bladder Cancer*, vol 7,no.3,pp. 285-295,2021. doi:10.3233/BLC-201535.
559. Claps F, van de Kamp MW, Mayr R, Bostrom PJ, Boormans JL, Eckstein M, Mertens LS, Boevé ER, Neuzillet Y, Burger M, Pouessel D, Trombetta C, Wullich B, van der Kwast TH, Hartmann A, Allory Y, **Lotan Y**, Shariat SF, Zuiverloon TCM, Mir MC, van Rhijn BWG. Risk factors associated with positive surgical margins' location at radical cystectomy and their impact on bladder cancer survival. *World J Urol*. 2021 Dec;39(12):4363-4371. doi: 10.1007/s00345-021-03776-5. Epub 2021 Jul 1.PMID: 34196758.
560. Miranda AF, Howard JM, McLaughlin M, Meng X, Clinton T, Şanlı Ö, Garant A, Bagrodia A, Margulis V, **Lotan Y**, Hannan R, Desai N, Woldu SL. Metastasis-directed radiation therapy after radical cystectomy for bladder cancer. *Urol Oncol*. 2021 Nov;39(11):790.e1-790.e7. doi: 10.1016/j.urolonc.2021.05.005. Epub 2021 Jun 30.PMID: 34215505.
561. Necchi A, Raggi D, Gallina A, Bandini M, de Jong JJ, Marandino L, Briganti A, Montorsi F, Davicioni E, **Lotan Y**, Gibb EA. Molecular subtyping and immune-gene

- signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition. *Urol Oncol*. 2021 Oct;39(10):734.e11-734.e17. doi: 10.1016/j.urolonc.2021.06.011. Epub 2021 Jul 21.PMID: 34301456.
562. Raman JD, Kavalieris L, Konety B, Porten S, Daneshmand S, **Lotan Y**, Loo R. The diagnostic performance of Cxbladder resolve, alone and in combination with other cxbladder test, in the identification and priority evaluation of patients at risk for urothelial carcinoma. *J Urol*. 2021 Dec;206(6):1380-1389. doi: 10.1097/JU.0000000000002135. Epub 2021 Aug 5.PMID: 34348469 **Free PMC article**.
563. Woldu SL, **Lotan Y**. Re: ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. *Eur Urol*. 2021 Oct;80(4):517-518. doi: 10.1016/j.eururo.2021.07.018. Epub 2021 Aug 6.PMID: 34366211 No abstract available.
564. D'Andrea D, Black PC, Zargar H, Zargar-Shoshtari K, Soria F, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, **Lotan Y**, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Shariat SF. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. *World J Urol*. 2021 Dec;39(12):4345-4354. doi: 10.1007/s00345-021-03793-4. Epub 2021 Aug 9.PMID: 34370078 **Free PMC article**.
565. Gold SA, Kenigsberg AP, **Lotan Y**. Diagnostic and cost implications of the 2020 AUA Microhematuria guidelines: Modeling impact in a large public health care system.*J Urol*. 2022 Jan;207(1):52-60. doi: 10.1097/JU.0000000000002175. Epub 2021 Aug 25.PMID: 34428924
566. Dropkin BM, Sanders SC, Kavoussi M, Shaaban A, Joice GA, Hudak SJ, **Lotan Y**, Morey AF. Same day discharge versus overnight observation protocols – similar outcomes following artificial urinary sphincter surgery. *Urology*. 2021 Nov;157:206-210. doi: 10.1016/j.urology.2021.08.016. Epub 2021 Aug 23.PMID: 34437897
567. D'Andrea D, Black PC, Zargar H, Dinney CP, Soria F, Cookson MS, Montgomery JS, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Wright JL, Thorpe AC, Holzbeierlein JM, Carrión DM, Di Trapani E, Bivalacqua TJ, North S, Barocas DA, **Lotan Y**, Grivas P, Stephenson AJ, van Rhijn BW, Daneshmand S, Spiess PE, Shariat SF; Identifying the optimal number of neoadjuvant chemotherapy cycles in patients with muscle invasive bladder cancer. Contributors.*J Urol*. 2022 Jan;207(1):70-76. doi: 10.1097/JU.0000000000002190. Epub 2021 Aug 27.PMID: 34445891.
568. Mori K, Schuettfort VM, Katayama S, Laukhtina E, Pradere B, Quhal F, Sari Motlagh R, Mostafaei H, Grossmann NC, Rajwa P, König F, Aydh A, Soria F, Moschini M, Karakiewicz PI, **Lotan Y**, Scherr D, Haydter M, Nyirady P, Teoh JYC, Egawa S, Compérat E, Shariat SF. The value of preoperative plasma VEGF levels in urothelial carcinoma of the bladder treated with radical cystectomy. *Eur Urol Focus*. 2021 Aug 25:S2405-4569(21)00221-2. doi: 10.1016/j.euf.2021.08.006. Online ahead of print.PMID: 34454852.
569. Russo GI, Sholklipper TN, Cocci A, Broggi G, Caltabiano R, Smith AB, **Lotan Y**, Morgia G, Kamat AM, Witjes JA, Daneshmand S, Desai MM, Gill IS, Cacciamani GE. Performance of narrow band imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence imaging compared to white light cystoscopy (WLC) in detecting non-Muscle invasive bladder cancer: A systematic review and lesion-level diagnostic meta-analysis. *Cancers (Basel)*. 2021 Aug 30;13(17):4378. doi: 10.3390/cancers13174378.PMID: 34503188 **Free PMC article**. Review.

570. Ahmadi H, Ladi-Seyedian SS, Konety B, Pohar K, Holzbeierlein JM, Kates M, Willard B, Taylor JM, Liao JC, Kaimakliotis HZ, Porten SP, Steinberg GD, Tyson MD, **Lotan Y**, Daneshmand S; Role of blue-light cystoscopy in detecting invasive bladder tumours: data from a multi-institutional registry. Blue Light Cystoscopy with Cysview Registry Group. *BJU Int.* 2021 Oct 12. doi: 10.1111/bju.15614. Online ahead of print.PMID: 34637596.
571. **Lotan Y**, de Jong JJ, Liu VYT, Bismar TA, Boorjian SA, Huang HC, Davicioni E, Mian OY, Wright JL, Necchi A, Dall'Era MA, Kaimakliotis HZ, Black PC, Gibb EA, Boormans JL. Patients with muscle-invasive bladder cancer with nonluminal subtype derive greatest results from platinum based neoadjuvant chemotherapy. *J Urol.* 2022 Mar;207(3):541-550. doi: 10.1097/JU.0000000000002261. Epub 2021 Oct 13.PMID: 34643090.
572. Meng X, Vazquez L, Howard JM, Kenigsberg AP, Singla N, Margulis V, Bagrodia A, **Lotan Y**, Xi Y, Woldu SL. The early impact of Medicaid expansion on urologic malignancies in the United States. *Urol Oncol.* 2021 Oct 16:S1078-1439(21)00414-2. doi: 10.1016/j.urolonc.2021.09.002. Online ahead of print.PMID: 34666919.
573. Chappidi MR, Yang H, Meng MV, Bivalacqua TJ, Daneshmand S, Holzbeierlein JM, Kaimakliotis HZ, Konety B, Liao JC, Pohar K, Steinberg GD, Taylor JM, Tyson MD, Willard B, **Lotan Y**, Porten SP, Kates M. Utility of blue light cystoscopy for post-bacillus calmette-guerin bladder cancer recurrence detection: Implications for clinical trial recruitment and study comparisons. *J Urol.* 2022 Mar;207(3):534-540. doi: 10.1097/JU.0000000000002308. Epub 2021 Oct 25.PMID: 34694916.
574. Badia RR, Wong D, Ghandour R, Chertack N, Meng X, Hutchinson R, Margulis V, **Lotan Y**, Madrigales A, Woldu S, Bagrodia A. Validation of testicular germ cell tumor staging in nationwide cancer registries. *Urol Oncol.* 2021 Dec;39(12):838.e1-838.e6. doi: 10.1016/j.urolonc.2021.09.011. Epub 2021 Oct 26.PMID: 34711464.
575. Laukhtina E, Shim SR, Mori K, D'Andrea D, Soria F, Rajwa P, Mostafaei H, Compérat E, Cimadamore A, Moschini M, Teoh JY, Enikeev D, Xylinas E, **Lotan Y**, Palou J, Gontero P, Babjuk M, Witjes JA, Kamat AM, Roupret M, Shariat SF, Pradere B; Diagnostic accuracy of novel urinary biomarker tests in non-muscle-invasive bladder cancer: A Systematic review and network meta-analysis. *European Association of Urology–Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group.* *Eur Urol Oncol.* 2021 Dec;4(6):927-942. doi: 10.1016/j.euo.2021.10.003. Epub 2021 Nov 6.PMID: 34753702 **Free article.** Review.
576. Hannan R, Salamekh S, Desai NB, Garant A, Folkert MR, Costa DN, Mannala S, Ahn C, Mohamad O, Laine A, Kim DWN, Dickinson T, Raj GV, Shah RB, Wang J, Jia X, Choy H, Roehrborn CG, **Lotan Y**, Timmerman RD. SAbR for high-risk prostate cancer- A prospective multilevel MRI-based dose escalation trial. *Int J Radiat Oncol Biol Phys.* 2021 Nov 11:S0360-3016(21)03047-9. doi: 10.1016/j.ijrobp.2021.10.137. Online ahead of print.PMID: 34774676.
577. Chien TM, Lee HY, Singla N, Margulis V, **Lotan Y**, Woldu SL, Huang CN, Li CC, Ke HL, Li WM, Li CY, Huang AM, Yang SF, Tu HP, Wu WJ, Yeh HC. Prognostic factors for contralateral recurrence of upper tract urothelial carcinoma after nephroureterectomy: A large multiregional study. *Cancers (Basel).* 2021 Nov 25;13(23):5935. doi: 10.3390/cancers13235935.PMID: 34885042 **Free PMC article.**
578. Mertens LS, Claps F, Mayr R, Bostrom PJ, Shariat SF, Zwarthoff EC, Boormans JL, Abas C, van Leenders GJLH, Götz S, Hippe K, Bertz S, Neuzillet Y, Sanders J, Broeks A, Peters D, van der Heijden MS, Jewett MAS, Stöhr R, Zlotta AR, Eckstein M, Soorobjally Y, van der Schoot DKE, Wullich B, Burger M, Otto W, Radvanyi F, Sirab N, Pouessel D, van der Kwast TH, Hartmann A, **Lotan Y**, Allory Y, Zuiverloon TCM, van Rhijn BWG. Prognostic markers in invasive bladder cancer: FGFR3 mutation status

- versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. *Urol Oncol*. 2021 Dec 11:S1078-1439(21)00475-0. doi: 10.1016/j.urolonc.2021.10.010. Online ahead of print.PMID: 34906411.
579. Katayama S, Schuettfort VM, Pradere B, Mori K, Mostafaei H, Quhal F, Sari Motlagh R, Laukhtina E, Grossmann NC, Aydh A, Rajwa P, König F, Karakiewicz PI, Haydter M, Moschini M, Abufaraj M, **Lotan Y**, Lee RK, Trinh QD, Compérat E, Teoh J, Nasu Y, Shariat SF. Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer. *J Cancer Res Clin Oncol*. 2022 Jan 8. doi: 10.1007/s00432-021-03887-x. Online ahead of print.PMID: 34997350.
580. Laukhtina E, Shim SR, Mori K, D'Andrea D, Soria F, Rajwa P, Mostafaei H, Compérat E, Cimadamore A, Moschini M, Teoh JY, Enikeev D, Xylinas E, **Lotan Y**, Palou J, Gontero P, Babjuk M, Witjes JA, Kamat AM, Roupert M, Shariat SF, Pradere B; Corrigendum to "Diagnostic accuracy of novel urinary biomarker tests in non-muscle-invasive bladder cancer: A systematic review and network meta-analysis" (*Eur Urol Oncol* 2021;4:927-42.) European Association of Urology–Young Academic Urologists EAU-YAU Urothelial Carcinoma Working Group.*Eur Urol Oncol*. 2022 Jan 19:S2588-9311(22)00004-9. doi: 10.1016/j.euo.2022.01.003. Online ahead of print.PMID: 35063436 **Free article**. No abstract available.
581. Howard J, Cook GS, Tverye A, Nandy K, Margulis V, Woldu S, **Lotan Y**. Outcomes of patients with Bacillus Calmette-Guerin (BCG)-Unresponsive non-muscle invasive bladder cancer as defined by the U.S. Food and Drug Administrative Bladder Cancer. *Jan* 2022:303-314.
582. Mir MC, Marchioni M, Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP, Krabbe LM, Cookson MS, Jacobsen NE, Griffin J, Montgomery JS, Vasdev N, Yu EY, Xylinas E, McGrath JS, Kassouf W, Dall'Era MA, Sridhar SS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, **Lotan Y**, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Daneshmand S, Black PC. Corrigendum to "Nomogram predicting bladder cancer-specific mortality after neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: Results of an international consortium: (Eur Urol Focus 2021;7:1347-54) *Eur Urol Focus*. 2022 Feb 15:S2405-4569(22)00016-5. doi: 10.1016/j.euf.2022.01.009. Online ahead of print.PMID: 35181282 No abstract available.
583. Chen L, Gannavarapu BS, Desai NB, Folkert MR, Dohopolski M, Gao A, Ahn C, Cadeddu J, Bagrodia A, Woldu S, Raj GV, Roehrborn C, **Lotan Y**, Timmerman RD, Garant A, Hannan R. Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer. *Front Oncol*. 2022 Feb 21;12:779182. doi: 10.3389/fonc.2022.779182. eCollection 2022.PMID: 35265519
584. Carpinito GP, Cook GS, Tverye AN, Gold SA, **Lotan Y**, Margulis V, Howard JM. Outcomes of patients undergoing concurrent radical cystectomy and nephroureterectomy: A single-institution series. *Can Urol Assoc J*. 2022 Feb 28. doi: 10.5489/cuaj.7612. Online ahead of print.PMID: 35230936
585. Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, **Lotan Y**, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. *Eur Urol Oncol*. 2022 Feb 22:S2588-9311(21)00215-7. doi: 10.1016/j.euo.2021.11.005. Online ahead of print.PMID: 35216942
586. Mori K, Schuettfort VM, Katayama S, Laukhtina E, Pradere B, Quhal F, Sari Motlagh R, Mostafaei H, Grossmann NC, Rajwa P, Teoh JY, Resch I, Fajkovic H, Moschini M, D'andrea D, Abufaraj M, Karakiewicz PI, **Lotan Y**, Scherr D, Egawa S, Compérat E,

- Shariat SF; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU). Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. *Ann Surg Oncol*. 2022 Mar 26. doi: 10.1245/s10434-022-11575-4. Online ahead of print.PMID: 35347517
587. Mitra AP, Narayan VM, Mokkupati S, Miest T, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown GA, Canter D, Luchey A, **Lotan Y**, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL, Sankin AI, Boyd A, O'Donnell MA, Philipson R, Ylä-Herttuala S, Sawutz D, Parker NR, McConkey DJ, Dinney CPN. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. *Eur Urol*. 2022 Mar;81(3):223-228. doi: 10.1016/j.eururo.2021.12.009. Epub 2021 Dec 18.PMID: 34933753
588. Sari Motlagh R, Schuettfort VM, Mori K, Katayama S, Rajwa P, Aydh A, Grossmann NC, Laukhtina E, Pradere B, Mostafai H, Quhal F, Abufaraj M, Lee R, Karakiewicz PI, **Lotan Y**, Comprate E, Moschini M, Gontero P, Shariat SF. Prognostic impact of insulin-like growth factor-I and its binding proteins, insulin-like growth factor-I binding protein-2 and -3, on adverse histopathological features and survival outcomes after radical cystectomy. *Int J Urol*. 2022 Apr 2. doi: 10.1111/iju.14869. Online ahead of print.PMID: 35368130
589. Mertens LS, Claps F, Mayr R, Hodgson A, Shariat SF, Hippe K, Neuzillet Y, Sanders J, Burger M, Pouessel D, Otto W, van der Kwast TH, **Lotan Y**, Allory Y, Downes MR, van Rhijn BWG. The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis. *Int J Surg Pathol*. 2022 Apr 24:10668969221095173. doi: 10.1177/10668969221095173. Online ahead of print.PMID: 35466737
590. Bhanvadia RR, Carpinito G, Kavoussi M, **Lotan Y**, Margulis V, Bagrodia A, Roehrborn C, Gahan JC, Cadeddu JA, Woldu S. Safety and Feasibility of Telehealth Only Preoperative Evaluation Prior to Minimally Invasive Robotic Urologic Surgery. *J Endourol*. 2022 May 20. doi: 10.1089/end.2021.0819. Online ahead of print.PMID: 35596562
591. Bhanvadia RR, Baky FJ, Ashbrook CQ, **Lotan Y**, Woldu SL. Pathologic fracture in metastatic kidney cancer: Identifying widening disparities and opportunity for quality improvement. *Urol Oncol*. 2022 May 31:S1078-1439(22)00156-9. doi: 10.1016/j.urolonc.2022.05.002. Online ahead of print.PMID: 35662499
592. Bhanvadia RR, **Lotan Y**. Progress in the development of tissue-based biomarkers for urothelial cancer. *Expert Rev Anticancer Ther*. 2022 Jun;22(6):605-619. doi: 10.1080/14737140.2022.2070154. Epub 2022 Apr 29.PMID: 35459430
593. Badia RR, Chertack N, Meng X, Howard J, Singla N, Margulis V, **Lotan Y**, Woldu S, Bagrodia A. Predictive factors of diagnostic delay and effect on treatment patterns in testicular germ cell tumor patients. *Urol Oncol*. 2022 May;40(5):201.e1-201.e7. doi: 10.1016/j.urolonc.2022.02.019. Epub 2022 Apr 7.PMID: 35400569
594. Roumiguié M, Kamat AM, Bivalacqua TJ, Lerner SP, Kassouf W, Böhle A, Brausi M, Buckley R, Persad R, Colombel M, Lamm D, Palou-Redorta J, Soloway M, Brothers K, Steinberg G, **Lotan Y**, Sylvester R, Alfred Witjes J, Black PC. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer. *Eur Urol*.

- 2022 Jul;82(1):34-46. doi: 10.1016/j.eururo.2021.12.005. Epub 2021 Dec 23.PMID: 34955291 Review.
595. Hannan R, Salamekh S, Desai NB, Garant A, Folkert MR, Costa DN, Mannala S, Ahn C, Mohamad O, Laine A, Kim DWN, Dickinson T, Raj GV, Shah RB, Wang J, Jia X, Choy H, Roehrborn CG, **Lotan Y**, Timmerman RD. SABR for High-Risk Prostate Cancer: A Prospective Multilevel MRI-Based Dose Escalation Trial. *Int J Radiat Oncol Biol Phys*. 2022 Jun 1;113(2):290-301. doi: 10.1016/j.ijrobp.2021.10.137. Epub 2021 Nov 11.PMID: 34774676 Clinical Trial.
596. Katayama S, Schuetfort VM, Pradere B, Mori K, Mostafaei H, Quhal F, Sari Motlagh R, Laukhtina E, Grossmann NC, Aydh A, Rajwa P, König F, Karakiewicz PI, Haydter M, Moschini M, Abufaraj M, **Lotan Y**, Lee RK, Trinh QD, Compérat E, Teoh J, Nasu Y, Shariat SF. Prognostic value of hepatocyte growth for muscle-invasive bladder cancer.*J Cancer Res Clin Oncol*. 2022 Nov;148(11):3091-3102. doi: 10.1007/s00432-021-03887-x. Epub 2022 Jan 8.PMID: 34997350.
597. Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, **Lotan Y**, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY. TROP2 expression across molecular subtypes of urothelial carcinoma and enfortumab vedotin-resistant cells. *Eur Urol Oncol*. 2022 Dec;5(6):714-718. doi: 10.1016/j.euo.2021.11.005. Epub 2022 Feb 23.PMID: 35216942.
598. Carpinito GP, Cook GS, Tverye AN, Gold SA, **Lotan Y**, Margulis V, Howard JM. Outcomes of patients undergoing concurrent radical cystectomy and nephroureterectomy: A single-institution series.*Can Urol Assoc J*. 2022 Jul;16(7):E363-E369. doi: 10.5489/cuaj.7612.PMID: 35230936 .
599. Chen L, Gannavarapu BS, Desai NB, Folkert MR, Dohopolski M, Gao A, Ahn C, Cadeddu J, Bagrodia A, Woldu S, Raj GV, Roehrborn C, **Lotan Y**, Timmerman RD, Garant A, Hannan R. Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer.*Front Oncol*. 2022 Feb 21;12:779182. doi: 10.3389/fonc.2022.779182. eCollection 2022.PMID: 35265519.
600. Mori K, Schuetfort VM, Katayama S, Laukhtina E, Pradere B, Quhal F, Sari Motlagh R, Mostafaei H, Grossmann NC, Rajwa P, Teoh JY, Resch I, Fajkovic H, Moschini M, D'andrea D, Abufaraj M, Karakiewicz PI, **Lotan Y**, Scherr D, Egawa S, Compérat E, Shariat SF; Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy.European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU).*Ann Surg Oncol*. 2022 Aug;29(8):5307-5316. doi: 10.1245/s10434-022-11575-4. Epub 2022 Mar 26.PMID: 35347517 **Free PMC article**.
601. Sari Motlagh R, Schuetfort VM, Mori K, Katayama S, Rajwa P, Aydh A, Grossmann NC, Laukhtina E, Pradere B, Mostafai H, Quhal F, Abufaraj M, Lee R, Karakiewicz PI, **Lotan Y**, Comprate E, Moschini M, Gontero P, Shariat SF. Prognostic impact of insulin-like growth factor-I and its binding proteins, insulin-like growth factor-I binding protein-2 and -3, on adverse histopathological features and survival outcomes after radical cystectomy.*Int J Urol*. 2022 Jul;29(7):676-683. doi: 10.1111/iju.14869. Epub 2022 Apr 2.PMID: 35368130 **Free PMC article**.
602. Badia RR, Chertack N, Meng X, Howard J, Singla N, Margulis V, **Lotan Y**, Woldu S, Bagrodia A. Predictive factors of diagnostic delay and effect on treatment patterns in testicular germ cell tumor patients.*Urol Oncol*. 2022 May;40(5):201.e1-201.e7. doi: 10.1016/j.urolonc.2022.02.019. Epub 2022 Apr 7.PMID: 35400569.

603. Bhanvadia RR, **Lotan Y**. Progress in the development of tissue-based biomarkers for urothelial cancer. *Expert Rev Anticancer Ther.* 2022 Jun;22(6):605-619. doi: 10.1080/14737140.2022.2070154. Epub 2022 Apr 29. PMID: 35459430.
604. Mertens LS, Claps F, Mayr R, Hodgson A, Shariat SF, Hippe K, Neuzillet Y, Sanders J, Burger M, Pouessel D, Otto W, van der Kwast TH, **Lotan Y**, Allory Y, Downes MR, van Rhijn BWG. The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis. *Int J Surg Pathol.* 2022 Apr 24:10668969221095173. doi: 10.1177/10668969221095173. Online ahead of print. PMID: 35466737.
605. Bhanvadia RR, Carpinito GP, Kavoussi M, **Lotan Y**, Margulis V, Bagrodia A, Roehrborn CG, Gahan JC, Cadeddu J, Woldu S. Safety and Feasibility of Telehealth Only Preoperative Evaluation Before Minimally Invasive Robotic Urologic Surgery. *J Endourol.* 2022 Aug;36(8):1070-1076. doi: 10.1089/end.2021.0819. Epub 2022 Jul 5. PMID: 35596562.
606. Bhanvadia RR, Baky FJ, Ashbrook CQ, **Lotan Y**, Woldu SL. Pathologic fracture in metastatic kidney cancer: Identifying widening disparities and opportunity for quality improvement. *Urol Oncol.* 2022 Aug;40(8):384.e1-384.e8. doi: 10.1016/j.urolonc.2022.05.002. Epub 2022 May 31. PMID: 35662499.
607. Kami Reddy KR, Piyaathna DWB, Kamal AHM, Putluri V, Ravi SS, Bollag RJ, Terris MK, **Lotan Y**, Putluri N. Lipidomic Profiling Identifies a Novel Lipid Signature Associated with Ethnicity-Specific Disparity of Bladder Cancer. *Metabolites.* 2022 Jun 14;12(6):544. doi: 10.3390/metabo12060544. PMID: 35736477 **Free PMC article.**
608. Pohar KS, Patel S, **Lotan Y**, Trabulsi E, Woods M, Downs T, Huang WC, Jones J, Taylor J, O'Donnell M, Bivalacqua TJ, DeCastro J, Steinberg G, Kamat AM, Resnick MJ, Konety B, Schoenberg M, Jones JS, Daneshmand S; Safety of repeat blue light cystoscopy with hexaminolevulinatate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study. Flexible Blue Light Study Group Collaborators. *Urol Oncol.* 2022 Aug;40(8):382.e1-382.e6. doi: 10.1016/j.urolonc.2022.04.012. Epub 2022 Jun 22. PMID: 35750559.
609. Klein EA, Partin A, **Lotan Y**, Baniel J, Dineen M, Hafron J, Manickam K, Pliskin M, Wagner M, Kestranek A, Stovsky M. Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter study. *Urol Oncol.* 2022 Sep;40(9):408.e9-408.e18. doi: 10.1016/j.urolonc.2022.06.002. Epub 2022 Jul 13. PMID: 35840465 **Free article.**
610. Pallauf M, König F, D'Andrea D, Laukhtina E, Mostafaei H, Motlagh RS, Quhal F, Aydh A, Yanagisawa T, Kawada T, Rajwa P, Lusuardi L, Soria F, Karakiewicz PI, Rouprêt M, Rink M, **Lotan Y**, Margulis V, Singla N, Xylinas E, Shariat SF, Pradere B. A Systematic Review and Meta-Analysis of Prognostic Nomograms After UTUC Surgery. *Front Oncol.* 2022 Jul 1;12:907975. doi: 10.3389/fonc.2022.907975. eCollection 2022. PMID: 35847838 **Free PMC article.**
611. de Jong JJ, Pijpers OM, van Kessel KEM, Boormans JL, Van Criekinge W, Zwarthoff EC, **Lotan Y**. A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines. *Eur Urol Oncol.* 2022 Sep 8:S2588-9311(22)00141-9. doi: 10.1016/j.euo.2022.08.002. Online ahead of print. PMID: 36089502.
612. Taylor J, **Lotan Y**. Is Office-based Management of Intermediate-risk Low-grade Non-muscle-invasive Bladder Cancer Ready For Prime Time? *Eur Urol.* 2023 Feb;83(2):131-132. doi: 10.1016/j.eururo.2022.09.001. Epub 2022 Sep 22. PMID: 36153249 No abstract available.
613. Einerhand SMH, Black AJ, Zargar H, Fairey AS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobson NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Kassouf W,

- Dall'Era MA, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, **Lotan Y**, Grivas P, Garcia JA, Stephenson AJ, Shah JB, Daneshmand S, Zargar-Shoshtari K, Spiess PE, van Rhijn BWG, Black PC, Mertens LS. Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer. *World J Urol.* 2022 Nov;40(11):2707-2715. doi: 10.1007/s00345-022-04160-7. Epub 2022 Sep 28. PMID: 36169695.
614. Lobo N, Afferi L, Moschini M, Mostafid H, Porten S, Psutka SP, Gupta S, Smith AB, Williams SB, **Lotan Y**. Epidemiology, Screening, and Prevention of Bladder Cancer. *Eur Urol Oncol.* 2022 Dec;5(6):628-639. doi: 10.1016/j.euo.2022.10.003. Epub 2022 Nov 1. PMID: 36333236 Review.
615. **Lotan Y**, Baky FJ. Urine-Based Markers for Detection of Urothelial Cancer and for the Management of Non-muscle-Invasive Bladder Cancer. *Urol Clin North Am.* 2023 Feb;50(1):53-67. doi: 10.1016/j.ucl.2022.09.009. PMID: 36424083 Review.
616. Woldu SL, Labbate C, Murray KS, Rose K, Sexton W, Tachibana I, Kaimakliotis H, Jacob J, Dickstein R, Linehan J, Nieder A, Bjurlin MA, Humphreys M, Ghodoussipour S, Quek ML, O'Donnell M, Eisner BH, Feldman AS, Matin SF, **Lotan Y**. Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes. *Urol Oncol.* 2022 Nov 21:S1078-1439(22)00429-X. doi:10:1016/j.urolonc.2022.10.029. Online ahead of print. PMID: 36424224.
617. Alsyof M, Ladi-Seyedian SS, Konety B, Pohar K, Holzbeierlein JM, Kates M, Willard B, Taylor JM, Liao JC, Kaimakliotis HZ, Porten SP, Steinberg GD, Tyson MD, **Lotan Y**, Daneshmand S; Is a restaging TURBT necessary in high-risk NMIBC if the initial TURBT was performed with blue light? Blue Light Cystoscopy with Cysview Registry Group. *Urol Oncol.* 2022 Nov 23:S1078-1439(22)00427-6. doi: 10.1016/j.urolonc.2022.10.026. Online ahead of print. PMID: 36435710.
618. Kardoust Parizi M, Margulis V, **Lotan Y**, Aydh A, Shariat SF. A Systematic Review and Meta-Analysis of Clinicopathologic Factors Predicting Upper Urinary Tract Recurrence After Radical Cystectomy for Urothelial Bladder Cancer. *Clin Genitourin Cancer.* 2022 Nov 13:S1558-7673(22)00236-1. doi: 10.1016/j.clgc.2022.11.002. Online ahead of print. PMID: 36513557.
619. Hekman MCH, Wijn SRW, **Lotan Y**, Govers TM, Witjes JA. Bladder EpiCheck urine test in the follow-up of NMIBC: a cost analysis. *World J Urol.* 2022 Dec 19. doi: 10.1007/s00345-022-04252-4. Online ahead of print. PMID: 36534153.
620. **Lotan Y**, Raman JD, Konety B, Daneshmand S, Schroeck F, Shariat SF, Black P, de Lange M, Asroff S, Goldfischer E, Efros M, Chong KT, Huang E, Chua HL, Wu QH, Yeow S, Lau W, Yong J, Eng M.J. Urinary Analysis of *FGFR3* and *TERT* Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification. *Urol.* 2022 Dec 30:101097JU00000000000003126. doi: 10.1097/JU.00000000000003126. Online ahead of print. PMID: 36583640.
621. Gerald T, Margulis V, Meng X, Bagrodia A, Cole S, Qin Q, Call SG, Maurer E, **Lotan Y**, Woldu SL. Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients. *Urol Oncol.* 2023 Jan 16:S1078-1439(22)00493-8. doi: 10.1016/j.urolonc.2022.12.008. Online ahead of print. PMID: 36653279.
622. Labbate C, Woldu S, Murray K, Rose K, Sexton W, Tachibana I, Kaimakliotis H, Jacob J, Dickstein R, Linehan J, Nieder A, Bjurlin M, Humphreys M, Ghodoussipour S, Quek M, O'Donnell M, Eisner B, Feldman A, **Lotan Y**, Matin SF. Efficacy and safety of mitomycin gel (UGN-101) as an adjuvant therapy after complete endoscopic management of Upper Tract Urothelial Carcinoma. *J Urol.* 2023 Jan 19:101097JU00000000000003185. doi: 10.1097/JU.00000000000003185. Online ahead of print. PMID: 36657029.

623. Claps F, van de Kamp MW, Mayr R, Bostrom PJ, Shariat SF, Hippe K, Bertz S, Neuzillet Y, Sanders J, Otto W, van der Heijden MS, Jewett MAS, Stöhr R, Zlotta AR, Trombetta C, Eckstein M, Mertens LS, Burger M, Soorojebally Y, Wullich B, Bartoletti R, Radvanyi F, Pavan N, Sirab N, Mir MC, Pouessel D, van der Kwast TH, Hartmann A, **Lotan Y**, Bussani R, Allory Y, van Rhijn BWG. Prognostic impact of variant histologies in urothelial bladder cancer treated by radical cystectomy. *BJU Int.* 2023 Feb 6. doi: 10.1111/bju.15984. Online ahead of print. PMID: 36748180.
624. Kirk PS, **Lotan Y**, Zargar H, et al. Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort. *J Urol.* 2023 Feb 16;101097JU0000000000003193. doi: 10.1097/JU.0000000000003193. Online ahead of print. PMID: 36795962
625. Bezwada D, Lesner NP, Brooks B, Vu HS, Wu Z, Cai L, Kasitinon S, Kelekar S, Cai F, Aurora AB, Patrick M, Leach A, Ghandour R, Zhang Y, Do D, Sudderth J, Dumesnil D, House S, Rosales T, Poole AM, **Lotan Y**, Woldu S, Bagrodia A, Meng X, Cadeddu JA, Mishra P, Pedrosa I, Kapur P, Courtney KD, Malloy CR, Margulis V, DeBerardinis RJ. Mitochondrial metabolism in primary and metastatic human kidney cancers. *bioRxiv.* 2023 Feb 7:2023.02.06.527285. doi: 10.1101/2023.02.06.527285. Preprint. PMID: 36798172
626. Scovell JM, Stovsky M, Partin A, **Lotan Y**, Baniel J, Dineen M, Hafron J, Manickam K, Pliskin M, Wagner M, Kestranek A, Klein. IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the IsoPSA Validation Study. *EA.Urology.* 2023 May;175:132-136. doi: 10.1016/j.urology.2023.01.037. Epub 2023 Feb 16. PMID: 36804443. **Free article.**
627. Kirk PS, **Lotan Y**, Zargar H, Fairey AS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobson NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Aning J, Shariat SF, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Grivas P, Garcia JA, Stephenson AJ, Shah JB, Daneshmand S, Spiess PE, van Rhijn BWG, Mertens L, Black P, Wright JL. Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort. *J Urol.* 2023 May; 209(5):882-889. doi: 10.1097/JU.0000000000003193. Epub 2023 Feb 16. PMID: 36795962.
628. Claps F, van de Kamp MW, Mayr R, Bostrom PJ, Shariat SF, Hippe K, Bertz S, Neuzillet Y, Sanders J, Otto W, van der Heijden MS, Jewett MAS, Stöhr R, Zlotta AR, Trombetta C, Eckstein M, Mertens LS, Burger M, Soorojebally Y, Wullich B, Bartoletti R, Radvanyi F, Pavan N, Sirab N, Mir MC, Pouessel D, van der Kwast TH, Hartmann A, **Lotan Y**, Bussani R, Allory Y, van Rhijn. Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy.
629. Taylor JI, Souter LH, Barocas DA, Boorjian SA, Raman JD, **Lotan Y**. Diagnostic Imaging in the Evaluation of Asymptomatic Microhematuria: Systematic Review and Meta-analysis. *J Urol.* 2023 Jun;209(6):1099-1106. doi: 10.1097/JU.0000000000003395. Epub 2023 Mar 8. PMID: 36883858. Review.
630. Vanarsa K, Castillo J, Wang L, Lee KH, Pedroza C, **Lotan Y**, Mohan C. Comprehensive proteomics and platform validation of urinary biomarkers for bladder cancer diagnosis and staging. *BMC Med.* 2023 Apr 5;21(1):133. doi: 10.1186/s12916-023-02813-x. PMID: 37016361. **Free PMC article.**
631. Rose KM, Murray KS, Labbate C, Woldu S, Linehan J, Jacob J, Kaimakliotis H, Dickstein R, Feldman A, Matin SF, **Lotan Y**, Humphreys MR, Sexton W. Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial Carcinoma in Patients with Imperative Indications and High-grade Disease. *J. Eur Urol Focus.* 2023 Sep;9(5):807-812. doi: 10.1016/j.euf.2023.03.016. Epub 2023 Apr 12. PMID: 37059620. Review.

632. Gold SA, Goueli R, Mostardeiro TR, Carpinito GP, El-Eishy A, Mauck R, Woldu SL, Strand DW, **Lotan Y**, Roehrborn CG, Costa DN, Gahan JC. Optimal Prostate Cancer Diagnostic Pathways for Men with Prostatomegaly in the MRI Era. *Urology*. 2023 Sep;179:95-100. doi: 10.1016/j.urology.2023.05.003. Epub 2023 May 13. PMID: 37182648.
633. von Deimling M, Mertens LS, van Rhijn BWG, **Lotan Y**, Spiess PE, Daneshmand S, Black PC, Pallauf M, D'Andrea D, Moschini M, Soria F, Del Giudice F, Afferi L, Laukhtina E, Yanagisawa T, Kawada T, Teoh JY, Abufaraj M, Ploussard G, Roumiguié M, Karakiewicz PI, Babjuk M, Gontero P, Xylinas E, Rink M, Shariat SF, Pradere B. Carbonoplatin Induction Chemotherapy in Clinically Lymph Node-positive Bladder Cancer. *Eur Urol Open Sci*. 2023 Mar 25;51:39-46. doi: 10.1016/j.euros.2023.02.014. eCollection 2023 May. PMID: 37187719 **Free PMC article**.
634. Kaimakliotis HZ, Tachibana I, Woldu S, Labbate C, Jacob J, Murray K, Rose K, Sexton W, Dickstein R, Linehan J, Nieder A, Bjurlin M, Humphreys M, Ghodoussipour S, Quek M, O'Donnell M, Eisner BH, Matin SF, **Lotan Y**, Feldman AS. The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma. *Urol Oncol*. 2023 Sep;41(9):387.e1-387.e7. doi: 10.1016/j.urolonc.2023.04.010. Epub 2023 May 26. PMID: 37246135.
635. Linehan J, Gottlieb J, Woldu SL, Labbate C, Rose K, Sexton W, Kaimakliotis H, Jacob J, Dickstein R, Nieder A, Bjurlin M, Humphreys M, Ghodoussipour S, Quek M, O'Donnell M, Eisner BH, Feldman AS, Matin SF, **Lotan Y**, Murray KS. Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes. *Eur Urol Focus*. 2023 Nov;9(6):1052-1058. doi: 10.1016/j.euf.2023.05.012. Epub 2023 May 30. PMID: 37263827.
636. von Deimling M, D'Andrea D, Pradere B, Laukhtina E, Yanagisawa T, Kawada T, Majdoub M, Rajwa P, Pallauf M, Singla N, Soria F, Margulis V, Chlosta P, Karakiewicz PI, Roupert M, Teoh JY, Fisch M, Rink M, Moschini M, **Lotan Y**, Shariat SF. Clinical value of cholinesterase in patients treated with radical nephroureterectomy for upper urinary tract carcinoma. *World J Urol*. 2023 Jul;41(7):1861-1868. doi: 10.1007/s00345-023-04449-1. Epub 2023 Jun 9. PMID: 37294372. **Free PMC article**.
637. Salari K, Sundi D, Lee JJ, Wu S, Wu CL, DiFiore G, Yan QR, Pienkny A, Lee CK, Oberlin D, Barne G, Piser J, Kahn R, Collins E, Phillips KG, Caruso VM, Goudarzi M, Garcia-Ransom M, Lentz PS, Evans-Holm ME, MacBride AR, Fischer DS, Haddadzadeh IJ, Mazzarella BC, Gray JW, Koppie TM, Biccoca VT, Levin TG, **Lotan Y**, Feldman AS. Development and Multicenter Case-Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction. *Clin Cancer Res*. 2023 Sep 15;29(18):3668-3680. doi: 10.1158/1078-0432.CCR-23-0570. PMID: 37439796. **Free PMC article**.
638. Jacob JM, Woldu SL, Linehan J, Labbate C, Rose KM, Sexton WJ, Tachibana I, Kaimakliotis H, Nieder A, Bjurlin MA, Humphreys M, Ghodoussipour SB, Quek ML, Johnson B, O'Donnell M, Eisner BH, Feldman AS, Murray KS, Matin SF, **Lotan Y**, Dickstein RJ. First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors. *Urol Oncol* 2024 Jan;42(1):20.e17-20.e23. doi: 10.1016/j.urolonc.2023.07.004. Epub 2023 Jul 28. PMID: 37517898.
639. Johnson BA, Raman JD, Best SL, **Lotan Y**. Prospective Randomized Trial of Single-Use vs Reusable Cystoscope for Ureteral Stent Removal. *J Endourol*. 2023 Oct;37(10):1139-1144. doi: 10.1089/end.2023.0134. PMID: 37565290.
640. Linehan J, Gottlieb J, Woldu SL, Labbate C, Rose K, Sexton W, Kaimakliotis H, Jacob J, Dickstein R, Nieder A, Bjurlin M, Humphreys M, Ghodoussipour S, Quek M, O'Donnell M, Eisner BH, Feldman AS, Matin SF, **Lotan Y**, Murray KS. Corrigendum to "Route of Administration for UGN-101 and Impact on Oncological and Safety

- Outcomes" [Eur. Urol. Focus (2023)]. Eur Urol Focus. 2023 Aug 26:S2405-4569(23)00190-6. doi: 10.1016/j.euf.2023.08.006. Online ahead of print.PMID: 37640582 No abstract available.
641. Ho MD, Black AJ, Zargar H, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Montgomery JS, Yu EY, Xylinas E, Kassouf W, Dall'Era MA, Vasdev N, Sridhar SS, McGrath JS, Aning J, Holzbeierlein JM, Thorpe AC, Shariat SF, Wright JL, Morgan TM, Bivalacqua TJ, North S, Barocas DA, **Lotan Y**, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black PC. The effect of cisplatin-based neoadjuvant chemotherapy on the renal function of patients undergoing radical cystectomy. *Can Urol Assoc J* 2023 Oct;17(10):301-309.doi:10.5489/cuaj.8570.PMIS:37851909. **Free PMC article.**
642. von Deimling M, Furrer M, Mertens LS, Mari A, van Ginkel N, Bacchiani M, Maas M, Pichler R, Li R, Moschini M, Bianchi A, Vetterlein MW, Lonati C, Crocetto F, Taylor J, Tully KH, Afferi L, Soria F, Del Giudice F, Longoni M, Laukhtina E, Antonelli A, Rink M, Fisch M, **Lotan Y**, Spiess PE, Black PC, Kiss B, Pradere B, Shariat SF. Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node-positive bladder cancer. *BJUInt.*2023 Oct.doi:10-1111/bju.16210. Online ahead of print PMID: 37904652.
643. Zemdegs J, Iroz A, Vecchio M, Roze S, **Lotan Y**. Water intake and recurrent urinary tract infections prevention: economic impact analysis in seven countries. *BMC Health Serv Res.* 2023 Nov 3;23(1):1197.doi:10-1186/s12913-023-10234-y. PMID: 37924070. **Free PMC article.**
644. Khene ZE, Kammerer-Jacquet SF, Bigot P, Rabilloud N, Albiges L, Margulis V, De Crevoisier R, Acosta O, Rioux-Leclercq N, **Lotan Y**, Rouprêt M, Bensalah K. Clinical Application of Digital and Computational Pathology in Renal Cell Carcinoma: A Systematic Review. *Eur Urol Oncol.* 2023 Nov 2:S2588-9311(23)00234-1. doi: 10.1016/j.euo.2023.10.018. Online ahead of print.PMID: 37925349 Review.
645. Gore JL, Wolff EM, Comstock BA, Follmer KM, Nash MG, Basu A, Chisolm S, MacLean DB, Lee JR, **Lotan Y**, Porten SP, Steinberg GD, Chang SS, Gilbert SM, Kessler LG, Smith AB. Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer. CISTO Collaborative.*BMC Cancer.* 2023 Nov 18;23(1):1127. doi: 10.1186/s12885-023-11605-8.PMID: 37980511. **Free PMC article.**
646. Gore JL, Follmer K, Reynolds J, Nash M, Anderson CB, Catto JWF, Chamie K, Daneshmand S, Dickstein R, Garg T, Gilbert SM, Guzzo TJ, Kamat AM, Kates MR, Lane BR, **Lotan Y**, Mansour AM, Master VA, Montgomery JS, Morris DS, Nepple KG, O'Neil BB, Patel S, Pohar K, Porten SP, Riggs SB, Sankin A, Scarpato KR, Shore ND, Steinberg GD, Strobe SA, Taylor JM, Comstock BA, Kessler LG, Wolff EM, Smith AB. Interruptions in bladder cancer care during the COVID-19 public health emergency. *Urol Oncol.* 2023 Dec 11:S1078-1439(23)00362-9. doi: 10.1016/j.urolonc.2023.11.010. Online ahead of print.PMID: 38087711.
647. Khene Z, Lotan Y. An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer. *Expert Opinion on Biological Therapy.*doi.org/10.1080/14712598.2024.236802, June 2024.
648. **Lotan Y**, Agarwal P, Black P, Dickstein R, Kamat AM, Lee B, Narayan VM, Porten S, Psutka SP, Smith AK, Svatek RS, Williams SB, Woldu S. Standardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle

invasive bladder cancer clinical trials. *Urol Oncol*. 2024 Aug;42(8):223-228. doi: 10.1016/j.urolonc.2024.01.019. Epub 2024 Feb 1. PMID: 38307803 .

649. Amara CS, Kami Reddy KR, Yuntao Y, Chan YS, Piyarathna DWB, Dobrolecki LE, Shih DJH, Shi Z, Xu J, Huang S, Ellis MJ, Apolo AB, Ballester LY, Gao J, Hansel DE, **Lotan Y**, Hodges HC, Lerner SP, Creighton CJ, Sreekumar A, Zheng WJ, Msaouel P, Kavuri SM, Putluri N. The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer. *Nat Commun*. 2024 Feb 14;15(1):1373. doi: 10.1038/s41467-024-45132-2. PMID: 38355560.
650. **Lotan Y**, Daneshmand S, Shore N, Black P, Scarpato KR, Patel A, Lough T, Shoskes DA, Raman JD. A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria: The Safe Testing of Risk for Asymptomatic Microhematuria Trial. *J Urol*. 2024 Jul;212(1):41-51. doi: 10.1097/JU.0000000000003991. Epub 2024 May 3. PMID: 38700731 Clinical Trial.
651. Tosoian JJ, Zhang Y, Xiao L, Xie C, Samora NL, Niknafs YS, Chopra Z, Siddiqui J, Zheng H, Herron G, Vaishampayan N, Robinson HS, Arivoli K, Trock BJ, Ross AE, Morgan TM, Palapattu GS, Salami SS, Kunju LP, Tomlins SA, Sokoll LJ, Chan DW, Srivastava S, Feng Z, Sanda MG, Zheng Y, Wei JT, Chinnaiyan AM; EDRN-PCA3 Study Group. Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer. *JAMA Oncol*. 2024 Apr 18. doi: 10.1001/jamaoncol.2024.0455. Online ahead of print. PMID: 38635241.
652. Schroeck FR, Grubb R, MacKenzie TA, Ould Ismail AA, Jensen L, Tsongalis GJ, **Lotan Y**, Ladi-Seyedian SS, Ghoreifi A, Konety B, Pohar K, Holzbeierlein JM, Taylor J, Kates M, Willard B, Taylor JM, Liao JC, Kaimakliotis HZ, Porten SP, Steinberg GD, Tyson MD, **Lotan Y**, Daneshmand S, Blue Light Cystoscopy With Cysview Registry Group. Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry. *Cancers (Basel)*. 2024 Mar 24;16(7):1268. doi: 10.3390/cancers16071268. PMID: 38610946 **Free PMC article**.
653. Schroeck FR, Grubb R, MacKenzie TA, Ould Ismail AA, Jensen L, Tsongalis GJ, **Lotan Y**. Clinical Trial Protocol for "Replace Cysto": Replacing Invasive Cystoscopy with Urine Testing for Non-muscle-invasive Bladder Cancer Surveillance-A Multicenter, Randomized, Phase 2 Healthcare Delivery Trial Comparing Quality of Life During Cancer Surveillance with Xpert Bladder Cancer Monitor or Bladder EpiCheck Urine Testing Versus Frequent Cystoscopy. *Eur Urol Open Sci*. 2024 Mar 21;63:19-30. doi: 10.1016/j.euros.2024.02.018. eCollection 2024 May. PMID: 38558761 **Free PMC article**.
654. Reike MJ, de Jong JJ, Bismar TA, Boorjian SA, Mian OY, Wright JL, Dall'Era MA, Kaimakliotis HZ, **Lotan Y**, Boormans JL, Black PC, Gibb EA. Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers. *Urol Oncol*. 2024 Jun;42(6):177.e5-177.e14. doi: 10.1016/j.urolonc.2024.01.027. Epub 2024 Mar 12. PMID: 38480079.
655. von Deimling M, Mertens LS, Furrer M, Li R, Tendijck GAH, Taylor J, Crocetto F, Maas M, Mari A, Pichler R, Moschini M, Tully KH, D'Andrea D, Laukhtina E, Del Giudice F, Marcq G, Velev M, Gallioli A, Albisinni S, Mori K, Khanna A, Rink M, Fisch M, Minervini A, Black PC, **Lotan Y**, Spiess PE, Kiss B, Shariat SF, Pradere B; CLIPOLY Study Group Collaborators. The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer. *BJU Int*. 2024 Mar 12. doi: 10.1111/bju.16319. Online ahead of print. PMID: 38470089.
656. Narayan VM, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Mashni J Jr, Lane BR, Guzzo TJ,

- Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, **Lotan Y**, Inman BA, Williams MB, Cookson MS, Chang SS, Sankin AI, O'Donnell MA, Sawutz D, Philipson R, Parker NR, Yla-Herttuala S, Rehm D, Jakobsen JS, Juul K, Dinney CPN. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. *Urol.* 2024 Jul;212(1):74-86. doi: 10.1097/JU.0000000000004020. Epub 2024 May 5. PMID: 38704840.
657. Ladner T, Black AJ, Zargar H, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Cookson MS, Jacobsen N, Fairey AS, Dinney C, Mir M, Krabbe LM, Montgomery JS, Vasdev N, Yu E, Xylinas E, Stephenson AJ, Shah JB, Daneshmand S, Shoshtari K, Spiess P, Mertens L, Rhijn B, Grivas P, Kassouf W, Dall'Era M, Sridhar S, McGrath J, Aning J, Shariat S, Bivalacqua T, North S, Barocas D, Lotan Y, Black P. Perioperative blood transfusion is associated with worse survival in patients undergoing radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer. *Soc. Int. Urol. J.* **2024**, 5, 202–213. <https://doi.org/10.3390/siuj5030031>.
658. Howard JM, Cook GS, Tverye A, Nandy K, Margulis V, Woldu SL, **Lotan Y**. Outcomes of patients with Bacillus Calmette-Guerin (BCG)-Unresponsive non-muscle invasive bladder cancer as defined by the U.S. Food and Drug Administration. *Bladder Cancer.* 2022 Sep 15;8(3):303-314. doi: 10.3233/BLC-211657. eCollection 2022. PMID: 38993682.
659. Reyes RM, Rios E, Barney S, Huguenin CM, Michalek JE, **Lotan Y**, Messing EM, Svatek RS. A randomized feasibility trial comparing surveillance regimens for patients with low and low-intermediate risk non-muscle invasive bladder cancer. *Bladder Cancer.* 2021;7(3):285-295. doi: 10.3233/blc-201535. PMID: 34621937.
660. **Lotan Y**, Gakis G, Manfredi M, Morote J, Mostafid H, Porpiglia F, Poyet C, Roupret M, Schulman C, Shariat SF, Witjes JA. Alternating cystoscopy with bladder EpiCheck in the surveillance of low-grade intermediate-risk NMIBC: A cost comparison model. *Bladder Cancer.* 2021 Aug 31;7(3):307-315. doi: 10.3233/BLC-211528. eCollection 2021. PMID: 38993615.
661. Folgosa Cooley L, Weiner AB, Meng X, Woldu SL, Meeks JJ, **Lotan Y**. Survival by T stage for patients with localized bladder cancer: Implications for future screening trials. *Bladder Cancer.* 2021 Mar 19;7(1):23-31. doi: 10.3233/BLC-200381. eCollection 2021. PMID: 38993212.

Invited Papers/Reviews

1. **Lotan Y**. Novel Mitomycin-Based therapy shows promise as “Game-Changing” option for UTUC. *GUOncology Now*, February 2023.

2. **Lotan Y**, Peer review of MS# ONC22-2524, Uptake of maintenance immunotherapy and changes in upstream treatment selection among patients with urothelial cancer, reviewed November 1, 2022. JAMA Oncology Review.
3. **Lotan Y**, Photodynamic diagnosis-Guided laser destruction of bladder tumors vs Transurethral tumor resection in patients with recurrent intermediate-Risk low-Grade bladder tumors. Practice Update. Published in Urology, September 22, 2022.
4. **Lotan Y**, Barocas DA, Boorjian SA, Souter LH, Raman JD. Strategies to mitigate impact of intravenous ICM shortage. Urology Times, June 24, 2022.
5. Woldu SL, **Lotan Y**. Re: ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Eur Urol. 2021 Oct;80(4):517-518. doi: 10.1016/j.eururo.2021.07.018. Epub 2021 Aug 6. PMID: 34366211 No abstract available.
6. **Lotan Y**. New American Urological Association Guideline for Risk Classification of Hematuria. Journal of Urology. Practice Update. May 2021.
7. **Lotan Y**. Metabolic syndrome and bladder cancer. BJU Int. 2021 Jul;128(1):1-2. doi: 10.1111/bju.15322. PMID: 34160131 No abstract available.
8. **Lotan Y**. Novel technologies that change the diagnostic and treatment paradigm in urology: standard turbt remains the standard. Curr Opin Urol. 2020 Mar 9. doi: 10.1097/MOU.0000000000000746. Epub ahead of print. PMID: 32168193.
9. **Lotan Y**, Meng X. Critical treatment choices for patients with platinum-refractory urothelial carcinoma. Lancet Oncol. 2020 Jan;21(1):11-13. doi: 10.1016/S1470-2045(19)30661-8. Epub 2019 Nov 18. PMID: 31753728.
10. **Lotan Y**, Kenigsberg AP. How Do I Do Office Cystoscopic Fulguration? AUANews article <https://epub.auanet.org/publication/?m=52864&i=672572&p=24> . 2020 September, vol. 25 issue 9.
11. **Lotan Y**. Effectiveness of Intravesical Doxorubicin Immediately Following Resection of Primary Non–Muscle-Invasive Bladder Cancer: A Propensity Score-Matched Analysis. PracticeUpdate website. Available at: <https://www.practiceupdate.com/content/effectiveness-of-intravesical-doxorubicin-immediately-following-resection-of-primary-non-muscle-invasive-bladder-cancer/100164/65/3/1> .
12. **Lotan Y**. Comprehensive Assessment of Immuno-Oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-Cell Carcinoma of the Bladder. PracticeUpdate website. Available at: <https://www.practiceupdate.com/content/immuno-oncology-biomarkers-in-adenocarcinoma-urothelial-carcinoma-and-squamous-cell-carcinoma-of-the-bladder/96036/65/3/1> .
13. **Lotan Y**. An Evaluation of Monthly Maintenance Therapy Among Patients Receiving Intravesical Combination Gemcitabine/Docetaxel for Nonmuscle-Invasive Bladder Cancer. PracticeUpdate website. Available at: <https://www.practiceupdate.com/content/intravesical-combination-gemcitabinedocetaxel-for-non-muscle-invasive-bladder-cancer/89206/65/3/1> .
14. **Lotan Y**. Bladder Mapping of Tumour Recurrence After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma and Its Influence on Oncological Outcomes. PracticeUpdate website. Available at: <https://www.practiceupdate.com/content/bladder-mapping-of-tumor-recurrence-after-radical-nephroureterectomy-for-upper-tract-urothelial-carcinoma/81476/65/3/1> .
15. Amara CS, Vantaku V, **Lotan Y**, Putluri N. Recent advances in the metabolomic study of bladder cancer. PMID: 30773067.
16. Joseph JV, Brasacchio R, Fung C, Reeder J, Bylund K, Sahasrabudhe D, Yeh SY, Ghazi A, Fultz P, Rubens D, Wu G, Singer E, Schwarz E, Mohile S, Mohler J, Theodorescu D, Lee YF, Okunieff P, McConkey D, Rashid H, Chang C, Fradet Y, Guru

- K, Kukreja J, Sufrin G, **Lotan Y**, Bailey H, Noyes K, Schwartz S, Rideout K, Bratslavsky G, Campbell SC, Derweesh I, Abrahamsson PA, Soloway M, Gomella L, Golijanin D, Svatek R, Frye T, Lerner S, Palapattu G, Wilding G, Droller M, Trump D. A Festschrift in Honor of Edward M. Messing, MD, FACS. *Bladder Cancer*. 2018 Oct 3;4(Suppl 1):S1-S43. doi: 10.3233/BLC-189037. No abstract available. PMID: 30443561
17. Soria F, Krabbe LM, Todenhöfer T, Dobruch J, Mitra AP, Inman BA, Gust KM, **Lotan Y**, Shariat SF. Molecular markers in bladder cancer. *World J Urol*. 2019 Jan;37(1):31-40. doi: 10.1007/s00345-018-2503-4. Epub 2018 Sep 26. PMID: 30259123
 18. Soria F, D'Andrea D, Pohar K, Shariat SF, **Lotan Y**. Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer: any role in clinical practice? *Curr Opin Urol*. 2018 Nov;28(6):577-583. doi: 10.1097/MOU.0000000000000545. PMID: 30217763.
 19. Soria F, Droller MJ, **Lotan Y**, Gontero P, D'Andrea D, Gust KM, Rouprêt M, Babjuk M, Palou J, Shariat SF. An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. *World J Urol*. 2018 Jun 21. doi: 10.1007/s00345-018-2380-x. [Epub ahead of print] Review. PMID: 29931526
 20. Clinton TN, **Lotan Y**. The use of blue light flexible cystoscopy with hexaminolevulinate & the diagnosis of bladder cancer. *Future Oncol*. 2018 Jun 21. doi: 10.2217/fon-2018-0328. [Epub ahead of print] PMID: 29925279
 21. Rose TL, **Lotan Y**. Advancements in optical techniques and imaging in the diagnosis and management of bladder cancer. *Urol Oncol*. 2-18 Mar;36(3):97-102. doi: 10.1016/j.urol onc.2017.11.014. Epub 2017 Dec 26. Review. PMID: 29288006.
 22. Şanlı Ö, **Lotan Y**. Alternative therapies in patients with non-muscle invasive bladder cancer. *Turk J Urol*. 2017 Dec;43(4):414-424. doi: 10.5152/tud.2017.64624. Epub 2017 Dec 1. Review. PMID: 29201501.
 23. Şanlı Ö, **Lotan Y**. Current approaches for identifying high-risk non-muscle invasive bladder cancer. *Expert Rev Anticancer Ther*. 2018 Mar;18(3):223-235. doi: 10.1080/14737140.2018.1432358. Epub 2018 Jan 31:1-13. PMID: 29359984
 24. Clinton TN, Bagrodia A, **Lotan Y**, Margulis V, Raj GV, Woldu SL. Tissue-based biomarkers in prostate cancer. *Expert Rev Precis Med Drug Dev*. 2017;2(5):249-260. doi: 10.1080/23808993.2017.1372687. Epub 2017 Sep 5. PMID: 29226251.
 25. Clinton T, **Lotan Y**. Review of the Clinical Approaches to the Use of Urine-based Tumor Markers in Bladder Cancer. *Rambam Maimonides Med J*. 2017 Aug 22. doi: 10.5041/RMMJ.10314. [Epub ahead of print]. Review. PMID: 28872454.
 26. Hutchinson R, **Lotan Y**. Cost consideration in utilization of multiparametric magnetic resonance imaging in prostate cancer. *Transl Androl Urol*. 2017 Jun;6(3):345-354. doi: 10.21037/tau.2017.01.13. Review. PMID: 28725576.
 27. Şanlı Ö, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, **Lotan Y**. Bladder cancer. *Nat Rev Dis Primers*. 2017 Apr 13;3:17022. doi: 10.1038/nrdp.2017.22. Review. PMID: 28406148.
 28. Woldu SL, Şanlı Ö, **Lotan Y**. Tackling non-muscle invasive bladder cancer in the clinic. *Expert Rev Anticancer Ther*. 2017 May;17(5):467-480. doi:10.1080/14737140.2017.1313119. Epub 2017 Apr 11. PMID: 28359179
 29. Aydin AM, Woldu SL, Hutchinson RC, Boegemann M, Bagrodia A, **Lotan Y**, Margulis V, Krabbe LM. Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. *Onco Targets Ther*. 2017 Mar 9;10:1487-1502. doi: 10.2147/OTT.S109453. eCollection 2017 Mar 9. Review. PMID: 28331342. PMCID: PMC5352238.
 30. Woldu SL, Bagrodia A, **Lotan Y**. Guideline of Guidelines - Non-Muscle Invasive Bladder Cancer. *BJU Int*. 2017 Mar;119(3):371-380. doi: 10.1111/bju.13760. Epub 2017 Jan 24. PMID: 28058776. PMCID: PMC5315602.

31. Krabbe LM, Woldu SL, Shariat SF, **Lotan Y**. Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence. *Expert Rev Mol Diagn*. 2016 Nov;16(11):1189-1199. Epub 2016 Oct. 4. PMID: 27696932.
32. Soria F, Shariat SF, Lerner SP, Fritsche HM, Rink M, Kassouf W, Spiess PE, **Lotan Y**, Ye D, Fernández MI, Kikuchi E, Chade DC, Babjuk M, Grollman AP, Thalmann GN. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). *World J Urol*. 2017 Mar;35(3):379-387. doi: 10.1007/s00345-016-1928-x. Epub 2016 Sep 7. Review. PMID: 27604375.
33. **Lotan Y**, Urothelial Cancer – Epidemiology, Pathogenesis, and Diagnosis (TID 11099). *Scientific American Urology*. Decker Intellectual Properties. Hamilton, ON. Review. *In press*.
34. Pradere B, **Lotan Y**, Roupret M. Lynch syndrome in upper tract urothelial carcinoma: significance, screening, and surveillance. *Curr Opin Urol*. 2017 Jan;27(1):48-55. Epub 2016 Aug 16. PMID: 27533503.
35. **Lotan Y**, O'Sullivan P, Darling D, Pownall B, Luxmanan C, Suttie J. A Novel High Sensitivity Test for the Detection of Recurrent Urothelial Carcinoma. *AUA News*. 2016 June; 21(6): 5.
36. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, Guo CC, **Lotan Y**, Kassouf W. Bladder cancer. *Lancet*. 2016 Dec 3;388(10061):2796-2810. doi: 10.1016/S0140-6736(16)30512-8 Epub 2016 Jun 23. Review. PubMed PMID: 27345655.
37. **Lotan Y**, Hutchinson R, Folkert M. Placement of a Hydrogel Rectal Spacer Before RT for Prostate Ca. *Urology Times*. 2016 April;(44)4:13-15. Invited Paper.
38. Mbeutcha A, Lucca I, Mathieu R, **Lotan Y**, Shariat SF. Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer. *Urol Clin North Am*. 2016 Feb;43(1):47-62. Review. PMID: 26614028.
39. Hutchinson RC, Costa DN, **Lotan Y**. The economic effect of using magnetic resonance imaging and magnetic resonance ultrasound fusion biopsy for prostate cancer diagnosis. *Urol Oncol*. 2015 Dec 22. pii: S1078-1439(15)00525-6. [Epub ahead of print] Review. PMID: 26725249.
40. Krabbe LM, Margulis V, **Lotan Y**. Prognostic Role of Cell Cycle and Proliferative Markers in Clear Cell Renal Cell Carcinoma. *Urol Clin North Am*. 2016 Feb;43(1):105-115. Epub 2015 Oct 31. Review. PMID: 26614033.
41. Mbeutcha A, Lucca I, Mathieu R, **Lotan Y**, Shariat SF. Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer. *Urol Clin North Am*. 2016 Feb;43(1):47-62. Review. PMID: 26614028.
42. Mbeutcha A, Lucca I, De Martino M, Mathieu R, Rieken M, Xylinas E, Kluth L, Crivelli J, **Lotan Y**, Shariat S, Klatte T, Karakiewicz P. Le rapport neutrophiles/lymphocytes est un facteur prédictif indépendant de récurrence et de progression dans les tumeurs de vessie non infiltrantes. *Prog Urol*. 2015 Nov;25(13):759-60. French. PMID: 26544285.
43. Dobruch J, Daneshmand S, Fisch M, **Lotan Y**, Noon AP, Resnick MJ, Shariat SF, Zlotta AR, Boorjian SA. Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology and Outcomes. *Eur Urol*. 2016 Feb;69(2):300-10. Epub 2015 Sep 4. Review. PMID: 26346676.
44. **Lotan Y**. Capsule Commentary on Bassett et al., Gender, Race, and Variations in the Evaluation of Microscopic Hematuria among Medicare Beneficiaries. *J Gen Intern Med*. 2015 Apr; 30(4): 491. Epub 2014 Dec 23. PMID: 25533390.
45. Neuzillet Y, Mertens L, Shariat S, Bostrom P, Mirtti T, Sagalowsky A, Ashfaq R, Broeks A, Van der Heijden M, Peters D, Curial C, De Jong J, Horenblas S, Hurst C, Tomlinson D, Knowles M, Bapat B, Jewett M, Zlotta A, Sanders J, **Lotan Y**, Van der Kwast T, Van Rhijn B. Le Fibroblast Growth Factor Receptor 3 (FGFR3), cible thérapeutique pour le

- traitement personnalisé du cancer de la vessie : validation anatomo-pathologique du concept. *Prog Urol*. 2014 Nov;24(13):806-7. Epub 2014 Oct 30. French. PMID: 26461579.
47. Apolo AB, Hoffman V, Kaag MG, Latini DM, Lee CT, Rosenberg JE, Knowles M, Theodorescu D, Czerniak BA, Efstathiou JA, Albert ML, Sridhar SS, Margulis V, Matin SF, Galsky MD, Hansel D, Kamat AM, Flaig TW, Smith AB, Messing E, Zipursky Quale D, **Lotan Y**. Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. *Urol Oncol*. Feb; 33(2):53-64. Epub 2014 Jul 25. Review. PMID: 25065704.
 48. Haddad A, **Lotan Y**. Bladder cancer in 2013: From genomics to imaging-advances along the care continuum. *Nat Rev Urol*. 2014 Feb; 11(2): 71-3. Epub 2013 Dec 10. PMID: 24323128.
 49. **Lotan Y**. Molecular Markers for the Predication of Recurrence and Cancer Specific Survival after Radical Cystectomy. *AUA News*. 2013 November;18 (11):1, 7-8. Invited Paper.
 50. **Lotan Y**. Pathogenesis and Cost-Effectiveness of Preventing Kidney Stones. *Nutr Today*. 2013;48(4S):S22-S24. Invited Paper.
 51. **Lotan Y**, Daudon M, Bruyère F, Talaska G, Strippoli G, Johnson RJ, Tack I. Impact of fluid intake in the prevention of urinary system diseases: a brief review. *Curr Opin Nephrol Hypertens*. 2013 May;22 Suppl 1:S1-10. PMID: 23673384.
 52. Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, Shariat SF, Xylinas E, Schmitz-Dräger BJ, **Lotan Y**, Jenkins LC, Droller M, van Rhijn BW, Karakiewicz PI; International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. *Eur Urol*. 2013 Jan;63(1):4-15. Epub 2012 Oct 4. Review. PMID: 23083902.
 53. Cadeddu J, Herman M, Lapor H, **Lotan Y**, Mottrie A, Patel V, Pruthi R, Rane A, Smith JA Jr. Robotically speaking: Experts consider the current and future state of robotic surgery. Interview by Kevin D. Blanchet. *BJU Int* 2011 Sep; 108(6):ii-vii. PMID: 21884351.
 54. **Lotan Y**. Is robotic surgery cost-effective: no. *Curr Opin Urol* 2012 Jan; 22(1): 66-9. PMID: 22080872.
 55. **Lotan Y**. Cost-effectiveness of fluorescent cystoscopy for noninvasive papillary tumors: con. *J Urol*. 2012 May; 187(5): 1538-9. PMID: 22606696.
 56. **Lotan Y**, Amiel G, Boorjian SA, Clark PE, Droller M, Gingrich JR, Guzzo TJ, Inman BA, Kamat AM, Karsh L, Nielsen ME, Smith ND, Shariat SF, Svatek RS, Taylor JM; on Behalf of the Bladder Cancer Think Tank, and Bladder Cancer Advocacy Network. Comprehensive handbook for developing a bladder cancer cystectomy database. *Urol Oncol*. 2013 Aug; 31(6): 812-26. Epub 2011 Nov 6. Review. PMID: 22056403.
 57. Youssef RF, **Lotan Y**. Predictors of outcome of non-muscle-invasive and muscle-invasive bladder cancer. *ScientificWorldJournal*. 2011 Feb 14;11:369-81. Review. PMID: 21336453.
 58. Sleeper J, **Lotan Y**. Cost-effectiveness of robotic-assisted laparoscopic procedures in urologic surgery in the USA. *Expert Rev Med Devices*. 2011 Jan;8(1):97-103. Review. PMID: 21158544.
 59. Barbieri CE, **Lotan Y**, Lee RK, Sonpavde G, Karakiewicz PI, Robinson B, Scherr DS, Shariat SF. Tissue-based molecular markers for bladder cancer. *Minerva Urol Nefrol*. 2010 Sep;62(3):241-58. Review. PMID: 20940694.
 60. Shariat SF, **Lotan Y**, Vickers A, Karakiewicz PI, Schmitz-Dräger BJ, Goebell PJ, Malats N. Statistical consideration for clinical biomarker research in bladder cancer. *Urol Oncol*. 2010 Jul-Aug;28(4):389-400. Review. PMID: 20610277.
 - 61.

62. Bolenz C, **Lotan Y**. Translational research in bladder cancer: From molecular pathogenesis to useful tissue biomarkers. *Cancer Biol Ther*. 2010 Sep;10(5):407-15. Epub 2010 Sep 14. PMID: 20686360.
63. **Lotan Y**. Role of biomarkers to predict outcomes and response to therapy. *Urol Oncol* 2010 Jan-Feb; 28(1): 97-101. PMID: 20123357.
64. Kamat AM, **Lotan Y**. Perioperative Intravesical Therapy After Transurethral Resection for Bladder Cancer. *J Urol*. 2010 Jan;183(1):19-20. Epub 2009 Nov 12. Oposing View. PMID: 19913827.
65. **Lotan Y**. Economics of robotics in urology. *Curr Opin Urol* 2010 Jan; 20(1): 92-7. Review. PMID: 19875963.
66. **Lotan Y**, Pearle MS. QoL in Patients with Stones. *Renal & Urology News*. 2009 Apr; 8(4):1, 17. 29.
67. **Lotan Y**, Schoenberg M, Kamat, AM, Porter, MP, Robinson, VL, Shore, N, Schelhammer, PF, deVere White, RW, Loughlin, KR, Steinberg, GD, Jewett, MAS, Lerner, SP, Au, JLS, Quale, DZ, Lee, CT. Key Concerns about the Current State of Bladder Cancer. *AUA News*. 2009 Apr; 14(4):1, 3-4, 6.
68. **Lotan Y**. Economics and cost of care of stone disease. *Adv Chronic Kidney Dis*. 2009 Jan;16(1):5-10. Review. PMID: 19095200.
69. Bolenz C, **Lotan Y**. Molecular biomarkers for urothelial carcinoma of the bladder: challenges in clinical use. *Nat Clin Pract Urol*. 2008 Dec; 5(12): 676-85. Review. PMID: 19050710.
70. Svatek RS, **Lotan Y**, Karakiewicz PI, Shariat SF. Screening for bladder cancer using urine-based tumor markers. *Minerva Urol Nefrol*. 2008 Dec;60(4):247-53. Review. PMID: 18923361.
71. Herman MP, Svatek RS, **Lotan Y**, Karakiewicz PI, Shariat SF. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer. *Minerva Urol Nefrol*. 2008 Dec;60(4):217-35. Review. PMID: 18923359.
72. Konety B, **Lotan Y**. Urothelial bladder cancer. Biomarkers for detection and screening. *BJU Int* 2008 Nov; 102(9 Pt B): 1234-41. PMID: 19035887.
73. Shariat SF, Karam JA, **Lotan Y**, Karakiewicz PI. Critical evaluation of Urinary Markers for Bladder Cancer Detection and Monitoring. *Reviews in Urology*. Spring 2008;10(2):120-135. PMID: 18660854.
74. Svatek RS, **Lotan Y**. Is there a rationale for bladder cancer screening? *Curr Urol Rep*. 2008 Sep;9(5):339-41. Review. PMID: 18702915.
75. **Lotan Y**, Svatek RS, Malats N. Screening for bladder cancer: a perspective. *World J Urol* 2008 Feb; 26(1): 13-8. Epub 2007 Nov 21. PMID: 18030473.
76. **Lotan Y** and Pearle MS. Economics of Stone Management. *Urol Clin North Am*. 2007 Aug;34(3):443-53. PMID: 17678993.
77. **Lotan Y** and Svatek RS. Cost-effectiveness of Bladder Cancer Screening. *Expert Review of Pharmacoeconomics and Outcomes Research*. 2007 Dec; 7(6): 627-32. PMID: 20528324.
78. Shariat SF, Margulis V, **Lotan Y**, Montorsi F, Karakiewicz PI. Nomograms for Bladder Cancer. *Eur Urol*. 2008 Jul;54(1):41-53. Epub 2008 Jan 15. Review. PMID: 18207314.
79. Bensalah K, **Lotan Y**, Karam JA, Shariat SF. New circulating biomarkers for prostate cancer. *Prostate Cancer Prostatic Dis*. 2008;11(2):112-20. Epub 2007 Nov 13. Review.
80. **Lotan Y**. Bladder Cancer Screening. *International Hospital Equipment and Solutions*. 2007 Sept.
81. Svatek RS and **Lotan Y**. Use of Urine-Based Tumor Markers for Bladder Cancer Screening. *Contemporary Urology*. 2007 Oct 19;10: 12-19.

82. Roehrborn CG, **Lotan Y**, Tubaro A, de Nunzio C. Open to debate. The motion: prevention of prostate cancer with a 5alpha-reductase inhibitor is feasible. *Eur Urol* 2006 Feb; 49(2): 396-400. PMID: 16455190.
83. Stern J and **Lotan Y**. Imaging for Hematuria: Which Test is Best? *Contemporary Urology* July 2006; 10-22.
84. Walsh L and **Lotan Y**. Clinically Significant Molecular Markers for Urologic Disease: Focus on Bladder, Kidney and Prostate Cancer. *LabMedicine* July 2006; 37 (7): 2-8.
85. **Lotan Y** and Pearle MS. Economics of Stone Management. *EAU Update Series Volume 3, Issue 1, March 2005*, 51-60.
86. **Lotan Y**, Johnson, MJ. Fluorescent urine cytology for screening and surveillance of bladder cancer. *BJU International. Practice Update* 2021.
87. **Lotan Y**, Effect of perioperative continuation of anticoagulants on the intraoperative blood loss and blood transfusion rates in patients undergoing radical cystectomy. *BJU International, Practice Update* 2022.
88. **Lotan Y**, Natural History of multiple recurrences in intermediate-risk non-muscle invasive bladder cancer: lessons from a prospective cohort. *PraticeUpdate* 2023

Editorials & Replies

1. Zine-Eddine K, Tachibana I, Bhanvadia R, **Lotan Y**, Margulis V. Reconsidering nephron-sparing strategies for the management of small renal tumors: a call for the inclusion of level 1 evidence in the debate. *TAU Vol 13, No 6 (June 2024): Translation Andrology and Urology*. Jun 11, 2024: DOI:10.21037/tau-23-661.
2. Ecke TH, **Lotan Y**, Massfelder T. Identifying novel biomarkers in bladder cancer. *Frontiers in Oncology*. 2023 July 4. Doi: 10.3389/fonc.2023.1191736. eCollection 2023. PMID: 37469396. **Free PMC article**. No abstract available.
3. **Lotan Y**, Margulis V. Predicting recurrence in patients with localised renal cell carcinoma after nephrectomy. *Lancet Oncol*. 2019 Mar 14. pii: S1470-2045(19)30024-5. doi: 10.1016/S1470-2045(19)30024-5. [Epub ahead of print] No abstract available. PMID: 30880069.
4. Hooton TM, Vecchio M, **Lotan Y**. Delivery of Bottled Water to Women With Recurrent Urinary Tract Infections: Why in Bulgaria?-Reply. *JAMA Intern Med*. 2019 Mar 1;179(3):449. doi: 10.1001/jamainternmed.2018.7977. No abstract available. PMID: 30830193.
5. **Lotan Y**. Re: Who Should be Investigated for Hematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients. *Eur Urol*. 2018 Jul;74(1):15-16. doi: 10.1016/j.eururo.2018.03.019. Epub 2018 Apr 4. No abstract available. PMID: 29625759
6. Freifeld Y, **Lotan Y**. Value of nutrition supplementation prior to cystectomy. *Can J Urol*. 2017 Aug;24(4):8902. PMID: 28832308.
7. Bagrodia A, **Lotan Y**. Words of Wisdom - Re: Multi-institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy. *Eur Urol*. 2017 Jun 24. pii: S0302-2838(17)30512-2. doi: 10.1016/j.eururo.2017.06.017. [Epub ahead of print]. PMID: 28655542.
8. **Lotan Y**, Merseburger AS. Editorial comment. *Curr Opin Urol*. 2017 Jan;27(1):34. PubMed PMID: 27902674.
9. Woldu SL, **Lotan Y**. Re: Efficacy of High-intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis from the National Cancer Data Base. *Eur Urol*. 2016 Nov;70(5):893. Epub 2016 Aug 4. PMID: 27498598.
10. **Lotan Y**. Analysis of genetics to identify susceptibility to secondary malignancies in patients with bladder cancer. *BJU Int*. 2016 Jul;118(1):12-3. PMID: 27311549.

11. **Lotan Y.** Words of Wisdom: Re: prognostic factors and risk group in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. *Eur Urol* 2014 Nov; 66(5): 968-9. PMID: 25763447
12. **Lotan Y.** Would the benefits of hexaminolevulinate fluoroexcence cystostopy be eliminated if every patient received postoperative installation of intravesical chemotherapy? *BJU Int* 2013 Dec; 112(8): 1053-254. PMID: 24283995. Comment on: Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer. O'Brien T, Ray E, Chatterton K, Khan MS, Chandra A, Thomas K. *BJU Int.* 2013 Dec;112(8):1096-104. PMID: 24053153.
13. **Lotan Y.** Medical management strategies to prevent recurrent nephrolithiasis are stagnant and stronger evidence is needed to reduce morbidity. *Evid Based Med.* 2014 Feb; 19(1): 12. Epub 2013 Jun 8. PMID: 23749601.
14. **Lotan Y.** The Challenge of Bacillus Calmette-Guérin Failure in Nonmuscle Invasive Bladder Cancer-What is the Next Step in Management? *J Urol.* 2013 Sep; 190(3): 832- 3. Epub 2013 Jun 18. PMID: 23791573.
15. Bagrodia A, **Lotan Y.** Words of Wisdom - Re: Radiotherapy With or Without Chemotherapy in Muscle-invasive Bladder Cancer. *Eur Urol* 2013 Mar; 63(3): 580-1. PMID: 23357892.
16. **Lotan Y.** Editorial comment. *J Urol.* 2012 Dec; 188(6): 2203. Epub 2012 Oct 22. PMID: 23083661
17. **Lotan Y.** Editorial. Controlling Health Care Costs for Prostate Cancer. *Eur Urol.* 2013 Jul; 64(1): 17-8. Epub 2012 Sep 17. PMID: 22999812.
18. **Lotan Y.** Editorial Comment on: Long-term Survival Following Partial vs Radical Nephrectomy among Older Patients with Early-stage Kidney Cancer. *Eur Urol.* 2012 Aug; 62(2):352-3. Epub 2012 Jun 26. PMID: 22748396.
19. **Lotan Y,** Adibi M, Pearle MS. Reply. Cost-Effectiveness of Standard vs Intensive Antibiotic Regimesn for Transrectal Ultrasonography (TRUS-Guided Prostate Biopsy Prophylaxis). *BJU Int* 2012 Apr; 109(8):E26-7. PMID: 22455405.
20. **Lotan Y.** Editorial Comment on: Hazard of Prostate Cancer Specific Mortality after Radical Prostatectomy. *J Urol.* 2012 Jan; 187(1): 124-128. Epub 2011 Nov 23. PMID: 22114812.
21. **Lotan Y.** Editorial. The Challenges of Harnessing New Technology. *Eur Urol.* 2012 Feb; 61(2): 269-70. Epub 2011 Nov 10. PMID: 22093296.
22. **Lotan Y.** Editorial Comment: Hazard of prostate cancer specific mortality after radical prostatectomy. *J Urol.* 2012 Jan; 187(1): 127-128. Epub 2011 Nov 23. PMID: 22114812
23. **Lotan Y.** Editorial. The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria. *Cancer.* 2012 May 15; 118(10): 2566-7. Epub 2011 Sep 14. PMID: 21918966.
24. **Lotan Y.** Editorial Comment on: *J Urol.* 2011 May; 185(5):1591-7 and *J Urol.* 2011 May; 185(5): 1604-10. The Future of Nephron Sparing Procedures for Renal Masses: Balancing Costs, Efficacy, Patient Outcomes and Experience. *J Urol.* 2011 May;185(5):1560-1561. Epub 2011 Mar 21. PMID: 21419436.
25. **Lotan Y.** Editorial Comment on: *Urology.* 2011 Jan;77(1):154-159. Use of the NMP22 BladderCheck Test in the Diagnosis and Follow-up of Urothelial Cancer: A Cross- sectional Study. *Urology.* 2011 Jan;77(1):159. PMID: 21195838.

26. **Lotan Y.** Editorial Comment on: Urology. 2010 Aug;76(2):391-7. Epub 2010 Apr 14. Regional differences in early stage bladder cancer care and outcomes. Urology 2010 Aug; 76(2): 396-7. PMID: 20696343.
27. **Lotan Y.** Words of wisdom. Re: randomized phase III trial on gemcitabine versus mitomycin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. Eur Urol. 2010 Jun;57(6):1116-7. PMID: 20965050.
28. **Lotan Y.** Editorial Comment on: Urology. 2010 Jun;75(6):1278-82. Utility of urine cytology in the workup of asymptomatic microscopic hematuria in low-risk patients. Urology. 2010 Jun;75(6); author reply 1282-3. PMID: 20513488.
29. **Lotan Y.** Editorial Comment on: J. Urol. 2010 May; 183(5):1822-9. Epub 2010 Mar 29. Quality of Life after Open or Robotic Prostatectomy, Cryoablation or Brachytherapy for Localized Prostate Cancer. J. Urol. 2010 May; 183(5): 1828-9. Epub 2010 Mar 29. PMID: 20303111.
30. **Lotan Y.** Editorial Comment on: J. Urol. 2010 May; 183(5): 1678-84. Epub 2010 Mar 17. Marker Lesion Experiments in Bladder Cancer-What Have We Learned? J. Urol 2010 May; 183(5): 1685. Epub 2010 Mar 16. PMID: 20299063.
31. **Lotan Y.** Editorial Comment on: J Urol. 2010 April;183(4):1366-1372. Comparative Effectiveness of Prostate Cancer Surgical Treatments: A Populations Based Analysis of Postoperative Outcomes. J Urol. 2010 April;183(4):1372. Epub 2010 Feb 25.PMID: 20188380.
32. **Lotan Y.** Comment: Re: JSLS. 2008;12(1):9-12 A da Vinci robot system can make sense for a mature laparoscopic prostatectomy program. JSLS. 2009 Jul-Sep;13(3):465; author reply 465-6. PMID: 19793498.
33. **Lotan Y.** Editorial Comment on: Long-term Outcomes of Simultaneous Transurethral Resection of Bladder tumor and Prostate in Non-muscle-Invasive Bladder Tumor Patients with Bladder Outlet Obstruction. J. Urol. (Forthcoming: May 2009).
34. **Lotan Y.** Words of wisdom. Re: Evaluating the learning curve for robot- assisted laparoscopic radical cystectomy. Eur Urol. 2009 May;55(5):1237-9. Comment on JEndourol. 2008 Nov;22(11):2469-74. PMID: 19650205.
35. Bolenz C, **Lotan Y.** Decision making in the management of renal cell carcinoma: can nomograms assist? Eur Urol 2009 Feb; 55(2): 296-8. Discussion 298-9. Epub 2008 Sep 1. PMID: 18771847.
36. **Lotan Y.** Editorial Comment on: Long-Term Oncological Outcomes in Women Undergoing Radical Cystectomy and Orthotopic Diversion for Bladder Cancer. J. Urol. 2009 May;181(5):2052-2059. Epub 2009 Mar 14. PMID: 19286204.
37. **Lotan Y.** Editorial Comment on: Serum Proteomic Profiling in Patients with Bladder Cancer. Eur Urol. 2009 Dec; 56(6): 996-7. Epub 2009 Mar 6. PMID: 19282102.
38. **Lotan Y.** Commentary on prostate and urothelial carcinoma in cystoprostatectomy specimens. J Urol 2008 May; 179(5 Suppl):S33-4. PMID: 18405746.
39. **Lotan Y.** Editorial Comment on: Prognostic Implications of Lymphangiogenesis in Muscle-Invasive Transitional Cell Carcinoma of the Bladder. Eur Urol. 2008 Mar;53(3):579-80. PMID: 17804152.
40. **Lotan Y, Lotan R.** Prevention of bladder cancer recurrence by retinoic acid-ketoconazole: A promising strategy? Cancer Biol Ther. 2008 Jan; 7(1): 101-2. Epub 2008 Feb 21. PMID: 18347420.
41. **Lotan Y.** Editorial Comment on: Lymphovascular Invasion is Independently Associated with Poor Prognosis in Patients with Localized Upper Urinary Tract Urothelial Carcinoma Treated Surgically. J Urol. 2007 Dec;178 (6): 2291-2296.

42. **Lotan Y.** Prostate cancer-specific survival in men treated with hormonal therapy after radical prostatectomy failure. *Eur Urol.* 2007 Aug;52(2):453-4. PMID: 17674436.
43. **Lotan Y.** Finasteride decreases the risk of prostatic intraepithelial neoplasia. Thompson IM, Lucia MS, Redman MW, Darke A, La Rosa FG, Parnes HL, Lippman SM, Coltman CA. *J Urol.* 2007 Jul;178(1):107-9; discussion 110. Epub 2007 May 11.
44. **Lotan Y.** Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. *Eur Urol.* 2007 Feb; 51(2): 567-568. PMID: 17396294.
45. **Lotan Y.** Surgical management of growing teratoma syndrome: The M.D. Anderson Cancer Center Experience. Philippe E. Spiess, Wassim Kassouf, Gordon A. Brown, Ashish M. Kamat, Ping Liu, Jose A. Gomez, Shi-Ming Tu, Nizar M. Tannir and Louis L. Pisters. *J Urol.* 2007 Apr; 177(4): 1330-1334.
46. **Lotan Y.** A survivin gene signature predicts aggressive tumor behavior Salz W, Eisenberg D, Plescia J, Garlick DS, Weiss RM, Wu XR, Sun TT, Altieri DC, Department of Cancer Biology and the Cancer Center, University of Massachusetts Medical School, Worcester, MA. *Urol Oncol.* 2006 Nov-Dec;24(6):563-4.
47. **Lotan Y.** Novel blood biomarkers of human urinary bladder cancer Osman I, Bajorin DF, Sun T-T, Zhong H, Douglas D, Scattergood J, Zheng R, Han M, Marshall KW, Liew CC, Wayne Marshall and Choong-Chin Liew. New York University School of Medicine, New York, NY. *Urol Oncol.* 2006 Nov-Dec;24(6):562-3.
48. **Lotan Y.** Discovery and validation of new protein biomarkers for urothelial cancer: A prospective analysis Theodoreescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, Mischak H, Frierson HF, Department of Molecular Physiology, Mellon Prostate Cancer Institute, University of Virginia, Charlottesville, VA.
49. **Lotan Y.** Editorial comment. *International Braz J Urol.* May - June 2006, Volume 32 Number 3.
50. **Lotan Y.** Editorial comment. *J Urol.* 2006 Apr;175(4):1324-5.
51. Roehrborn CG, **Lotan Y.** For the motion. *Eur Urol.* 2006 Feb;49(2):396-8.
52. Roehrborn CG, **Lotan Y.** Rebuttal 1. *Eur Urol.* 2006 Feb;49(2):399.
53. Lotan R, **Lotan Y.** Retinoic acid receptor beta2 hypermethylation: implications for prostate cancer detection, prevention, and therapy. *Clin Cancer Res.* 2004 Jun 15;10(12 Pt 1):3935-6. PMID: 15217922.
54. **Lotan Y.** Editorial Comment. *BJU International* 2021 *BJU Int* 2021: 128: 1-2 doi:10-1111/bju.15322.
55. Klotz L, Pavlovich CP, Chin J, Hatiboglu G, Koch M, Penson D, Raman S, Oto A, Fütterer J, Serrallach M, Relle J, **Lotan Y,** Heidenreich A, Bonekamp D, Haider M, Tirkes T, Arora S, Macura KJ, Costa DN, Persigehl T, Pantuck AJ, Bomers J, Burtnyk M, Staruch R, Eggener S. Reply by Authors. *J Urol.* 2021 Mar;205(3):779. doi: 10.1097/JU.0000000000001362.03. Epub 2020 Dec 23.PMID: 33355501 No abstract available.
56. Perioperative continuation of aspirin, oral anticoagulants or bridging with therapeutic low-molecular-weight heparin does not increase intraoperative blood loss and blood transfusion rate in cystectomy patients:an observational cohort study. *Urology Practice Update (Elsevier) Commentary.* 2022.
57. Lotan, Y, Barocas DA, Chang S, Daneshmand S, Konety B, Meeks JJ, Porten S, Raman JD, Rosser CJ, Scarpato KR, Sexton WJ, Sfakianos JP, Shore ND, Svatek RS. Commentary on Novitas LCD. *Bladder cancer* 9 (2023) 305-312. Doi 10.3233/BLC-230057. IOS Press.

Book Chapters

1. **Yair Lotan**, Margaret S. Pearle, and Jeffrey A. Cadeddu. Laparoscopic Renal Cyst Decortication. *In* Essential Urologic Laparoscopy: The Complete Clinical Guide, (Nakada SY, ed.). Totowa, N.J.: Humana Press. Chapter 5, pp 59-78. 2003.
2. **Yair Lotan**, Jeffrey A. Cadeddu, Jay T. Bishoff. Nephron-sparing minimally invasive surgery for renal malignancy. *In* Minimally Invasive Uro-oncologic Surgery. (Jay T. Bishoff and Robert Moore, eds.). Taylor & Francis, UK. Chapter 10, pp 143-164. 2005.
3. **Yair Lotan**, Jeffrey A. Cadeddu, Jay T. Bishoff. Minimally invasive, nephron sparing interventions for renal lesions: laparoscopy and ablative techniques. *In* Minimally Invasive Urological Surgery. (Jay T. Bishoff, Steven Docimo, Stefan Loening and Robert Moore, eds.). Taylor & Francis, UK. Chapter 35, pp 527-548. 2005.
4. **Yair Lotan** and Margaret S. Pearle. Urinary calculi: pathogenesis, metabolic evaluation and medical therapy. *In* Minimally Invasive Urological Surgery. (Jay T. Bishoff, Steven Docimo, Stefan Loening and Robert Moore, eds). Taylor & Francis, UK. Chapter 26, pp 375-393. 2005.
5. **Yair Lotan** and Margaret S. Pearle. Laparoscopic Renal Cyst Decortication. *In* Recent Advances in Endourology, Vol. 5: New Challenges in Laparoscopic Urologic Surgery. (E. Higashihara, S. Naito, T. Matsuda, eds.). Springer-Verlag, Tokyo. pp 93-111. 2004.
6. **Yair Lotan**, Jeffrey A. Cadeddu. Financial Aspect of Laparoscopy. *In* Textbook of Laparoscopic Urology (I Gill, ed.). Informa Healthcare USA, Inc., N.Y. Chapter 90, pp. 1009-1016. 2006.
7. **Yair Lotan**, David A. Swanson, Arthur I. Sagalowsky. Partial cystectomy. *In* Textbook of Bladder Cancer. (Seth P. Lerner, Mark P. Schoenberg, Cora N. Sternberg, eds.), Taylor & Francis, Section 7, Chapter 53, pp 543-550. 2006.
8. Margaret S Pearle and **Yair Lotan**. Urinary Lithiasis: Etiology, Epidemiology and Pathogenesis. *In* Campbell-Walsh Urology 9th Edition. Wein, A. J., Kavoussi, L.R., Novick, A. C., Partin, A. W. and Peters, C. A., (eds.). Elsevier Inc. Philadelphia, PA, Chapter 42, pp 1363-1392, 2007.
9. **Yair Lotan** and Margaret S Pearle. Economics of Stone Management. *In* Urolithiasis, An Issue of Urologic Clinics. (Margaret S. Pearle, ed.); Vol 34; Number 3. pp 443-453, Saunders, Philadelphia, PA. 2007.
10. Robert S. Svatek and **Yair Lotan**. Urothelial bladder cancer: screening with urine-based tumor markers. *In* Methods of Cancer Diagnosis, Therapy and Prognosis. (M. A. Hayat, ed.). Gardners Books. 2008.
11. Joshua M. Stern, Ilia S. Zeltser, **Yair Lotan**, Jeffrey A. Cadeddu. Laparoscopic Renal Cyst Decortication. *In* Essential Urologic Laparoscopy: The Complete Clinical Guide. 2nd Edition. (S. Nakada, S. Hedican, eds.). Humana, Totowa, N.J. 2009.
12. **Yair Lotan**. Understanding Concepts Related to Health Economics. *In* Evidence-Based Urology. (Phillipp Daham and Roger R. Dmochowski, eds.), Chapter 6, pp 45-49. Wiley- Blackwell Publishing. Hoboken, N.J. 2010.
13. Best S, **Lotan Y**, Pearle MS. Cost-Effective Strategies for Management of Renal and Ureteral Calculi. *In* Smith's Textbook of Endourology, 3rd Edition. (Arthur D. Smith, Glenn Preminger, Gopal Badlani, Lousi Kavoussi, eds.). Wiley-Blackwell. Publication Date: Feb. 7, 2012.
14. Josh Sleeper and **Yair Lotan**. Economics of Bladder Cancer Diagnosis and Surveillance. *In* Bladder Tumors: Molecular Aspects and Clinical Management. (V.

- Lokeshwar et al., eds.), Chapter 7, pp 121-137. Springer Science and Business Media. Humana Press, New York, 2011.
15. Margaret S. Pearle and **Yair Lotan**. Urinary Lithiasis: Etiology, Epidemiology and Pathogenesis. In: Campbell-Walsh Urology, 10th ed. (Alan J. Wein, Louis R. Kavoussi, Andrew C. Novick, Alan W. Partin, Craig A. Peters, eds.). Saunders, Philadelphia, 2012. Vol. 2, Chapter 45. pp 1257-1286.
 16. Daniel Ramirez and **Yair Lotan**. Cost-Effectiveness in Minimally Invasive Urologic Surgery. In Minimally Invasive Urology: An Essential Clinical Guide to Endourology, Laparoscopy, LESS and Robotics. (Sara L. Best and Stephen Y. Nakada, eds.). Springer Science and Business Media, New York, 2015. Chapter 19. pp 239-250.
 17. Laura-Maria Krabbe, Robert S. Svatek and **Yair Lotan**. Screening for Bladder Cancer. In: Management of Bladder Cancer: A Comprehensive Text with Clinical Scenarios. (Badrinath R. Konety and Sam S. Chang, eds.). Springer, New York, 2015. Chapter 2. pp 17-28.
 18. Ahmed Haddad and **Yair Lotan**. Reimbursement for Prostate Cancer Treatment. In Prostate Cancer: Science and Clinical Practice 2nd ed. (Mydlo, Jack H. and Godec, Cyril J., eds.). Academic Press, Amsterdam, 2015. Chapter 41. pp 367-374.
 19. Margaret S. Pearle, Jodi A. Antonelli and **Yair Lotan**. Urinary Lithiasis: Etiology, Epidemiology and Pathogenesis. In: Campbell-Walsh Urology, 11th ed. (Alan J. Wein, Louis R. Kavoussi, Alan W. Partin, Craig A. Peters, eds.). Elsevier, Philadelphia, 2016. Vol. 2, Chapter 51. pp 1170-1199.
 20. Margaret S. Pearle, Jodi A. Antonelli and **Yair Lotan**. Urinary Lithiasis: Etiology, Epidemiology and Pathogenesis. In: Campbell-Walsh Urology Eleventh Edition Review, 11th ed. (W. Scott McDougal, Alan J. Wein, Louis R. Kavoussi, Alan W. Partin, Craig A. Peters, eds.). Elsevier, Philadelphia, 2016. Vol. 2, Chapter 51. pp 1170-1199.
 21. Laura-Maria Krabbe, Vitaly Margulis, Yair Lotan. Prognostic Role of Cell Cycle and Proliferative Markers in Clear Cell Renal Cell Carcinoma. In Urologic Clinic of North America: Biomarkers in Urologic Cancer. (Kevin R. Loughlin, ed). Elsevier, Philadelphia, 2016. Vol. 43:1, pp105118.
 22. Aditya Bagrodia and **Yair Lotan**. Low and intermediate risk non-muscle-invasive bladder cancer. In: Oxford Textbook of Urological Surgery, (Freddie C. Hamdy, Ian Eardley, eds.). Oxford University Press, United Kingdom, 2017. Section 6.19. pp 625-637.
 23. **Yair Lotan**. Understanding Concepts Related to Health Economics. In Evidence-Based Urology. (Phillipp Daham and Roger R. Dmochowski, eds.), Wiley-Blackwell Publishing. Hoboken, N.J., *In press*.
 24. **Yair Lotan**. Chapter 3: Financial Consideration in the Management of Small Renal Masses. In Renal Mass Biopsy: Indications, Risks, Technical Aspects and Future Trends. ISBN: 978-3-030-36035-1. Springer Nature.
 25. Rashed A. Ghandour, Nirmish Singla, Yair Lotan. Chapter 3. pp 21-31. Using Urinary Biomarkers in Urothelial Carcinoma of the Bladder and Upper Tracts. In: Bladder Cancer a Practical Guide. Springer Nature.
 26. Yair Lotan, Fady Baky. Urine-based markers for detection of urothelial cancer and for the management of non-muscle invasive bladder cancer. In Press.

Non-Peer Reviewed Publications

1. Graham WR, **Lotan Y**, Painton T. Elevated Serum Amylase Levels after Seizures. *Ann Intern Med.* 1997 Jan 1;126(1):89. (letter to the editor).

AUA Core Curriculum Author and Editor

1. Yair Lotan (Author and Ed.), Brant Inman, Sima Porten, Sumeet Bhanvadia. Bladder Neoplasms: Non-Muscle Invasive Bladder Cancer". American Urological Association Core Curriculum. 2017-2021.
2. Yair Lotan (Author and Ed.), Sia Daneshmand, Robert Svatek, Parminder Singh, Solomon Woldu. Bladder Neoplasms: Muscle Invasive Bladder Cancer". American Urological Cor Curriculum. 2017-2021.

Visiting Professorship

1. Medical University of Vienna, Vienna, Austria
3rd Michael J. Marberger (MJM) Annual Meeting - Frontiers in Urology
December 15, 2017
 - a. MJM Lectureship - "A glimpse into the future of Urology"
 - b. "Genomic landscape of bladder cancer"
2. University of Michigan - Dow Division of Health Services Research Visiting
Professor July 10-12, 2012
 - a. "Chemoprevention of Prostate Cancer: Outcomes and Implications" – Grand
Rounds
 - b. "Cost-effectiveness of Stone Prevention"
3. University of Rochester Department of Urology March 22-23, 2006

Community Service/ Public Mass Media

1. UT Southwestern MedBlog on vasectomy: August 25, 2022.
2. Time: July 27, 2022: The latest breakthroughs that could help bladder cancer patients.
3. Urology Times: The iodine-based contrast media shortage. June 13, 2022.
4. SIRIUS-XM Radio interview Parkland: October 26, 2016: "Prostate Cancer"
5. KDAF-TV CH 33 News at 9:00: June 12, 2008: "Ask the Doctor"
6. Interview for NBC News: August 31, 2006: "Researchers Test At-Home Bladder
Cancer Detector"
7. Interview for ABC News Health Watch: July 18, 2006: "Over-the-Counter Erectile
Drugs Comes with Health Risks"
8. CBS 11 Evening News: Dallas, TX: June 30, 2006: "PSA screening key in
prostate cancer detection"
9. Urology Times Vol. 32, No. 2: February 1, 2004: Lap vs. open partial nephrectomy:
How to decide?
10. Urology Times Vol. 32, No. 2: February 1, 2004: Lap nephrectomy associated with
lower hospital costs.

CME Courses/Invited Speaker

1. 2024 2nd Christopher G. Woods Symposium, April 12-14, 2024, Austin, TX.
 - a. Moderator: Session II: Bladder (Localixed)
 - b. Moderator: Intermediate Risk Disease: Title Debate: Ablation vs Upfront TURBT: Pro vs Con.
 - c. Moderator: Session II: Bladder (Localized) Title: Case Discussions.
2. 2023 Society of Urologic Oncology, November 28 – December 1, 2023, Washington, DC.
3. 2023 UT Christopher G. Wood Advances in Urology Oncology. March 31-April 2, 2023, Austin, TX.
 - a. Speaker: Session II (Bladder Ca Localized) – Title: Screening/biomarkers.
4. 2023 American Urological Association, March 3-4, 2023
 - a. Clinical and Biological Implications of Tumor Heterogeneity
5. 2023 Annual Paul C. Peters Urology Symposium, Irving, TX, F
 - a. Management of Recurrent LGTa Disease. Speaker
 - b. Update on FDA approval of Nadofarrgene Firadenovec.
 - c. Case discussion. Panelist.
6. 2022 Society of Urologic Oncology, San Diego, CA. November 30 – December 2, 2022.
 - a. Speaker: Career Development Panel: Research Across Your Career-Changes Happen.
7. South Central Section Meeting of the AUA, Inc. Scottsdale, AZ. September 29 – October 2, 2021.
 - a. Panelists: Panel Discussion: Non-Invasive Bladder Cancer-How to Reduce Recurrence and Progression rates.
8. 26th Annual Paul C. Peters Urology Symposium, Irving, TX, Jan 17 – 19, 2020.
 - a. Moderator: Bladder Cancer.
 - b. Speaker: Office Blue Light Cystoscopy and Bladder Biopsy: An Important Tool in Managing Bladder Cancer Patients
9. 2019 Asymptomatic Hematuria Guideline Panel, Linthicum, MD. October 12 - 13.
10. 34th Annual Congress of the European Association of Urology, Barcelona, Spain, March 15 – 19, 2019.
11. 2019 AACR Special Conference - Bladder Cancer: Transforming the Field, Denver, CO. May 18-21.
 - a. Urine Molecular Diagnosis
12. Advancing Bladder Cancer Research, A US-Israel Forum for Collaboration, Linthicum, MD. February 24 - 25, 2019.
 - a. Identifying Research Needs Best Suited for International Collaboration.
13. 2019 Genitourinary Cancers Symposium, San Francisco, CA. February 14 – 16.
 - a. Genomic Insights and Biomarkers for Treatment Selection in Muscle-Invasive and Non-Muscle-Invasive Bladder Cancer.
14. 25th Annual Paul C. Peters Urology Symposium, Irving, TX. Jan 18 – 20, 2019.
 - a. Bladder Cancer Biomarkers: Ready for Primetime?
 - b. Panel Discussion: Difficult Bladder Cancer Cases. Moderator: Arthur I. Sagalowsky, MD. Panelists: Aditya Bagrodia, MD Yair Lotan, MD Robert S. Svatek, MD, MSCI Solomon L. Woldu, MD
15. 2018 Global Summit on Genitourinary Malignancies, Banff, Canada. November 1 - 4.
 - a. Blue Light Flexible cystoscopy with Hexaminolevulinate for Surveillance of Bladder Cancer
16. 2018 University of Rochester Department of Urology Festschrift Honoring

- Edward M. Messing, MD, FACS, Rochester, New York. October 18 - 19, 2018
- a. Screening for Bladder Cancer/Epidemiology
17. UA 2018 Annual Meeting, San Francisco, CA, May 18-22, 2018
- a. Evaluation of the UroVYsion™ Test for Predicting Recurrence and Progression in Patients Receiving BCG for High Grade Non-Muscle Invasive Bladder Cancer
 - b. Tumor Board: Bladder Cancer
 - c. A Genomic Classifier for Identifying a Neuroendocrine-like Bladder Cancer Subtype
 - d. Debate: Can Biomarkers Decrease Need for Surveillance Cystoscopy?
 - e. General & Epidemiological Trends & Socioeconomics: Value of Care: Cost & Outcomes Measures I
18. 2018 Genitourinary Cancers Symposium, Orlando, FL, February 8-10, 2018
Program Committee (Member)
- a. General Session 5: Multimodality Approach to Locally Advanced Bladder Cancer (ARS) – Session Chair
 - b. Urothelial Carcinoma – Poster Walk Leader
19. 24th Paul C. Peters Urology Symposium. Dallas. Jan. 19-21, 2018
- a. AUA Guideline: Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer
 - b. Biomarker based approach to select patients with MIBC for neoadjuvant chemo
 - c. Bladder Cancer Case Discussion: Sam Chang (moderator), **Yair Lotan MD**, Aditya Bagrodia MD, Vitaly Margulis MD
20. AUA 2017 Annual Meeting, Boston, MA, May 12-16, 2017
- a. Second Opinion Cases: Panelist: Non-muscle Invasive Bladder Cancer
 - b. General & Epidemiological Trends & Socioeconomics: Value of Care: Cost and Outcomes. Poster Session Moderator. MP32
21. 2017 Genitourinary Cancers Symposium, Orlando, FL, February 16-18, 2017
Program Committee (Member)
- a. General Session 5: Barriers to Progress in Muscle-Invasive and Nonmuscle - Invasive Bladder Cancer – Chair
 - b. General Session 4: Optimizing Outcomes in Muscle-Invasive and Metastatic Bladder (ARS). Auditor
 - c. Urothelial Carinoma Year in Review and Keynote Lecture. Auditor
22. 23rd Paul C. Peters Urology Symposium. Dallas. Jan. 27-29, 2017
- a. Blue Light Cystoscopy is the Standard of Care: Pro – **Yair Lotan**; Con – Aditya Bagrodia
 - b. Rectal Spacer Program in Radiotherapy of Prostate Cancer
23. Texas Urological Society. Dallas. June 9, 2016. Review of AUA Guidelines: Non-muscle Invasive Bladder Cancer. Invited Speaker.
“Role of Urine Markers in Detection or Surveillance of Bladder Cancer”
24. AUA 2016 Annual Meeting, San Diego, CA, May 6-10, 2016
- a. Second Opinion Cases: Malignant Panelist: “Bladder Cancer”
 - b. “The Development and Clinical Validation of a High Sensitivity Urine biomarker test for the Determination of Recurrence in Urothelial Carcinoma Patients”
Session Title: Plenary I – Tuesday. Abstract: 745
25. USC Institute of Urology, L.A. “Live” International Robotic & Open Live Surgery Pre-AUA Symposium, Los Angeles, CA, May 4-5, 2016
26. 22nd Paul C. Peters Urology Symposium. Dallas. Jan. 29-31, 2016
-

- a. "Should Everyone Have a Microhematuria Workup? Should We Follow the AUA Guidelines?" Pro - Arthur Sagalowsky; Con – **Yair Lotan**
 - b. Breakout Session: Surveillance and Treatment of Non-Muscle Invasive Bladder Cancer. Arthur Sagalowsky, MD (moderator), **Yair Lotan**, Vitaly Margulis
27. 2016 Genitourinary Cancers Symposium, San Francisco, CA, January 7-9, 2016 Program Committee (Member)
General Session 5: Challenging Cases in Urothelial Carcinoma – Co-Chair with Jonathan Rosenberg
28. 5th Annual Collaborative Forum of KUS/MUA, March 28, 2015. Invited Speaker. Current Concepts in the Management of Non-Muscle Invasive High Risk Bladder Cancer
29. 21st Paul C. Peters Urology Symposium. Dallas. Jan. 23-25, 2015
- a. Bladder Cancer Update
 - b. Case Discussion: Urothelial Carcinoma: Arthur Sagalowsky (moderator); **Yair Lotan**, Vitaly Margulis
30. ICUD/SIU Consultation on Stone Disease. Oct.11-15, 2014. Glasgow, Scotland. Sub Committee Chair: "Epidemiology and Economics of Stone Disease." Parallel Plenary 5: ICUD Consultation on Stone Disease.
31. Bladder Cancer Think Tank. Aug. 7-9, 2014. San Diego, CA. Chair. Patient Advocacy Session – Co-presenter
32. University of Nebraska. Omaha. June 20, 2014. Invited Speaker.
- a. Why Open Cystectomy?
 - b. Prostate Cancer Chemoprevention
 - c. Early detection of bladder cancer: Evaluation of hematuria and use of urine markers
33. Community-Oriented Primary Care and Jail Health Educational Forum. Dallas. May 6, 2014.
"Urinary Retention, Hematuria and Recurrent UTI".
34. 20th Annual Paul C. Peters Day Symposium. Dallas. Jan. 31- Feb. 2, 2014.
- a. AUA Guidelines on Prostate Cancer Update – Speaker
 - b. Challenging Cases in Urothelial Cancer - Breakout Session: **Yair Lotan**, Vitaly Margulis, Arthur Sagalowsky)
35. II Advanced Robotic Surgery Symposium. Jan. 10-11, 2014. Rome, Italy. Invited Speaker. "Why Open?" Radical Cystectomy.
36. 2013-14 Hydration Lecture Series. Nov. 13, 2013. University of Arkansas, Human Performance Laboratory in the College of Education and Health Profession. Invited Speaker: "Kidney Stones: Epidemiology and Cost"
37. 2013 CURC and CUOG Retreat Conference. C2R Conference "New Pathways and New Methods in Urological Care." October 4-6, 2013. Toronto, Canada. Invited Faculty: Molecular Markers in High Grade Bladder Cancer
38. Annual Residents' Day. October 3-4, 2013. McMaster University. Hamilton, Canada. Keynote Speaker.
- a. Keynote Lecture: Best of Practice: Screening, Diagnosis and Markers for Bladder Cancer
 - b. Keynote Lecture: Cost Effectiveness Considerations in the Treatment and Imaging of Kidney Stones

39. Bladder Cancer Think Tank. Aug. 8-10, 2013. Snowmass, CO. Chair.
 - a. "Status Update on Working Groups". Chair.
 - b. Understanding Gender Disparities in Bladder Cancer: "Impact of Gender on Diagnosis and Outcomes of Bladder Cancer." Chair/Speaker.
 - c. Update on Working Groups: "Non-muscle Invasive Bladder Cancer." Speaker/Group Leader.
 - d. Gender Panel. Panel Discussion, Case Presentations and Q&A. Speaker.
40. H4H Hydration for Health 5th Annual Scientific Conference, Evian-les-Bains, France July 2-4, 2013.
Invited Speaker: "Primary Prevention of Lithiasis"
41. The 50th Harry M. Spence Visiting Professor Conference, May 22-23, 2013. Dallas, TX
Prospective Validation of Clinical Utility of Molecular Marker Panel for Management of Bladder Cancer
42. 19th Annual Paul C. Peters Day Symposium. Dallas. Feb. 1-3, 2013
 - a. Non-Muscle Invasive Bladder Cancer – Moderator
 - b. Practical Approach to Urine Markers
43. Bladder Cancer Think Tank. Aug. 9-11, 2012. Stowe, VT. Co-Chair.
Speaker: Panel: "Ways to Move Forward in Early Detection of Bladder Cancer Screening Trials"
44. H4H Hydration for Health 4th Annual Scientific Conference, Evian-les-Bains, France July 3-5, 2012.
Invited Speaker: "Prevention of Stone Disease: Cost-effectiveness"
45. Danone Expert Kidney Meeting, Paris, France. Nov. 6-8, 2011
 - a. "Epidemiology and Risk Factors of Lithiasis"
 - b. "Prevention of Stone Disease: Cost-Effectiveness"
 - c. "Bladder Cancer Risk Factors and epidemiology"
46. AUA 2012 Annual Meeting. Atlanta, GA. May 19, 2012.
Hands-on Prostate Ultrasound Course. Station Proctor
47. NCI Workshop: Novel Neoadjuvant Therapy for Bladder Cancer. Gaithersburg, MD. September 20, 2011.
Invited Speaker: "Prognostic and Predictive Biomarkers in a Neoadjuvant Trial"
48. 14th Annual Highlights of the American Urological Association 2011 National Meeting. Clayton, MO. June 19, 2011.
Invited Speaker: "Bladder and Kidney Cancer"
49. Society of Urological Robotic Surgery (SURS). Washington, DC. May 15, 2011
Invited Speaker: Session II – Debate: "Is Robotic Surgery Cost Effective? – No"
50. AUA 2011 Annual Meeting. Washington, DC. May 14, 2011
 - a. AUA Foundation Research Forum: Showcasing Young Investigators.
"Clinical Use of Molecular Biomarkers for Urothelial Carcinoma of the Bladder." Invited Speaker and Poster.
 - b. Hands-on Prostate Ultrasound Course. Station Proctor
51. Society of Urologic Nurses and Associates 7th Annual Urology Symposium. Dallas. April 30, 2011.
Invited Speaker: "Updates in Bladder Cancer"
52. Symposium "Urine Proteomics, Proteine-based Tumor Markers and Bladder Cancer", Bochum, Germany. November 23, 2010.
Invited Speaker: "Bladder Cancer Screening – The Economic Perspective"

53. South Central Section Meeting of the AUA, White Sulphur Springs, WV, September 23, 2010.
Poster Session 1. Co-Moderators: **Yair Lotan** and Damara L. Kaplan
54. University of Colorado Division of Urology. Denver. September 17, 2010.
Invited Speaker: "Role of Biomarkers to Predict Outcomes and Response to Therapy in Bladder Cancer"
55. ISN-Danone Symposium. Geneva. June 30, 2010.
Invited Speaker: "The Economics of Kidney Stone Management"
56. AUA 2010 Annual Meeting. San Francisco, CA. May 29, 2010.
Hands-on Prostate Ultrasound Course. Station Proctor
57. 16th Annual Paul C. Peters Day Symposium. Dallas. Jan. 29-30, 2010. Faculty
- a. Invasive Bladder Cancer (Moderator)
 - b. Invasive Bladder Cancer: Adjuvant Chemotherapy
 - c. Stones: Stones and Global Warming
 - d. Chemoprevention in Prostatic Diseases: Cost Effectiveness of Chemoprevention
58. 2009 Society of Urologic Oncology
Utility (or lack of) of FDA approved voided urine biomarkers
Pro: Badrinath Konety
Con: Yair Lotan
59. 2009 SBUR/ESUR Joint Meeting. New Orleans. November 6, 2009.
Invited Speaker: "Cost-Effectiveness of Urine-Based Tumor Markers for Bladder Cancer: Current and Potential Uses"
60. The American Society of Nephrology Renal Week Meeting. San Diego. October 30, 2009.
Invited Speaker: "Climate-related Increase in the Prevalence of Urolithiasis in the United States"
61. South Central Section of the AUA. Scottsdale, AZ. October 14-17, 2009
- a. Prospective Validation of Multiple Biomarkers for Improved Clinical Decision-Making in Patients with Urothelial Carcinoma of the Bladder
 - b. Phase 1 Study of Stereotactic Body Radiation Therapy (SBRT) for Low and Intermediate Risk Prostate Cancer: Initial Results
62. The PSA *and* Prostate Puzzle. Dallas. September 26, 2009. Faculty
63. AUA 2009 Annual Meeting. Chicago. April 25, 2009.
Prostate Ultrasound, Imaging/ Radiology. Course Director
64. North Texas Chapter of the American College of Surgeons 2009 Annual Meeting. Dallas. Feb. 21, 2009.
Invited Speaker: The Harry M. Spence Memorial Lectureship. "Impact of BMI on Outcomes and Cost of Urologic Procedures"
65. 15th Annual Paul C. Peters Day Symposium. Dallas. Jan. 23-24, 2009
- a. Case Management: Renal Stones (Moderator)
 - b. Imaging in GU Malignancies (Breakout Session)
 - c. Case Management: Bladder Cancer (Moderator)
66. 9th Annual Society of Urologic Oncology Winter Meeting. Bethesda. December 4-6, 2008.
Invited Speaker: "Role of Biomarkers to Predict Outcomes and Response to Therapy"
67. The International Bladder Cancer Network. Oct. 15, 2008. Barcelona.
Invited Speaker: "Screening High Risk Patients"
68. Bladder Cancer Think Tank. Aug. 17-20, 2008. Mont-Tremblant, Quebec.
Invited Speaker: "Evaluation Of Where And How Urologists Should Use Markers: Is There Sufficient Evidence To Support Marker Use?"

69. AUA 2008 Annual Meeting. Orlando. May 17, 2008.
Course Director: Prostate Ultrasound, Imaging/Radiology.
70. ROCK Society Annual Meeting. Jun. 6-7, 2008. Durham.
Invited Speaker: "Quality of Life in Stone Formers"
71. Prostate Cancer Update 2008. Mar. 14-15, 2008. Coral Springs, FL. Invited Speaker:
- What Should We Tell Patients About Androgen Supplementation and Prostate Cancer?
 - Surgical Prostate Anatomy: Intra vs. Extra Fascial Dissection
 - Penile Rehabilitation for Potency Return: What Is Known and What Is Best?
 - Robotic-assisted Laparoscopic Prostatectomy (Smith, JA Jr, Lotan, Y, Amling CL)
72. NIDDK Urolithiasis Treatment and Outcomes Symposium. Washington, DC. Feb. 28-29, 2008.
Invited Speaker: Economics and Cost of Care
73. UT Southwestern Department of Family and Community Medicine. Dallas. Feb. 20, 2008.
Invited Speaker: Nephrolithiasis
74. 14th Annual Paul C. Peters Day Symposium. Dallas. Jan. 25-26, 2008:
Debate: Management of Stone Disease: Endoscopic vs ESWL (ESWL)
75. AUA 2007 Annual Meeting. Anaheim May 21, 2007.
Course Director: Prostate Ultrasound, Imaging/Radiology.
76. Texas Academy of Physician Assistants 32nd Annual Primary Care CME Conference. Feb. 9-11, 2007.
Robotics in Surgery: The Robotic-Assisted Laparoscopic Prostatectomy
77. 13th Annual Paul C. Peters Day Symposium. Dallas. Jan. 26-27, 2007: Co-Course Director
78. ACS Relay for Life Organizers Meeting.
Invited Speaker.
79. DFW SUNA Chapter Meeting. Sept. 23, 2006. Urinary Markers and Bladder Cancer
80. Stereotactic Body Radiation Therapy: Clinical, Technical, and Translational Aspects May 19, 2006.
Invited Speaker: "SBRT models for dose effects in kidney and prostate cancer"
81. Prostate Cancer Update. April 1, 2006. Lubbock.
Invited Speaker
82. 12th Annual Paul C. Peters Day Symposium. Dallas. Jan. 20-21, 2006. Invited Speaker: "Cost-Effectiveness of Prostate Cancer Chemoprevention"
83. Oncology Update. "New Innovations: An Update in the Fight against Cancer". Oct. 1, 2005. Invited Speaker: "Bladder Tumor Markers: Role in Screening and Surveillance of Bladder Cancer"
84. UT Southwestern Department of Family and Community Medicine. Dallas. Aug 31, 2005. Invited Speaker: Bladder Cancer Screening
85. 3rd Annual Men's Health Conference. Parkland Health and Hospital System. June 11, 2005: Invited Speaker and Panel on Prostate Cancer
86. ROCK Society Annual Meeting. Chicago. April 29-30, 2005. Invited Speaker: "International comparison of cost effectiveness of medical management strategies for nephrolithiasis"
87. 11th Annual Paul C. Peters Day Symposium. Dallas. Jan. 20-22, 2005. Invited Speaker: "What Qualifies as a Successful Intervention?"
88. 11th Annual Paul C. Peters Day Symposium. Dallas. Jan. 20-22, 2005. Discussion Panel: Prostate Cancer

89. Dallas, Texas. Oct. 23, 2004. Co-director CME course: "Piecing Together the Puzzle on Prostate Cancer"
90. Texas Association of Genito-Urinary Surgeons Meeting. Dallas, Texas. July 31, 2004: "Management of Ureteropelvic Junction Obstruction: An Update" and "Radical Prostatectomy: An Update on Minimally Invasive Techniques"
91. Texas Urological Society 2004 Annual Meeting, Puerto Rico. Invited Speaker: "Bladder Cancer – Role of Cytology and Biomarkers"
92. Cancer Biology Graduate Student Course at UT Southwestern Medical Center. Dallas. Apr. 27, 2004: "Urologic Oncology"
93. 10th Annual Paul C. Peters Day Symposium. Dallas. Jan. 22-24, 2004.
 - a. "Stone Prophylaxis: A Critical Cost-effectiveness Analysis" (Invited Speaker)
 - b. "Urine-based Screening Markers: A Critical Assessment" (Invited Speaker)
 - c. Urolithiasis (Discussion Panel)
 - d. Future of Urologic Surgery (Discussion Panel)
94. National Foundation for Sexual Medicine. Sexual Health Hospital Symposia. Dec. 13, 2003. Moderator and Speaker: "Male Sexual Circuitry: Sexual Dysfunction and Rapid Ejaculation"

Videos

1. Xiasong Meng, Iftach Chaplin, Rashed Gandour, **Yair Lotan**, Office-Based Blue Light Flexible Cystoscopy Improves Diagnostic Capabilities, Videourology. 2008, DOI: 10.1089/vid.2019.0081.
2. Robert S. Svatek, Vitaly Margulis, Edward D. Matsumoto, Wareef Kabbani, Jeffrey A. Cadeddu, **Yair Lotan**: "Application of A Novel Hemostatic Agent QuickClot During Laparoscopic Partial Nephrectomy" (AUA 100th Annual Meeting, San Antonio, TX, 2005).
3. **Yair Lotan**, Matthew T. Gettman, Guy Lindberg, Cheryl A. Napper, John Hoopman, Margaret S. Pearle, and Jeffrey A. Cadeddu: "Laparoscopic Partial Nephrectomy Using Holmium Laser" (AUA 97th Annual Meeting, Orlando, 2002).

Meeting Abstracts

2024 AUA Annual Meeting, May 2024, San Antonio, TX

1. Desai AP, Basak R, Lotan Y, Sperger J, Schroeck F, Chaplain I, Roberson H, Lopez P, Jenkins W, Gore JL, Kosorok MR, Smith AB. "Interventions to Reduce Cystoscopy Discomfort: A Multi-Site Quality Improvement Pilot." American Urological Association Annual Meeting, San Antonio, TX, May 2024. Podium presentation.
2. Lotan Y. Health Services Research: Value of care: Cost and Outcomes I. American Urological Association Annual Meeting, San Antonio, TX, May 2024. Podium presentation PD08.
3. Lotan Y, Daneshmand S, Shore N, Black N, Scarpato K, Patel A, Lough T, Shoskes D, Raman J. A Multicenter prospective randomized controlled trial comparing Cxbladder triage to cystoscopy in patients with microhematuria. American Urological Association Annual Meeting, San Antonio, TX, May 2024. Podium presentation PD08-08.

4. Lotan Y. A lncRNA-based classifier identifies high grade T1 bladder cancer patients with excellent outcomes after radical cystectomy. American Urological Association Annual Meeting, San Antonio, TX, May 2024. Podium presentation MP15-02.
5. Lotan Y, de Jong J, Proudfoot J, Daneshmand S, Svatek R, Narayan V, Joshi S, Li R, Inman B, Wright J, Shah p, Gibb E. Molecular subtypes for predicting non-organ confined disease and survival outcomes after radical cystectomy in clinical high-grade T1 and T2 bladder cancer patients. American Urological Association Annual Meeting, San Antonio, TX, May 2024. Podium presentation MP15-07.
6. Lotan Y, Shah J, Krishna V, Launer B, Krishna V, Shiddhant S, Gordetsky J, Gerald T, Shkolyar E, Hayne D, Redfern A, Spalding L. Development and validation of generalizable interpretable AI biomarkers to predict clinical outcomes in BCG-treated patients with non-muscle invasive bladder cancer. American Urological Association Annual Meeting, San Antonio, TX, May 2024. Podium presentation PD27-12.
7. Lotan Y, Krishna V, Launer B, Krishna V, Singhi S, Gordetsky J, Shah J, Gerlad T, Shkolyar E, Hayne D, Redfern A, Spalding L. Predicting response to intravesical BCG in high risk non-muscle invasive bladder cancer using an artificial intelligence-powered pathology assay: development and validation in an international 12 center cohort. American Urological Association Annual Meeting, San Antonio, TX, May 2024. Podium presentation PD30-03.
8. Woldu S, Johnson B, Murray K, Miyagi H, Sexton W, Tachibana I, Kaimakliotis H, Jacob J, Dickstein R, Linehan J, Nieder A, Bjurlin M, Heidenberg D, Humphreys M, Ghodoussipour S, Quek M, O'Donnell M, Eisner B, Matin S, Feldman, Lotan Y. Longitudinal follow up of multicenter study of UGN-101 for upper tract urothelial cancer. American Urological Association Annual Meeting, San Antonio, TX, May 2024. Podium presentation PD41-11.
9. Lotan Y, Pohar K, Bree K. Role of Urinary markers in surveillance of NMIBC patients. American Urological Association Annual Meeting, San Antonio, TX, May 2024. Podium presentation.
10. Bhanvadia R, Taylor J, Bagrodia A, Gaston K, Woldu S, Tachibana I, Lotan Y, Margulis V. Overcoming medical vulnerability: Cancer center partnership associated with improved outcomes for bladder cancer. American Urological Association Annual Meeting, San Antonio, TX, May 2024. Podium presentation PD08-09.
11. Bhanvadia R, Taylor J, Bagrodia A, Gaston K, Woldu S, Tachibana I, Lotan Y, Margulis V. A safety net for safety net hospitals: Affiliation with cancer centers improves survival in metastatic genitourinary cancers among the medically vulnerable. American Urological Association Annual Meeting, San Antonio, TX, May 2024. Podium presentation MP5719.
12. Inman B, Grossman H.B, Fleshner N, Wright J, Moses K, Berglund R, Hafron J, Karsh L, Saltzstein D, Lotan Y. Pivotal study evaluating performance of bladder epicheck, an FDA cleared test, in non-muscle invasive bladder cancer. American Urological Association Annual Meeting, San Antonio, TX, May 2024. Podium presentation PD48-07.

13. Kalota S, Joshi S, Bui M, Dickstein R, Liu J, Lotan Y, Johnson S, Taylor J, Bryce R, Tosone C, Zbell J, Steinberg G, Brown G. Legend: A phase ½ study of EG-70 (Detalimogene Voraplasmid), A Novel, non-viral intravesical gene therapy for patients with BCG-Unresponsive non-muscle invasive bladder cancer with carcinoma in SITU (CIS). American Urological Association Annual Meeting, San Antonio, TX, May 2024. Podium presentation P2-08.
14. Holland L, Ibeziakp N, Bhanvadia R, Taylor J, Gerit D, Chaplin I, Bagrodia A, Zhang T, Cole S, Gaston K, Lotan Y, Margulis V, Woldu S. Socioeconomic and demographic disparities in immunotherapy for advanced renal cell carcinoma and urothelial carcinoma. American Urological Association Annual Meeting, San Antonio, TX, May 2024. Podium presentation PD05-11.
15. Desai A, Basak R, Lotan Y, Sperger J, Schroeck F, Chaplin I, Roberson H, Lopez P, Jenkins W, Gore J, Kosorok M, Smith A. Interventions to reduce cystoscopy discomfort: A multi-site quality improvement pilot. American Urological Association Annual Meeting, San Antonio, TX, May 2024. Podium presentation PD62-01.
16. Lotan Y, Shah J, Krishna V, Launer B, Krishna V, Shingi S, Gordetsky J, Gerald T, Shkolyar E, Hayne D, Redfern A, Spalding L. Development and validation of generalizable interpretable AI biomarkers to predict clinical outcomes in BCG-treated patients with non-muscle invasive bladder cancer. American Urological Association Annual Meeting, San Antonio, TX, May 2024. Podium presentation PD27-12.
17. Narayan V, Eyrich N, Huang E, Zheng Y, Wei J, Sokoll L, Chan D, Patil D, Chinnaiyan A, Tomlins S, Lotan Y, Lin D, Scherr D, Kibel A. Combining serum prostate health index with urinary PCA3 and TMPRSS2:ERG RNA testing improves detection of clinically-significant prostate cancer. American Urological Association Annual Meeting, San Antonio, TX, May 2024. Podium presentation MP41-02.
18. Fledman A, Woldu S, Johnson B, Murray K, Miyagi H, Sexton W, Tachibana I, Kaimakliotis H, Jacob J, Dickstein R, Linehan J, Nieder A, Bjurlin M, Heidenberg D, Humpreys M, Ghodoussipour S, Quek M, O'Donnell M, Eisner B, Lotan Y, Matin S. Exploring recurrence after initial response to UGN-101 induction in expanded settings. American Urological Association Annual Meeting, San Antonio, TX, May 2024. Podium presentation PD41-12.

2024 88th Annual Meeting of the SE of the AUA, March 2024, Austin, TX

1. Desai AP, Basak R, Lotan Y, Sperger J, Schroeck F, Gore JL, Kosorok MR, Smith AB. "Feasibility and Outcomes of Interventions to Reduce Cystoscopy Discomfort: A Quality Improvement Project." 88th Annual Meeting of the Southeastern Section of the American Urological Association, Austin, TX, March 2024. Poster presentation.

2023 SUO Annual Meeting, November 28 – December 1, 2023, Washington, DC

19. Desai AP, Basak R, Lotan Y, Sperger J, Schroeck F, Gore JL, Kosorok MR, Smith AB. "Feasibility and Outcomes of Interventions to Reduce Cystoscopy Discomfort: A Quality Improvement Pilot." 24th Annual Meeting of the Society of Urologic Oncology, Washington, DC, November 2023. Poster presentation.
20. Holland L, Taylor J, Bhanvadia R, Gerit D, Chaplin I, Bagrodia A, Gaston K, Lotan Y, Margulis V, Woldu S. Socioeconomic and demographic disparities in immunotherapy for advanced clear cell renal cell carcinoma. Poster #101, 2024 SUO Annual Meeting, November 28 – December 1, 2023, Washington, D.C.
21. Steinberg G, Kolata S, Lotan Y, Tosone C, Mazanet R. Legend, A phase ½ study of detalimogene voroplasmid (EG-70) intravesical monotherapy demonstrated clinical responses in BCG-Unresponsive NMIBC patients with CIS. Poster #112, 2024 SUO Annual Meeting, November 28 – December 1, 2023, Washington, D.C.
22. Taylor J, Annapureddy D, Howard J, Tan WS, McElree IM, Davaro F, Yim K, Harrington S, Dyer S, Black A, Kanabur P, Roumiguie M, Lerner S, Black P, Raman J, Preston M, Steinburg G, Huang W, Li R, Packiam VT, O'Donnell M, Kamat A, Woldu S, Lotan Y. Natural history of bladder-sparing therapy in patients with BCG-unresponsive disease; results from a large multi-center cohort. Poster #114, 2024 SUO Annual Meeting, November 28 – December 1, 2023, Washington, D.C.
23. Annapureddy D, Taylor J, Howard J, Tan WS, McElree IM, Facundo D, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguie M, Lerner S, Black P, raman J, Preston MA, Steinberg G, Huang W, Li R, Packiam VT, O'Donnell M, Kamat A, Woldu S, Lotan Y. Oncologic outcomes of gemcitabine-docetaxel combination intravesical bladder sparing therapy compared to upfront radical cystectomy in BCG-unresponsive non-muscle invasive bladder cancer. Poster #122, 2024 SUO Annual Meeting, November 28 – December 1, 2023, Washington, D.C.
24. Daneshmand S, Zaucha R, Vasdev N, Gartrell BA, Lotan Y, Hussain SA, Lee EK, Procopio G, Galanternik F, Pignot G, Sundi D, Cutuli HJ, Crow L, Naini V, Triantos S, Baig M, Maranchie JK. Marker-lesion study of oral erdafitinib in patients with intermediate-risk non-muscle-invasive bladder cancer with FGR3/2 alterations in Thor-2: updated cohort 3 results. Poster #134, 2024 SUO Annual Meeting, November 28 – December 1, 2023, Washington, D.C.
25. Fleshner N, Lotan Y, Grossman B, Inman B, Wright JI, Berglund R, Hafron J, Karsh L, Moses K, Saltzstein D, Pierconti F, Trenti E, Witjes AJ. Consistent performance of bladder epi-check for NMIBC surveillance in the USA and European pivotal studies and in real world studies. Poster #146, 2024 SUO Annual Meeting, November 28 – December 1, 2023, Washington, D.C.
26. Bocher E, Taylor J, Minnis E, Vu E, Lotan Y. Imaging performance for genitourinary cancers in single institution hematuria population without previous urologic evaluation. Poster #153, 2024 SUO Annual Meeting, November 28 – December 1, 2023, Washington, D.C.
27. Bochner E, Taylor J, Minnis E, Vu E, Lotan Y. Risk-based hematuria referral patterns at a large single institution in patients with no previous urologic

- evaluation. Poster #154, 2024 SUO Annual Meeting, November 28 – December 1, 2023, Washington, D.C.
28. Boorjan S, Narayan V, Konety B, Master V, Shore N, Kamat A, Bivalacqua T, Kates M, Montgomery J, Lerner S, Crispen P, Steinberg G, Agarwal P, Schuckman A, Svatek R, Lane B, Karsh L, Bjurlin M, Brown G, Lotan Y, Inman B, Williams M, Cookson M, Chang S, Kim E, Sankin A, O'Donnell M, Jakobsen J, Juul K, Dinney C. Efficacy of intravesical nadofaragene firadenovec for patients with BCG-unresponsive carcinoma in situ of the bladder:36-month follow-up from a phase 3 trial. Poster #164, 2024 SUO Annual Meeting, November 28 – December 1, 2023, Washington, D.C.
 29. Bochner E, Balcazar J, Recchimuzzi D, Gold S, de Leon A, Goldberg K, Lotan Y, Costa D, Meng X. MRI-guided transurethral ultrasound ablation (TULSA) of localized prostate cancer: single institution experience of treatment efficacy. Poster #188, 2024 SUO Annual Meeting, November 28 – December 1, 2023, Washington, D.C.
 30. Eggener S, Pavlovich C, Koch M, Gardner T, Zagaja G, Penson D, Relle J, Pantuck A, Lotan Y, Sedelaar JP, Hatiboglu G, Serrallach M, Heidenreich A, Oto A, Raman S, Haider M, Futterer J, Tirkes T, Arora S, Macura K, Costa D, Bomers J, Bonekamp D, Persigehl T, Clarke G, Staruch R, Chin J, Kltz L. Pivotal study of MRI-guided transurethral ultrasound ablation (TULSA) of localized prostate cancer:5-year follow up. Poster #197, 2024 SUO Annual Meeting, November 28 – December 1, 2023, Washington, D.C.
 31. Holland L, Bhanvadia R, Iftach J, Taylor J, Bagrodia A, Gaston K, Lotan Y, Margulis V, Woldu S. Socioeconomic and demographic disparities in administration of immunotherapy for advanced urothelial carcinoma of the bladder. Poster #68, 2024 SUO Annual Meeting, November 28 – December 1, 2023, Washington, D.C.

2023 AUA Annual Meeting, April 28 – May 1, 2023, Chicago, IL

32. Kirk P, Lotan Y, Zargar H, Fairey A, Dinney C, Mir M, Krabbe LM, Cookson M, Jacobson N, Montgomery J, Vasdev N, Yu E, Xylinas E, Kassouf W, Dall'Era M, Sridar S. Impact of maximal transurethral resection on pathological outcomes at cystectomy in a large, Multi-institutional cohort. 2023 AUA Annual Meeting, April 28 – May 1, 2023, Chicago, IL.
33. Labbate C, Woldu S, Murray K, Rose K, Sexton W, Tachcibana I, Kaimakliotis H, Jacob J, Dickstein R, Linehan J, Nieder A, Bjurlin M, Humphreys M, Ghodoussipour S, Quek M, O'Donnell M. Efficacy and safety of mitomycin fel (UGN-101) as an adjuvant therapy after complete endoscopic management of upper tract urothelial carcinoma. (PD46-08) 2023 AUA Annual Meeting, April 28 – May 1, 2023, Chicago, IL.
34. Pavlovich C, Eggener S, Koch M, Penson D, Relle D, Raman S, Lotan Y, Futterer J, Hatiboglu G, Serrallach M, Heidenreich A, Oto A, Haider M, Sedelaar JP, Tirkes T, Arora S, Macura K, Costa D. Pivotal study of MRI-guided transurethral ultrasound ablation (TULSA) of localized prostate cancer: 4-year follow up.(MP73-05) 2023 AUA Annual Meeting, April 28 – May 1, 2023, Chicago, IL.

35. Jacob J, Woldu S, Linehan J, Labbate C, Rose K, Sexton W, Tachibana I, Kaimakliotis H, Nieder A, Bjurlin M, Humphreys M, Ghodoussipor S, Quek M, O'Donnell M, Eisner B, Feldman. First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors. (PD24-07). 2023 AUA Annual Meeting, April 28 – May 1, 2023, Chicago, IL.
36. Lotan Y, Salari K, Feldman A, Sundi D, Lee J, DiFiore G, Poustchi H, Khoshnia M, Roshandel G, Etemadi A, Goudarzi M, Lentz P, Phillips K, Bicocca V, Koppie T, Gray J. Urinary comprehensive genomic profiling predicts urothelial cancer up to 12 years ahead of clinical diagnosis. An expanded analysis of the golestan cohort study (MP22-19) 2023 AUA Annual Meeting, April 28 – May 1, 2023, Chicago, IL.
37. Johnson B, Raman J, Sara B, Lotan Y. Randomized trial of single-use versus reusable cystoscope for ureteral stent removal. (MP26-20) 2023 AUA Annual Meeting, April 28 – May 1, 2023, Chicago, IL.
38. Lotan Y, Health services research: Value of care, Cost & Outcomes measures. (MP39-Moderator). 2023 AUA Annual Meeting, April 28 – May 1, 2023, Chicago, IL.
39. Lotan Y, Case-based debate – pathology or “Markers”; What is more important? 2023 AUA Annual Meeting, April 28 – May 1, 2023, Chicago, IL.

2022 Society of Urologic Oncology, November 30 – December 2, 2022, San Diego, CA

40. Daneshmand S, Helay P, Kenny R, Halvorsen-Young K, Bivalacqua TJ, Holzberlein JM, Kaimakliotis H, Konety B, Liao J, Pohar K, Steinberg G, Taylor J, Tyson M, Willard B, Joshi S, Gore J, Lotan Y, Porten S, Kates M, Alsyof M, McKee C. The impact of blue light cystoscopy on tumor recurrence in non-muscle invasive bladder cancer patients treated in a real-world setting. Poster# 87. 2022 SUO Annual Meeting, November 30-December 2, 2022. San Diego, CA.
41. Taylor J, Woldu S, Labbate C, Murray K, Rose K, Sexton W, Tachibana I, Kaimakliotis H, Jacob J, Dickstein R, Linehan J, Nieder A, Bjurlin M, Humphreys M, Ghodoussipor S, Quek M, O'Donnell M, Eisner B, Feldman A, Matin S, Lotan Y. Early experience with UGN-101 for the treatment of upper tract urothelial cancer- A multi-center evaluation of practice patterns and outcomes. Poster# 152. Poster# 87. 2022 SUO Annual Meeting, November 30-December 2, 2022. San Diego, CA.
42. Linehan J, Jacob J, Labbate C, Rose K, Sexton W, Tachibana I, Kaimakliotis H, Nieder A, Bjurlin M, Humphreys M, Ghodoussipor S, Dickstein R, Quek M, O'Donnell M, Eisner B, Feldman A, Woldu S, Matin S, Lotan Y, Murray K. Comparison of administration route for UGN-101 on upper tract urothelial carcinoma: A multi center evaluation. Poster# 157. Poster# 87. 2022 SUO Annual Meeting, November 30-December 2, 2022. San Diego, CA.
43. Meng X, Gold S, Bochner E, Khalighinejad P, de Leon A, Goldberg K, Lotan Y, Costa D. MRI-Guided transurethral ultrasound ablation in men with localized prostate cancer: Evaluation of trial findings in post-study clinical program. Poster# 220.

AUA Annual Meeting, May 13-16, 2022, New Orleans, LA

44. Babar M, Zhu D, Loloi J, Laudano M, Ohmann E, Abraham N, Small A, Watts K. Telemedicine satisfaction and outcome for adult urological postoperative care: Results from the randomized evaluation and metrics observing telemedicine efficacy (Remote) trial. (Moderator: Y Lotan - Abstract: MP39-01) 2022 AUA Annual Meeting, May 13-16, 2021. New Orleans, LA.
45. Golla V, Shan Y, Farran E, Stewart C, Vu K, Yu A, Khaki AR, Keegan K, Kamat A, Tyler DS, Freedland SJ, Williams SB. Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer. (Moderator: Y Lotan - Abstract: MP39-02) 2022 AUA Annual Meeting, May 13-16, 2021. New Orleans, LA.
46. Sharma P, Bartolone S, Ward E, Varabulea A, Peters K, Janicki J, Abraham N, Laudano M, Smith C, Zwaans B, Chancellor M, Lamb L. A cost and time analysis of participant recruitment and urine sample collection through social media optimization. (Moderator: Y Lotan - Abstract: MP39-03) 2022 AUA Annual Meeting, May 13-16, 2021. New Orleans, LA.
47. Okhawere K, Milky G, Shih I, Bandani K. Comparison of one-year healthcare expenditure and utilizations between minimally invasive and open surgical approaches among patients undergoing nephrectomy. (Moderator: Y Lotan - Abstract: MP39-04) 2022 AUA Annual Meeting, May 13-16, 2021. New Orleans, LA.
48. Nauheim J, Fang R, Meeks W, Confesor K, North A. Urology advanced practice providers in rural America: An opportunity to provide care. (Moderator: Y Lotan - Abstract: MP39-05) 2022 AUA Annual Meeting, May 13-16, 2021. New Orleans, LA.
49. Wymer K, Narang G, Slade A, Sharma V, Thao V, Borah B, Rivera M, Cheney S, Humphreys M. Evaluating the real-world payer and patient costs of BPH surgical Management. (Moderator: Y Lotan - Abstract: MP39-06) 2022 AUA Annual Meeting, May 13-16, 2021. New Orleans, LA.
50. Kurtman J, Wang C, Melendez E, Finkelstein J, Carpenter C. The impact of patient and provider demographics on press ganey – Ratings in Urology: Who is at risk of bias? (Moderator: Y Lotan - Abstract: MP39-07) 2022 AUA Annual Meeting, May 13-16, 2021. New Orleans, LA.
51. Towe M, Nackeeran S, Hout M, Bhat A, Ramasamy R, Shah H. Impact of SARS-CoV2 pandemic on the diagnosis and surgical intervention of common urological conditions: Results from a multi-institutional database from the United States. (Moderator: Y Lotan - Abstract: MP39-08) 2022 AUA Annual Meeting, May 13-16, 2021. New Orleans, LA.
52. Kirk P, Wang A, Raskolnikov D, Psutka S, Schade G, Gore J, Nyame Y, Kelly J, Wright. Comparison of alvimopan versus naloxegol for enhancing postoperative recovery following radical cystectomy for bladder cancer. (Moderator: Y Lotan - Abstract: MP39-09) 2022 AUA Annual Meeting, May 13-16, 2021. New Orleans, LA.
53. Bree K, Shan Y, Hensley P, Lobo N, Hu C, Tyler D, Chamie K, Kamat A, Williams S. Management, Surveillance patterns, and costs associated with low-grade Ta non-muscle invasive bladder cancer. (Moderator: Y Lotan - Abstract: MP39-10) 2022 AUA Annual Meeting, May 13-16, 2021. New Orleans, LA.
54. Wymer K, Narang G, Slade A, Sharma V, Thao V, Borah B, Rivera M, Cheney S, Humphreys M. Cost-effectiveness of holmium laser enucleation of the prostate: Insights from a Markov model comparing BPH surgical options for Glands<80g. (Moderator: Y Lotan - Abstract: MP39-11) 2022 AUA Annual Meeting, May 13-16, 2021. New Orleans, LA.
55. Butaney M, Johnson A, Bulusu, Gandham D, Jamil M, Noyes S, Anema J, Levin M, Rosenberg B, Lane B, Rogers C. Reducing post-operative emergency department visits and readmissions after nephrectomy: an initial evaluation of the MUSIC-KIDNEY

- registry. (Moderator: Y Lotan - Abstract: MP39-12) 2022 AUA Annual Meeting, May 13-16, 2021. New Orleans, LA.
56. Joyce DD, Wyner KM, Shama V, Moriaty J, Borah BJ, Geynisman D, Plimack E, Costello B, Pagliaro L, Boorjan S. Cost-effectiveness of neoadjuvant chemotherapy regimens prior to radical cystectomy for muscle-invasive bladder cancer. (Moderator: Y Lotan - Abstract: MP39-13) 2022 AUA Annual Meeting, May 13-16, 2021. New Orleans, LA.
 57. Fero K, Shan Y, Movva G, Baillargeon J, Tyler D, Chamie K, Williams S. Comparing healthcare utilization and costs according to renal preservation versus radical nephroureterectomy management for patients with non-metastatic upper tract urothelial carcinoma. (Moderator: Y Lotan - Abstract: MP39-14) 2022 AUA Annual Meeting, May 13-16, 2021. New Orleans, LA.
 58. Saltzman R, Golan R, Masterson T, Ramasamy R. Restorative therapy clinical trials for erectile dysfunction: A scoping review of endpoint measures. (Moderator: Y Lotan - Abstract: MP39-15) 2022 AUA Annual Meeting, May 13-16, 2021. New Orleans, LA.
 59. Hebert K, Horns J, Driggs N, Das R, Matta R, McCormick B, Hotaling J, Myers J. Impact of high-grade radiation injury following prostate cancer radiation on healthcare cost and utilization. (Moderator: Y Lotan - Abstract: MP39-16) 2022 AUA Annual Meeting, May 13-16, 2021. New Orleans, LA.
 60. Singh A, Lassner J, Diaz A, Sleiman M, Modi P. Advanced practice providers and patients access in academic medical centers: A secret shopper study. (Moderator: Y Lotan - Abstract: MP39-17) 2022 AUA Annual Meeting, May 13-16, 2021. New Orleans, LA.
 61. Wood A, Kaltowitz E, Kaplans-Marans E, Lubin M, Teper E, Silver D, Schulman A. Same day discharge after robotic partial nephrectomy: Is it worth it?. (Moderator: Y Lotan - Abstract: MP39-18) 2022 AUA Annual Meeting, May 13-16, 2021. New Orleans, LA.
 62. Reynolds J, Gadzinski A, Dwyer E, Stewart B, Abarro I, Holt S, Gore J. Interstate telemedicine for urologic oncology care during the COVID-19 pandemic. (Moderator: Y Lotan - Abstract: MP39-19) 2022 AUA Annual Meeting, May 13-16, 2021. New Orleans, LA.
 63. Nyugen D, Labban M, Briggs L, Cole AP, Lipsitz S, Iyer H, Rebbeck T, Weissman J, Trinh Q. Access to definitive treatment and survival for intermediate-risk and high-risk prostate cancer at hospitals systems serving health disparity populations (HSDPs). (Moderator: Y Lotan - Abstract: MP39-20) 2022 AUA Annual Meeting, May 13-16, 2021. New Orleans, LA.

AUA Annual Meeting, Virtual, September 10-13, 2021

64. Cook G, Howard J, Margulis V, **Lotan Y**. Outcomes of patients with BCG-Unresponsive non-muscle invasive bladder cancer: A single-institution, real-world series. (Abstract: PD09-10) 2021 AUA Annual Meeting, Virtual, September 10-13, 2021.
65. Ashbrook C, Bhanvadia R, Bagrodia A, **Lotan Y**, Margulis V, Woldu S. Population-based analysis of cost and per-operative outcomes between open and robotic primary retroperitoneal lymph node dissection for germ cell tumors. (Abstract: MP40-03). 2021 AUA Annual Meeting, Virtual, September 10-13, 2021.
66. Cook G, Howard J, Margulis V, Sagalowsky A, Raj G, Woldu S, Bagrodia A, **Lotan Y**. Perioperative and oncologic outcomes after concurrent cystectomy and nephroureterectomy. (Abstract: MP48-16). 2021 AUA Annual Meeting, Virtual, September 10-13, 2021.
67. Bhanvadia R, Carpinito G, **Lotan Y**, Bagrodia A, Gahan J, Margulis V, Cadeddu J, Roehrborn C, Woldu S. Preoperative telehealth evaluation alone prior to urologic

- surgery: Safety, Feasibility, Surgical Outcomes. (Abstract: PD28-03) 2021 AUA Annual Meeting, Virtual, September 10-13, 2021.
68. Bhanvadia R, Baky F, Kenigsberg A, **Lotan Y**, Howard J, Meng X, Bagrodia A, Margulis V, Woldu S. Hospital safety net burden predicts disparities in presentation of pathologic fracture in metastatic prostate and renal cancer. (Abstract: MP58-06) 2021 AUA Annual Meeting, Virtual, September 10-13, 2021.
69. Bhanvadia R, Baky F, Kenigsberg A, **Lotan Y**, Howard J, Meng X, Bagrodia A, Margulis V, Woldu S. Hospital safety net burden identifies disparities in non-definitive management and survival in high risk localized prostate cancer. (Abstract: PD46-06) 2021 AUA Annual Meeting, Virtual, September 10-13, 2021.
70. Bhanvadia R, Baky F, Kenigsberg A, **Lotan Y**, Howard J, Meng X, Bagrodia A, Margulis V, Woldu S. Safety net hospital status impacts treatment choice for small renal masses: A population based analysis. (Abstract: MP45-14) 2021 AUA Annual Meeting, Virtual, September 10-13, 2021.
71. Miranda A, Howard J, McLaughlin M, Meng X, Garant A, Bagrodia A, Margulis V, **Lotan Y**, Hannan R, Desai N, Woldu S. Metastasis-directed radiation therapy after radical cystectomy for bladder cancer. (Abstract: PD55-05) 2021 AUA Annual Meeting, Virtual, September 10-13, 2021.
72. Seyedian S, Meng X, Roberts S, Ahmadi H, Howrad J, Chaplin I, Bagrodia A, Margulis V, Woldu S, **Lotan Y**, Daneshmand S. Utility of blue light flexible cystoscopy for bladder cancer surveillance after intravesical therapy. (Abstract: PD63-03) 2021 AUA Annual Meeting, Virtual, September 10-13, 2021.
73. Kenigsberg A, Carpinito G, Gold S, Meng X, Sundarm C, Farrow J, Derweesh I, Meagher M, Uzzo R, Abdollah F, Jamil M, Ferro M, Minervini A, Djaladat H, Ghoreifi A, Mottrie A, Rha M, Autorino R, Cabonara U, Simone G, Mehrazin R, Katims A, Eun D, Reese A, Gonzalgo M, Bhattu A, Porter J, Wu Z, **Lotan Y**, Margulis V. Perioperative intravesical chemotherapy in minimally invasive radical nephroureterectomy for upper tract urothelial carcinoma: low but increasing utilization worldwide. (Abstract: MP48-11) 2021 AUA Annual Meeting, Virtual, September 10-13, 2021.
74. Gold S, Kenigsberg A, Lotan Y. Evaluating performance of the 2020 American Urological Association (AUA) Microhematuria (MH) guidelines: Retroactive application in a large healthcare system. (Abstract: PD470-02). 2021 AUA Annual Meeting, Virtual, September 10-13, 2021.
75. Lotan Y, Schuckman A, Boorjan S, Cilwas K, Dinney C. Phase III trial of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive, non-muscle invasive bladder cancer: Two year follow-up in the TA/TI cohort. (Abstract: MP16-02) 2021 AUA Annual Meeting, Virtual, September 10-13, 2021.
76. Gold S, Kenigsberg A, Carpinito G, Lotan Y. Diagnostic and cost implications of the 2020 American Urological Association (AUA) microhematuria (MH) guidelines: Modeling impact in a large public healthcare system. (Abstract: PD4701-01) 2021 AUA Annual Meeting, Virtual, September 10-13, 2021.
77. Kenigsberg A, Gold S, Grant L, Lotan Y. The economics of cystoscopy: A microcost Analyst. (Abstract: MP17-10) 2021 AUA Annual Meeting, Virtual, September 10-13, 2021.
78. Schuckman A, Lotan Y, Boorjan S, Cilwa K, Dinney C. Efficacy of intravesical nadofaragene firadenovec for patients with carcinoma in situ (CIS), BCG-unresponsive non-muscle invasive bladder cancer (NMIBC): Longer-term follow-up from the phase III trial. (Abstract: MP16-01) 2021 AUA Annual Meeting, Virtual, September 10-13, 2021.
79. Lotan Y, Jong J, Liu V, Bismar T, Boorjan S, Huang H, Davicioni E, Mian O, Wright J, Necchi A, Dall'Era M, Kaimakiotis H, Black P, Gibb E, Boormans J. Luminal primary muscle-invasive bladder cancer patients are less likely to benefit from platinum-based

- neoadjuvant chemotherapy. (Abstract: PD51-08) 2021 AUA Annual Meeting, Virtual, September 10-13, 2021.
80. Klein E, Partin A, Lotan Y, Baniel J, Dineen M, Hafron J, Manickam K, Pliskin M, Wagner M, Zhu H, Chait A, Kestranek A, Gawande P, Ferreira L, Zaslavsky B, Stovsky M. Isopso: Clinical performance of a single parameter, structure based test for high grade prostate cancer in a large, multicenter, prospective validation trial. (Abstract: MP60-03) 2021 AUA Annual Meeting, Virtual, September 10-13, 2021.
 81. Klotz L, Paviovich C, Chin J, Hatiboglu G, Koch M, Penson D, Raman S, Oto A, Futterer J, Serrallach M, Relle J, Lotan Y, Heidenreich A, Bonekamp D, Haider M, Sedelaar JP, Tirkes T, Arora S, Macura K, Costa D, Pantuck A, Bormers J, Clarke G, Staruch R, Eggener S. (Abstract: MP46-03) 2021 AUA Annual Meeting, Virtual, September 10-13, 2021.
 82. Mitra A, Narayan V, Boorjian S, Alemozaffar M, Konety B, Shore N, Gomella L, Karnat A, Bivalacqua T, Montgomery J, Lerner S, Busby J, Poch M, Crispin P, Steinberg G, Schuckman A, Downs T, Svatek R, Mashni J, Lane B, Guzzo T, Bratslavsky G, Karch L, Woods M, Brown G, Canter D, Luchey A, Lotan Y, Krupski T, Inman B, Williams M, Cookson M, Keegan K, Andriole G, Sankin A, Boyd A, O'Donnell M, Yang M, Sawutz D, Philipson R, Herttuala S, Parker N, Dinney C. Anti-adenoviral antibody levels predict nadofaragene firadenovec response in BCG-Unresponsive NMIBC: Results from a phase 3 trial. (Abstract: PD09-02) 2021 AUA Annual Meeting, Virtual, September 10-13, 2021.
 83. Lotan Y, Moderator – Health services research: Value of Care: Cost and Outcomes Measures II (Abstract: PD25), 2021 AUA Annual Meeting, Virtual, September 10-13, 2021.

34th Annual European Association of Urology Congress in Barcelona, Spain. March 15 – 19, 2019

84. **Lotan Y**, Boorjian SA, Zhang J, Bivalacqua TJ, Porten SP, Lerner SP, Wheeler TM, Hutchinson R, Francis F, Du Plessis M, Davicioni E, Svatek R, Black P, Gibb EA. Molecular subtyping reveals luminal bladder tumors have lower rates of pathological upstaging at radical cystectomy.
85. Batista Da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Zarni Oo H, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall'Era MA, Douglas J, Boormans L, Van Der Heijden MS, Wu C-L, Van Rhijn BWG, Gupta S, Grivas P, Mouw KW, Konety BR, Seiler R, Daneshmand S, Mian OY, Efstathiou JA, **Lotan Y**, Black P. Molecular characterization of neuroendocrine-like bladder cancer.

97th Annual Meeting of the South Central Section of the AUA. Nashville, TN. September 26 - 29, 2018

86. Timothy Clinton MD, MPH, Solomon Woldu MD, Oner Sanli MD, Richard Wang MD, Ganesh Raj MD, PhD, Authur Sagalowsky MD, **Yair Lotan MD**, Vitaly Margulis MD UT Southwestern (Presented By: Timothy Clinton MD, MPH). Does Robotic Cystectomy Compromise Oncologic Outcomes?
87. Solomon Woldu MD, Oner Sanali MD, Timothy Clinton MD, Richard Wang BA, **Yair Lotan MD**, UT Southwestern, Istanbul University (Presented By: Solomon Woldu MD). Validating the Predictors of Outcomes Following Radical Cystectomy.
88. Timothy Clinton MD, MPH, Solomon Woldu MD, Oner Snli MD, Richard Wang MD, Vltaly Margulis MD, **Yair Lotan MD** (Presented By: Timothy Clinton MD, MPH). What is the Impact of Robotics and U-Opioid Antagonist Therapy on the Cost of Radical Cystectomy?

AUA Annual Meeting. San Francisco, CA. May 18-21, 2018

1. Yuval Freifeld, Yin Xi, Claus Roehrborn, Franto Francis, Niccolo Passoni, **Yair Lotan**, Kenneth Goldberg, Brad Hornberger, Vitaly Margulis, Ivan Pedrosa, Ganesh Raj, Jeffery Cadeddu, Daniel Costa. Added Value of Systematic Biopsies in Men with Abnormal Multiparametric MRI Undergoing MRI-TRUS Fusion Prostate Biopsy. Abstract: PD23-04.
2. Solomon Woldu, Justin Matulay, Timothy Clinton, Nirmish Singla, Yuval Freifeld, Oner Sanli, Laura-Maria Krabbe, Ryan Hutchinson, **Yair Lotan**, Hans Hammers, Raquibul Hannan, James Brugarolas, Aditya Bagrodia, Vitaly Margulis. Incidence and Outcomes of Delayed Targeted Therapy Following Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Nationwide Cancer Registry Study. Abstract: PD24-04.
3. Eric Klein, Arnon Chait, Jason Hafron, Kenneth Kernen, Kannan Manickam, Andrew Stephenson, Matthew Wagner, Hui Zhu, Martin Dineen, **Yair Lotan**, Alan Partin, Jack Baniel, Petah Tikva, Aimee Kestranek, Boris Zaslavsky, Mark Stovsky. Prospective Validation of the ISOPSA™ Assay for Detection of High Grade Prostate Cancer. Abstract: PD60-05.
4. John Gore, Marguerite du lessis, Darlene Dai, Kasra Yousefi, Darby Thompson, Lawrence Karsh, Brian Lane, Michael Franks, David Chen, Mark Bandyk, Adam Kibel, Hyung Kim, William Lowrance, Paul Morani, Scott Perrapato, Edouardo Trabulsi, Elai Davicioni, **Yair Lotan**, Daniel Lin. Decipher Test Impacts Adjuvant and Salvage Treatments Received Following Radical Prostatectomy. Abstract: PD60-07.
5. Solomon Woldu, Joseph Moore, Yuval Freifeld, Timothy Clinton, Nirmish Singla, Laura-Maria Krabbe, Ryan Hutchinson, **Yair Lotan**, Yull Arriaga, Vitaly Margulis, Aditya Bagrodia. Utilization and Impact of Post-Chemotherapy Retroperitoneal Lymph Node Dissection in Advanced Non-Seminomatous Germ Cell Tumor. Abstract: MP37-01.
6. Timothy Clinton, Solomon Woldu, Oner Sanli, Richard Wang, Louis Gianni, Ganesh Raj, Arthur Sagalowsky, Vitaly Margulis, **Yair Lotan**. Implications of Neoadjuvant Chemotherapy on Cost and Outcomes in Muscle Invasive Bladder Cancer. Abstract: MP41-06.
7. Solomon Woldu, Oner Sanli, Peter Black, Matthew Milowsky, **Yair Lotan**. Cost-Effectiveness Analysis of a Biomarker-Based Approach to Select Patients with Muscle-Invasive Bladder Cancer for Neoadjuvant Chemotherapy. Abstract: MP47-09.

2018 Genitourinary Cancers Symposium. San Francisco, CA. February 8-10, 2018

1. Solomon L. Woldu, Justin T. Matulay, Timothy N Clinton, Nirmish Singla, Yuval N Freifeld, Oner N Sanli, Laura-Maria Krabbe, Ryan C Hutchinson, **Yair Lotan**, Hans J. Hammers, Raquibul Hannan, James Brugarolas, Aditya Bagrodia, Vitaly Margulis. Utilization and survival implications of a delayed approach to targeted therapy for metastatic renal cell carcinoma: A nationwide cancer registry study. Poster Session C: Renal Cell Cancer. Abstract: 586.
2. Jonathan L. Wright, Marc Dall'era, Trinity Bivalacqua, Roland Seiler, Yang Liu, Ewan Gibb, Natalie Qiqi Wang, Nicholas Erho, Mohammed Alshalalfa, Elai Davicioni, Jason A. Efsthathiou, James G. Douglas, Joost L Boormans, Michiel Simon Van Der Heijden, **Yair Lotan**, Peter C. Black. A genomic classifier for identifying a neuroendocrine-like bladder cancer subtype. Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers. Abstract: 440.
3. John L. Gore, Marguerite Du Plessis, Darlene Dai, Kasra Yousefi, Darby Thompson, Lawrence Ivan Karsh, Brian R. Lane, Michael Franks, David Chen, Mark Bandyk, Adam S. Kibel, Hyung Lae Kim, William Thomas Lowrance, Paul Maroni, Scott David Perrapato, Edouard John Trabulsi, Robert J. Waterhouse, Elai Davicioni, **Yair Lotan**,

Daniel W. Lin. Impact of decipher test on adjuvant and salvage treatments received following radical prostatectomy. Poster Session A: Prostate Cancer. Abstract 112.

2017 Society of Urologic Oncology. San Antonio, TX. November 29-December 7, 2017

1. Solomon Woldu, MD; Justin Matulay, MD; Nirmish Singla, MD; Timothy Clinton, MD; Laura-Maria Krabbe, MD; Ryan Hutchinson, MD; Yuval Freifeld, MD; Arthur Sagalowsky, MD; Yair Lotan, MD; Vitaly Margulis, MD and Aditya Bagrodia, MD. Impact of Hospital Case Volume on Testicular Cancer Outcomes and Practice Patterns. Oral Abstract Session: Podium #7. Presented By: Solomon L. Woldu, MD.
2. Solomon Woldu, MD; Oner Sanli, MD; Peter Black, MD; Matthew Milowsky, MD and **Yair Lotan, MD**. Cost-Effectiveness Analysis of a Biomarker-Based Approach to Select Patients with Muscle-Invasive Bladder Cancer for Neoadjuvant Chemotherapy. Poster Session I: Poster #1. Presented By: Solomon L. Woldu, MD.
3. Nirmish Singla, MD; Laura-Maria Krabbe, MD; Ahmet Aydin ; Vandana Panwar, MD; Ryan Hutchinson, MD; Solomon Woldu, MD; Christopher Wood, MD; Jose Karam, MD; Alon Weizer, MD; Jay Raman, MD; Mesut Remzi, MD; Nathalie Rioux-Leclercq, MD; Andrea Haitel, MD; Marco Roscigno, MD; Christian Bolenz, MD; Karim Bensalah, MD; Arthur Sagalowsky, MD; Shahrokh Shariat, MD; **Yair Lotan, MD**; Aditya Bagrodia, MD; Payal Kapur, MD and Vitaly Margulis, MD. Prognostic Significance of Ezh2 Expression in Upper Tract Urothelial Carcinoma. Session I: Poster #11. Presented By: Nirmish Singla, MD.
4. Angela Smith, MD; Siamak Daneshmand, MD; Kamal Pohar, MD; Michael Cookson, MD; Michael Woods, MD; Eduard Trabulsi, MD; William Huang, MD; Jeffrey Jones, MD; Jennifer Taylor, MD; Trinity Bivalacqua, MD; Tracy Downs, MD; Michael O'Donnell, MD, Gary Steinberg MD, Joel DeCastro MD, Ashish Kamat MD, Badrinath Konety MD, Matthew Resnick MD, Mark Schoenberg MD; J. Stephen Jones, MD and **Yair Lotan, MD**. Assessment of Blue Light Flexible Cystoscopy with Cysview on Patient Reported Outcomes: A Prospective, Multicenter, Within-Patient Controlled Study in Detection of Bladder Cancer during Surveillance. Session I: Poster #23. Presented By: Angela B. Smith, MD, MS.
5. Solomon Woldu, MD; Justin Matulay, MD; Timothy Clinton, MD; Yuval Freifeld, MD; Ryan Hutchison, MD; Yair Lotan, MD; James Brugarolas, MD; Hans Hammers, MD; Vitaly Margulis, MD and Aditya Bagrodia, MD. Impact of Delayed Targeted Therapy in Renal Cell Carcinoma: A Nationwide Cancer Registry Study. Session I: Poster #52. Presented By: Solomon L. Woldu, MD.
6. Laura-Maria Krabbe, MD; Nirmish Singla, MD; Ahmet Murat Aydin, MD; Vandana Panwar, MD; Ryan Hutchinson, MD; Solomon Woldu, MD; May Westerman, MD; Christopher Wood, MD; Jose Karam, MD; Alon Weizer, MD; Jay Raman, MD; Mesut Remzi, MD; Nathalie Rioux-Leclercq, MD; Andrea Haitel, MD; Marco Roscigno, MD; Christian Bolenz, MD; Karim Bensalah, MD; Arthur Sagalowsky, MD; Shahrokh Shariat, MD; **Yair Lotan, MD**; Aditya Bagrodia, MD; Payal Kapur, MD and Vitaly Margulis, MD. Prognostic Significance of Bap1 Expression in Upper Tract Urothelial Carcinoma. Session I: Poster #56. Presented By: Laura-Maria Krabbe, MD.

AUA Annual Meeting. Boston, MA. May 12-16, 2017

1. Ryan Hutchinson, Nirmish Singla, Solomon Woldu, Abdulhadi Akhtar, Justin Haridas, Deepa Bhat, Claus Roehrborn, **Yair Lotan**. Impact of Primary Care Physician Factors on Adherence to United States Preventative Services Task Force Recommendation against PSA Screening. Abstract: PD40-11.

2. Solomon Woldu, Ryan Hutchinson, Nirmish Singla, Boyd Viers, Laura-Maria Krabbe, Arthur Sagalowsky, **Yair Lotan**, Aditya Bagrodia, and others. Adherence to Guidelines: Surgical Staging of Inguinal Lymph Nodes in High-Risk Clinically Localized Penile Cancer and Survival Implications. Abstract: PD49-03.
 3. Daniel Costa, Niccolo Passoni, Yin Xi, John Leyendecker, Alberto Diaz de Leon, Susana Otero-Muinelo, Harpreet Grewal, Franto Francis, Claus Roehrborn, **Yair Lotan**, Payal Kapur, Aditya Bagrodia, Neil Rofsky, Ivan Pedrosa. Diagnostic Performance and Reproducibility of a Likert Scale Versus Qualitative Descriptors for Determination of Extraprostatic Tumor Extension with Multiparametric Magnetic Resonance Imaging of The Prostate. Abstract: PD61-06.
 4. John L. Gore, Marguerite du Plessis, Maria Santiago-Jimenez, Kasra Yousefi, Darby J. S. Thompson, Lawrence Karsh, Brian Lane, Michael Franks, David Chen, Mark Bandyk, Fernando Bianco, Gordon Brown, William Clark, Adam Kibel, Hyung Kim, William Lowrance, Murugesan Manoharan, Paul Maroni, Scott Perrapato, Paul Sieber, Edouard Trabulsi, Robert Waterhouse, Elai Davicioni, **Yair Lotan**, Daniel W. Lin. Decipher Test Impacts Decision-Making Among Patients Considering Adjuvant and Salvage Treatment Following Radical Prostatectomy: Interim Results From The Multicenter Prospective Pro-Impact Study. Abstract PD71-01.
 5. D Laura-Maria Krabbe, Barbara Heitzplatz, Ryan Hutchinson, Solomon Woldu, Nirmish Singla, Sina Preuss, Martin Boegemann, Christopher Wood, Jose Karam, Alon Weizer, Jay Raman, Mesut Remzi, Nathalie Rioux-Leclercq, Rennes, Andrea Haitel, Marco Roscigno, Christian Bolenz, Karim Bensalah, Arthur Sagalowsky, Shahrokh Shariat, **Yair Lotan**, Evanguelos Xylinas, Vitaly Margulis. Prognostic Value of PD-1 and PD-L1 Expression in Patients with High-Grade Urothelial Carcinoma of the Upper Urinary Tract. Abstract: MP71-03.
 6. Ralf Kittler, Christine Shiang, Ryan Hutchinson, Rahul Kollipara, Payal Kapur, Franto Francis, **Yair Lotan**. Low Grade Bladder Tumors Progress to High Grade Via Two Distinct Mechanisms. Abstract: MP44-03.
-
7. Homayoun Zargar, Jay B Shah, Elisabeth E Fransen van de Putte, Kylea R. Potvin, Kamran Zargar-Shoshtari, Bas W van Rhijn, Siamak Daneshmand, Jeff M Holzbeierlein, Philippe E Spiess, Eric Winkquist, Simon Horenblas, Colin Dinney, Adrian S Fairey, Evan Kovac, Laura-Maria Krabbe, Michael S Cookson, Niels-Erik Jacobsen, Nilay Gandhi, Joshua Griffin, Jeffrey S Montgomery, Nikhil Vasdev, Evan Y Yu, Evanguelos Xylinas, Nicholas J. Campaign, Jo-An Seah, Cesar E Ercole, Srikala S Sridhar, John S McGrath, Jonathan Aning, Shahrokh F Shariat, Jonathan L Wright, Andrew C Thorpe, Todd M Morgan, Petros Grivas, Andrew J Stephenson, Trinity J Bivalacqua, Scott North, Daniel A Barocas, **Yair Lotan**, Peter C Black, Wassim Kassouf. Dense Dose Mvac Versus Gc in Patients with Ct3-4a Bladder Cancer Treated with Radical Cystectomy: A Real World Experience. Abstract: MP58-04.
 8. Nirmish Singla, Ahmet Aydin, Vandana Panwar, Ryan Hutchinson, Solomon Woldu, Christopher Wood, Jose Karam, Alon Weizer, Jay Raman, Mesut Remzi, Nathalie Rioux-Leclercq, Andrea Haitel, Marco Roscigno, Christian Bolenz, Karim Bensalah, Arthur Sagalowsky, Shahrokh Shariat, **Yair Lotan**, Aditya Bagrodia, Payal Kapur, Vitaly Margulis, Laura-Maria Krabbe. Prognostic Significance of Bap1 Expression in Upper Tract Urothelial Carcinoma. Abstract: MP71-05.

9. Ahmet Aydin, Nirmish Singla, Vandana Panwar, Ryan Hutchinson, Solomon Woldu, Christopher Wood, Jose Karam, Alon Weizer, Jay Raman, Mesut Remzi, Nathalie Rioux-Leclercq, Andrea Haitel, Marco Roscigno, Christian Bolenz, Karim Bensalah, Arthur Sagalowsky, Shahrokh Shariat, **Yair Lotan**, Aditya Bagrodia, Payal Kapur, Vitaly Margulis, Laura-Maria Krabbe. Prognostic Significance of Ezh2 Expression in Upper Tract Urothelial Carcinoma. Abstract: MP71-06.
10. Ryan Hutchinson, Nirmish Singla, Laura-Maria Krabbe, Solomon Woldu, Gong Chen, Charles Rew, Isamu Tachibana, **Yair Lotan**, Jeffrey A. Cadeddu, Vitaly Margulis. Differential Hemodynamic and Antihypertensive Changes after Partial Nephrectomy versus Radical Nephrectomy. Abstract MP72-20.
11. Jodi Antonelli, Thomas Bentley, Sara Best, Stephen Nakada, Chad Tracy, Lewis Thomas, Ryan Steinberg, Tracy Marien, Nicole Miller, Adam Cohen, Elysha Kowitz, Xilong Li, Beverley Huet, Margaret Pearle, Yair Lotan. 24 Hour Urine Utilization in Nephrolithiasis Treatment: Results from M-Stone (Multi-Center Collaboration to Study Treatment Outcomes in Nephrolithiasis Evaluation). Abstract MP90-13.
12. Solomon Woldu, Ryan Hutchinson, Nirmish Singla, Boyd Viers, Laura-Maria Krabbe, Arthur Sagalowsky, **Yair Lotan**, Aditya Bagrodia, Vitaly Margulis. Factors Associated with Stage at Presentation and Survival in Penile Cancer. Abstract MP92-14.
13. Siamak Daneshmand, Sanjay Patel, **Yair Lotan**, Kamal Pohar, Edouard Trabulsi, Michael Woods, Tracy Downs, William Huang, Jennifer Taylor; Michael O'Donnell, Trinity Bivalacqua, Joel DeCastro, Gary Steinberg, Ashish Kamat, Matthew Resnick, Badrinath Konety, Mark Schoenberg, Stephen Jones. Blue Light Flexible Cystoscopy (Blfc) with Hexaminolevulinate (Hal) and White Light Flexible Cystoscopy: A Prospective, Comparative, Within-Patient Controlled Multi-Center Phase 3 Study in the Detection of Bladder Cancer during Surveillance. Abstract PPTLBA-02.

2017 Genitourinary Cancers Symposium. Orlando, FL. February 16-18, 2017

1. Laura-Maria Krabbe, Barbara Heitplatz, Ryan C Hutchinson, Solomon L. Woldu, Sina Preuss, Christopher G. Wood, Jose A. Karam, Alon Z. Weizer, Jay D. Raman, Mesut Remzi, Nathalie Rioux-Leclercq, Andrea Haitel, Marco Roscigno, Christian Bolenz, Karim Bensalah, Arthur I. Sagalowsky, Shahrokh F. Shariat, **Yair Lotan**, Evangelos Xylinas, Vitaly Margulis. Prognostic value of PD-1 and PD-L1 expression in patients with high-grade urothelial carcinoma of the upper urinary tract. Abstract #179246. Presented by: Laura-Maria Krabbe, MD.
2. John L. Gore, Marguerite Du Plessis, Maria Santiago-Jimenez, Kasra Yousefi, Darby Thompson, David Chen, William Clark, Michael Franks, Lawrence Ivan Karsh, Adam S. Kibel, Hyung Lae Kim, Brian R. Lane, **Yair Lotan**, William Thomas Lowrance, Paul Maroni, Scott David Perrapato, Edouard John Trabulsi, Robert J. Waterhouse Jr., Elai Davicioni, Daniel W. Lin. Effect of decipher test on adjuvant treatment decision-making among men with high-risk pathology at radical prostatectomy: Results from a multicenter prospective PRO-IMPACT study. Abstract# 174919. Presented by: John L. Gore, MD, MS.
3. Stephen A. Boorjian, Neal D. Shore, Daniel Canter, Kenneth Ogan, Lawrence Ivan Karsh, Tracy Downs, Leonard G. Gomella, Ashish M. Kamat, **Yair Lotan**, Robert S. Svatek, Trinity Bivalacqua, Robert Grubb III, Tracey Krupski, Seth P. Lerner, Michael Woods, Brant Allen Inman, Matthew I. Milowsky, Nigel Parker, David Sawutz, Colin P.N. Dinney. Intravesical rad-IFN α /Syn3 for patients with high-grade, bacillus Calmette-Guérin (BCG) refractory or relapsed non-muscle invasive bladder cancer: A phase II randomized study. Abstract # 178275. Presented by: Stephen A. Boorjian, MD.

2016 Society of Urologic Oncology. San Antonio, TX. November 30-December 2, 2016

1. Laura-Maria Krabbe, MD; Barbara Heitplatz, MD; Ryan Hutchinson, MD; Solomon Woldu, MD; Sina Preuss Cand, MD; Martin Bögemann, MD; Christopher Wood, MD; Jose Karam, MD; Alon Weizer, MD; Jay Raman, MD; Mesut Remzi, MD; Nathalie Rioux- Leclercq, MD; Andrea Haitel, MD; Marco Roscigno, MD; Christian Bolenz, MD; Karim Bensalah, MD; Arthur Sagalowsky, MD; Sharokh Shariat, MD; **Yair Lotan, MD**; Evanguelos Xylinas, MD and Vitaly Margulis, MD. Prognostic Value of Pd-1 and Pd-L1 Expression in Patients with High-Grade Urothelial Carcinoma of the Upper Urinary Tract. Oral Abstract Session: Podium 9. Presented By: Laura-Maria Krabbe, MD
2. Ralf Kittler, Christine Shiang, Ryan Hutchinson, Payal Kapur and **Yair Lotan**. Whole Exome Assessment of Grade Progression in Low-Grade Non-Invasive Bladder Tumors. Whole Exome Assessment of Grade Progression in Low-Grade Non-Invasive Bladder Tumors. Poster Session 1: Poster #: 28; Presented by: Ryan Hutchinson, MD
3. John Gore MD, MS, Marguerite du Plessis BSc, Maria Santiago-Jimenez MS, Kasra Yousefi MS, Darby Thompson PhD, Mark Bandyk MD, Fernando Bianco MD, Gordon Brown MD, David Chen MD, William Clark MD, Michael Franks MD, Lawrence Karsh MD, Adam Kibel MD, Hyung Kim MD, Brian Lane MD, **Yair Lotan MD**, William Lowrance MD, Murugesan Manoharan MD, Paul Maroni MD, Scott Perrapato MD, Paul Sieber MD, Edouard Trabulsi MD, Robert Waterhouse MD, Elai Davicioni PhD and Daniel Lin MD. Decipher Test Impacts Adjuvant Treatment Decision-Making among Patients with High-Risk Pathology at Radical Prostatectomy: Results from The Multicenter Prospective Pro-Impact Study. Poster Session 1: Poster #: 75; Presented by: John Gore MD, MS
4. John Gore, MD, MS; Marguerite du Plessis, BSc; Maria Santiago-Jimenez, MS; Kasra Yousefi, MD; Darby Thompson, PhD; Mark Bandyk, MD; Fernando Bianco, MD; Gordon Brown, MD; David Chen, MD; William Clark, MD; Michael Franks, MD; Lawrence Karsh, MD; Adam Kibel, MD; Hyung Kim, MD; Brian Lane, MD; Yair Lotan, MD; William Lowrance, MD; Murugesan Manoharan, MD; Paul Maroni, MD; Scott Perrapato, MD; Paul Sieber, MD; Edouard Trabulsi, MD; Robert Waterhouse, MD; Elai Davicioni, PhD and Daniel Lin, MD. Decipher Test Impacts Treatment Decision-Making among Patients with Biochemical Recurrence after Radical Prostatectomy: Results from The Multicenter Prospective Pro-Impact Study. Poster Session 1: Poster #76. Presented By: John L. Gore, MD, MS
5. Ryan Hutchinson, MD; Solomon Woldu, MD; Nirmish Singla, MD; Abdulhadi Akhtar, MD; Justin Haridas; Deepa Bhat, MS; Claus Roehrborn, MD and Yair Lotan, MD. Impact of Primary Care Physician Experience on Adherence to United States Preventative Services Task Force Recommendation against PSA Screening. Poster Session 1: Poster #111. Presented by: Solomon Woldu, MD
6. Solomon Woldu, MD; Ryan Hutchinson, MD; Nirmish Singla, MD; Brad Hornberger, PA; Claus Roehrborn, MD and **Yair Lotan, MD**. Adapting Strategies for Prevention of Infection Following Transrectal Prostate Biopsy and Fiducial Marker Placement. Poster Session 1: Poster #113. Presented by: Solomon Woldu, MD

2016 American Society of Clinical Oncology Annual Meeting. Chicago, IL. June 3-7, 2016

1. John L. Gore, Marguerite Du Plessis, Maria Santiago-Jiminez, Kasra Yousefi, Darby J.

- S. Thompson, David Y. T. Chen, William R. Clark, Michael E. Franks, Lawrence Ivan Karsh, Adam S. Kibel, Brian R. Lane, **Yair Lotan**, William Thomas Lowrance, Paul Maroni, Scott David Perrapato, Edouard John Trabulsi, Robert J. Waterhouse Jr., Elai Davicioni, Daniel W. Lin; University of Washington, Seattle, WA; GenomeDx Biosciences, Inc., Vancouver, BC; EMMES Canada, Burnaby, BC; Fox Chase Cancer Center, Philadelphia, PA; Alaska Clinical Research Center, Anchorage, AK; Virginia Urology, Richmond, VA; The Urology Center of Colorado, Denver, CO; Brigham and Women's Hospital, Boston, MA; Spectrum Health Medical Group, Grand Rapids, MI; UT Southwestern Medical Center, Dallas, TX; Huntsman Cancer Hospital, Institute, University of Utah, Salt Lake City, UT; University of Colorado, Denver Medical Campus, Denver, CO; University of Vermont Medical Center, Burlington, VT; Thomas Jefferson University, Philadelphia, PA; Carolina Urology Partners, Gastonia, NC. A Genomic Classifier Impacts Treatment Decision-Making among Patients with Biochemical Recurrence after Radical Prostatectomy: Results from the Multicenter Prospective PRO- IMPACT study. Abstract: #162746.
2. John L. Gore, Marguerite Du Plessis, Maria Santiago-Jiminez, Kasra Yousefi, Darby J.
- S. Thompson, David Y. T. Chen, William R. Clark, Michael E. Franks, Lawrence Ivan Karsh, Adam S. Kibel, Hyung Lae Kim, Brian R. Lane, **Yair Lotan**, William Thomas Lowrance, Paul Maroni, Scott David Perrapato, Edouard John Trabulsi, Robert J. Waterhouse Jr., Elai Davicioni, Daniel W. Lin; University of Washington, Seattle, WA; GenomeDx Biosciences, Inc., Vancouver, BC; EMMES Canada, Burnaby, BC; Fox Chase Cancer Center, Philadelphia, PA; Alaska Clinical Research Center, Anchorage, AK; Virginia Urology, Richmond, VA; The Urology Center of Colorado, Denver, CO; Brigham and Women's Hospital, Boston, MA; Cedars-Sinai Medical Center, Los Angeles, CA; Spectrum Health Medical Group, Grand Rapids, MI; UT Southwestern Medical Center, Dallas, TX; Huntsman Cancer Hospital, Institute, University of Utah, Salt Lake City, UT; University of Colorado, Denver Medical Campus, Denver, CO; University of Vermont Medical Center, Burlington, VT; Thomas Jefferson University, Philadelphia, PA; Carolina Urology Partners, Gastonia, NC. A Genomic Classifier Impacts Adjuvant Treatment Decision-Making among Patients with High-Risk Pathology at Radical Prostatectomy: Results from the Multicenter Prospective PRO- IMPACT Study. Abstract #162383.

AUA Annual Meeting. San Diego, CA. May 12-16, 2016

1. Ahmed Haddad, Ryan Hutchinson, Nirmish Singla, Erika Wood, Gus Miranda, Boris Gershman, Vitaly Margulis, Arthur Sagalowsky, Ganesh Raj, Robert Svatek, Peter Black, Stephen Boorjian, Jay Shah, Sia Daneshmand, **Yair Lotan**. Association of Distance to Treatment Facility with Survival and Quality Outcomes Following Radical Cystectomy: A Multi-Institutional Study. Session Title: Bladder Cancer: Epidemiology & Evaluation I. Abstract: MP01-17.
2. Daniel Costa*, Qing Yuan, Yin Xi, Claus Roehrborn, Neil Rofsky, **Yair Lotan**, Franto Francis, Robert Lenkinski, Debbie Travalini, Ivan Pedrosa. A Comparison of Prostate Cancer Detection at 3T MRI with and Without an Endorectal Coil: a Prospective, Paired- Patient Study. Session Title: Prostate Cancer: Detection & Screening I. Abstract: MP16- 04.
3. Ryan Hutchinson, Abdulhadi Akhtar, Justin Haridas, Deepa Bhat, Claus Roehrborn, **Yair Lotan**. Prostate Cancer Screening and Referral Patterns in the Years

- Surrounding the United States Preventative Services Task Force Recommendation against PSA Screening in All Men. Session Title: Prostate Cancer: Detection & Screening II. Abstract: PD09-02.
4. Lauren Shuman, Joshua Warrick, David DeGraff, Shahrokh Shariat, Jose Karam, Christopher Wood, Alon Weizer, Mesut Remzi, Andrea Haitel, Karim Bensalah, Nathalie Rioux-Ceclerq, Rennes, France, Christian Bolenz, Marco Roscigno, Laura-Maria Krabbe, Payal Kapur, **Yair Lotan**, Vitaly Margulis, Jay Raman. Loss of FOXA1 Expression is Associated with Adverse Pathologic Features and Inferior Oncologic Outcomes Following Radical Nephroureterectomy. Session Title: Bladder Cancer: Upper Tract Transitional Cell Carcinoma I. Abstract: PD13-01.
 5. Nirmish Singla, Ryan Hutchinson, Dong Fang, Xiaohong Su, Zhengqing Bao, Zhenpeng Cao, Syed Jafri, Gengyan Xiong, Lei Zhang, Arthur Sagalowsky, **Yair Lotan**, Xuesong Li, Liqun Zhou, Jay Raman, Vitaly Margulis. A Multi-Institutional Evaluation of Clinical and Tumor Characteristics in Upper Tract Urothelial Carcinoma from China and the United States. Session Title: Bladder Cancer: Upper Tract Transitional Cell Carcinoma. Abstract: PD13-03.
 6. Ryan Hutchinson, Nirmish Singla, Abdulhadi Akhtar, Justin Haridas, Deepa Bhat, Claus Roehrborn, **Yair Lotan**. Practice Time of Primary Care Physicians is Associated with Change in PSA Ordering Habits in the Years Surrounding the United States Preventative Services Task Force Recommendation Against PSA Screening. Session Title: Prostate Cancer: Detection & Screening IV. Abstract: PD15-02.
 7. Nirmish Singla, Ryan Hutchinson, Ahmed Haddad, Arthur Sagalowsky, **Yair Lotan**, Vitaly Margulis. Comparing changes in renal function after radical surgery for upper tract urothelial carcinoma and renal cell carcinoma. Session Title: Kidney Cancer: Localized: Surgical Therapy I. Abstract: MP41-02.
 8. Timothy Tausch, **Yair Lotan**, Lee Zhao, Allen Morey. Cost-Effectiveness of Elective Urethroplasty without Primary Realignment in Treatment of Pelvic Fracture Urethral Injuries. Session Title: General & Epidemiological Trends & Socioeconomics: Value of Care: Cost and Outcomes Measures II. Abstract: MP46-04.
 9. Wilhelmina Duivenvoorden, Siamak Daneshmand, Daniel Canter, **Yair Lotan**, Peter Black, Hamidreza Abdi, Bas van Rhijn, Elisabeth Fransen van de Putte, Peter Boström, Ilmari Koskinen, Piotr Zareba, Janet Baack Kukreja, Wassim Kassouf, Samer Traboulsi, Jehonathan Pinthus. Incidence and significance of thrombo-embolic events in bladder urothelial carcinoma patients undergoing neo-adjuvant chemotherapy and radical cystectomy: Results from multi-centre North-American and European contemporary data. Session Title: Bladder Cancer: Invasive II. Abstract: PD27-09.
 10. Noah Canvasser, Kylee Stouder, Aaron Lay, Jeffrey Gahan, **Yair Lotan**, Vitaly Margulis, Ganesh Raj, Arthur Sagalowsky, Jeffrey Cadeddu. The Utility of Chest X-Rays for Pathologic T1a Renal Cell Carcinoma Surveillance. Session Title: Kidney Cancer: Localized: Surgical Therapy III Abstract: MP64-12.
 11. Ahmed Haddad, Jun-Hang Luo, Guangzhou, Laura-Maria Krabbe, Oussama Darwish, Bishoy Gayed, Ramy Youssef, Payal Kapur, Dinesh Rakheja, **Yair Lotan**, Arthur Sagalowsky, Vitaly Margulis. Prognostic value of tissue based biomarker signature in clear cell renal cell carcinoma. Session Title: Kidney Cancer: Epidemiology & Evaluation/Staging II. Abstract: MP78-17.
 12. Billy Cordon, Ryan Hutchinson, Matthias Hofer, Gregory Broderick, **Yair Lotan**, Allen Morey. Superior Cost Effectiveness of Penile Plication Versus Intralesional

Collagenase Injection for Treatment of Peyronie's Disease Deformities. Session Title: Sexual Function/Dysfunction: Peyronie's Disease, Abstract: PD45-06.

13. **Yair Lotan**, Jay Raman, Shahrokh Shariat, Laimonis Kavalieris, Chris Frampton, Henry Crist, Elsie Jacobson, Jimmie Suttie, David Darling, Scott Asroff, Doug Scherr, George Adams, Evan Goldfischer, Jeffrey Thill, Joseph Williams, Joshua Stein, Paul O'Sullivan. The Development and Clinical Validation of a High Sensitivity Urine biomarker test for the Determination of Recurrence in Urothelial Carcinoma Patients Session Title: Plenary I – Tuesday. Abstract: 745.

2016 Genitourinary Cancers Symposium. San Francisco, CA. January 7-9, 2016

1. Vasu Tumati, Corbin Jacobs, James Ying, Claus G Roehrborn, **Yair Lotan**, Vitaly Margulis, David A. Pistenmaa, Dong W. Kim, Raquibul Hannan. Outcomes in patients with high-risk prostate cancer treated with definitive versus adjuvant radiation therapy. Abstract #: 157985.
2. Divya Sahu, **Yair Lotan**, Bryan Wittman, Bruce Neri, Donna E. Hansel; University of California, San Diego, La Jolla, CA; The University of Texas Southwestern Medical Center, Dallas, TX; Metabolon, Inc., Durham, NC. Metabolomics analysis of non-muscle invasive and muscle-invasive bladder cancer. Abstract #: 156789.
3. Wilhelmina CM Duivenvoorden, Siamak Daneshmand, Daniel J. Canter, **Yair Lotan**, Peter C. Black, Hamidreza Abdi, Bas W.G. Van Rhijn, Elisabeth E. Fransen van de Putte, Peter J. Bostrom, Ilmari Koskinen, Piotr Zareba, Janet E. Baack Kukreja, Wassim Kassouf, Samer Traboulsi, Jehonathan H Pinthus; McMaster University, Hamilton, ON; University of Southern California, Institute of Urology, Los Angeles, CA; Fox Chase Cancer Center, Philadelphia, PA; The University of Texas Southwestern Medical Center, Dallas, TX; University of British Columbia, Vancouver, BC; Department of Urologic Sciences, University of British Columbia, Vancouver, BC; Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Badhoevedorp, Netherlands; The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; University Health Network, Princess Margaret Hospital, Toronto, ON; University of Helsinki, Helsinki, Finland; Juravinski Cancer Centre, Hamilton, ON; University of Rochester Medical Center, Rochester, NY; McGill University Health Centre, McGill University, Montreal, QC; McGill University, Montreal, QC. Incidence, characteristics, and implications of thrombo-embolic events in patients with urothelial carcinoma of the bladder undergoing neoadjuvant chemotherapy. Abstract #: 157966.

16th Annual Society of Urologic Oncology. Washington, DC. December 2-4, 2015

1. Niccolo Maria Passoni, Bishoy Gayed, Payal Kapur, Arthur Sagalowsky, Shahrokh Shariat and **Yair Lotan**. Assessment of Cell-Cycle Markers in Improving Discrimination of Eortc and Cueto Risk Models in Predicting Recurrence and Progression of Non- Muscle Invasive High-Risk Bladder Cancer. Poster Session II: Poster #129. Presented by: Niccolo Maria Passoni.

South Central Section Meeting of the AUA, Inc. Scottsdale, AZ. October 28-31, 2015

1. **Yair Lotan**, Jodi Antonelli, Inmaculada Buendia Jiménez, Hakam Gharbi, Ron Herring, Allison Beaver, Aphrihl Dennis, Dendra Von Merveldt, Suzie Carter, Adam Cohen, John Poindexter and Margaret Pearle. The kidney stone and increased water Intake trial in steel workers: results from the pilot study. Poster #42. Presenter.

2. Nirmish Singla MD, Ahmed Haddad MD, Matthew Meissner MD, Niccolo Passoni MD and **Yair Lotan MD**. Anti-inflammatory use does not negatively impact oncologic outcomes following intravesical BCG for high grade non-muscle invasive bladder cancer. Podium #33.

AUA Annual Meeting. New Orleans, LA. May 15-19, 2015

1. Laura-Maria Krabbe, Aditya Bagrodia, Ahmed Haddad, Payal Kapur, Dina Khalil, Linda Hynan, Christopher Wood, Jose Karam, Alon Weizer, Jay Raman, Mesut Remzi, Nathalie Rioux-Leclercq, Adrea Haitel, Marco Roscigno, Christian Bolenz, Karim Bensalah, Arthur Sagalowsky, Shahrokh Shariat, **Yair Lotan**, Vitaly Margulis. Multi- Institutional Validation of the Predictive Value of KI-67 in Patients with High-Grade Urothelial Carcinoma of the Upper Urinary Tract. (Abstract no. MP2-06, J Urol. 193(4S), e12, 2015).
2. Laura-Maria Krabbe, Okyaz Eminaga, Shahrokh Shariat, **Yair Lotan**, Arthur Sagalowsky, Jay Raman, Christopher Wood, Alon Weizer, Marco Roscigno, Francesco Montorsi, Christian Bolenz, Mesut Remzi, Karim Bensalah, Wassim Kassouf, Vitaly Margulis. Nomogram for Prediction of Recurrence-Free Survival in Patients with High- Grade Upper Tract Urothelial Carcinoma after Extirpative Therapy. (Abstract no. MP2- 09, J Urol. 193(4S): e13, 2015).
3. Jay D. Raman, Carla Caruso, Zhaohai Yang, David DeGraff, Shahrokh Shariat, Jose Karam, Christopher Wood, Alon Weizer, Mesut Remzi, Andrea Haitel, Karim Bensalah, Nathalie Rioux-Leclercq, Christian Bolenz, Marco Roscigno, Laura-Maria Krabbe, Payal Kapur, **Yair Lotan**, Vitaly Margulis. Increased EZH2 Expression is Associated with Adverse Oncologic Outcomes following Radical Nephroureterectomy. (Abstract no. MP7-09, J Urol. 193(4S): e67, 2015).
4. Kyle Spradling, Zharnshid Okhunov, **Yair Lotan**, Arthur Sagalowsky, Shahrokh Shariat, Jaime Landman, Ramy Youssef. External Validation of TALL Score for Prediction of Oncological Outcomes of High Grade Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy. (Abstract no. MP7-18, J Urol. 193(4S): e70, 2015).
5. Ahmed Q. Haddad, Daniel Costa, Ivan Pedrosa, Neil Rofsky, Claus Roehrborn, **Yair Lotan**. Cost Effectiveness of Multiparametric Magnetic Resonance Imaging for Detection of Prostate Cancer. (Abstract no. MP17-11, J Urol. 193(4S): e180, 2015).
6. Casey Seideman, **Yair Lotan**, Lane Palmer. Cost Effectiveness of Antimicrobial Prophylaxis for Children in RIVUR Trial. (Abstract no. MP54-03, J Urol. 193(4S): e665, 2015).
7. Kamran Zargar-Shoshtari, Homayoun Zargar, Adrian S. Fairey, Laura S. Mertens, Colin P. Dinney, Maria C. Mir, Laura-Maria Krabbe, Michael S. Cookson, Niels-Erik Jacobsen, Nilay Gandhi, Joshua Griffin, Jeffrey S. Montgomery, Nikhil Vasdev, Evan Y. Yu, Evangelos Xylinas, Nicholas J. Campaign, Wassim Kassouf, Marc A. Dall'Era, Jo-An Seah, Pranav Sharma, Cesar E. Ercole, Simon Horenblas, Srikanan S. Sridhar, John S. McGrath, Jonathan Aning, Shahrokh F. Shariat, Jonathan L. Wright, Andrew C. Thorpe, Todd M. Morgan, Jeff M. Holzbeierlein, Trinity J. Bivalacqua, Scott North, Daniel A. Barocas, **Yair Lotan**, Jorge A. Garcia, Andrew J. Stephenson,

- Jay B. Shah, Bas W. van Rhijn, Siamak Daneshmand, Philippe E. Spiess, Peter Blac. A Multi-Institutional Analysis of Outcomes in Patients with Clinically Node Positive Urothelial Bladder Cancer treated with Induction Chemotherapy and Radical Cystectomy. (Abstract no. MP65-06, J Urol. 193(4S): e809, 2015).
8. Evangelos Xylinas, Kamran Zargar-Shoshtari, Jay Shah, Homayoun Zargar, Adrian Fairey, Laura Mertens, Maria Mir, Jorge Garcia, Andrew Stephenson, Laura-Maria Krabbe, Michael Cookson, **Yair Lotan**, Niels-Erik Jacobsen, Nilai Gandhi, Joshua Griffin, Jeffrey Montgomery, Nikhil Vasdev, Evan Yu, Nicholas Campaign, Wassim Kassouf, Marc Dall'Era, Jo-An Seah, Cesar Ercole, Simon Horenblas, Srikala Sridhar, Jonathan McGrath, Jonathan Aning, Jonathan Wright, Andrew Thorpe, Todd Morgan, Jeff Holzbeierlein, Trinity Bivalacqua, Scott North, Daniel Barocas, Siamak Daneshman, Bass Van Rhijn, Philippe Spiess, Colin Dinney, Peter Black, Shahrokh Shariat. The Interval between Diagnosis and Radical Cystectomy does not Impact the Outcomes of Patients Treated with Neoadjuvant Chemotherapy. (Abstract no. MP72-15, J Urol. 193(4S): e926, 2015).
 9. Malte Rieken, Luis Kluth, Harun Fajkovic, Pierre Karakiewicz, **Yair Lotan**, Christian Seitz, Alberto Briganti, Morgan Rouprêt, Wolfgang Loidl, Richard Lee, Quoc-Dien Trinh, Peter Nyirady, Alexander Bachmann, Gholam-Reza Pourmand, Shahrokh Shariat. Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence in Patients Treated with Radical Prostatectomy for Prostate Cancer. (Abstract no. MP78-12, J Urol. 193(4S): e1007, 2015).
 10. Jodi Antonelli, Monica Morgan, Justin Friedlander, Niccolo Passoni, Adam Cohen, Daniel Mollengarten, Jeffrey Shoss, Clayton Trimmer, Sanjeeva Kalva, **Yair Lotan**, Margaret Pearle. Predictors of Septic Shock in Patients with Obstructive Pyelonephritis due to Calculi. (Abstract no. MP80-05, J Urol. 193(4S): e1020, 2015).
 11. Daniel Carter, Stephen Boorjian, Kenneth Ogan, Neal Shore, Trinity Bivalacqua, Bernard Bochner, Tracy Downs, Leonard Gomella, Robert Grubb III, Brant Inman, Ashish Kamat, Larry Karsh, Tracey Krupski, Seth Lerner, **Yair Lotan**, Matthew Milowsky, Mark Schoenberg, Robert Svatek, Michael Woods, Colin Dinney. Randomized Phase II Trial of Intravesical Adenoviral Mediated Interferon- α Gene Therapy with the Excipient SYN3 (RAD-IFN α /SYN3) in Patients with BCG Refractory or Relapsing High Grade (HG) Non-Muscle Invasive Bladder Cancer (NMIBC). (Abstract no. PD17-06, J Urol. 193(4S): e383, 2015).
 12. Nathan Starke, Nirmish Singla, Ahmed Q. Haddad, **Yair Lotan**. Long-Term Outcomes of High Risk Bladder Cancer Screening Cohort. (Abstract no. PD23-02, J Urol. 193(4S): e485, 2015).
 13. Homayoun Zargar, Kamran Zargar-Shoshtari, Adrian S. Fairey, Laura S. Mertens, Colin P. Dinney, Maria C. Mir, Laura-Maria Krabbe, Michael S. Cookson, Niels-Erik Jacobsen, Nilay Gandhi, Joshua Griffin, Jeffrey S. Montgomery, Nikhil Vasdev, Evan Y. Yu, Evangelos Xylinas, Nicholas J. Campaign, Wassim Kassouf, Marc A. Dall'Era, Jo-An Seah, Cesar E. Ercole, Simon Horenblas, Srikala S. Sridhar, John S. McGrath, Jonathan Aning, Shahrokh F. Shariat, Jonathan L. Wright, Andrew C. Thorpe, Todd M. Morgan, Jeff M. Holzbeierlein, Trinity J. Bivalacqua, Scott North, Daniel A. Barocas, **Yair Lotan**, Jorge A. Garcia, Andrew J. Stephenson, Jay B. Shah, Bas W. Van Rhijn, Siamak Daneshmand, Philippe E. Spiess, Peter C. Black. Final Pathologic Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer: Does PT0 Predict Better Survival Therapy than PTA/NPIS/PT1? (Abstract no. PD41-05, J Urol. 193(4S): e841, 2015).

European Association of Urology. Madrid, Spain. March 20-24, 2015

1. Xylinas EN, Kluth LA, Rieken M, Scherr DS, Margulis V, **Lotan Y**, Martinez-Salamanca J, Matsumoto K, Karakiewicz PI, Shariat SF. Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy. Poster Session 27, Abstract 327.
2. Rieken M, Kluth L, Fajkovic H, Karakiewicz P, **Lotan Y**, Sietz C, Rouprêt M, Loidl W, Lee R, Trinh Q-D, Nyirady P, Bachmann A, Pourmand G-R, Shariat SF. Association of cigarette smoking cessation with biochemical recurrence in patients with radical prostatectomy for prostate cancer. Poster Session 42, Abstract 508.
3. Zargar H, Zargar-Shoshtari K, Fairey A, Mertens L, Dinney C, Mir M, Krabbe L-M, Cookson M, Jacobsen-NE, Gandhi N, Griffin J, Montgomery J, Vasdev N, Yu E, Xylinas E, Campain N, Kassouf W, Dall'Era M, Seah J-A, Ercole C, Horenblas S, Sridhar S, McGrath JS, Aning J, Shariat S, Wright J, Thorpe AC, Morgan T, Holzbeierlein J, Bivalacqua T, North S, Barocas D, **Lotan Y**, Garcia J, Stephenson A, Shah J, Van Rhijn B, Daneshmand S, Spiess PS, Black P. Final pathologic stage after neoadjuvant chemotherapy and radical cystectomy for bladder cancer: Does pT0 predict better survival than pTa/pTis/pT1? Poster Session 42, Abstract 532.
4. Lucca I, Shariat SF, Rouprêt M, Rieken M, Kluth LA, Mathieu R, Fajkovic H, Briganti A, Seitz C, Karakiewicz PI, De Martino M, **Lotan Y**, Babjuk M, Klatte T. The neutrophil-to-lymphocyte ratio as a prognostic factor for patients with urothelial carcinoma of the bladder following radical cystectomy: validation and meta-analysis. Poster Session 53, Abstract 647.
5. Zargar-Shoshtari K, Zargar H, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe L-M, Cookson MS, Jacobsen NE, Gandhi N, Griffin J, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole C, Horenblas S, Sridhar S, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, **Lotan Y**, Garcia JA, Stephenson AJ, Shah JB, Van Rhijn BW, Daneshmand S, Spiess PE, Black P. A multi-institutional analysis of pathological and survival outcomes in patients with clinically node positive urothelial bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. Poster Session 53, Abstract 650.
6. Mir Maresma MC, Ercole E, Zargar H, Espiritu PN, Fairey SA, Mertens LLS, Dinney CP, Krabbe L-M, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Vasdev N, Yu EY, Youseff D, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, **Lotan Y**, Garcia JA, Shah JB, Van Rhijn BW, Daneshmand S, Spiess PE, Black PPC, Stephenson AJ. Nomogram predicting cancer specific mortality (CSM) after neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer (BC): Results of an international consortium. Poster Session 61, Abstract 735.
7. Xylinas E, Zargar-Shoshtari K, Shah JB, Zargar H, Fairey AS, Mertens LS, Krabbe L-M, Cookson MS, Jacobsen N-E, Gandhi N, Mir MC, Griffin J, Montgomery JS, Vasdev N, Yu EY, Campain NJ, Kassouf W, Dall'Era MA, Seah J-A, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, **Lotan Y**, Garcia JA, Stephenson AJ, Van Rhijn BW, Daneshmand S, Dinney CP, Spiess PE, Black P, Shariat SF. The interval between diagnosis and radical cystectomy does not impact the outcomes of patients treated with neoadjuvant chemotherapy. Poster Session 61, Abstract 737.

Society of Urologic Oncology. Bethesda, MD. December 3-5, 2014

1. Ahmed Haddad, Nirmish Singla, Neil Gupta, Ganesh Raj, Arthur Sagalowsky, Vitaly Margulis, **Yair Lotan**. Distance to Treatment Facility and Survival Outcomes Following Radical Cystectomy for Bladder Cancer. Poster Session I: Poster #4.
2. Laura-Maria Krabbe, MD, Aditya Bagrodia, MD, Ahmed Haddad, MD, PhD, Bishoy Gayed, MD, Payal Kapur, MD, Dina Khalil, MD, Linda Hynan, PhD, Christopher Wood, MD, Jose Karam, MD, Alon Weizer, MD, Jay Raman, MD, Mesut Remzi, MD, Nathalie Rioux-Leclercq, MD, Andrea Haitel, MD, Marco Roscigno, MD, Christian Bolenz, MD, Karim Bensalah, MD, Arthur Sagalowsky, MD, Sharokh Shariat, MD, **Yair Lotan, MD** and Vitaly Margulis, MD. Multi-Institutional Validation of the Predictive Value of Ki-67 in Patients with High-Grade Urothelial Carcinoma of the Upper Urinary Tract. Poster Session 1: Poster #7. Presented by: Laura-Maria Krabbe
3. Ramy Youssef, Payal Kapur, MD, Dina Wahib, MD, Ahmed Mosbah, MD, Hassan Abol- Enein, MD, Mohamed Ghoniem, MD and **Yair Lotan, MD**. Clinico-Biological Prognostic Score for Prediction of Oncological Outcomes after Radical Cystectomy for Squamous Cell Carcinoma of the Bladder. Poster Session 1: Poster #21. Presented by: Ramy Youssef
4. Ramy Youssef, Payal Kapur, MD, Ahmed Mosbah, MD, Hassan Abol-Enein, MD, Mohamed Ghoniem, MD and **Yair Lotan, MD**. Prognostic Biomarkers for Bilharzial and Non-Bilharzial Related Bladder Cancer: Immunohistochemistry Study of 14 Markers. Poster Session 1: Poster #22. Presented by: Ramy Youssef
5. Ahmed Haddad, Payal Kapur, Nirmish Singla, Jay Raman, Matthew Then, Philipp Nuhn, Alexander Buchner, Patrick Bastian, Christian Seitz, Shahroh Shariat, Karim Bensalah, Nathalie Rioux-Lecercq, Arthur Sagalowsky, **Yair Lotan** and Vitaly Margulis. Validation of Mammalian Target of Rapamycin Biomarker Panel in Patients with Clear Cell Renal Cell Carcinoma. Poster Session 1, Poster #35.
6. Nathan Starke, Ahmed Haddad, Nirmish Singla and **Yair Lotan**. Long-term Outcomes of High Risk Bladder Cancer Screening Cohort. Poster Session II, Poster #105.
7. Ramy Youssef, Laura-Maria Krabbe, MD, Shahrokh F. Shariat, MD, **Yair Lotan, MD**, Arthur I. Sagalowsky, MD, Jay Raman, MD, Christopher G. Wood, MD, Alon Weizer, MD, Marco Roscigno, MD, Francesco Montorsi, MD, Christian Bolenz, MD, Mesut Remzi, MD0, Karim Bensalah, MD1, Wassim Kassouf, MD and Vitaly Margulis, MD. Tall Score for Prediction of Oncological Outcomes after Radical Nephroureterectomy for High Grade Upper Tract Urothelial Carcinoma. Poster Session II: Poster #189. Presented by: Ramy Youssef

South Central Section Meeting of the AUA. Rancho Mirage, CA. October 8-11, 2014

1. Radical nephroureterectomy for pathologic T4 upper tract urothelial cancer: Can oncologic outcomes be improved with multimodality therapy? Ramy Youssef, **Yair Lotan**, Arthur Sagalowsky, Shahrokh Shariat, Christopher Wood, Jay Raman, Vitaly Margulis, Marco Roscigno, Francesco Montorsi, Christian Bolenz, and Wassim Kassouf. Abstract #31 Podium Session.
2. Tall score for prediction of oncological outcomes after radical nephroureterectomy for high grade upper tract urothelial carcinoma. Ramy Youssef, **Yair Lotan**, Shahrokh Shariat, Arthur Sagalowsky, Christopher Wood, Alon Weizer, Jay Raman, Marco Roscigno, Francesco Montorsi, Christian Bolenz, Wassim Kassouf, Laura-Maria Krabbe, and Vitaly Margulis. Abstract #32 Podium Session.

3. Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma. Ahmed Haddad, Nirmish Singla, Payal Kapur, Jay Raman, Matthew Then, Phillip Nuhn, Alexander Buchner, Patrick Bastian, Christian Seitz, Sharohk Shariat, Karim Bensalah, Nathalie Rioux-Leclerog, **Yair Lotan** and Vitaly Margulis. Abstract #37 Podium Session.
4. Predictors of septic shock in patients with obstructive ureteral calculi and infection. Jodi Antonelli, Justin Friedlander, Daniel Mollengardent, Beverly Adams-Huet, Jeffrey Shoss, Clayton Trimmer, Sanjeeva Kalva, **Yair Lotan**, Margaret Pearle. Abstract #40 Podium Session.
5. Prognostic biomarkers for bilharzial and non-bilharzial related bladder cancer: immunohistochemistry study of 14 markers. Ramy Youssef, Payal Kapur, Ahmed Mosbah, Hassan Abol-Enein, Mohamed Ghoniem, and **Yair Lotan**. Poster Session #1.
6. Clinico-biological prognostic score for prediction of oncological outcomes after radical cystectomy for squamous cell carcinoma of the bladder. Ramy Youssef, Payal Kapur, Dina Khalil, Ahmed Mosbah, Hassan Abol-Enein, Mohamed Ghoniem, and **Yair Lotan**. Poster Session #2.

AUA Annual Meeting. Orlando, FL. May 16-21, 2014

1. Laura-Maria Krabbe, Robert Svatek, Shahrokh F. Shariat, Edward Messing, **Yair Lotan**: Bladder cancer screening: Use of the PLCO and NLST to identify a suitable screening cohort. Abstract No. MP22-07, J Urol 191(4S), 2014.
2. Laura Mertens, Tahlita Zuiverloon, Yann Neuzillet, Shahrokh Shariat, Chen Abas, Peter Bostrom, Marcel Vermeij, Tuomas Mirtti, Arthur Sagalowsky, Joost Boormans, Dennis Peters, Raheela Ashfaq, Jeroen de Jong, Annegien Broeks, Neil Fleshner, Simon Horenblas, Arno van Leenders, Bharati Bapat, Michael Jewett, Zalexandre Zlotta, Joyce Sanders, **Yair Lotan**, Theo van der Kwast, Ellen Zwarthoff, Bas van Rhijn: Molecular markers (FGFR3 mutation; P53&KI-67 expression) and clinical outcome of radical cystectomy for bladder cancer: A multicenter, multilab study. Abstract No. MP28- 12, J Urol 191(4S), 2014.
3. Yann Neuzillet, Laura Mertens, Shahrokh Shariat, Peter Bostrom, Tuomas Mirtti, Arthur Sagalowsky, Raheela Ashfaq, Annegien Broeks, Michiel Van, Der Heijden, Dennis Peters, Chantall Curial, Jeroen De Jong, Simon Horenblas, Carolyn Hurst, Darren Tomlinson, Margaret Knowles, Bharati Bapat, Michael Jewett, Alexandre Zlotta, Joyce Sanders, **Yair Lotan**, Theo Vad Der Kwast, Bas Van Rhijn: Pathological validation of adjuvant anti-fibroblast growth factor receptor 3 (FGFR3) for personalized treatment of bladder cancer. Abstract No. MP28-20, J Urol 191(4S), 2014.
4. Nirmish Singla, Aditya Bagrodia, Bishoy Gayed, Kerrin Palazzi, Hossein Mirheydar, Brian Harrow, Corbin Jacobs, Ramy Youssef, Oussama Darwish, Arthur Sagalowsky, **Yair Lotan**, Ithaar Derweesh, Vitaly Margulis: Multi-institutional analysis

- of renal function outcomes following radical nephroureterectomy and partial ureterectomy for upper tract urothelial carcinoma. (Abstract No. MP30-08, J Urol 191(4S), 2014.
5. Paul Chung, Oussama Darwish, Sandeep Mehta, Claus Roehrborn, **Yair Lotan**: Patients meeting active surveillance criteria on saturation biopsy are at high risk for histologic grade progression on prostatectomy. Abstract No. MP42-17, J Urol 191(4S), 2014.
 6. Homayoun Zargar, Adrian S. Fairey, Laura Mertens, Patrick N. Espiritu, Colin P. Dinney, Laura-Maria Krabbe, Michael S. Cookson, Nils E. Jacobsen, Jeffrey S. Montgomery, Nilay Gandhi, Joshua Griffin, Evan Y. Yu, Nikhil Vasdev, Nicholas J. Campaign, Evangelos Xylinas, Simon Horenblas, David Youssef, Wassim Kassouf, Shahrokh F. Shariat, Jonathan J. Aning, Jonathan L. Wright, Andrew C. Thorpe, Jeff M. Holzbeierlein, Trinity J. Bivalacqua, Todd M. Morgan, Scott North, Daniel A. Barocas, **Yair Lotan**, Jay B. Shah, Philippe E. Spiess, B.W. van Rhijn, Siamak Daneshmand, Peter C. Black: Pathologic response to neoadjuvant chemotherapy in a multicenter cohort of patients with muscle invasive bladder cancer. Abstract No. MP55-08, J Urol 191(4S), 2014.
 7. Malte Rieken, Shahrokh Shariat, Bashir Al Hussein Al Awamlh, Luis Kluth, Joseph Crivelli, James Chrystal, Talia Faison, **Yair Lotan**, Pieere Karakiewicz, Marek Babjuk, Harun Fajkovic, Christian Seitz, Tobias Klatter, Armin Pycha, Alexander Bachmann, Mithat Gönen, Evangelos Xylinas: Comparison of the EORTC tables and the newly introduced EAU categories for risk stratification of patients with non-muscle invasive bladder cancer. Abstract No. MP56-07, J Urol 191(4S), 2014.
 8. Bishoy Gayed, Matthew Meissner, Ramdev Konijeti, Laura-Maria Krabbe, Paul Chung, Adita Bagrodia, Ahmad Haddad, Ganesh Raj, Arthur Sagalowsky, **Yair Lotan** and Vitaly Margulis: Statin use is an independent predictor of improved survival in patients with metastatic renal cell carcinoma. (Abstract No. MP57-02, J Urol 191(4S), 2014.
-
9. Bernard Bochner, Dahlia Sperling, Andrew Feifer, Joseph Mashni Jr, Dean Bajorin, Guido Dalbagni, Harry Herr, Sherri M. Donat, Matthew Milowsky, Jay Shah, Ashish Kamat, H. Barton Grossman, Robert Grubb III, Stephen Brandes, Arnold Bullock, Seth Strome, Bruce Roth, Adam Kibel, Luois Weigand, Gary Steinberg, Walter Stadler, Natali Rutiaga, Mark Schoenberg, Trinity Bivalacqua, Charlene Rogers, Peter Black, Alan So, Martin Gleave, Wassim Kassouf, Bassel Bachir, Faysal Yafi, Seth Lerner, Guilherme Godoy, Gilead Amiel, Alexandre Zlotta, Neil Fleshner, Michael Jewett, Girish Kulkarni, Srikala Sridhar, Ian Tanock, Anthony Joshua, Peter Bostrom, Cynthia Kuk, **Yair Lotan**: Multi-institutional quality care initiative to improve the care of patients with muscle invasive bladder cancer. Abstract No. MP60-12, J Urol 191(4S), 2014.
 10. Justin Friedlander, Jodi Antonelli, Shreeya Popat, Margaret Pearle, and **Yair Lotan**: Characterization and recurrence rates of first time stone formers in the era of CT. Abstract No. MP73-03, J Urol. 191(4S), 2014.
 11. Daniel Lee, Evangelos Xylinas, Malte Rieken, Francesca Khani, Tobias Klatter, Christopher Wood, Jose Karam, Alon Weizer, Jay Raman, Mesut Remzi, Charles Guo, Nathalie Rioux-Leclercq, Andrea Haitel, Christian Bolenz, Karim Bensalah,

- Arthur Sagalowsky, Francesco Montorsi, **Yair Lotan**, Shahrokh Shariat, Brian Robinson, Vitaly Margulis: Insulin-like growth factor mRNA-binding protein 3 (IMP3) expression helps prognostication in patients with upper tract urothelial carcinoma. Abstract No. MP77-02, J Urol 191(4S), 2014.
12. Aditya Bagrodia, Laura Krabbe, Bishoy Gayed, Payal Kapur, Oussama Darwish, Ira Bernstein, Xian-Jin Xie, Christopher Wood, Richard Zigeugern Alon Weizer, Jay Raman, Mesut Remzi, Cord Langner, Marco Roscigno, Francesco Montorsi, Christian Bolenz, Karim Bensalah, Jose Karam, Arthur Sagalowsky, Shahrokh Shariat, **Yair Lotan**, Vitaly Margulis: Multi-institutional evaluation of the prognostic significance of altered mammalian target of rapamycin (MTOR) pathway biomarkers in upper tract urothelial carcinoma (UTUC). Abstract No. MP77-04, J Urol 191(4S), 2014.
 13. Malte Rieken, Tina Schubert, Evangelos Xylinas, Luis Kluth, Morgan Rouprêt, Quoc-Dien Trinh, Richard Lee, Bashir Al Hussein Al Awamlh, Harun Fajkovic, Giacomo Novara, Vitaly Margulis, **Yair Lotan**, Juan Martinez-Salamanca, Kazumasa Matsumoto, Christian Seitz, Mesut Remzi, Pieere Karakiewicz, Douglas Scherr, Alberto Briganti, , Alexander Bachmann, Shahrokh Shariat: Association of perioperative blood transfusion with oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Abstract No. MP77-05, J Urol 191(4S), 2014.
 14. Malte Rieken, Evangelos Xylinas, Daniel Lee, Francesca Khani, Tobias Klatte, Christopher Wood, Jose Karam, Alon Weizer, Jay Raman, Mesut Remzi, Charles Guo, Nathalie Rioux-Leclercq, Andrea Haitel, Christian Bolenz, Karim Bensalah, Arthur Sagalowsky, Francesco Montorsi, **Yair Lotan**, Alexander Bachmann, Angelo De Marzo, Shahrokh Shariat, Brian Robinson, Vitaly Margulis: Frequency and prognostic value of PTEN loss in patients with upper tract urothelial carcinoma. Abstract No. 77-06, J Urol 191(4S), 2014.
 15. Evangelos Xylinas, Luis Kluth, Malte Rieken, Tobias Klatte, **Yair Lotan**, Eiji Kikuchi, Alon Weizer, Mesut Remzi, Jay Raman, Karim Bensalah, Francesco Montorsi, Vitaly Margulis, Juan-Ignazio Martinez-Salamanca, Morgan Rouprêt, Marc Zerbib, Shahrokh Shariat: Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy. Abstract No. MP77- 07, J Urol 191(4S), 2014.
 16. Bishoy Gayed, Aditya Bagrodia, Mani Gaitonde, Laura-Maria Krabbe, Matthew Meissner, Payal Kapur, Ramy Youssef, Arthur Sagalowsky, **Yair Lotan** and Vitaly Margulis: Feasibility of obtaining biomarker profiles from endoscopic biopsy specimens in upper tract urothelial carcinoma: Preliminary results. Abstract No. MP77-09, J Urol 191(4S), 2014.
 17. Paul Chung, Laura-Maria Krabbe, Oussama Darwish, Mary Westerman, Aditya Bagrodia, Bishoy Gayed, Ahmed Haddad, Payal Kapur, Arthur Sagalowsky, **Yair Lotan** and Vitaly Margulis: Degree of hydronephrosis predicts adverse pathological features and worse oncologic outcomes in high-grade upper tract urothelial carcinoma. Abstract No. 77-15, J Urol 191(4S), 2014.
 18. Laura-Maria Krabbe, **Yair Lotan**, Aditya Bagrodia, Bishoy A. Gayed, Oussama M. Darwish, Ramy F. Youssef, Christian Bolenz, Arthur I. Sagalowsky, Ganesh V. Raj, Shahrokh F. Shariat, Payal Kapur and Vitaly Margulis: Is there evidence of discordant biology in urothelial cancer of the lower and upper urinary tract? Prospective comparison of molecular signatures. Abstract No. MP77-17, J Urol 191(4S), 2014.

19. Justin Friedlander, Jodi Antonelli, Daniel Mollengarden, Beverley Adams-Huet, Jeffrey Shoss, Clayton Trimmer, Sanjeeva Kalva, **Yair Lotan**, Margaret Pearle: Predictors of septic shock in patients with obstructive pyelonephritis due to ureteral calculi. Abstract No. PD28-10, J Urol 191(4S), 2014.
20. Ramy Youssef, Laura-Maria Krabbe, Shahrokh F. Shariat, **Yair Lotan**, Arthur Sagalowsky, Jay D. Raman, Christopher G. Wood, Alon Z. Weizer, Christian Bolenz, Mesut Remzi, Karim Bensalah, Wassim Kassouf, Francesco Montorsi, Vitaly Margulis, UTUC Collaboration: TALL score for prediction of oncological outcomes after radical nephroureterectomy for high grade upper tract urothelial carcinoma. Abstract No. PD35- 09, J Urol 191(4S), 2014.

14th Annual Meeting of the Society of Urologic Oncology. Bethesda, MD. December 4-6, 2013.

1. Casey Seideman, Daniel Canter, Phillip Kim, Billy Cordon, Alon Weizer, Ima Oliva, Jianyu Rao, Brant inman, Richardmond Owusu, Michael Posch, Harry Herr and **Yair Lotan**. Multicenter Evaluation of Therole of Urovysion Fish Assay in Surveillance of Patients with Bladder Cancer: Does Fish Positivity Anticipate Recurrence? (Poster Session 1: Poster #18). Presenter.
2. Aditya Bagrodia, Laura-Maria Krabbe, Bishoy Gayed, Payal Kapur, Ira Bernstein, Xian- Jin Xie, Christopher Wood, Jose Karam, Eiji Kikuchi, Alon Weizer, Jay Raman, Mesut Remzi, Charles Guo, Nathalie Rioux-Leclerq, Andrea Haitel, Marco Roscigno, Francesco Montorsi, Christian Bolenz, Karim Bensalah, Arthur Sagalowsky, Shahrokh Shariat, **Yair Lotan** and Vitaly Margulis. Evaluation of the Prognostic Significance of Altered Mammalian Target of Rapamycin (MTOR) Pathway Biomarkers in Upper Tract Urothelial Carcinoma (UTUC). (Poster Session 1: Poster # 62).
3. Larura-Marie Krabbe, Mary E Westeman, Aditya Bagrodia, Bishoy A Gayed, Oussama M Darwish, Ahmed Q Haddad, Dina Khalil, Payal Kapur, Arthura Sagalowsky, **Yair Lotan**, and Vitaly Margulis. Dysregulation of the Beta-catenin Complex is an Independent Predictor of Oncological Outcomes in Patients with CCRCC. (Oral Abstract Session: Poster #9).
4. Oussama M. Darwish, Laura-Maria Krabbe, Paul H. Chung, Mary E. Westeman, Aditya Bagrodia, Bishoy A. Gayed, Ahmed Q. Haddad, Ramy F. Youssef, Payal Kapur, Arthur I Sagalowsky, **Yair Lotan** and Vitaly Margulis. The Degree of Preoperative Hydronephrosis Predicts Adverse Pathologic Features and Worse Oncological Outcomes in High-Grade Upper Tract Urothelial Carcinoma. (Poster Session II: Poster #155).

South Central Section Meeting of the AUA. Chicago, IL. September 17-22, 2013

1. Aditya Bagrodia, Bishoy Gayed, Payal Kapur, Oussama Darwish, Ira Bernstein, Laura Krabbe, Christopher Wood, Shahrokh Shariat, Richard Zigeuner, Christian Bolenz, Alon Weizer, Jay Raman, Karim Bensalah, Giacomo Novara, Hans-Martin Fritsche, Arthur Sagalowsky, **Yair Lotan**, Vitaly Margulis. Multi-institutional

evaluation of the prognostic significance of altered mammalian target of rapamycin (MTOR) pathway biomarkers in upper tract urothelial carcinoma (UTUC). (Abstract Podium #5).

2. Jodi Antonelli, Naim Maalouf, Margaret Pearle, Yair Lotan: The impact of obesity and diabetes on cost and prevalence of urolithiasis. (Abstract Podium #69).
3. Aditya Bagrodia, Bishoy Gayed, Mansi Gaitonde, Ramy Youssef, Payal Kapur, Arthur Sagalowsky, **Yair Lotan** and Vitaly Margulis. Feasibility of obtaining biomarker profiles from endoscopic biopsy specimens in upper tract urothelial carcinoma: Preliminary results. (Abstract Poster #41).
4. Aditya Bagrodia, Bishoy Gayed, Ramy Youssef, Payal Kapur, Oussama Darwish, Laura- Maria Krabbe, Arthur Sagalowsky, **Yair Lotan** and Vitaly Margulis. Prognostic role of cell cycle and proliferative biomarkers in patients with clear cell renal cell carcinoma. (Abstract Poster #42).

AUA Annual Meeting. San Diego, CA. May 4-8, 2013

1. Michael Belsante, Lee C. Zhao, Steven J. Hudak, **Yair Lotan**, Allen F. Morey. Cost effectiveness of risk-stratified follow-up after urethral reconstruction: decision analysis. (Abstract #4-Trauma/Reconstruction: Trauma Reconstructive Surgery (I) Moderated Poster).
2. Luis A Kluth; Evangelos Xylinas; Felix KH Chun; Harun Fajkovic; Pierre I Karakiewicz; Niccolo Passoni; Marianne Schmid; Mike Herman; **Yair Lotan**; Christian Seitz ; Paul Schramek; Mesut Remzi; Wolfgang Loidl; Bertrand Guillonneau; Alberto Briganti; Douglas S Scherr; Markus Graefen; Ashutosh Tewari; Shahrokh F Shariat. Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical prostatectomy? (Abstract #358-Prostate Cancer: Localized (I) Podium).
3. Casey Seideman; Daniel Canter; Phillip Kim; Billy Cordon; Alon Weizer; Irma Oliva; Jianyu Rao; Brant Inman; Michael Posch; Margaret Lakowske; Harry Herr; **Yair Lotan**. Multicenter Evaluation of the Role of Urovysion FISH Assay in Surveillance of Patients with Bladder Cancer: Does FISH Positivity Anticipate Recurrence? (Abstract #391- Urethelial Cancer: Natural History, Markers & Pathophysiology Podium)
4. **Yair Lotan**; Aditya Bagrodia; Niccolo Passoni; Varun Rachakonda; Payal Kapur; Arthur Sagalowsky; Shahrokh F. Shariat. Concordance in Molecular Marker Status between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study. (Abstract #394- Urethelial Cancer: Natural History, Markers & Pathophysiology Podium). Awarded: 2013 AUA Best Abstract.
5. Evangelos Xylinas; Quoc-Dien Trinh; Luis Kluth; David Green; Douglas Scherr; Giacomo Novara; **Yair Lotan**; Pierre Karakiewicz; Francesco Montorsi; Marc Zerbib; Armin Pycha; Evi Comploj; Morgan Roupert; Jay Raman; Alon Weizer; Christian Seitz; Vitaly Margulis; Shahrokh Shariat. Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool. (Abstract #896- Urothelial Cancer Upper Tract Tumors (II) Podium).
6. Ramy Youssef; Payal Kapur; Ahmed Mosbah; Hassan Abol-Enein; Mohamed Ghoniem; **Yair Lotan**. Best Prognostic Biomarkers for Bilharzial and Non-Bilharzial related bladder cancer: Immunohistochemistry study of 14 markers. (Abstract #930-Bladder Cancer: Basic Research (II) Moderated Poster).
7. Michael Belsante; Oussama Darwish; Ramy Youssef; Aditya Bagrodia; Payal Kapur; Arthur Sagalowsky; **Yair Lotan**; Vitaly Margulis. Lymphovascular Invasion in

- Clear Cell Renal Cell Carcinoma - Association with Disease Free and Cancer Specific Survival. (Abstract #1075-Kidney Cancer: Evaluation & Staging (III) Podium).
8. Rodrigo Donalisio-da-Silva; Evangelos Xylinas; Luis Kluth; Joseph Crivelli; Daher Chade; Giuliano Guglielmetti; **Yair Lotan**; Pierre Karakiewicz; Maxine Sun; Armin Pycha; Francesco Montorsi; Marc Zerbib; Douglas Scherr; Shahrokh Shariat. Impact of Statin Use on Oncological Outcomes of Patients with Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. (Abstract #1427-Bladder Cancer: Invasive (I) Moderated Poster).
 9. **Yair Lotan**; Aditya Bagrodia; Niccolo Passoni; Varun Rachakonda; Payal Kapur; Yull Arriaga; Vitaly Margulis; Ganesh Raj; Arthur Sagalowsky; Shahrokh F. Shariat. : Five Year Prospective Evaluation of a Molecular Marker Panel for Prediction of Recurrence after Radical Cystectomy. (Abstract #1433-Bladder Cancer: Invasive (II) Moderated Poster). Awarded: 2013 AUA Best Poster of Moderated Poster Session MP52.
 10. Michael Rink; Evangelos Xylinas; Helena Furberg; Luis A. Kluth; Emily C. Zabor; Behfar Ehdaie; **Yair Lotan**; Richard K. Lee; Felix K. Chun; Armin Pycha; Pierre I. Karakiewicz; Giacomo Novara; Marek Babjuk; Brian Robinson; Douglas S. Scherr; Margit Fisch; Shahrokh F. Shariat. Does cigarette smoking and smoking cessation influence outcomes in bladder cancer patients treated with radical cystectomy? (Abstract #1445- Bladder Cancer: Invasive (II) Moderated Poster).
 11. Evangelos Xylinas; Matthew Kent; Dan Sjoberg; Luis Kluth; Armin Pycha; Evi Compoj; **Yair Lotan**; Robert Svatek; Quoc-Dien Trinh; Pierre Karakiewicz; Douglas Scherr; Marc Zerbib; Shahrokh Shariat. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non muscle-invasive urothelial carcinoma of the bladder. (Abstract #1701-Bladder Cancer: Superficial (I) Podium).
 12. Ramy Youssef; Payal Kapur; Dina Khalil; Ahmed Mosbah; Hassan Abol-Enein; Mohamed Ghoniem; **Yair Lotan**. Clinico-biological prognostic score for prediction of oncological outcomes after radical cystectomy for squamous cell carcinoma of the bladder. (Abstract #1757-Bladder Cancer: Invasive (III) Moderated Poster).
 13. Khurshid Guru; Adam Kibel; Ahmed Aboumohamed; Alex Mottrie; Alon Weizer; Ashok Hemal; Derya Tilki; Douglas Scherr; Evangelos Xylinas; Fajkovic Harun; Francis Schanne; Giacomo Novara; Gregory Wilding; H Martin Fritsche; James Peabody; Joan Redorta; John Pattaras; Ketan Badani; Koon Rha; Lee Richstone; Luis Kluth; Mani Menon; Maxine Sun; Mevlana Balbay; Michael Stoekle; Michael Woods; Peter Wiklund; Pierre Karakiewicz; Piyush Agarwal; Prokar Dasgupta; Raj Pruthi; Reza Ghavamian; Sia Daneshmand; Shamim Khan; Stefan Siemer; Timothy Wilson; Wassim Kassouf; **Yair Lotan**; Yi Shi; Shahrokh Shariat. Comparative Oncologic Effectiveness between Robot- assisted and Open Radical Cystectomy. (Abstract #1764-Bladder Cancer: Invasive (III) Moderated Poster).
 14. Luis A Kluth; Harun Fajkovic; Evangelos Xylinas; Joseph J Crivelli; Niccolo Passoni; Morgan RouprÃ©t; Andreas Becker; Evi Compoj; Armin Pycha; Sten Holmang; Amit Gupta; Pierre I Karakiewicz; **Yair Lotan**; Paolo Gontero; Felix KH Chun; Douglas S Scherr; Shahrokh F Shariat. Female gender is associated with higher risk of disease recurrence in patients with primary T1 high grade urothelial carcinoma of the bladder. (Abstract #1780-Bladder Cancer: Superficial (III) Moderated Poster).
 15. Tori Sutherland; Margaret Pearle; **Yair Lotan**. How much is a kidney worth? Cost- effectiveness of routine imaging after ureteroscopy for prevention of silent

obstruction. (Abstract #1810-Stone Disease: SWL, Ureteroscopy or Percutaneous Stone Removal (III) Moderated Poster).

16. Luis A Kluth; Evangelos Xylinas; Michael Rink; Matt Kent; Dan Sjoberg; Marek Babjuk; Antonin Brisuda; Atiqullah Aziz; Hans-Martin Fritsche; Evi Comploj; Armin Pycha; Debasish Sundi; Trinity Bivalacqua; Giacomo Novara; Jack Baniel; Roy Mano; Paolo Gontero; Robert S Svatek; Lukas Lusuardi; Anirban Mitra; Sia Daneshmand; Matthew D. Galsky; **Yair Lotan**; Douglas S Scherr; Shahrokh F Shariat. Prognostic value of Bajorin criteria for cancer-specific survival in patients who have disease recurrence after radical cystectomy for urothelial carcinoma of the bladder. (Abstract #1868-Bladder Cancer: Metastatic Disease + Staging Moderated Poster).
17. Jodi Antonelli; Naim Maalouf; Margaret Pearle; **Yair Lotan**. The impact of obesity on cost and prevalence of urolithiasis. (Abstract #2245- Stone Disease: Evaluation & Medical Management (II) Moderated Poster).

South Central Section Meeting of the AUA. Colorado Springs, CO. October 24-27, 2012

1. Michael Belsante, Oussama Darwish, Ramy Youssef, Aditya Bagrodia, Payal Kapur, **Yair Lotan**, Vitaly Margulis: Lymphovascular invasion is an independent predictor of cancer recurrence in organ confined, but not in locally advanced clear cell renal cell carcinoma. (Abstract #3 – Resident Essay Finalist Podium).
2. Casey Seideman, Michael Posch, Ramy Youssef, **Yair Lotan**: Evaluation of anticipatory FISH positive assays in bladder cancer surveillance patients. (Abstract #18 – Oncology- Bladder & Testis Podium).
3. Yury Rapoport, Oussama Darwish, Ramy Youssef, Michael Belsante, Aditya Bagrodia, Payal Kapur, **Yair Lotan**, Vitaly Margulis: Prognostic role of lymphovascular invasion in papillary renal cell carcinoma. (Abstract #21 – Kidney Poster Session).
4. Casey Seideman, Anna Buteau, Ramy Youssef, Robert Svatkek, Gaurab Chakrabarti, Gary Reed, Deepa Bhat, **Yair Lotan**. What is evaluation of hematuria by primary care physicians: use of electronic medical records to assess practice patterns? (Poster #31 – General Urology Poster Session).
5. Aditya Bagrodia, Varun Rachakonda, Karen Delafuente, Yair Lotan. Surgeon fatigue: impact of case order on perioperative parameters. (Poster #35 –General Urology Poster Session).
6. Mehrad Adibi, **Yair Lotan**. Reduction in hospital admission rates due to post-prostate biopsy infections after augmenting standard antibiotic prophylaxis. (Abstract #41 – Prostate Cancer – Treatment/Diagnosis Podium).
7. Daniel Ramirez, Aditya Bagrodia, **Yair Lotan**, Claus Roehrborn, Philippe Zimmern: Perioperative characteristics, surgical and post-operative outcomes in the geriatric population undergoing robotic-assisted laparoscopic prostatectomy: is this population at risk? (Abstract #49 – Prostate Cancer – Treatment/Diagnosis Podium).

AUA Annual Meeting. Atlanta, GA. May 18-23, 2012

1. Aditya Bagrodia, Ramy Youssef, Oussama Darwish, Chase Cannon, Michael Belsante, Payal Kapur, **Yair Lotan**, Vitaly Margulis: Prospective evaluation of cell cycle biomarkers for prediction of cancer-specific mortality in patients with upper tract urothelial carcinoma. J Urology 187, No. 4 Supplement (Abstract no. 387) 2012.
2. Eugene Cha, Christopher E. Barbieri, Michael Rink, Thomas F. Chromecki, Allison Dunning, **Yair Lotan**, Harun Fajkovic, Douglas S. Scherr, Madhu Mazumdar, Shahrokh F. Shariat: Clinical utility of NMP22 for bladder cancer surveillance: a multi-center cross sectional study. J Urology 187, No 4. Supplement (Abstract no. 391) 2012.
3. Jay D. Raman, **Yair Lotan**, Wassim Kassouf, Hans-Martin Fritsche, Karim Bensalah, Alon Weizer, Eiji Kikuchi, Marco Roscigno, Mesut Remzi, Kazumasa Matsumoto, Richard Zigeuner, Douglas S. Scherr, Madhu Mazumdar, Guru Sonpavde, Shahrokh F. Shariat, Eugene K. Cha, Harun Fajkovic, Michael Rink, Armin Pycha, Allison Dunning, Giacomo Novara, Pierre I. Karakiewicz, Vitaly Margulis: Disease-free survival at a surrogate for 5-year overall survival in upper tract urothelial carcinoma. J Urology 187, No. 4 Supplement (Abstract no. 392) 2012.
4. Mehrad Adibi, Ramy Youssef, Shahrokh Shariat, **Yair Lotan**, Christopher Wood, Arthur Sagalowsky, Richard Zigeuner, Cord Langner, Francesco Montorsi, Christian Bolenz, Vitaly Margulis: Oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: Comparison over the three decades. J Urology 187, No. 4 Supplement (Abstract no. 645) 2012.
5. Ramy Youssef, **Yair Lotan**, Shahrokh Shariat, Christopher Wood, Arthur Sagalowsky, Oussama Darwish, Jay Raman, Cord Langner, Marco Roscigno, Francesco Montorsi, Christian Bolenz, Wassim Kassouf, Vitaly Margulis: Impact of lymphadenectomy and systematic chemotherapy on survival of patients with t4 upper tract urothelial cancer. J Urology 187, No. 4 Supplement (Abstract no. 647) 2012.
6. Ramy Youssef, Oussama Darwish, Michael Belsante, Aditya Bagrodia, Payal Kapur, Feras Alhalabi, **Yair Lotan** and Vitaly Margulis. Clear cell renal carcinoma: alterations in mammalian target of rapamycin pathway constituents correlate with pathological features. J Urology 187, No. 4 Supplement (Abstract no. 983) 2012.
7. **Yair Lotan**, Phyllis Goodman, Ramy Youssef, Robert Svatek, Shahrokh Shariat, Catherine Tangen, Ian M. Thompson, Eric A. Klein: Evaluation of vitamin e and selenium supplementation on the prevention of bladder cancer in SWOG-Coordinated SELECT. J Urology 187, No. 4 Supplement (Abstract no. 1273) 2012.
8. Oussama Darwish, Ramy Youssef, Payal Kapur, Aditya Bagrodia, Michael Belsante, Feras Alhalabi, **Yair Lotan**, and Vitaly Margulis. Number of altered biomarkers in the mammalian target of rapamycin independently correlates with oncologic outcomes in patients with clear cell renal cell carcinoma. J Urology 187, No. 4 Supplement (Abstract no. 1297) 2012.
9. Michael Rink, Behfar Ehdaie, Eugene K. Cha, Robert S. Svatek, Thomas Chromecki, Harun Fajkovic, Jens Hansen, Giacomo Novara, Siamak Daneshmand, Yves Fradet, **Yair Lotan**, Arthur Sagalowsky, Derya Tilki, Patrick Bastian, Wassim Kassouf, Hans- Martin Fritsche, Maximilian Burger, Jonathan I. Izawa, Firas Abdollah, Pierre I. Karakiewicz, Felix K. Chun, Margit Fisch, Guru Sonpavde, Douglas S. Scherr, Mithat Gonen, Shahrokh Shariat. Clinical nodal staging scores for bladder cancer: A new preoperatively nodal assessment tool. J Urology 187, No. 4 Supplement (Abstract no. 1400) 2012.
10. Michael Rink, Shahrokh F. Shariat, David Green, Eugene K. Cha, Jens Hansen, John P. Fitzgerald, Colin P. Dinney, Giacomo Novara, Yves Fradet, Siamak Daneshmand,

- Derya Tilki, Patrick Bastian, Wassim Kassouf, Hans-Martin Fritsche, Roland Dhalem, Felix K. Chun, Pierre I. Karakiewicz, Margit Fisch, Douglas S. Scherr, Axel Merseburger, **Yair Lotan**, Robert S. Svatek: Is the nodal yield associated with outcomes in bladder cancer patients without nodal metastasis at radical cystectomy? J Urology 187, No. 4 Supplement (Abstract no. 1401) 2012.
11. Harun Fajkovic, Eugene Cha, Claudio Jeldres, Brian Robinson, Michael Rink, Thomas Chromecki, Eckart Breinl, Gerhard Donner, Robert Svatek, Derya Tilki, Patrick Bastian, Pierre Karakiewicz, Bjoern Volkmer, Giacomo Novara, Christian Seitz, Guru Sonpavde, Siamak Daneshmand, **Yair Lotan**, Talia Faison, Douglas Scherr, Shahrokh Shariat. Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis. J Urology 187, No. 4 Supplement (Abstract no. 1904) 2012.
 12. Edwin Morales, Shahrokh Shariat, Pierre Karakiewicz, Bjorn Volkmer, Wassim Kassouf, Yves Fradet, Giacomo Novara, Hans-Martin Fritsche, Patrick Bastian, Jonathan Izawa, Christian Stief, Vincenzo Ficarra, Michael Rink, Seth Lerner, Mark Schoenberg, Colin Dinney, Eila Skinner, **Yair Lotan**, Arthur Sagalowsky, and Robert Svatek. Positive surgical margins contribute to delayed failures in patients undergoing radical cystectomy for bladder cancer. J Urology 187, No. 4 Supplement (Abstract 1906) 2012.
 13. Ramy Youssef, Payal Kapur, Ahmed Mosbah, Hassan Abol-Enein, Mochamed Ghoneim, **Yair Lotan**: Prognostic biomarkers for squamous cell carcinoma of the bladder. J Urology 187, No. 4 Supplement (Abstract no. 1912) 2012.
 14. John Wei, Martin Sanda, Ian Thompson, Alan Partin, Ziden Feng, Lori Sokoll, Jack Groskopf, Elissa Brown, **Yair Lotan**, Adam Kibel, Erik Busby, Mohamed Bidair, Dan Lin, Samir Taneja, Rosalia Viterbo: The NCI early detection research network (EDRN) urinary pca3 validation trial. J Urology 187, No. 4 Supplement (Abstract no. 2206) 2012.

Society of Urologic Oncology, Rockville, MD, November 30-December 3, 2011

1. Casey Seideman, Ramy Youssef, Anna Buteau, Robert Svatek, Gaurab Chakrabarti, Gary Reed, Deepa Bhat and **Yair Lotan**. What Is Evaluation of Hematuria by Primary Care Physician's: Use of Electronic Medical Records to Assess Practice Patterns? (Poster #4).
2. Eugene Cha, Harun Fajkovic, Claudio Jeldres, Thomas Chromecki, Brian Robinson, Robert Svatek, Derya Tilki, Patrick Bastian, Pierre Karakiewicz, Giacomo Novara, Hans- Martin Fritsche, Maximilian Burger, Guru Sonpavde, Siamak Daneshmand, **Yair Lotan**, Douglas Scherr and Shahrokh Shariat. Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis (Poster #6).
3. Thomas Chromecki, Michael Rink, Eugene Cha, Harun Fajkovich, Behfar Ehdaie, Robert Svatek, Pierre Karakiewicz, **Yair Lotan**, Derya Tilki, Patrick Bastian, Siamad Daneshmand, Wassim Kassouf, Giacomo Novara, Hans-Martin Fritsche, Maximilian Burger, Jonathan Izawa, Yves Fradet, Marek Babjuk and Shahrokh F. Shariat. Obesity Is Associated with Worse Oncological Outcomes In Patients Treated With Radical Cystectomy. (Poster #16).
4. Eugene Cha, Christopher Barbieri, Thomas Chromecki, Allison Dunning, **Yair Lotan**, Michael Rink, Douglas Scherr, Pierre Karakiewicz, Madhu Mazumdar and Shahrokh Shariat. Clinical Utility of Nmp22 for the Surveillance of Patients with Recurrent Bladder Cancer: A Multi-Center Cross-Sectional Study. (Poster #18).

5. Ramy Youssef, Payal Kapur, Tyler Arendt, Ahmed Mosbah, Hassan Abol-Enein, Mohamed Ghoniem and **Yair Lotan**. Prognostic Value of Apoptotic Markers in Squamous Cell Carcinoma of the Bladder. (Poster #22).
6. Michael Rink, Shahrokh Shariat, Eugene Cha, Behfar Ehdai, Robert Svatek, Thomas Chromecki, Giacomo Novara, Siamak Daneshmand, Yves Fradet, **Yair Lotan**, Arthur Sagalowsky, Patrick Bastian, Wassim Kassouf, Hans-Martin Fritsche, Maximilian Burger, Jonathan Izawa, Derya Tilki, Firas Abdollah, Felix Chun. Clinical Nodal Staging Scores for Bladder Cancer: A Proposal for Preoperative Risk Assessment. (Poster #24).
7. Casey Seideman, Michael Posch, Ramy Youssef and **Yair Lotan**. Evaluation of Anticipatory Fish Positive Assays in Bladder Cancer Surveillance Patients. (Poster #27).
8. Oussama Darwish, Ramy Youssef, Payal Kapur, Aditya Bagrodia, Michael Belsante, Feras Alhalabi, **Yair Lotan** and Vitaly Margulis. Clear Cell Renal Cell Carcinoma: Can Tissue Biomarkers Predict Prognosis? (Poster #36).
9. Aditya Bagrodia, Ramy Youssef, Chase Cannon, Oussama Darwish, Michael Belsante, Payal Kapur, **Yair Lotan** and Vitaly Margulis. Prospective Evaluation of Cell Cycle Biomarkers for Prediction of Cancer-Specific Mortality in Patients with Upper Tract Urothelial Carcinoma. (Poster #56).
10. Ramy Youssef, Shahrokh Shariat, **Yair Lotan**, Nicholas Cost, Christopher Wood, Arthur Sagalowsky, Richard Zigeuner, Cord Langner, Thomas Chromecki, Francesco Montorsi, Christian Bolenz and Vitaly Margulis. Urothelial Carcinoma at the Uretero-Enteric Junction: Multi-Center Evaluation of Oncologic Outcomes after Radical Nephroureterectomy. (Poster #57).
11. Eugene Cha, Harun Fajkovic, Michael Rink, Claudio Jeldres, Thomas Chromecki, Vitaly Margulis, Giacomo Novara, **Yair Lotan**, Jay Raman, Wassim Kassouf, Alon Weizer, Pierre Karakiewicz, Douglas Scherr, Shahrokh Shariat and for the UTUC Collaboration. Prognostic Value of Extranodal Extension in Patients with Upper Tract Urothelial Carcinoma. (Poster #60).
12. Mehrad Adibi, Margaret Pearle and **Yair Lotan**. Cost-Effectiveness of Standard Versus Intensive Antibiotic Regimens for Trans-Rectal Ultrasound Guided Prostate Biopsy Prophylaxis. (Poster #94).
13. **Yair Lotan**, Phyllis Goodman, Ramy Youssef, Robert Svatek, Shahrokh Shariat, Catherine Tangen, Ian Thompson and Eric Klein. Evaluation of Selenium Supplementation on the Prevention of Bladder Cancer in Swog-Coordinated Select. (Poster #122). Presented by **Yair Lotan**.
14. Michael Belsante, Ramy Youssef, Oussama Darwish, Aditya Bagrodia, Payal Kapur, Feras Alhalabi, Vitaly Margulis and **Yair Lotan**. Prognostic Role of Lymphovascular Invasion in Clear Cell Renal Cell Carcinoma. (Poster #139).
15. Eugene Cha, Thomas Chromecki, Vitaly Margulis, Giacomo Novara, Douglas Scherr, **Yair Lotan**, Jay Raman, Wassim Kassouf, Karim Bensalah, Alon Weizer, Shahrokh Shariat and for the UTUC Collaboration. Tumor Multifocality Is Associated with Worse Outcomes in Patients with Organ-Confined Upper Tract Urothelial Carcinoma. (Poster #155).

South Central Section Meeting of the AUA, San Antonio, TX, September 14-17, 2011

1. Ramy Youssef, Shahrokh Shariat, **Yair Lotan**, Nicholas Cost, Christopher Wood, Arthur Sagalowsky, Richard Zigeuner, Cord Langner, Thomas Chromecki, Francesco

- Montorsi, Christian Bolenz, Vitaly Margulis. Urothelial Carcinoma at the Uretero-Enteric Junction: Multi-Center Evaluation of Oncologic Outcomes after Radical Nephroureterectomy (Abstract #31, Renal and Ureteral Disease Podium).
2. Mehrad Adibi, Margaret S. Pearle, **Yair Lotan**. Cost-Effectiveness of Standard Versus Intensive Antibiotic Regimens for Transrectal Ultrasound –Guided Prostate Biopsy Prophylaxis (Abstract #45, Prostate Cancer Treatment/Diagnosis Podium).
 3. Paul Smith, **Yair Lotan**, Ganesh Raj, Arthur Sagalowsky, Vitaly Margulis. Assessing Treatment Response after Induction BCG for CIS of the Urinary Bladder: Can Post- Induction Random Bladder Biopsies Be Avoided? (Abstract #67, Bladder Cancer Podium).
 4. Ramy Youssef, Payal Kapur, Tyler Arendt, Wareef Kabbani, Ahmed Mosbah, Hassan Abol-Enein, Mohamed Ghoniem, **Yair Lotan**. Prognostic Value of Apoptotic Markers in Squamous Cell Carcinoma of the Bladder (Abstract #70, Bladder Cancer Podium).
 5. Ramy Youssef, Payal Kapur, Tyler Arendt, Wareef Kabbani, Ahmed Mosbah, Hassan Abol-Enein, Mohamed Ghoniem, **Yair Lotan**. Prognostic Value of Fibroblast Growth Factor in Squamous Cell Carcinoma of the Bladder (Abstract #71, Bladder Cancer Podium).

AUA Annual Meeting, Washington, DC, May 13 - May 18, 2011

1. Robert Svatek, **Yair Lotan**. Cost Utility of Prostate Cancer Chemoprevention with Dutasteride in Men with an Elevated PSA. (Podium 310).
2. Ramy Youssef, Tyler Arendt, Nicholas Cost, Arthur Sagalowsky, **Yair Lotan**, Vitaly Margulis. Prospective Evaluation of Biomarkers in Patients with Upper Tract Urothelial Carcinoma: Prognostic Role of Cell Cycle Regulators (Podium 363).
3. Andrew Feifer, Jennifer Taylor, Marwan Shouery, Caroline Savage, Gary Steinberg, Walter M. Stadler, Joel DeCastro, Seth Lerner, Guilherme Godoy, **Yair Lotan**, Adam S. Feldman, Sarah Psutka, Wassim Kassouf, Faysal Yafi, Alexander Zlotta, Peter Black, Mark Schoenberg, Robert Grubb III, Michael O'Donnell, Henry Rosevear, Andrew Stephenson, Amit Patel, Cheryl Lee, Alon Weizer, Dean Bajorin, Matthew Milowsky, Guido Dalbagni, Ethan Basch, Bernard Bochner. Multi-Institutional Quality of Care Initiative for Non-Metastatic Muscle-Invasive Transitional Cell Carcinoma of the Bladder: Phase 1. (Podium 485).
4. Ramy Youssef, Shahrokh Shariat, **Yair Lotan**, Nicholas Cost, Christopher Wood, Arthur Sagalowsky, Richard Zigeuner, Cord Langner, Francesco Montorsi, Christian Bolenz, Vitaly Margulis. Prognostic Impact of Urinary Bladder Carcinoma In Situ On Clinical Outcome of Subsequent Upper Tract Urothelial Carcinoma. (Podium 663).
5. Joshua Sleeper, Nicholas Cost, **Yair Lotan**. Cost Comparison of Robotic-Assisted and Laparoscopic Pyeloplasty. (Moderated Poster 942).
6. Ramy Youssef, Payal Kapur, Tyler Arendt, Wareef Kabbani, Ahmed Mosbah, Hassan Abol-Enein, Mohamed Ghoniem, **Yair Lotan**. Prognostic Value of Fibroblast Growth Factor in Squamous Cell Carcinoma of the Bladder. (Moderated Poster 1068).
7. Vitaly Margulis, Ramy Youssef, Payal Kapur, Wareef Kabbani, Feras Alhalabi, Tyler Arendt, Dinesh Rakheja, Karim Bensalah, Adita Bagrodia, **Yair Lotan**. The Number of Aberrantly Expressed Constituents of the Mammalian Target of Rapamycin Pathway: Correlation with Oncologic Outcomes in Clear Cell Renal Cell Carcinoma. (Moderated 1081).

8. Ramy Youssef, Cenk Gurbuz, Shahrokh Shariat, **Yair Lotan**, Christopher Wood, Arthur Sagalowsky, Nicholas Cost, Richard Zigeuner, Cord Langner, Francesco Montorsi, Christian Bolenz, Eiji Kikuchi, Alon Weizer, Jay Raman, Mesut Remzi, Marco Roscigno, Wassim Kassouf, Vitaly Margulis. The Impact of Previous Ureteroscopic Tumor Ablation on Oncologic Outcomes after Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma. (Moderated Podium 1388).
9. Ramy Youssef, Shahrokh Shariat, Payal Kapur, Wareef Kabbani, Tarek Ghoneim, Ellen King, Amber Cockburn, Ahmed Mosbah, Hassan Abol-Enein, Mohamed Ghoneim, **Yair Lotan**. Expression of Cell Cycle-Related Molecular Markers in Patients Treated with Radical Cystectomy for Squamous Cell Carcinoma of the Bladder. (Moderated Poster 1400).
10. Bas W van Rhijn, Peter J Bostrom, Shahrokh F Shariat, Antonio Finelli, Arthur I Sagalowsky, Neil E Fleshner, Bharati Bapat, Hannes Kortekangas, Raheela Ashfaq, Tuomas Mirtti, Michael A Jewett, **Yair Lotan**, Theo H van der Kwast, Alexandre R Zlotta. The FGFR3 Mutation Identifies Patients with Favorable Disease At Radical Cystectomy for Bladder Cancer. (Moderated Poster 1401).
11. Eugene Cha, Thomas Chromecki, Maxine Sun, Robert Svatek, Michael Rink, Mesut Remzi, **Yair Lotan**, Giacomo Novara, Christian Seitz, Felix Chun, Richard Lee, Karl Pummer, Armin Pycha, Wassim Kassouf, Vincenzo Ficarra, Douglas Scherr, Pierre Karakiewicz, Shahrokh Shariat. Prognostic Tool to Help Identify Pt1-3n0 Patients Likely to Benefit from Adjuvant Chemotherapy after Radical Cystectomy. (Moderated Poster 1418).
12. Jay Raman, Yu-Kuan Lin, Lucas Nikkel, Christopher Hollenbeak, Zeeshan Danawala, Vincent Olorunnisomo, Ramy Youssef, Margaret Pearle, **Yair Lotan**. Residual Fragments Following Ureteroscopic Lithotripsy: Incidence and Predictors in Over 250 Patients with Post-Operative Computed Tomography (Ct) Imaging. (Podium 1692).
13. Shahrokh Shariat, Ramy Youssef, Suzette Toombs, Joseph Scales, Christian Bolenz, Raheela Ashfaq, Arthur Sagalowsky, **Yair Lotan**. Prospective Validation of Prognostic Biomarker Panel for Bladder Cancer Management at Time of Transurethral Resection of Bladder Tumors. (Moderated Poster 1888).
14. Jay Raman, Yu-Kuan Lin, Lucas Nikkel, Christopher Hollenbeak, Zeeshan Danawala, Vincent Olorunnisomo, Ramy Youssef, Margaret Pearle, **Yair Lotan**. Residual Fragments Following Ureteroscopic Lithotripsy: Incidence and Predictors in Over 250 Patients with Post-Operative Computed Tomography (Ct) Imaging. (Podium 1692).
15. Shahrokh Shariat, Ramy Youssef, Suzette Toombs, Joseph Scales, Christian Bolenz, Raheela Ashfaq, Arthur Sagalowsky, **Yair Lotan**. Prospective Validation of Prognostic Biomarker Panel for Bladder Cancer Management at Time of Transurethral Resection of Bladder Tumors. (Moderated Poster 1888).
16. Derya Tilki, Oliver Reich, Pierre Karakiewicz, Giacomo Novara, Wassim Kassouf, Yves Fradet, Vincenzo Ficarra, Michael Seitz, Eila Skinner, Robert Svatek, **Yair Lotan**, Arthur Sagalowsky, Christian Stief, Shahrokh Shariat. PT2 Substaging in Urothelial Carcinoma of the Bladder: Deep Muscle Invasion Is Associated with Worse Outcome. (Moderated Poster 1892).
17. Derya Tilki, Oliver Reich, Robert Svatek, Pierre Karakiewicz, Wassim Kassouf, Giacomo Novara, Vincenzo Ficarra, Michael Seitz, Hans-Martin Fritsche, Seth Lerner, Eila Skinner, **Yair Lotan**, Arthur Sagalowsky, Christian Stief, Shahrokh

Shariat. Clinical Carcinoma in Situ Only Disease: Outcomes of Patients Treated with Radical Cystectomy. (Moderated Poster 1898).

11th Annual Society of Urologic Oncology Winter Meeting, Bethesda, December 2010

1. Ramy Youssef, Shahrokh Shariat, Yair Lotan, Nicholas Cost, Christopher Wood, Arthur Sagalowsky, Richard Zigeuner, Cord Langner, Francesco Montorsi, Christian Bolenz and Vitaly Margulis. Prognostic Impact of Urinary Bladder Carcinoma Insitu on Clinical Outcome of Subsequent Upper Tract Urothelial Carcinoma. (Poster #56)
2. Ramy Youssef, Shahrokh Shariat, Payal Kapur, Wareef Kabbani, Tarek Ghoneim, Ellen King, Amber Cockburn, Ahmed Mosbah, Hassan Abol-Enein, Mohamed Ghoneim and Yair Lotan. Expression of Cell Cycle-Related Molecular Markers in Patients Treated with Radical Cystectomy for Squamous Cell Carcinoma of the Bladder. (Poster #66)
3. Andrew Feifer, Jennifer Taylor, Marwan Shouery, Caroline Savage, Gary Steinberg, Walter Stadler, Joel Decastro, Seth Lerner, Guilherme Godoy, Yair Lotan, Adam S. Feldman, Wassim Kassouf, Faysal Yafi, Alex Zlotta, Peter Black, Marc Schoenberg, Robert Grubb III, Andrew Stephenson, Amit Patel, Cheryl Lee, Alon Weizer, Dean Bajorin, Matthew Milowsky, Ethan Basch and Bernard Bochner. Multi-Institutional Quality of Care Initiative for Non-Metastatic Muscle-invasive Transitional Cell Carcinoma of the Bladder: Phase 1. (Oral Abstract #13)
4. Shahrokh Shariat, Ramy Youssef, Suzette Toombs, Joseph Scales, Christian Bolenz, Arthur Sagalowsky, Raheela Ashfaq and Yair Lotan. Prospective Validation of Prognostic Biomarker Panel for Bladder Cancer Management at Time of Transurethral Resection of Bladder Tumors. (Oral Abstract #14)
5. Ramy Youssef, Tyler Arendt, Nicholas Cost, Arthur Sagalowsky, Yair Lotan and Vitaly Margulis. Prospective Evaluation of Biomarkers in Patients with Upper Tract Urothelial Carcinoma: Prognostic Role of Cell Cycle Regulators. (Poster #150)

South Central Section Meeting of the AUA, White Sulphur Springs, WV, September 2010

1. Ramy Youssef, Shahrokh F. Shariat, Payal Kapur, Wareef Kabbani, Ahmed Mosbah, Hassan Abol-Enein, Mohamed Ghoniem, **Yair Lotan**. Prognostic Value of Cyclooxygenase-2 Expression in Squamous Cell Carcinoma of the Urinary Bladder. (Podium Presentation #25)
2. Josh Sleeper, Chet Donnally, Yair Lotan. Cost Comparison of Robotic-Assisted and Laparoscopic Pyeloplasty. (Podium Presentation #48)
3. Ramy Youssef, Shahrokh F. Shariat, Pierre I. Karakiewicz, Yair Lotan, Christopher Wood, Richard Zigeuner, Eiji Kikuchi, Alon Weizer, Jay D. Raman, Mesut Remzi, Marco Roscigno, Francesco Montorsi, Christian Bolenz, Wassim Kassouf, Vitaly Margulis: Pre- Operative Multivariable Prognostic Model for Prediction of Non-Organ Confined Urothelial Carcinoma of the Upper Urinary Tract. (Podium Presentation #57)

AUA Annual Meeting, San Francisco, CA, May 28 - June 2, 2010

1. Shahrokh Shariat, Ramy Youssef, Daher Chade, Pierre Karakiewicz, Hendrik Isbarn, Claudio Jeldres, Arthur Sagalowsky, Raheela Ashfaq, **Yair Lotan**. Association of angiogenesis-related markers with bladder cancer outcomes and other molecular markers. (Abstract 159)

2. Ramy Youssef, Shahrokh Shariat, **Yair Lotan**, Christopher Wood, Arthur Sagalowsky, Richard Zigeuner, Eiji Kikuchi, Alon Weizer, Jay Raman, Mesut Remzi, Marco Roscigno, Francesco Montorsi, Christian Bolenz, Wassim Kassouf, Vitaly Margulis. Upper urinary tract urothelial carcinoma with locoregional nodal metastases: experience with aggressive integration of systemic therapy followed by radical nephroureterectomy. (Abstract 421)
3. John Terrell, James Brien, Michael Herman, Casey Ng, Douglas Scherr, Benjamin Scoll, Stephen Boorjian, Robert Uzzo, Mark Wille, Scott Eggener, Steven Lucas, **Yair Lotan**, Shahrokh Shariat, Jay Raman. Multi-institutional validation of the predictive value of preoperative hydronephrosis for advanced stage upper-tract urothelial carcinoma. (Abstract 430)
4. Charles Scales, Tracey Krupski, Lesley Curtis, Margaret Pearle, Brian Matlaga, **Yair Lotan**, Dallas, TX; Christopher Saigal, Mark Litwin, Glenn Preminger. Variation in second procedures for stone fragmentation in the United States. (Abstract 482)
5. Ramy Youssef, Shahrokh Shariat, Feras Alhalabi, Christian Bolenz, Raheela Ashfaq, Yull Arriaga, Ganesh Raj, Arthur Sagalowsky, **Yair Lotan**. Prospective validation of multiple biomarkers for improved clinical decision-making in patients with urothelial carcinoma of the bladder. (Abstract 1021)
6. Ramy Youssef, Shahrokh Shariat, Wareef Kabbani, Payal Kapur, Ahmed Mosbah, Hassan Abol-Enein, Mohamed Ghoniem, **Yair Lotan**. Expression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder. (Abstract 1155)
7. John Terrell, Keren Elias, Chester Donnally, Richard Ho, Arthur Sagalowsky, **Yair Lotan**. Urine cytology provides no additional diagnostic value in patients with a negative cystoscopy and negative nmp22 bladderchek test for the detection of transitional cell carcinoma of the bladder. (Abstract 1169)
8. William Caraway, Yu Kuan Lin, Lucas Nikkel, Christopher Hollenbeak, Jay Raman, Zeeshan Danawala, Vincent Olorunnisomo, Ramy Youssef, Margaret Pearle, **Yair Lotan**. Is routine imaging following ureteroscopy for urinary calculi necessary? (Abstract 1325)
9. Sunshine Murray, Rashel Haverkorn, **Yair Lotan**, Gary Lemack. Mesh kits for anterior vaginal prolapse (avp) are not cost effective. (Abstract 1391)
10. Christian Bolenz, Shahrokh F. Shariat, Pierre I. Karakiewicz, Raheela Ashfaq, Richard Ho, Arthur I. Sagalowsky, **Yair Lotan**. HER-2 expression status provides independent prognostic information in patients with urothelial carcinoma of the bladder. (Abstract 1716)
11. Ramy Youssef, Payal Kapur, Wareef Kabbani, Shahrokh Shariat, Ahmed Mosbah, Hassan Abol-Enein, Mohamed Ghoniem, **Yair Lotan**. Bilharzial related bladder cancer: pathological characteristics and value of cyclooxygenase-2 expression. (Abstract 1717)
12. Charles Scales, Tracey Krupski, Lesley Curtis, Margaret Pearle, Brian Matlaga, **Yair Lotan**, Christopher Saigal, Mark Litwin, Glenn Preminger. Variation in surgical management of urinary lithiasis in the United States. (Abstract 1804)
13. Oliver Reich, Derya Tilki, Robert Svatek, Pierre Karakiewicz, Hendrik Isbarn, Wassim Kassouf, Yves Fradet, Giacomo Novara, Hans-Martin Fritsche, Patrick Bastian, Jonathan Izawa, Vincenzo Ficarra, Seth Lerner, Mark Schoenberg, Colin Dinney, Eila Skinner, Yair Lotan, Arthur Sagalowsky, Christian Stief, Shahrokh Shariat. Clinical outcome in patients with pT4 urothelial carcinoma at radical cystectomy. (Abstract 1825)

14. Chad Tracy, Amit Gupta, Richard Ho, Margaret Pearle, Yair Lotan. Calcium phosphate content does not effect stone free rates following percutaneous neprolithotomy (PCNL). (Abstract 1889)

Genitourinary Cancers Symposium, San Francisco, CA, March 2010

1. T P Boike, **Y Lotan**, L C Cho, J Brindle, A Perkins, R Abdulrahman, D Pistenmaa, R Timmerman. A phase I dose-escalation study of stereotactic body radiation therapy (SBRT) for low- and intermediate-risk prostate cancer. (Poster Session)

American Association for Cancer Research. Washington, DC, April 17-12, 2010

1. Prospective validation of multiple biomarkers for improved clinical decision-making in patients with urothelial carcinoma of the bladder.

South Central Section Meeting of the AUA, Scottsdale, AZ, October 2009

1. John Terrell, Christian Bolenz, Richard Ho, Keren Elias, Arthur Sagalowsky, **Yair Lotan**. Urine Cytology Provides No Additional Diagnostic Value in Patients with a Negative Cystoscopy and Negative Bladderchek Nmp22 Test for the Detection of Transitional Cell Carcinoma. (Abstract #26)
2. Saumil Karavadia, Richard Ho, Yull Arriaga, Arthur Sagalowsky, **Yair Lotan**, Ganesh Raj. Contemporary Utilization of Perioperative Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Bladder Cancer. (Abstract #27)
3. Christian Bolenz, Shahrokh Shariat, Raheela Ashfaq, Travis Edwards, Yull Arriaga, Ganesh Raj, Arthur Sagalowsky, **Yair Lotan**. Prospective Validation of Multiple Biomarkers for Improved Clinical Decision-Making in Patients with Urothelial Carcinoma of the Bladder. (Abstract #30; Presenter)
4. Christian Bolenz, Ann Marie West, Wareef Kabbani, Nicolas Ortiz, Richard Ho, Arthur Sagalowsky, **Yair Lotan**. Detection of Urothelial Bladder Cancer: Influence of Higher Throughput and Experience Level on the Performance of Urinary Cytology. (Abstract #31)
5. **Yair Lotan**, David Pistenmaa, L. Chinsoo Cho, Jeffrey Brindle, Alida Perkins, Robert Timmerman. Phase I Study of Stereotactic Body Radiation Therapy Sbrt for Low and Intermediate Risk Prostate Cancer: Iniital Results. (Abstract #41; Presenter) John Terrell, James Brien, Michael Herman, Casey Ng, Douglas Scherr, Benjamin Scoll, Stephen Boorjian, Robert Uzzo, Mark Wille, Scott Eggener, Steven Lucas, **Yair Lotan**, Shahrokh Shariat, Jay Raman. Multi-Institutional Validation of the Predictive Value of Preoperative Hydronephrosis for Advanced Stage Upper-Tract Urothelial Carcinoma. (Abstract #57)

AUA Annual Meeting, Chicago, IL, April 25 – 30, 2009

1. Shahrokh F Shariat, Robert S Svatek, Eila Skinner, Pierre I Karakiewicz, Umberto Capitanio, Patrick J Bastian, Bjoern G Volkmer, Francesco Montorsi, Wassim Kassouf, Giacomo Novara, Hans-Martin Fritsche, Stefan C Müller, Stefan C Müller, Jonathan I Izawa, Hendrik Isbarn, Christian G Stief, Vincenzo Ficarra, Seth P Lerner, Arthur I Sagalowsky, Mark P Schoenberg, Ashish Kamat, Colin P Dinney, **Yair Lotan**, Yves Fradet. Lymphovascular invasion is a powerful predictor of clinical outcomes in node-negative radical cystectomy patients: an international external validation study. (Moderated Poster 58)

2. Robert S Svatek, Shahrokh F Shariat, Wassim Kassouf, Giacomo Novara, Yves Fradet, Patrick J Bastian, Pierre I Karakiewicz, Hans-Martin Fritsche, Stefan C. Muller, Jonathan I. Izawa, Colin P. Dinney, Christian G. Stief, Vincenzo Ficarra, Ashish Kamat, Bjoern G Volkmer, Francesco Montorsi, Hendrik Isbarn, Seth P Lerner, Arthur I. Sagalowsky, Mark P Schoenberg, **Yair Lotan**, Eila Skinner. Prognostic value of lymph node density in a multi-center, international cohort of patients with node positive urothelial carcinoma of the bladder. (Podium 11)
3. Shahrokh F Shariat, Christian Bolenz, Raheela Ashfaq, Pierre I Karakiewicz, Yves Fradet, Hendrik Isbarn, Claudio Jeldres, Jerome Rigaud, Arthur I Sagalowsky, **Yair Lotan**. Predictive value of the combination of immunohistochemical markers in patients with pt1 disease at radical cystectomy. (Podium 27)
4. Aditya Bagrodia, Amit Gupta, Jay D Raman, Karim Bensalah, Margaret S Pearle, **Yair Lotan**. Predictors of cost and clinical outcomes for patients undergoing percutaneous nephrostolithotomy (pcnl). (Podium 35)
5. Shahrokh F Shariat, Pierre I Karakiewicz, Umberto Capitanio, Jay D Raman, **Yair Lotan**, Wassim Kassouf, Richard E Zigeuner, Marco Roscigno, Mesut Remzi, Christian Bolenz, Cord Langner, Alon Z Weizer, Francesco Montorsi, Eiji Kikuchi, Karim Bensalah, Theresa M Koppie, Mario I Fernández, Jeffrey Wheat, Mototsugu Oya, Casey K Ng, Charles C Guo, Christopher G Wood, Vitaly Margulis. Development of prognostic models for individual risk stratification in patients treated with radical nephroureterectomy: a new tool to help with patient selection for adjuvant therapy (Moderated Poster 12)
6. Giacomo Novara, Robert S Svatek, Pierre I Karakiewicz, Eila Skinner, Yves Fradet, **Yair Lotan**, Umberto Capitanio, Patrick J Bastian, Francesco Montorsi, Wassim Kassouf, Hans-Martin Fritsche, Stefan C Müller, Jonathan I Izawa, Hendrik Isbarn, Christian G Stief, Vincenzo Ficarra, Colin P Dinney, Seth P Lerner, Mark P Schoenberg, Arthur I Sagalowsky, Ashish Kamat, Bjoern G Volkmer, Shahrokh F Shariat. Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of over 4300 patients. (Podium 11)
7. Shahrokh F Shariat, Pierre I Karakiewicz, Yves Fradet, Raheela Ashfaq, Christian Bolenz, Patrick J Bastian, Matthew E Nielsen, Umberto Capitanio, Claudio Jeldres, Susan Groshen, Jérôme Rigaud, Stefan C Müller, Seth P Lerner, Francesco Montorsi, Arthur I Sagalowsky, Richard J Cote, **Yair Lotan**. Improved prediction of clinical outcomes in patients with advanced bladder cancer using a panel of four cell cycle regulators. (Moderated Poster 58)
8. Christian Bolenz, Richard Ho, Geoffrey R Nuss, Nicolas Ortiz, Ganesh V Raj, Arthur I Sagalowsky, **Yair Lotan**. Outcomes of elderly patients with urothelial carcinoma of the bladder and consequences of guideline-discordant treatment. (Moderated Poster 18)
9. Umberto Capitanio, Vitaly Margulis, Hendrik Isbarn, Jay D Raman, **Yair Lotan**, Wassim Kassouf, Richard E Zigeuner, Marco Roscigno, Francesco Montorsi, Mesut Remzi, Christian Bolenz, Cord Langner, Alon Z Weizer, Eiji Kikuchi, Karim Bensalah, Theresa M Koppie, Mario I Fernández, Jeffrey Wheat, Mototsugu Oya, Casey K Ng, Charles C Guo, Christopher Wood, Shahrokh F Shariat, Pierre I Karakiewicz. An assessment of the most significant determinants of the natural

- history of upper tract transitional cell carcinoma after nephroureterectomy: a multi-institutional recursive partitioning model. (Podium 8)
10. Shahrokh F. Shariat, Richard E Zigeuner, **Yair Lotan**, Wareef Kabbani, Vitaly Margulis, Christopher G. Wood, Charles C. Guo, Pierre I Karakiewicz, Marco Roscigno, Francesco Montorsi, Alon Z Weizer, Jeffrey Wheat, Eiji Kikuchi, Mototsugu Oya, Mesut Remzi, Matthias Waldert, Jay D. Raman, Casey K Ng, Christian Bolenz, Philipp Stroebel, Theresa M. Koppie, Karim Bensalah, Wassim Kassouf, Mario I. Fernandez, Cord Langner. Proposal for subclassification of pt3 urothelial cancer of the renal pelvis. (Moderated Poster 12)

 11. Shahrokh F Shariat, Richard E Zigeuner, Vitaly Margulis, Pierre I Karakiewicz, Marco Roscigno, Alon Z Weizer, Eiji Kikuchi, Mesut Remzi, Jay D. Raman, Christian Bolenz, Karim Bensalah, Theresa M. Koppie, Wassim Kassouf, Mario I. Fernández, Christopher G. Wood, Francesco Montorsi, Philipp Stroebel, Jeffrey Wheat, Matthias Waldert, Mototsugu Oya, Charles C. Guo, Casey K Ng, Wareef Kabbani, **Yair Lotan**, Cord Langner. Tumor necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. (Podium 8)
 12. Vitaly Margulis, **Yair Lotan**, Pierre I Karakiewicz, Yves Fradet, Raheela Ashfaq, Umberto Capitanio, Francesco Montorsi, Patrick J Bastian, Mathew E Nielsen, Stefan C Müller, Jerome Rigaud, Lukas Heukamp, George J Netto, Seth P Lerner, Arthur I Sagalowsky, Shahrokh F Shariat. Multi-institutional validation of the predictive value of KI-67 labeling index in patients with urinary bladder cancer. (Podium 8)
 13. Marco Roscigno, Shahrokh F. Shariat, Roberto Bertini, Pierre I Karakiewicz, Nazareno Suardi, Vitaly Margulis, Mesut Remzi, Richard E Zigeuner, Christian Bolenz, Eiji Kikuchi, Alon Z Weizer, Karim Bensalah, **Yair Lotan**, Theresa M Koppie, Jay D Raman, Mario I Fernandez, Philipp Stroebel, Wareef Kabbani, Masaru Murai, Cord Langner, Jeffrey Wheat, Charles C Guo, Andrea Haitel, Christopher G Wood, Francesco Montorsi. Removal of at least 8 nodes improves cancer-specific survival in non metastatic patients with upper tract urothelial carcinoma. (Podium 11)
 14. Christian Bolenz, Shahrokh F Shariat, Travis Edwards, Ganesh V Raj, Raheela Ashfaq, Arthur I Sagalowsky, **Yair Lotan**. Expression of multiple biomarkers is associated with locally advanced urothelial carcinoma of the bladder in a prospective evaluation. (Podium 27)
 15. Umberto Capitanio, Pierre I Karakiewicz, Vitaly Margulis, Jay D Raman, **Yair Lotan**, Wassim Kassouf, Richard E Zigeuner, Marco Roscigno, Mesut Remzi, Christian Bolenz, Cord Langner, Alon Z Weizer, Eiji Kikuchi, Francesco Montorsi, Karim Bensalah, Theresa M Koppie, Mario I Fernández, Jeffrey Wheat, Christopher G Wood, Hendrik Isbarn, Mototsugu Oya, Casey K Ng, Kanishka Sircar, Shahrokh F Shariat. Laparoscopic nephroureterectomy does not undermine cancer control outcomes in selected patients with non-metastatic upper tract urothelial carcinoma. (Podium 20)
 16. Robert S Svatek, Shahrokh F Shariat, Colin P. Dinney, Giacomo Novara, Yves Fradet, Patrick J Bastian, Wassim Kassouf, Pierre I Karakiewicz, Hans-

Martin Fritsche, Stefan C. Muller, Jonathan I. Izawa, Eila Skinner, Christian G. Stief, Vincenzo Ficarra, Bjoern G Volkmer, Francesco Montorsi, Hendrik Isbarn, Seth P Lerner, Arthur I. Sagalowsky, Mark P Schoenberg, **Yair Lotan**, Ashish Kamat. Evidence-based gender related outcomes after radical cystectomy: results of a large multicenter study. (Moderated Poster 58)

Genitourinary Cancers Symposium, Orlando, FL, February 2009

1. Amit Gupta, Christian Bolenz, Tim Hotze, Richard Ho, Jeffrey Cadeddu, Claus Roehrborn and **Yair Lotan**. Comparison of cost of robotic laparoscopic and open radical prostatectomy

9th Annual Society of Urologic Oncology Winter Meeting, Bethesda, December 2008

1. Vitaly Margulis, **Yair Lotan** Pierre Karakiewicz, Yves Fradet, Raheela Ashfaq, Umberto Capitanio, Francesco Montorsi, Patrick Bastian, Matthew Nielsen, Stefan Muller, Jerome Rigaud, Seth Lerner, George Netto, Arthur Sagalowsky, and Shahrokh Shariat. Multi-institutional validation of the predictive value of KI-67 labeling index in patients with urinary bladder cancer. (Poster #187)
2. Christian Bolenz, Shahrokh F. Shariat, Travis Edwards, Ganesh V. Raj, Raheela Ashfaq, Arthur I. Sagalowsky and **Yair Lotan**. Expression of multiple biomarkers is associated with locally advanced urothelial carcinoma of the bladder in a prospective evaluation. (Poster #191)
3. Christian Bolenz, Shahrokh F. Shariat, Pierre I. Karakiewicz, Yves Fradet, Raheela Ashfaq, Patrick J. Bastian, Matthew E. Nielsen, Nazareno Suardi, Susan Groshen, Jérôme Rigaud, Seth P. Lerner, Francesco Montorsi, Arthur I. Sagalowsky, Richard J. Cote and Yair Lotan (Poster #192)

AUA Annual Meeting. Orlando, FL. May 17 – 22, 2008

1. Jay D. Raman, Aditya Bagrodia, Karim Bensalah, Jeffrey A. Cadeddu, Margaret S. Pearle, **Yair Lotan**. Is second look flexible nephroscopy following percutaneous nephrostolithotomy cost effective? (Podium Session 04)
2. Aditya Bagrodia, Karim Bensalah, Amit Gupta, Jay D. Raman, Margaret S. Pearle, **Yair Lotan**. Impact of body mass index on cost and clinical outcomes following percutaneous nephrostolithotomy. (Podium Session 04)
3. Karim Bensalah, Jay D. Raman, Aditya Bagrodia, Andrea Marvin, **Yair Lotan**. Does obesity impact the costs of partial and radical nephrectomy? (Podium Session 04)
4. Shahrokh F. Shariat, **Yair Lotan**, Pierre Karakiewicz, Yves Fradet, Raheela Ashfaq, John P Stein, Patrick J. Bastian, Matthew E. Nielsen, Nazareno Suardi, Francesco Montorsi, Susan Groshen, Stefan C. Müller, Ganesh S. Palapattu, Jérôme Rigaud, Jose A. Karam, Lukas C. Heukamp, George Netto, Seth P. Lerner, Arthur I. Sagalowsky, Richard J. Cote. Multi-institutional evaluation of the

- predictive value of p53 immunohistochemical staining in patients with pT1-2 N0 disease at radical cystectomy (Podium Session 07)
5. Eiji Kikuchi, Takeo Kosaka, Vitaly Margulis, Francesco Montorsi, Mototsugu Oya, Shuji Mikami, Nazareno Suardi, **Yair Lotan**, Pierre Karakiewicz, Richard Zigeuner, Christian Bolenz, Casey K. Ng, Mesut Remzi, Alon Weizer, Theresa M. Koppie, Karim Bensalah, Mario Fernandez, Marco Roscigno, Charles C. Guo, Christopher G. Wood, Cord Langener, Jeffrey Wheat, Philipp Ströbel, Yingbei Chen, Shahrokh F. Shariat. Lymphovascular invasion is independently associated with cancer recurrence and survival in patients with negative lymph nodes at radical nephroureterectomy. (Podium Session 07)
 6. Mesut Remzi, Matthias Waldert, Vitaly Margulis, Francesco Montorsi, Eiji Kikuchi, Richard Zigeuner, Alon Weizer, Christian Bolenz, Shuji Mikami, **Yair Lotan**, Theresa M. Koppie, Casey K. Ng, Mario Fernández, Nazareno Suardi, Karim Bensalah, Stroebel Phillip, Marco Roscigno, Mohammed Akhtar, Charles C. Guo, Christopher G. Wood, Roberto Bertini, Takeo Kosaka, Wareef Kabbani, Pierre Karakiewicz, Shahrokh F. Shariat. Tumor architecture is an independent prognostic factor for disease relapse and cancer-specific in patients treated with nephroureterectomy: A multi-institutional analysis of 1363 patients from the Upper Tract Urothelial Carcinoma Collaboration. (Podium Session 07)
 7. Theresa M. Koppie, Shahrokh Shariat, Eric C. Nelson, Vitaly Margulis, Mesut Remzi, Francesco Montorsi, Jay Raman, Richard Ziguener, Nazareno Suardi, Alon Weizer, Pierre Karakiewicz, Christian Bolenz, Karim Bensalah, Mario Fernández, Christopher G. Wood, Charles C. Guo, Marco Roscigno, Eiji Kikuchi, Cord Langner, Jeffrey Wheat, Philipp Ströbel, **Yair Lotan**, Casey K. Ng, Christopher P. Evans. Adjuvant chemotherapy for upper tract transitional cell carcinoma: Results from the Upper Tract UCC Consortium. (Podium Session 10)
 8. Karim Bensalah, Altug Tuncel, Amit Gupta, Margaret Pearle, **Yair Lotan**. Determinants of quality of life in patients with kidney stones. (Moderated Poster 14)
 9. Vitaly Margulis, Shahrokh F. Shariat, Surena F. Matin, Ashish M. Kamat, **Yair Lotan**, Theresa M. Koppie. Eiji Kikuchi, Shuji Mikami, Takeo Kosaka, Richard Zigeuner, Cord Langner, Karim Bensalah, Nazareno Suardi, Pierre I. Karakiewicz, Alon Weizer, Jay D. Raman, Casey K. Ng, Mario Fernández, Mesut Remzi, Andrea Haitel, Christian Bolenz, Philipp Ströbel, Marco Roscigno, Francesco Montorsi, Christopher G. Wood. Outcomes of radical nephroureterectomy for urothelial carcinoma: a contemporary series from the upper tract urothelial carcinoma collaboration. (Moderated Poster 30)
 10. Jay D. Raman, Casey K. Ng, Vitaly Margulis, Douglas S. Scherr, **Yair Lotan**, Karim Bensalah Eiji Kikuchi, Francesco Montorsi, Richard Zigeuner, Alon Weizer, Christian Bolenz, Theresa M. Koppie, Nazareno Suardi, Mesut Remzi, Andrea Haitel, Charles C. Guo Christopher G. Wood, Marco Roscigno, Shuji Mikami, Cord Langner, J. Stuart Wolf, Philipp Ströbel, Mario Fernández, Pierre Karakiewicz, Shahrokh F.

- Shariat. Impact of tumor location on prognosis for upper-tract urothelial carcinoma: outcomes from over 1300 patients. (Moderated Session 30)
11. Marco Roscigno, Shahrokh F. Shariat, Roberto Bertini, Mesut Remzi, Vitaly Margulis, Andrea Haitel, Eiji Kikuchi, Richard Ziguener, Alon Weizer, Christian Bolenz, Theresa M. Koppie, Mario Fernández, Nazareno Suardi, Karim Bensalah, Philipp Ströbel, Jay D. Ramon, Wareef Kabbani, Masaru Murai, Cord Langner, **Yair Lotan**, Jeffrey Wheat, Charles C. Guo, Christopher G. Wood, Pierre Karakiewicz, Francesco Montorsi. More extensive lymphadenectomy improves the prognosis of patients with upper tract urothelial carcinoma without nodal metastases. (Moderated Session 30)
 12. Amit Gupta, Ilia S. Zeltser, Andrew Chi, Karim Bensalah, Jeffrey A. Cadeddu, Philipp Ströbel, **Yair Lotan**. Does renal Radio Frequency Ablation (RFA) result in development of postablation inflammatory response? (Moderated Poster 33)
 13. Aditya Bagrodia, Jay D. Raman, Karim Bensalah, Margaret S. Pearle, **Yair Lotan**. Synchronous bilateral percutaneous nephrostolithotomy: analysis of clinical outcomes, cost, and surgeon reimbursement. (Moderated Poster)
 14. Jay D. Raman, Aditya Bagrodia, Amit Gupta, Karim Bensalah, Jeffrey A. Cadeddu, **Yair Lotan**, Margaret S. Pearle. Natural history of residual fragments following percutaneous nephrostolithotomy. (Moderated Poster 48)
 15. Margaret S. Pearle, **Yair Lotan**, Tom Brikowski. Predicted climate-related increase in the prevalence and cost of nephrolithiasis in the U.S. (Podium 30)
 16. Amit Gupta, Shahrokh Shariat, Pierre I. Karakiewicz, Patrick J. Bastian, Ganesh S. Palapattu, Mark P. Schoenberg, Seth P. Lerner, Arthur I. Sagalowsky, **Yair Lotan**. Lymphovascular invasion (LVI) is independently associated with bladder cancer recurrence and survival in patients with T1 and negative Lymph nodes at radical cystectomy. (Moderated Poster 55)
 17. Nazareno Suardi, Shahrokh F. Shariat, **Yair Lotan**, Ganesh S. Palapattu, Patrick J. Bastian, Amit Gupta, Amnon Vazina, Mark Schoenberg, Seth P. Lerner, Arthur I. Sagalowsky, Pierre I. Karakiewicz. Assessment of the minimum number of lymph nodes needed at radical cystectomy in bladder cancer patients. (Moderated Poster 55)
 18. Claudio Jeldres, Shahrokh F. Shariat, Nazareno Suardi, **Yair Lotan**, Amit Gupta, Arthur I. Sagalowsky, Ganesh S. Palapattu, Patrick J. Bastian, Mark Schoenberg, Amnon Vazina, Seth P. Lerner, Pierre I. Karakiewicz. A conditional nomogram for prediction of early recurrence of bladder cancer after radical cystectomy. (Moderated Poster 55)
 19. Georg C. Huterer, Shahrokh F. Shariat, **Yair Lotan**, Patrick J. Bastian, Ganesh S. Palapattu, Amit Gupta, Craig G. Rogers, Arthur I. Sagalowsky, Mark Schoenberg, Seth P. Lerner, Pierre I. Karakiewicz. A systematic analysis of the prognostic ability of various nodal coding schemes in bladder cancer patients treated with radical cystectomy. (Moderated Poster 55)
 20. Shahrokh F. Shariat, Pierre I. Karakiewicz, Yves Fradet, Raheela Ashfaq, John P. Stein, Patrick J. Bastian, Matthew E. Nielsen, Nazareno Suardi, Francesco Montorsi, Susan Groshen, Stefan C. Müller, Jérôme Rigaud, Lukas C. Heukamp, George Netto, Seth P. Lerner, Arthur Sagalowsky, Richard J. Cote, **Yair Lotan**. Combination of cell Cycle regulating bio-markers improves prognosis in patients with organ confined urothelial cancer at radical cystectomy. (Podium 37)
 21. **Yair Lotan**, Karim Bensalah, Timothy Ruddell, Shahrokh F. Shariat, Arthur I. Sagalowsky, Raheela Ashfaq. Prospective evaluation of the clinical utility of

- reflex fluorescent in situ hybridization assay in patients with atypical cytology for detection of urothelial carcinoma of the bladder. (Podium 40)
22. Casey K. Ng, Jay D. Raman, Shahrokh F. Shariat, Steven M. Lucas, Aditya Bagrodia, **Yair Lotan**. Does hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper-tract urothelial carcinoma? (Moderated Poster 67)
 23. Amit Gupta, Claus G. Roehrborn, **Yair Lotan**, Shahrokh F. Shariat. Predictive value of hepatocyte growth factor/scatter factor (HGR/SF) in patients with clinically localized prostate cancer. (Moderated Poster 71)

AACR Annual Meeting, San Diego, CA April 2008

1. **Yair Lotan**, Robert S. Svatek, Keren Elias, Brett Moran, Arthur I. Sagalowsky. Bladder cancer screening in a high risk asymptomatic populations using the NMP22 BladderCheck test. (Minisymposia-Prevention Research 4)

South Central Section Meeting of the AUA, Colorado Springs, CO, September 2007

1. Amit Gupta, Shahrokh Shariat, Matthew Nielson, Patrick Bastian, Ganesh Palapattu, Craig Rogers, Amnon Vazina, Pierre Karakiewicz, Mark Schoenberg, Seth Lerner, Arthur Sagalowsky and **Yair Lotan**. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma (UCBC) treated with radical cystectomy. (Resident Essay Finalists Podium)
2. Shahrokh Shariat, Pierre Karakiewicz, Raheela Ashfaq, Seth Lerner, Ganesh Palapattu, Richard Cote, Arthur Sagalowsky and **Yair Lotan**. Multiple biomarkers for the prediction of bladder cancer recurrence and mortality. (Resident Essay Finalists Podium)
3. Jose Karam, **Yair Lotan**, Pierre Karakiewicz, Raheela Ashfaq, Arthur Sagalowsky, Claus Roehrborn, and Shahrokh Shariat. Use of apoptosis biomarkers for prediction of oncological outcomes after radical cystectomy. (Resident Essay Finalists Podium)
4. Jose Karam, **Yair Lotan**, Claus Roehrborn, Raheela Ashfaq, Pierre Karakiewicz and Shahrokh Shariat. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. (Prostate Cancer I: Diagnostic Podium)
5. **Yair Lotan**, Georg Hutterer, Shahrokh Shariat and Pierre Karakiewicz. Impact of clinical factors including a point-of-care NMP22 assay and cytology on risk of bladder cancer. (Bladder Cancer & Prostate Cancer II: Other Podium)
6. Amit Gupta, Claus Roehrborn, Pierre Karakiewicz, **Yair Lotan**, Kevin Slawin and Shahrokh Shariat. Predictive Value of Plasma hepatocyte growth factor in patients with clinically localized prostate cancer. (Bladder Cancer & Prostate Cancer II: Other Podium)
7. Amit Gupta, Shahrokh Shariat, Raheela Ashfaq, Claus Roehrborn, Ganesh Raj, Corinne Aragaki and **Yair Lotan**. Predictive value of the expression of urokinase plasminogen activation axis in patients treated with radical prostatectomy for clinically localized prostate cancer. (Bladder Cancer & Prostate Cancer II: Other Podium)

AUA Annual Meeting, Anaheim, CA, May 19 - 24, 2007

1. Joshua M. Stern, Jer-Tsong Hsieh, Sangtae Park, **Yair Lotan**, Jeffrey A. Cadeddu. Successful gold nanoshell assisted laser ablation of prostate carcinoma in vitro. (Moderated Poster 6)

2. Jose A. Karam, **Yair Lotan**, Raheela Ashfaq, Claus G. Roehrborn, Arthur I. Sagalowsky, Shahrokh F. Shariat. Combined effect of apoptotic biomarkers on bladder cancer recurrence and mortality after radical cystectomy. (Podium 7)
3. Hong-Ying Huang, Shahrokh F. Shariat, Tung-Tien Sun, Herbert Lepor, Ellen Shapiro, Jer-Tsong Hsieh, Raheela Ashfaq, **Yair Lotan**, Xue-Ru Wu. Persistent uroplakin expression in advanced urothelial carcinomas: implications in clinical outcome. (Moderated Poster 25)
4. **Yair Lotan** and NMP22 Clinical Investigation Group. Impact of risk factors on the performance of a point-of-care bladder cancer test. (Moderated Poster 31)
5. Amit Gupta, Shahrokh F. Shariat, Matthew Nielson, Patrick J. Bastian, Ganesh S. Palapattu, Craig G. Rogers, Amnon Vazina, Pierre I. Karakiewicz, Mark P. Schoenberg, Seth P. Lerner, Arthur I. Sagalowsky, **Yair Lotan**. Outcomes of patients with clinical t1 grade 3 bladder urothelial cell bladder carcinoma treated with radical cystectomy. (Podium 43)
6. Jose A. Karam, Shahrokh F. Shariat, Raheela Ashfaq, Hong-Ying Huang, Ellen Shapiro, **Yair Lotan**, Arthur I. Sagalowsky, Xue-Ru Wu, Jer-Tsong Hsieh. Loss of doc-2/dab2 expression is associated with aggressive features of bladder cancer. (Podium 45)

Annual EAU Congress, Berlin, March 2007

1. Gupta A, Nielsen M. Bastian P, Palapattu G, Vazina A, Lerner S, Schoenberg M, Sagalowsky A, **Lotan Y**, Shariat S. Outcomes of patients with clinical t1 grade 3 bladder urothelial cell carcinoma treated with radical cystectomy. (Oral Session 2)
2. **Lotan Y**, Svatek R.S., Nandi A, Gurnani P. Prospective evaluation of proteomics to discriminate between benign and malignant prostate in men with psa less than 10. (Poster Session 28)

Society of Urologic Oncology, Bethesda, Dec. 2006

1. **Yair Lotan**, Animesh Nandi, Prem Gurnani, Kevin Rosenblatt. Prospective evaluation of proteomics to discriminate between benign and malignant prostate in men with psa less than 10. (Podium)

South Central Section Meeting of the AUA, Santa Fe, NM 2006

1. Robert S. Svatek, Guadencio Olgin, Margaret S. Pearle, Jeffrey A. Cadeddu, Arthur I. Sagalowsky, and **Yair Lotan**. Experience with the Management of Upper Tract Transitional Cell Carcinoma at UT Southwestern. (Kidney and Ureter Cancer Podium)
2. **Yair Lotan**, Robert S. Svatek, and Arthur I. Sagalowsky. Should We Screen for Bladder Cancer in a High Risk Population: A Cost Per Life-Year Saved Analysis? (Bladder Cancer I Podium)

3. Shahrokh F. Shariat, Raheela Ashfaq, Arthur I. Sagalowsky, and **Yair Lotan**. Cooperative Effect of Cell Cycle Regulators Expression on Bladder Cancer Development and Aggressiveness. (Bladder Cancer I Podium)
4. Vitaly Margulis, Joshua Stern, **Yair Lotan** and Arthur I. Sagalowsky. Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: What Percentage of Patients Qualify for Bladder Preservation Protocols? (Bladder Cancer I Podium)
5. Shahrokh F. Shariat, Ganesh Palapattu, Pierre Karakiewicz, Gilad Amiel, Amit Gupta, Craig Rogers, Amnon Vazina, Patrick Bastian, Mark Schoenberg, Seth P. Lerner, Arthur I. Sagalowsky, and **Yair Lotan**. Discrepancy between Clinical and Pathologic Stage: Impact on Prognosis following Radical Cystectomy. (Bladder Cancer I Podium)
6. Shahrokh F. Shariat, Raheela Ashfaq, Osamah Saeedi, Arthur I. Sagalowsky, and **Yair Lotan**. Survivin Expression is Associated with Bladder Cancer Presence, Stage, Progression, Metastasis, and Mortality. (Bladder Cancer II Podium)
7. Shahrokh F. Shariat, Pierre Karakiewicz, Ganesh Palapattu, Amiel Gilad, **Yair Lotan**, Craig Rogers, Amnon Vazina, Amit Gupta, Patrick Bastian, Mark Schoenberg, Arthur I. Sagalowsky, and Seth P. Lerner. Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: A Contemporary Series from the Bladder Cancer Research Consortium. (Bladder Cancer II Podium)

AUA Annual Meeting, Atlanta, GA, May 20 - 25, 2006

1. Joshua M Stern, Robert S. Svatek, Sangtae Park, J. Kyle Anderson, **Yair Lotan**, Jeffrey A. Cadeddu. Intermediate follow-up comparison between partial nephrectomy and radio frequency ablation in T1A renal tumors. (Moderated Poster Session 1)
2. Joshua M. Stern, Sangtae Park, J. Kyle Anderson, Edward Matsumoto, Daniel Dugi, **Yair Lotan**, Jeffrey A. Cadeddu. Kidney tumor radiofrequency ablation: experience in ASA I and II patients. (Moderated Poster Session 2)
3. Lance P. Walsh, L. Chinsoo Cho, Cheng-Hui Chang, Kenneth Forster, Wareef Kabbani, Jeffrey A. Cadeddu, Jer-Tsong Hsieh, Hak Choy, Robert Timmerman, **Yair Lotan**. Efficacy of ablative high dose per fraction radiation for implanted human renal cell cancer in a nude mouse model. (Discussed Poster 6)
4. **Yair Lotan**, Robert S. Svatek, Arthur I. Sagalowsky. Screening high risk patients for bladder cancer is cost-effective. (Podium 10)
5. Daniel J. Lewinshtein, Serge Benayoun, Alberto Briganti, K-H Felix Chun, Shahrokh F. Shariat, Arthur I. Sagalowsky, Frank Wians, Jr., Claus G. Roehrborn, **Yair Lotan**, Craig D. Zippe, Raina Rupesh, Gerson Ludecke, Marta Sanchez-Carbayo, Robert Casella, Martin J. Friedrich, Hartwig Huland, Sanaa Eissa, Hideyuki Akaza, Naoto Miyanaga, Ihor S. Sawczuk, Michael Marberger, Hans Boman, Hans Hedelin, Paul Perrotte, Pierre I. Karakiewicz: Predictive accuracy, sensitivity, and specificity of nuclear matrix protein 22 and urine cytology for prediction of recurrence of non- transitional cell carcinoma of the bladder. (Podium 10)
6. Shahrokh F. Shariat, Michael Marberger, **Yair Lotan**, Marta Sanchez-Carbayo, Craig D. Zippe, Gerson Ludecke, Hans Boman, Karnsjukhuset Skovde, Ihor S. Sawczuk, Martin G. Friedrich, Roberto Casella, Christine Mian, Sanaa Eissa,

- Hideyuki Akaza, Vincenzo Serretta, Hartwig Huland, Hans Hedelin, Rupesh Raina, Naoto Miyanaga, Arthur I. Sagalowsky, Claus G. Roehrborn and Pierre I. Karakiewicz: Variability in the performance of nuclear matrix protein 22 in the detection of bladder cancer. (Podium 14)
7. Sangtae Park, Beau N. Dusseault, **Yair Lotan**, John Pattaras, Kenneth Ogan. Cost analysis for four techniques of renal tumor ablation: laparoscopic and percutaneous radiofrequency ablation and cryoablation. (Discussed Poster 13)
 8. Lance P. Walsh, Meredith R. Miller, James K. Anderson, Bumsoo Han, Jer-Tsong Hsieh, **Yair Lotan**, Jeffrey A. Cadeddu. In vitro assessment of the efficacy of thermal therapy in human renal cell carcinoma. (Discussed Poster 14)
 9. Gilad E. Amiel, Shahrokh F. Shariat, Steven Shen, Ganesh S. Palapattu, **Yair Lotan**, Pierre I. Karakiewicz, Amnon Vazina, Craig G. Rogers, Patrick J. Bastian, Matthew E. Nielsen, Amit Gupta, Mark P. Schoenberg, Arthur I. Sagalowsky, Seth P. Lerner. Evidence based gender related outcomes after radical cystectomy. (Discussed Poster 16)
 10. Matthew E. Nielsen, Shahrokh F. Shariat, Pierre I. Karakiewicz, Gilad E. Amiel, Craig G. Rogers, **Yair Lotan**, Patrick J. Bastian, Amnon Vazina, Amit Gupta, Seth P. Lerner, Arthur I. Sagalowsky, Mark P. Schoenberg, Ganesh S. Palapattu. Delay in radical cystectomy over 12 weeks is not associated with adverse outcome: results from the bladder cancer research consortium. (Discussed Poster 16)
 11. Alberto Briganti, K-H Felix Chun, Shahrokh F. Shariat, **Yair Lotan**, Ganesh S. Palapattu, Craig G. Rogers, Patrick J. Bastian, Amiel Gilad, Amit Gupta, Amnon Vazina, Arthur I. Sagalowsky, Seth P. Lerner, Mark P. Schoenberg, Pierre I. Karakiewicz. Internal validation of a competing-risks survival nomogram for patients treated with cystectomy for bladder cancer. (Discussed Poster 16)
 12. Shahrokh F. Shariat, Vitaly Margulis, Raheela Ashfaq, Melissa Thompson, Arthur I. Sagalowsky, Jer-Tsong Hsieh, **Yair Lotan**. Correlation of cyclooxygenase-2 expression with molecular markers, pathologic features, and clinical outcome of transitional cell carcinoma of the urinary bladder. (Discussed Poster 16)
 13. Shahrokh F. Shariat, Ganesh S. Palapattu, Gilad E. Amiel, Pierre I. Karakiewicz, Craig G. Rogers, Patrick J. Bastian, Amnon Vazina, Amit Gupta, Mark P. Schoenberg, Seth P. Lerner, Arthur I. Sagalowsky, **Yair Lotan**. Impact of concomitant carcinoma in situ on clinical outcomes after radical cystectomy. (Discussed Poster 16)
 14. Shahrokh F. Shariat, Raheela Ashfaq, Arthur I. Sagalowsky, **Yair Lotan**. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. (Discussed Poster 16)
 15. Patrick J. Bastian, Shahrokh F. Shariat, Craig G. Rogers, Gilad E. Amiel, Pierre I. Karakiewicz, **Yair Lotan**, Amit Gupta, Amnon Vazina, Arthur I. Sagalowsky, Seth P. Lerner, Mark P. Schoenberg, Ganesh S. Palapattu. Prognostic significance of deep muscular invasion and extravesical extension in pathological staging of bladder cancer after radical cystectomy. (Discussed Poster 16)
 16. K-H Felix Chun, Alberto Briganti, Shahrokh F. Shariat, Ganesh S. Palapattu, **Yair Lotan**, Craig G. Rogers, Patrick J. Bastian, Gilad E. Amiel, Amit Gupta, Amnon Vazina, Matt Nielsen, Arthur I. Sagalowsky, Seth P. Lerner, Mark P. Schoenberg, Pierre I. Karakiewicz. Competing risks nomogram predicting the probability of bladder cancer recurrence after cystectomy can reliably distinguish between those destined to recur and those who may die of other causes before recurrence. (Discussed Poster 16)

AACR Annual Meeting, Anaheim, CA April 2005

1. **Lotan Y**, Cadeddu JA, Lee JJ, Roehrborn CG, Lippman SM. Implications of the prostate cancer prevention trial: A decision analysis model of survival outcomes. (Poster)

AUA 100th Annual Meeting, San Antonio, TX, May 21 -26, 2005

1. Khaled F. Abdel-Aziz, Agnes Wang, **Yair Lotan**, Claus G. Roehrborn. Saturation Biopsy Does Not Influence Serum PSA Values or PSA Velocity. (Moderated Poster Session)
2. Shahrokh F. Shariat, Mike Herman, Roberto Casella, **Yair Lotan**, Jose Karam, Ulf- Hakan Stenman. Urinary Levels of Tumor-Associated Trypsin Inhibitor (TATI) In the Detection of Transitional Cell Carcinoma of the Urinary Bladder. (Podium Session)
3. Serge Benayoung, Shahrokh F. Shariat, Paul Perrotte, Martin G. Friedrich, Craig D. Zippe, Gerson Lodecke, Hans Boman, Kristina Skovde, Marta Sanchez- Carbayo, Roberto Casella, Christine Mian, Sanaa Eissa, Hideyuki Akaza, Ihor S. Sawczuk, Vincenzo Serretta, Hans Hedelin, Raina Rupesh, Naoto Miyanaga, Arthur I. Sagalowsky, Frank Wians, Jr., Claus G. Roehrborn, **Yair Lotan**, Tullio Sulser, Thomas C. Gasser, Michael J. Marberger, Pierre I. Karakiewicz. Institutional Variability in Predictive Accuracy of Urinary Cytology for Prediction of Transitional Cell Carcinoma Recurrence. (Podium Session)
4. Khaled F. Abdel-Aziz, Shahrokh F. Shariat, John D. McConnell, Claus G. Roehrborn, **Yair Lotan**. Percent Free PSA Is Associated With Clinical Outcomes In Patients With Total PSA Levels Below 10 ng/mL. (Discussed Poster)
5. Pierre I. Karakiewicz, Shahrokh F. Shariat, Paul Perrotte, Ganesh S. Palapattu, Craig G. Rogers, Patrick J. Bastian, **Yair Lotan**, Amit Gupta, Amnon Vazina, Amiel Gilad, Arthur I. Sagalowsky, Mark P. Schoenberg, Seth P. Lerner. A Prognostic Tool to Identify Patients at High Risk of Relapse at 2, 5, And 8 Years after Cystectomy for Transitional Cell Carcinoma (TCC) of the Urinary Bladder: Nomogram Development and Internal Validation. (Podium Session)
6. Ganesh P. Palapattu, Pierre I. Karakiewicz, Patrick J. Bastian, Craig G. Rogers, Shahrokh F. Shariat, **Yair Lotan**, Amit Gupta, Amnon Vazina, Gilad E. Amiel, Paul Perrotte, Arthur I. Sagalowsky, Seth P. Lerner, Mark P. Schoenberg. Are Patients Who Are pT0 Following Radical Cystectomy Cured of Bladder Cancer? Results from the Bladder Cancer Research Consortium (BCRC). (Podium Session)
7. Craig G. Rogers, Ganesh S. Palapattu, Pierre I. Karakiewicz, Patrick J. Bastian, Shahrokh F. Shariat, **Yair Lotan**, Amit Gupta, Amnon Vazina, Gilad E. Amiel, Paul Perrotte, Arthur I. Sagalowsky, Seth P. Lerner, Mark P. Schoenberg. Bladder Cancer-Specific Survival Following Radical Cystectomy for Primary Non- Transitional Cell Carcinoma (Non-TCC) of the Bladder: Results from the Bladder Cancer Research Consortium (BCRC). (Podium)
8. Robert S. Svatek, Vitaly Margulis, Edward D. Matsumoto, Wareef Kabbani, Jeffrey A. Cadeddu, **Yair Lotan**: "Application of a Novel Hemostatic Agent QuickClot during

Laparoscopic Partial Nephrectomy” (video)

AUA 99th Annual Meeting, San Francisco, CA, May 8 – 13, 2004

1. **Yair Lotan**, David M. Wilhelm, David A. Duchene, Margaret S. Pearle. Cost-Effectiveness of Medical Management Strategies of Nephrolithiasis in Different Health Care Systems. (Poster Presentation)
2. Shahrokh F. Shariat, Craig D. Zippe, X. Bowman, Martin G. Friedrich, Gerson Lüdecke, Marta Sanchez-Carbayo, Roberto Casella, Christine Mian, Ihor S. Sawczuk, Sanaa Eissa, Hideyuki Akaza, Vincenzo Serretta, Hartwig Huland, Frank Wians, Jr., Raina Rupesh, Naoto Miyanaga, Arthur I. Sagalowsky, **Yair Lotan**, Paul Perrotte, Michael Marberger, Pierre I. Karakiewicz. Nomograms for Bladder Cancer Recurrence According to Grade and Stage. (Poster Presentation)
3. Amnon Vazina, Shahrokh F. Shariat, Gilad E. Amiel, **Yair Lotan**, Amit Gupta, Mark P. Schoenberg, Arthur I. Sagalowsky, Seth P. Lerner. Pelvic Lymph Nodes as a Prognostic Factor in Patients Undergoing Radical Cystectomy for Invasive Transitional Cell Carcinoma: A Multi-Center Study. (Poster Presentation)
4. Amit Gupta, **Yair Lotan**, Shahrokh F. Shariat, Amnon Vazina, Pierre I. Karakiewicz, Gilad E. Amiel, Jeffrey L Evans, Daniel Dugi, Charlene Rogers, Mark P. Schoenberg, Seth P. Lerner, Arthur I. Sagalowsky. Lymphovascular Invasion Independently Predicts Increased Risk of Distant Recurrence and Decreased Overall Survival in Patients with Transitional Cell Carcinoma (TCC). (Poster Presentation)
5. Amit Gupta, **Yair Lotan**, Shahrokh F. Shariat, Amnon Vazina, Gilad E. Amiel, Jeffrey L. Evans, Daniel Dugi, Charlene Rogers, Mark P. Schoenberg, Seth P. Lerner, Arthur J. Sagalowsky. Risk Factors for Distant vs Local Recurrence in Patients Undergoing Radical Cystectomy for Transitional Cell Cancer (Poster Presentation)
6. **Yair Lotan***, Claus G. Roehrborn, Jeffrey A. Cadeddu. The Prostate Cancer Prevention Trial: Implications on Survival Outcomes. (Poster Presentation)
7. Shahrokh F. Shariat, **Yair Lotan**, Raheela Ashfaq, Seyeyd M. Khoddami, Hossein Saboorian, Claus G. Roehrborn, Kevin M. Slawin. Survivin Expression is Associated with Characteristics of Benign Prostatic Hyperplasia. (Poster Presentation)

21st World Congress on Endourology and SWL, Montreal, Canada, 2003

1. **Y. Lotan**, D.A. Duchene, J.A. Cadeddu, K.S. Koeneman. Cost Comparison for Hand-Assisted Laparoscopic Nephrectomy and Open Nephrectomy: Analysis of Individual Parameters. (Poster Presentation).
2. D. B. Johnson, G. D. Taylor, **Y. Lotan**, N. Siddiqi, A. I. Sagalowsky, K.S. Koeneman,

- J. A. Cadeddu. The Effects of Radiofrequency Ablation on Renal Function and Blood Pressure. (Poster Presentation).
3. **Y. Lotan**, R. Venkatesh, J. D. Cadeddu, J. Landman. Cost Comparison for Laparoscopic Partial Nephrectomy and Open Partial Nephrectomy: Analysis of Individual Parameters. (Poster Presentation).
 4. **Y. Lotan**, D.A. Duchene, J. A. Cadeddu, A. I. Sagalowsky, K.S. Koeneman. Changing Management of Organ Confined Renal Masses. (Open Poster Forum).

AUA 98th Annual Meeting, Chicago, April 26 – May 1, 2003

1. **Yair Lotan**, David A. Duchene, Jeffrey A. Cadeddu, Kenneth S. Koeneman. Cost Comparison For Hand-Assisted Laparoscopic Nephrectomy And Open Nephrectomy: Analysis Of Individual Parameters (Poster presentation)
2. Armando J Lorenzo, **Yair Lotan**, Steven G Docimo, Linda A Baker. What makes laparoscopy cost-effective in managing unilateral non-palpable undescended testicles? (Poster presentation)
3. Armando J Lorenzo, **Yair Lotan**, Steven G Docimo, Linda A Baker. Cost analysis of human chorionic gonadotropic (HCG) in the management of unilateral non-palpable undescended testicles. (Poster presentation)
4. David A. Duchene, **Yair Lotan**, Devin B Johnson, Kenneth S. Koeneman, Jeffrey A. Cadeddu. Cost comparison for standard laparoscopic and hand-assisted laparoscopic radical nephrectomy: analysis of individual parameters. (Poster Presentation)
5. David A. Duchene, **Yair Lotan**, Jeffrey A. Cadeddu, Arthur I. Sagalowsky, Kenneth S. Koeneman. Histopathology of Surgically Managed Renal Tumors: Analysis of a Contemporary Series. (Poster Presentation)
6. Khaled F Abdel-Aziz, **Yair Lotan**, Claus G Roehrborn. Saturation as a repeat biopsy strategy after a negative office biopsy. (Poster Presentation)

World Congress of Endourology, Genoa, Sept. 2002

1. **Yair Lotan**, Claus G. Roehrborn, Jeffrey A. Cadeddu, Margaret S. Pearle. Cost- effectiveness model for management of the stone-forming patient. (Poster presentation)
2. David M. Wilhelm, Kenneth Ogan, Guy Lindberg, **Yair Lotan**, Cheryl Napper, John Hoopman, Margaret S. Pearle and Jeffrey A. Cadeddu

AUA 97th Annual Meeting, Orlando, May 25 – 30, 2002

1. **Yair Lotan**, Matthew T. Gettman, Cheryl A. Napper, Margaret S. Pearle, and Jeffrey A. Cadeddu: Porcine Laparoscopic Partial Nephrectomy Using Holmium Laser: Surgical Technique (video)
2. **Yair Lotan**, Claus G. Roehrborn, John D. McConnell, Benjamin N. Hendin: Factors Influencing the Outcomes of Penile Prosthesis Surgery at a Teaching Institution (poster Presentation)
3. **Lotan Y**, Gettman MT, Roehrborn CG, Pearle MS, Cadeddu JA. Cost comparison for laparoscopic nephrectomy and open nephrectomy: analysis of individual parameters (Poster Presentation)
4. Gettman MT, **Lotan Y**, Roehrborn CG, Cadeddu JA, Pearle MS. Cost effective treatment of ureteropelvic junction obstruction: results of a decision tree analysis. (Poster presentation)

5. Kenneth Ogan, **Yair Lotan**, Kenneth Koeneman, Margaret S. Pearle and Jeffrey A. Cadeddu: Laparoscopic RPLND Versus Open RPLND: A Cost Analysis. (Poster presentation)

Society of Laparoendoscopic Surgeons 10th International Congress and Endo Expo, Dec. 2001

1. **Lotan Y**, Gettman MT, Lindberg G, Napper CA, Hoopman J, Pearle MS, and Cadeddu JA. Cost comparison for laparoscopic nephrectomy and open nephrectomy: analysis of individual parameters (Podium Presentation)

World Congress of Endourology, Bangkok, Nov. 2001

1. **Lotan Y**, Gettman MT, Lindberg G, Napper CA, Hoopman J, Pearle MS, and Cadeddu JA. Laparoscopic Partial Nephrectomy Using Holmium Laser. (Poster presentation: accepted but not presented).
2. **Lotan Y**, Gettman MT, Roehrborn CG, Cadeddu JA, Pearle MS. Management of ureteral calculi: a cost comparison and decision-making analysis. (Poster presentation)
3. Gettman MT, **Lotan Y**, Roehrborn CG, Cadeddu JA, Pearle MS.: Cost effective treatment of ureteropelvic junction obstruction: results of a decision tree analysis. (Poster presentation)

South-Central Section Meeting, Sept. 2001

1. **Lotan Y**, Gettman MT, Roehrborn CG, Pearle MS, Cadeddu JA. Cost comparison for laparoscopic nephrectomy and open nephrectomy: analysis of individual parameters (Podium Presentation)
2. **Lotan Y**, Gettman MT, Roehrborn CG, Pearle MS, Cadeddu JA. Laparoscopic nephrectomy is cost effective compared with open nephrectomy in a large county hospital (Podium Presentation)

AUA 96th Annual Meeting, Anaheim, June 2 – 7, 2001

1. **Lotan Y**, Roehrborn CG. Cost effectiveness of a modified care protocol substituting cystoscopy with bladder tumor markers in the follow-up of TCC patients: A decision analytical approach. (podium presentation)
2. **Lotan Y**, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: Results of a comprehensive literature review and meta-analysis. (poster presentation)

AUA 92nd Annual Meeting, New Orleans, April 1997

1. **Lotan Y**, Pavlik VN, Rodriguez S, Lerner SP. Predictors of bladder cancer survival in a multiethnic, low socioeconomic (SES) population. (Poster presentation).

YAIR LOTAN'S FEE SCHEDULE

**DEPARTMENT OF UROLOGY
LEGAL FEES
REVISED 4/10/18**

Fees for depositions, trial testimony and/or other legal discussions for the Department of Urology should be charged as listed below:

Review of legal documents and medical records (1 hour minimum)	\$800/hour
Telephone conference calls (1 hour minimum)	\$800/hour
Depositions (1 hour minimum)	\$1,000/hour
Witness stand time (1 hour minimum)	\$1,500/hour
Time away from office (minimum)	\$4,500/day
Retainer Fee	\$2,250

Notes:

1. Fees charged are in one-half hour increments after the first hour. One hour is the minimum charge for any service unless indicated otherwise.
2. Approval by the Chairman is required before faculty agree to provide testimony for a plaintiff.
3. Cancellation or postponement of a trial with scheduled faculty testimony with less than 48 hours' notice will be charged \$5,000.
4. Approval is not required to review records and provide an opinion to an attorney concerning the merits of a case.
5. Time away from the office begins when the faculty member leaves his/her office and ends upon return (during regular business hours).

YAIR LOTAN'S TESTIMONY HISTORY

IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF NORTH CAROLINA
SOUTHERN DIVISION

IN RE:)	
)	
CAMP LEJEUNE WATER LITIGATION)	
)	
This Document Relates to:)	Case Nos.:
)	
ALL CASES)	7:23-CV-897
)	
DAVID DOWNS)	7:23-CV-01145-BO
)	
DAVID WILLIAM FANCHER)	7:23-CV-00275-BO-BM
)	
ALLAN WAYNE HOWARD)	7:23-CV-00490-BO
)	
FRANK W. MOUSSER)	7:23-CV-00667-BO-RN
)	
JACQUELINE JORDAN TUKES)	7:23-CV-01553-BO-BM

**PLAINTIFFS' DESIGNATION AND DISCLOSURE OF PHASE III EXPERT
WITNESSES WITH RESPECT TO KIDNEY CANCER**

YAIR LOTAN, MD'S LIST OF TESTIMONY

Pursuant to Fed. R. Civ. P. 26(a)(2)(B)(v), Plaintiffs provide the following list of testimony:
During the previous 4 years, Yair Lotan, MD has testified as an expert at trial or by deposition in only one matter, namely *In the Estate of Philip Michael Gatz*, Denton County, Texas, docket number PR-2020-00010. The deposition was taken in or about July 2023.